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ABSTRACT

Chronic diseases and conditions such as liver and heart diseases are among the most
common, costly, and preventable of all health problems. As of 2012 in the U.S., about half of all
adults—117 million people—had one or more chronic health conditions. Aortic aneurysm and
liver fibrosis are among the most common chronic diseases which are generated by the formation
and deposition of excess extracellular matrix proteins (largely type I collagen) as a result of a
reparative process, represents one of the most major global health problems. Collagen type I is one
of the major diagnostic biomarkers and therapeutic targets for many chronic diseases including
heart and liver diseases. Early diagnosis, noninvasive detection and staging of these diseases,

remain as one of the major clinical barriers which can lead to effective treatment and stop further
progression toward major clinical consequences. MRI as one the popular imaging modalities has
several unique advantages for monitoring slow progression and detection of disease with high
resolution without using radiation, however, there is an unmet medical need to develop MRI
contrast agents with desired sensitivity and collagen specificity. In this dissertation, the successful
design of a protein-based contrast agent with collagen type I targeting capability
(ProCA32.collagen1) is reported to diagnose and stage liver and heart diseases in many mouse
models of caner, fibrosis and aortic aneurysm. ProCA32.collagen1 exhibits the highest relaxivity
values for r1 (34 ± 0.12 mM-1.s-1) and r2 (50 ± 0.16 mM-1.s-1) per Gd3+ at 1.4 T and r1 (21.3 ± 0.5
mM-1.s-1) and r2 (108.5 ± 1.2 mM-1.s-1) at 7.0 T. ProCA32.collagen1 can detect both early (Ishak
3 of 6) and late stage mouse liver fibrosis as well as early stage nonalcoholic steatohepatitis (Ishak
1 of 6) in different models with strong metal binding affinity and selectivity. The targeted contrast
agent is also capable of detecting disease heterogeneity with high collagen type I binding affinity
with dissociation constant of Kd=1.42  0.2 M. ProCA32.collagen1 has largely reduced dose and
strong resistance against transmetallation (104-1012-fold higher metal selectivity for Gd3+ over Ca2+
and Zn2+) compared to existing contrast agents. ProCA32.collagen1 is expected to have strong
translational potential to improve detection of different diseases at early stages with high
confidence, and subsequently monitor disease progression and patient response to treatment.
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DEVELOPMENT OF NOVEL COLLAGEN-TARGETED PROTEIN-BASED MRI
CONTRAST AGENT FOR IMAGING OF CHRONIC LIVER AND HEART DISEASES

by

MANI SALARIAN

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2018

Copyright by
Mani Salarian
2018

DEVELOPMENT OF NOVEL COLLAGEN-TARGETED PROTEIN-BASED MRI
CONTRAST AGENT FOR IMAGING OF CHRONIC LIVER AND HEART DISEASES

by

MANI SALARIAN

Committee Chair:
Committee:

Jenny J. Yang
Markus Germann
Ming Luo
Zhi-Ren Liu
Shella Keilholz
Phillip Zhe Sun

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
August 2018

iv

DEDICATION
I would like to dedicate my dissertation to my father; Firooz, my mother; Mahshid and my
brother; Khosro for their tremendous unconditional love, moral and financial support. They have
been the source of my strength throughout these years. I am extremely thankful to my parents for
all their sacrifices and hard work for providing me the best environment and bright future
throughout my education and showing me the right path. They taught me to never give up and
always fight for my goals and that hard work will eventually pay off. I would also like to thank
my brother who was always encouraging and supportive with his kind words during all these years,
he is the best brother anyone could ever have.

v

ACKNOWLEDGEMENTS
My deepest and sincerest gratitude goes to Dr. Jenny J. Yang, my Ph.D. advisor. She has
been one of the best role models that any graduate student could ever have. I am extremely thankful
to her for providing me the best environment for any graduate student ever needs to shine and
bloom. Her knowledge, experience, fighting spirit and passion in science have been such an
inspiration for me throughout these years. She has certainly played an essential role in developing
my career. I am grateful for her guidance and advice during my research and providing both moral
and financial support for moving my research forward and playing a crucial role in my research
progression. Because of her trainings, I have learnt a variety of valuable lab skills that I extremely
cherish. Because of her, I am a better problem solver, better in communication skills, team work
and in general better researcher and scientist.
I would also like to thank my previous mentors in the lab, Dr. Yanyi Chen and Xueyun
(Snow) Liu who were my first mentors when I joined Dr. Yang’s lab for their guidance and
patience. They were part of Gap Junction projects and I learned some of the basic techniques such
as PCR, expression and purification of proteins from them.
My highest gratitude goes to Dr. Shenghui Xue for his excellent mentorship and patience
in teaching me all the important techniques and skills required for conducting research in MRI
projects. His continued help, guidance, and support during my research has been valuable for my
project advancement. Dr. Jingjuan Qiao has also been one of my important mentors providing
detailed suggestions and teaching me some of the in vivo skills during all these years. Without Dr.
Shenghui Xue’s and Dr. Jingjuan Qiao’s help, this dissertation could not have been finished.
I am very thankful to other current and previous members of MRI group, first of all Anvi
Patel for also teaching me some of the important skills. Shanshan Tan for her helpful guidance and

vi

discussions regarding my research. I would also like to thank Dr. Fan Pu for her suggestions and
Oluwatosin Y. Ibhagui for her kind help during my research in the lab.
I am very thankful to Dr. Chen Zhang and Dr. Juan Zou as well for their suggestions and
help during some tough times in Gap Junction project. I would appreciate all our collaborators
help in these multi-disciplinary projects, my dear friend and collaborator Dr. Maysam Nezafati for
image processing, Drs. Ravi Chakra Turaga, Yinwei Zhang, Hua Yang and Ganesh Satyanarayana
for histology analysis and animal models’ development, Dr. Khan Hekmatyar for image processing
and operating the MRI instrument and providing helpful suggestions, Dr. Alton Brad Farris for his
pathology analysis in liver fibrosis project, Drs. Hans E. Grossniklaus and David H. Lawson for
their helpful discussions in Uveal Melanoma project, Drs. Xiaoping Hu, Jason Langley and Qun
Zhao for their guidance on MRI image analysis, and Dr. Pardeep Mittal for his suggestions on
clinical contrast agent field. I greatly appreciate Dr. Jibiao Li and Dr. Liqing Yu for their
contribution in generating nonalcoholic fatty liver disease animal models. I would also thank Dr.
Rao Mukkavilli for his tremendous help in analyzing pharmacokinetics data. I am very thankful to
Dr. Ming-Hui Zou and Dr. Ramprasath Tharmarajan for their contribution in generating the heart
disease animal models.
At the end, I would like to express my heartfelt gratitude to all my committee members,
Drs. Ming Luo, Markus Germann, Shella Keilholz, Phillip Zhe Sun and Zhi-Ren Liu for accepting
my invitation to be part of my dissertation committee, and their detailed analysis and assistance
for supporting my research.

vii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................ V
LIST OF TABLES ....................................................................................................... XVI
LIST OF FIGURES ................................................................................................... XVII
LIST OF ABBREVIATION....................................................................................... XXV
1

INTRODUCTION ...................................................................................................... 1
Magnetic resonance imaging (MRI) and contrast agents ................................ 1
Clinical Gd3+-based MRI contrast agents: Advantages and limitations ........ 3
Important criteria of an MRI Contrast Agent ................................................. 7
Strategies for the design of Gd3+-based MRI contrast agents ......................... 8
Relaxivity............................................................................................................ 14
1.5.1 Inner-Sphere Relaxivity ................................................................................ 18
1.5.2 Hydration number, q ..................................................................................... 19
1.5.3 Inner-Sphere water relaxation ..................................................................... 19
1.5.4 Gadolinium-water distance ........................................................................... 20
1.5.5 Rotational diffusion ...................................................................................... 21
1.5.6 Electronic relaxation..................................................................................... 22
1.5.7 Water exchange rate ..................................................................................... 23
1.5.8 2nd-sphere and outer-sphere relaxivity ........................................................ 24
1.5.9 Effect of field strength and temperature ...................................................... 25

viii

Current advancements in improving the relaxvity of Gd3+-based MRI Agents
27
Design of protein-based MRI contrast agent with improved relaxivity ....... 28
1.7.1 MRI contrast agents based on proteins ........................................................ 28
1.7.2 Choice of protein for designing Gd3+-based MRI contrast agents .............. 29
1.7.3 Design of MRI Contrast Agent based on -Parvalbumin ........................... 30
1.7.4 Factors Contributing to High Relaxivity in ProCA32 ................................. 31
1.7.5 Design of a Targeted Contrast Agent for Imaging of Biomarkers ............. 34
In vitro properties of MRI contrast agents ..................................................... 37
1.8.1 Optimizing peptide targeting capability of MRI contrast agents................. 37
1.8.2 Thermodynamic stability of MRI contrast agents ....................................... 39
1.8.3 The kinetic stability and metal selectivity of MRI contrast agents .............. 43
1.8.4 Size is essential for contrast agent distribution and excretion .................... 44
1.8.5 Transmetallation studies of MRI contrast agents........................................ 45
1.8.6 Toxicity studies of MRI contrast agents ....................................................... 46
Molecular imaging by MRI using a biomarker-targeted contrast agent ..... 47
Collagen type I: An appealing target for many chronic diseases ................. 50
Motivation and challenges to be addressed..................................................... 51
Overview of the dissertation ............................................................................. 52
2

MATERIALS AND EXPERIMENTAL METHODS ........................................... 54

ix

Molecular cloning, expression, purification and Lysine PEGylation. .......... 54
Liver fibrosis and metastasis animal models .................................................. 55
2.2.1 Thioacetamide (TAA)/alcohol induced fibrosis ........................................... 55
2.2.2 DEN induced Cirrhosis and HCC ................................................................ 56
2.2.3 Uveal melanoma liver metastasis model ...................................................... 57
Metal binding affinity measurements of ProCA32.collagen1 ....................... 58
Histology analysis .............................................................................................. 62
2.4.1 Immunohistochemistry and Hematoxylin and Eosin analysis .................... 62
2.4.2 Immunofluorescence staining ...................................................................... 62
Mouse MRI imaging.......................................................................................... 63
Statistical analysis ............................................................................................. 64
Determination of r1 and r2 relaxivity values ................................................... 65
Enzyme-linked immunosorbent assay (ELISA) assay ................................... 65
Pharmacokinetics, distribution and toxicity studies ...................................... 66
Serum stability and transmetallation of ProCA32.collagen1 ........................ 67
Measurement of water coordination number in ProCA32.collagen1........... 68
3

DESIGN, EXPRESSION AND PURIFICATION OF PROCA32.COLLAGEN1 .
.................................................................................................................................... 68
Introduction ....................................................................................................... 68
Design of ProCA32.collagen1 with collagen type I targeting capability ...... 69

x

Results ................................................................................................................ 70
3.3.1 Expression and purification of ProCA32.collagen1 .................................... 70
3.3.2 Lysine PEGylation of ProCA32.collagen1 ................................................... 75
Discussion ........................................................................................................... 77
3.4.1 Optimization of ProCA32.collagen1 purification ........................................ 77
Summary ............................................................................................................ 78
4

STUDIES OF BIOPHYSICAL PROPERTIES OF PROCA32.COLLAGEN1 . 79
Introduction ....................................................................................................... 79
4.1.1 Gadolinium deposition .................................................................................. 82
4.1.2 Gadolinium deposition in animals in approved contrast agents ................. 85
Results ................................................................................................................ 89
4.2.1 Metal binding affinity of ProCA32.collagen1 .............................................. 89
4.2.2 Relaxivity measurements of ProCA32.collagen1 ......................................... 98
4.2.3 Serum stability of ProCA32.collagen1 ....................................................... 100
4.2.4 Transmetallation studies of ProCA32.collagen1 ....................................... 101
4.2.5 Water number determination of ProCA32.collagen1 ................................ 103
4.2.6 Collagen type I binding affinity of ProCA32.collagen1 ............................ 105
4.2.7 Pharmacokinetic studies of ProCA32.collagen1 ....................................... 108
4.2.8 Safety studies of ProCA32.collagen1 ......................................................... 111
Discussion ......................................................................................................... 119

xi

4.3.1 Design of ProCA32.collagen1 with collagen targeting capability and dual
high relaxivity ..................................................................................................................... 119
4.3.2 High Gd3+ binding affinity and metal selectivity, and low toxicity of
ProCA32.collagen1 ............................................................................................................. 120
4.3.3 Additional improved safety properties of ProCA32.collagen1 .................. 121
Summary .......................................................................................................... 122
5

APPLICATION OF PROCA32.COLLAGEN1 IN IMAGING OF LIVER

FIBROSIS .................................................................................................................................. 122
Introduction ..................................................................................................... 122
5.1.1 Organ fibrosis.............................................................................................. 122
5.1.2 Non-invasive imaging of fibrosis ................................................................ 128
5.1.3 Liver fibrosis ................................................................................................ 129
Results .............................................................................................................. 137
5.2.1 Robust detection of early and late stages liver fibrosis with dual contrast
property

...................................................................................................................... 137

5.2.2 Histological validation of early and late stage fibrosis and correlation with
MRI

...................................................................................................................... 141
5.2.3 Biodistribution and pharmacokinetics of ProCA32.collagen1 ................. 145
5.2.4 Detection of vascular and architectural alterations with dynamic molecular

imaging

...................................................................................................................... 147

5.2.5 Quantitative mapping of liver fibrosis heterogeneity................................. 151

xii

5.2.6 Immunofluorescence staining of fibrotic liver .......................................... 157
5.2.7 Treatment monitoring of liver fibrosis with ProCA32.collagen1 .............. 158
5.2.8 Dynamic multi-color mapping of liver cirrhosis heterogeneity with
ProCA32.collagen1 ............................................................................................................. 160
Discussion ......................................................................................................... 167
5.3.1 Implication for early detection: Our developed contrast agent enabled novel
imaging methodology for early detection of liver fibrosis. ................................................ 167
5.3.2 Implication for detection of heterogeneity, intrahepatic angiogenesis and
portal hypertension ............................................................................................................. 169
5.3.3 Safety: Advantages of ProCA32.collagen1 Compared with Imaging Agents
of Liver Fibrosis .................................................................................................................. 172
Potential Application and Significance ......................................................... 174
Summary .......................................................................................................... 175
6

APPLICATION OF PROCA32.COLLAGEN1 IN IMAGING OF UVEAL

MELANOMA LIVER METASTASIS ................................................................................... 176
Introduction ..................................................................................................... 176
Results .............................................................................................................. 182
6.2.1 Molecular imaging of implanted mouse Uveal Melanoma in liver .......... 182
6.2.2 Immunofluorescence and collagen staining .............................................. 186
6.2.3 Molecular imaging of M15 Uveal Melanoma metastasized to the liver ... 188
6.2.4 Correlation of MRI with histology of Uveal Melanoma ............................ 190

xiii

6.2.5 ICP-OES organ distribution ....................................................................... 194
Discussion ......................................................................................................... 195
6.3.1 Advantages of ProCA32.collagen1 Compared with Imaging Agents of Liver
Metastasis

...................................................................................................................... 196

6.3.2 Noninvasive Biomarkers of Uveal Melanoma Liver Metastasis ............... 197
6.3.3 Nodular vs infiltrative growth pattern distinction using ProCA32.collagen1
...................................................................................................................... 199
6.3.4 Transmetallation of ProCA32.Collagen and Clinical MRI Contrast Agents .
...................................................................................................................... 200
Potential Application and Significance ......................................................... 202
Summary and Conclusion .............................................................................. 202
7

APPLICATION

OF

PROCA32.COLLAGEN1

IN

DETCTION

OF

HEPATOCELLULAR CARCINOMA (HCC) ...................................................................... 204
Introduction ..................................................................................................... 204
7.1.1 HCC in Cirrhosis ........................................................................................ 205
7.1.2 Benign versus malignant hepatic nodules in HCC ................................... 206
7.1.3 The challenges in diagnosis of hepatocellular carcinoma ........................ 208
7.1.4 Limitations of current clinical contrast agents in HCC diagnosis............ 210
Results .............................................................................................................. 212
7.2.1 DEN-induced HCC ..................................................................................... 212
7.2.2 MRI results of DEN-induced HCC mouse................................................. 214

xiv

7.2.3 Histology results of DEN-induced HCC mouse liver ................................ 223
Summary .......................................................................................................... 225
8

APPLICATION

OF

PROCA32.COLLAGEN1

IN

DETECTION

OF

THORACIC AORTIC ANEURYSM (TAA) ......................................................................... 225
Introduction ..................................................................................................... 225
8.1.1 Animal model of TAA and AAA ................................................................. 226
Results .............................................................................................................. 228
8.2.1 MRI procedure for cardiac gating ............................................................. 228
8.2.2 MRI pulse sequence .................................................................................... 231
8.2.3 MRI images of mouse with TAA ................................................................ 231
8.2.4 Histology results of TAA and normal mice ................................................ 236
Summary .......................................................................................................... 239
9

APPLICATION

OF

PROCA32.COLLAGEN1

IN

DETECTION

OF

NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) ................................................... 239
Introduction ..................................................................................................... 239
Results .............................................................................................................. 245
9.2.1 NASH animal model ................................................................................... 245
9.2.2 Analysis of LivKO group............................................................................. 245
9.2.3 MRI results of LivKO mice ......................................................................... 246
9.2.4 Analysis of WT group ................................................................................. 249

xv

9.2.5 Comparison of heavy T2-weighted MRI results of WT and KO groups ... 249
9.2.6 Comparison of R1 map MRI results of WT and KO groups ..................... 251
9.2.7 Histology results of NASH mice ................................................................. 252
Summary .......................................................................................................... 253
10 MAJOR FINDINGS AND FUTURE DIRECTION ............................................ 253
REFERENCES .............................................................................................................. 259
APPENDICES ............................................................................................................... 313
Appendix A. Identification of Calmodulin Binding Domain in Cx43 Gap Junction
Protein

........................................................................................................................... 313
Appendix A.1. Introduction .................................................................................... 313
Appendix A.2. Expression and purification of His-tagged Cx43 (99-154)........... 318
Appendix A.3. FPLC Purification of Cx43 (99-154) using His-tag Column ....... 320
Appendix A.4. Testing TEV Protease Cleavage Conditions with Purified Cx43(99-

154) with fusion protein...................................................................................................... 323
Appendix A.5. New method for Purification of Cx43 (99-154) ............................ 324
Appendix A.6. Monitoring the Interaction between Cx43 (99-154) and Calmodulin
...................................................................................................................... 326
Appendix A.7. Purification of Cx43 (88-163) Peptide........................................... 327
Appendix A.8. Summary and conclusion............................................................... 329

xvi

LIST OF TABLES
Table 1.1 Clinical MRI Contrast Agents Based on Gd3+ [1, 24-26]. ............................................. 6
Table 1.2 The relaxivity of some of the research-based Gd3+ MRI contrast agents [67, 84, 87, 89106]. .................................................................................................................................. 33
Table 1.3 Thermodynamic stability of some of clinical contrast agents compared to
ProCA32.collagen1 and ProCA32-P40 [151]. .................................................................. 42
Table 1.4 General data for all currently marketed Gd3+-based MRI contrast agents [1]. ............. 43
Table 4.1 Summary of metal binding affinities of ProCA32.collagen1 and clinical contrast
agents ................................................................................................................................ 98
Table 4.2 Summary of r1 and r2 relaxivity of ProCA32.collagen1 and clinical contrast agents 100
Table 4.3 Summary of PK parameters for ProCA32.collagen1 and ProCA32-P40. ................. 111

xvii

LIST OF FIGURES
Figure 1.1. Different types of motions and linking strategies affecting relaxivity. ..................... 12
Figure 1.2 Describing molecular parameters that are affecting inner- and 2nd-sphere relaxivity.
........................................................................................................................................... 17
Figure 1.3 A diagram demonstrating the parameters affecting relaxivity of a Gd3+-based MRI
contrast agent complex [6]. ............................................................................................... 26
Figure 1.4 Model structure of rat -parvalbumin (a) and ProCA32 (b) with several mutations . 31
Figure 1.5 Top 5 final modeled structures predicted by I-TASSER for ProCA32.collagen1 ..... 35
Figure 1.6 The model structure and development of ProCA32.collagen1................................... 36
Figure 1.7 Structure of some commonly used clinical contrast agents [149]. ............................. 41
Figure 3.1 Modeled structure of ProCA32.collagen1 and its expression and purification. ......... 72
Figure 3.2 Diagram of ProCA32.collagen1 purification using FPLC. ........................................ 73
Figure 3.3 UV-Vis spectrum of ProCA32.collagen1 after FPLC purification ............................ 74
Figure 3.4 SDS-page results for Lysine PEGylation of ProCA32.collagen1. ............................. 76
Figure 3.5 Structure of ProCA32.collagen1 after PEGylation..................................................... 77
Figure 4.1 Resonance energy transfer process between Tb3+ and Trp in ProCA32.collagen1 .... 90
Figure 4.2 Determination of Tb3+ binding affinity of ProCA32.collagen1. ................................ 90
Figure 4.3 Determination of Gd3+ binding affinity of ProCA32.collagen1. ................................ 92
Figure 4.4 Determination of Ca2+ binding affinity of ProCA32.collagen1. ................................ 94
Figure 4.5 Schematic demonstration of free Ca2+ calculation in Ca-EGTA buffer system ......... 95
Figure 4.6 Determination of Ca2+ binding affinity of ProCA32.collagen1 using Adair equation.
........................................................................................................................................... 96
Figure 4.7 Determination of Zn2+ binding affinity of ProCA32.collagen1. ................................ 97

xviii

Figure 4.8 Relaxation rate of ProCA32.collagen1 at different magnetic fields. .......................... 99
Figure 4.9 ProCA32.collagen1 stability in human serum. ......................................................... 101
Figure 4.10 Stability of ProCA32.collagen1 and clinical contrast agents. ................................ 102
Figure 4.11 The luminescence decay of Tb3+ in H2O (blue) or D2O (white) in solution of
ProCA32.collagen1. (A) Tb3+ and ProCA32.collagen1 were mixed with 1 to 2 ratios. (B)
Water number of Magnevist, Eovist, ProCA32-P40, ProCA32.collagen1. .................... 104
Figure 4.12 Basic principles of ELISA. ..................................................................................... 106
Figure 4.13 The dissociation constant of Lysine and Cysteine PEGylated ProCA32.collagen1 to
collagen type I using indirect ELISA. ProCA32-P40 without any targeting moiety did not
show any specific binding. .............................................................................................. 107
Figure 4.14 Pharmacokinetics of ProCA32.collagen1. .............................................................. 110
Figure 4.15 Biodistribution analysis of ProCA32.collagen1. .................................................... 112
Figure 4.16 Toxicity studies of ProCA32.collagen1.................................................................. 116
Figure 4.17 Tissue toxicity studies of ProCA32.collagen1. ...................................................... 118
Figure 5.1 Pathological characteristics of fibrosis in different tissues. ..................................... 125
Figure 5.2 Development of ProCA32.collagen1 for molecular imaging of liver fibrosis. ........ 137
Figure 5.3 Early and late stage liver fibrosis detection using ProCA32.collagen1. .................. 139
Figure 5.4 TAA/alcohol-induced liver fibrosis animal model procedure .................................. 140
Figure 5.5 R1 changes of liver over different MRI time points after injection of
ProCA32.collagen1, ProCA32-P40 and Eovist. It shows the dynamic enhancement by
ProCA32.collagen1 based on stage of fibrosis and its targeting capability. ................... 140
Figure 5.6 T2 map MRI images of normal and fibrotic livers. .................................................. 141
Figure 5.7 Quantitative analysis of T1 and T2 map. .................................................................. 142

xix

Figure 5.8 Histology validation of different stages of TAA/alcohol-induced liver fibrosis. ..... 143
Figure 5.9 Correlation of MRI with histology analysis in detection of different stages of liver
fibrosis............................................................................................................................. 144
Figure 5.10 Biodistribution analysis of contrast agents using ICP-OES. .................................. 146
Figure 5.11 Detection of vasculature structural changes during late stage fibrosis with
ProCA32.collagen1. ........................................................................................................ 148
Figure 5.12 Representative SEM images and ultrasound of sections from mice with normal and
severe fibrotic liver (Figure provided by Ravi Chakra). ................................................. 149
Figure 5.13 Representative images of IHC stains of CD31 and quantitation of CD31. ............ 150
Figure 5.14 R1 map histograms analysis of mouse livers. ........................................................ 151
Figure 5.15 Mapping liver cirrhosis heterogeneity with ProCA32.collagen1. .......................... 152
Figure 5.16 Sirius red staining and collagen proportionate area analysis. ................................. 153
Figure 5.17 Quantitative analysis of contrast to noise ratio of liver. ......................................... 153
Figure 5.18 Histogram analysis of DEN-induced cirrhotic liver. .............................................. 154
Figure 5.19 R1 map analysis of DEN-induced liver cirrhosis. .................................................. 155
Figure 5.20 Combination of STIR with long TE methodology with a T1-T2 MRI contrast agent.
......................................................................................................................................... 156
Figure 5.21 Immunofluorescence staining of ProCA32.collagen1 and collagen type I in fibrotic
liver tissues. Fibrotic liver injected with ProCA32.collagen1 clearly demonstrates that
ProCA32.collagen1 (red) can target collagen type I (green) in liver, however, ProCA32P40 does not show any targeting capability as it cannot be detected by
Immunofluorescence staining in fibrotic liver. ............................................................... 158
Figure 5.22 Liver cirrhosis treatment monitoring using ProCA32.collagen1............................ 159

xx

Figure 5.23 T2-weighted Multi-color map of 3 and 24 hrs enhancement in DEN-induced
cirrhotic mouse liver. ...................................................................................................... 161
Figure 5.24 T2-weighted Multi-color map of maintained vs washed out within 24 hrs of contrast
agent injection in DEN-induced cirrhotic mouse liver. .................................................. 162
Figure 5.25 Quantitative analysis of T2-weighted cirrhotic liver enhancement post injection of
ProCA32.collagen1. ........................................................................................................ 163
Figure 5.26 T1-weighted Multi-color map and quantitative analysis of maintained vs washed out
regions within 24 hrs of contrast agent injection in DEN-induced cirrhotic mouse liver.
......................................................................................................................................... 164
Figure 5.27 T1 inversion recovery Multi-color map and quantitative analysis of 3 and 24 hrs
post injection of ProCA32.collagen1. ............................................................................. 165
Figure 5.28 T1 inversion recovery Multi-color map of maintained vs washed out within 24 hrs
of contrast agent injection in DEN-induced cirrhotic mouse liver. ................................ 166
Figure 6.1 . Schematic cartoon of metastatic UM to the liver [332].......................................... 181
Figure 6.2 Precision imaging with progressive molecular MRI contrast agent,
ProCA32.collagen1. ........................................................................................................ 182
Figure 6.3 Demonstration of STIR with long TE sequence for the double suppression of liver
signal for tumor imaging. ................................................................................................ 184
Figure 6.4 MRI images of B16LS9 mouse implanted UM tumor before and after injection of
ProCA32.collagen1 in liver. ........................................................................................... 185
Figure 6.5 T2 map MRI images of B16LS9 mouse implanted UM tumor. ............................... 185
Figure 6.6 Immunofluorescence and collagen staining ............................................................. 187
Figure 6.7 Imaging of UM Tumor with different inversion times. ............................................ 189

xxi

Figure 6.8 T1 inversion recovery (IT=0.01 s) MRI images of mouse livers with M15 UM
metastasis model. ............................................................................................................ 190
Figure 6.9 MRI and histology correlation of UM tumor detected by ProCA32.collagen1. ...... 192
Figure 6.10 Histology confirmation of UM tumor and collagen expression. ............................ 193
Figure 6.11 Gd3+ concentration measurements showing contrast agent distribution in different
organs 48 hours post injection of ProCA32.collagen1. .................................................. 194
Figure 7.1 Different steps in generation of carcinogenesis for HCC in cirrhosis[387]. ............ 207
Figure 7.2 HCC mouse livers after treatment compared to normal liver. .................................. 213
Figure 7.3 T2-weighted images of HCC mouse post injection of ProCA32.collagen1 ............. 214
Figure 7.4 T2-weighted images of HCC mouse post injection of ProCA32.collagen1 in a
different slice of liver ...................................................................................................... 215
Figure 7.5 T2-weighted MRI images in slice 12 of HCC mouse liver ...................................... 215
Figure 7.6 T2-weighted MRI images in slice 13 of HCC mouse liver. ..................................... 216
Figure 7.7 T2-weighted MRI images of another HCC mouse liver before and 3 and 24 hrs post
injection of ProCA32.collagen1...................................................................................... 217
Figure 7.8 T2 map analysis of HCC tumors and cirrhotic areas in DEN-induced HCC mouse
liver. R2 map MRI images showing enhancement in tumors and quantitative analysis of
T2 values showing decrease in both tumors and cirrhotic regions in the liver. .............. 218
Figure 7.9 T2-weighted MRI images of slice 2 of DEN-induced HCC mouse liver before and 3
and 24 hrs post injection of ProCA32.collagen1. ........................................................... 219
Figure 7.10 R2 map MRI images and quantitative T2 analysis of slice 2 of DEN-induced HCC
mouse liver before and 3 and 24 hrs post injection of ProCA32.collagen1. .................. 220

xxii

Figure 7.11 T2-weighted MRI images of slice 4 of DEN-induced HCC mouse liver before and 3
and 24 hrs post injection of ProCA32.collagen1. ........................................................... 220
Figure 7.12 T1-weighted MRI images of another HCC mouse liver before and 3 and 24 hrs post
injection of ProCA32.collagen1...................................................................................... 221
Figure 7.13 T1-weighted MRI images of slice 4 of HCC mouse liver before and 3 and 24 hrs
post injection of ProCA32.collagen1. ............................................................................. 222
Figure 7.14 T1-weighted MRI images of slice 5 of HCC mouse liver before and 3 and 24 hrs
post injection of ProCA32.collagen1. ............................................................................. 222
Figure 7.15 Sirius red (left) and H&E (right) staining of mouse HCC liver. ............................ 223
Figure 7.16 Sirius red (left) and H&E (right) staining of mouse HCC liver. ............................ 224
Figure 7.17 Sirius red (left) and H&E (right) staining of mouse HCC liver. ............................ 224
Figure 8.1 ECG gating procedure in mouse with TAA ............................................................. 230
Figure 8.2 Cardiac and respiratory gating diagrams and module in mouse with TAA ............. 230
Figure 8.3 Graphic image of different sections of aorta ............................................................ 232
Figure 8.4 Black blood T1-weighted images of TAA mouse before and post injection of
ProCA32.collagen1. ........................................................................................................ 232
Figure 8.5 MRI images of black blood proton density-weighted of TAA-1 mouse before and
post injection of ProCA32.collagen1. ............................................................................. 233
Figure 8.6 MRI images of black blood T1-weighted of TAA-1 mouse before and post injection
of ProCA32.collagen1..................................................................................................... 233
Figure 8.7 MRI images of black blood proton density-weighted of normal mouse before and
post injection of ProCA32.collagen1. ............................................................................. 234

xxiii

Figure 8.8 MRI images of black blood T1-weighted of normal mouse before and post injection
of ProCA32.collagen1..................................................................................................... 234
Figure 8.9 MRI images of black blood proton density-weighted of TAA-2 mouse before and
post injection of ProCA32.collagen1. ............................................................................. 235
Figure 8.10 MRI images of black blood T1-weighted of TAA-2 mouse before and post injection
of ProCA32.collagen1..................................................................................................... 235
Figure 8.11 Aortic images (ex vivo) from mice infused with AngII (TAA) and normal mouse
(control). The area pointed with red arrow is where the MRI images where collected. . 236
Figure 8.12 Masson's trichrome stain of aorta in normal mouse. .............................................. 237
Figure 8.13 Masson's trichrome stain of aorta in TAA-1 mouse. .............................................. 238
Figure 8.14 Masson's trichrome stain of aorta in TAA-2 mouse. .............................................. 238
Figure 9.1 Schematic representation of the putative mechanisms underlying the contribution of
NAFLD to the increased risk of cardiovascular and kidney chronic diseases. ............... 243
Figure 9.2 Epidemiology of NAFLD. ........................................................................................ 244
Figure 9.3 Liver images of four LivKO mice with severe NASH and fibrosis. ........................ 245
Figure 9.4 Heavy T2-weighted MRI images of mouse 1 with significant fibrosis due to fatty
liver before and 3 and 24 hrs post injection of ProCA32.collagen1. .............................. 246
Figure 9.5 Heavy T2-weighted MRI images of mouse 2 with significant fibrosis due to fatty
liver before and 3 and 24 hrs post injection of ProCA32.collagen1. .............................. 247
Figure 9.6 Heavy T2-weighted MRI images of mouse 3 with significant fibrosis due to fatty
liver before and 3 and 24 hrs post injection of ProCA32.collagen1. .............................. 247
Figure 9.7 Heavy T2-weighted MRI images of mouse 4 with significant fibrosis due to fatty
liver before and 3, 19 and 24 hrs post injection of ProCA32.collagen1. ........................ 248

xxiv

Figure 9.8 Contrast to noise ratio (CNR) analysis of fibrotic livers pre- and 3 and 24 hrs post
injection of ProCA32.collagen1...................................................................................... 248
Figure 9.9 Liver images of four WT mice with mild NASH and fibrosis. ................................ 249
Figure 9.10 Heavy T2-weighted MRI images of WT and KO livers before and 3 and 24 hrs after
injection of ProCA32.collagen1 along with CNR their corresponding CNR. ................ 250
Figure 9.11 R1 map analysis of KO and WT Mice with fatty liver before and after injection of
ProCA32.collagen1. ........................................................................................................ 251
Figure 9.12 Sirius red staining collagen (red) of fatty mouse liver in KO and WT groups....... 252
Figure 9.13 Hematoxylin and eosin (H&E) staining of fatty mouse liver in KO and WT groups.
......................................................................................................................................... 253
Figure 10.1 Collagen type I binding affinity comparison between ProCA32.collagen1 and
EP3533. ........................................................................................................................... 256
Figure 10.2 Animal Models of Liver Fibrosis. .......................................................................... 257
Figure 10.3 Summary of application of ProCA32.collagen1in diagnosis of chronic diseases. . 258

xxv

LIST OF ABBREVIATION

3D: three-dimensional
3DGE: 3D gradient echo
AAA: abdominal aortic aneurysm
AIF: arterial input function
ALD: alcoholic liver disease
ALP: alkaline phosphatase
ALT: alanine transaminase
APRI: aspartate-to-platelet ratio index
AST: aspartate transaminase
BSA: bovine serum albumin
CCMV: cowpea chlorotic mottle virus
CD2: cluster of differentiation
CDC: center for disease control and prevention
CLD: chronic liver disease
CNR: contrast-to-noise ratio
CNS: central nervous system
CT: computed tomography
CV: column volume
Cys: cystein
DD: dipole-dipole
DEC-MRI: dynamic contrast enhanced-MRI

xxvi

DTPA: diethylene-triamine-pentaacetic acid
ECM; extracellular matrix
EDTA: ethylenediaminetetraacetic acid
EGFR: epidermal growth factor receptor
EGTA: ethylene glycol tetraacetic acid
EnDOR: Electron-nuclear double resonance spectroscopy
FDA: U S Food and Drug Administration
FOV: field of view
FPLC: fast protein liquid chromatography
FRET: Förster resonance energy transfer
FSE: fast spin echo
FSEMS: fast spin echo multi-slices
Gd3+: Gadolinium
Gd-DTPA: gadolinium-diethylene-triamine-pentaacetic acid
GRF: glomerular filtration rate
GRP: gastrin-releasing peptide
GRPR: gastric-releasing peptide receptor
HCC: hepatocellular carcinoma
HER2 or HER2/Neu: human epidermal growth factor receptor 2
HSC: hepatic stellate cell
ICP-OES: inductively coupled plasma atomic emission spectroscopy
IF: immunofluorescence
IHC: immunohistochemistry

xxvii

IPTG: isopropyl β-D-1-thiogalactopyranoside
Kd: dissociation constant
LRET: luminescence resonance energy transfer
MEMS: multi-echo-multi-slices
Mn-DPDP: manganese dipyridoxal diphosphate
MRE: magnetic resonance elastography
MRI: magnetic resonance imaging
MVD: mean vascular density
NAFL: nonalcoholic fatty liver
NAFLD: nonalcoholic fatty liver disease
NASH: nonalcoholic steatohepatitis
NHS: N-hydroxysuccinimide
NIR: near infared
NMRD: Nuclear Magnetic Relaxation Dispersion
NSF: nephrogenic systemic fibrosis
NTA: nitrilotriacetic acid
OD: optical density
OI: optical imaging
PAI: photo acoustic imaging
PCR: polymerase chain reaction
PEG: polyethylene glycol
PET: positron emission tomography
PMSF: phenylmethylsulfonyl fluoride

xxviii

ProCA: protein-based MRI contrast agent
ProCA32.collagen1: ProCA32 linked with collagen I peptide
PV: parvalbumin
R1: longitudinal relaxation rate
r1: longitudinal relaxivity
R2: transverse relaxation rate
r2: transverse relaxivity
RGD: Arg-Gly-Asp
SBM: Solomon-Bloembergen-Morgan
SC: scalar or contact
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis
SE: spin echo
SLE: systemic lupus erythematous
SPECT: single-photon emission computed tomography
SWE: shear wave elastography
TAA: thoracic aortic aneurysm
T1: longitudinal relaxation time
T2: transverse relaxation time
T1W: T1-weighted
T2W: T2-weighted
TBST: Tris-buffered saline with Tween 20
TE: echo time
TR: repetition time

xxix

US: ultrasound
UM: uveal melanoma
Vc: initial volume distribution
Vdss: steady state phase
VEGF: vascular endothelial growth factor
WT: wild type
ZFS: zero field splitting
ΔKobs: Difference in decay rates of Tb3+ in H2O and D2O
τ: life time
Г: the radiative decay

1

1

INTRODUCTION

Magnetic resonance imaging (MRI) and contrast agents
Magnetic resonance imaging (MRI) is an imaging modality and diagnostic technique in
current clinical medicine. MRI as a diagnostic imaging modality has so many advantages such as
its noninvasiveness, using no radiation, excellent spatial resolution, and soft tissue contrast. MRI
is one of the premiere techniques resulting in important anatomical information. In addition,
combination of MRI with other techniques leads to contrast in MRI which can provide noticeable
images from the same anatomical region. As can example, MRI pulse sequences can be applied to
create contrast between different tissues based on their proton density difference, T1 or T2
relaxation times, water diffusion rates, and chemical shifts based on difference between water and
lipids [2-6].
One of the major challenges associated with MRI is the lack of adequate sensitivity. In
clinical imaging field, the primary importance is observing hydrogen atoms from water that are
present in tissue at the concertation of approximately 90 M. In order to create more contrast to aid
the MRI modality, usually a compound is necessary to affect properties of the 90 M water protons
and this effect should be in a level that a noticeable change is reached. These compounds are called
MRI contrast agents [6]. They can be categorized into three general subgroups of paramagnetic,
superparamagnetic, or ferromagnetic compounds that will shorten the relaxation times of water
protons. All contrast agents can shorten both T1 and T2 relaxation times, however based on
whether the agent increases the transverse relaxation rate (1/T2) by roughly the same amount that
it increases the longitudinal relaxation rate (1/T1) or whether 1/T2 is altered to a much greater
extent, they can be classified into two groups of T1 agents and T2 agents, respectively [6, 7].
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In T1 agents, T1 lowering effect is dominant which increases the signal intensity; these are
positive contrast agents. The T2 agents mainly increase the 1/T2 property and results in reduction
in signal intensity, therefore, they are called negative contrast agents [6, 8]. One of the examples
of paramagnetic agents with T1 effect are gadolinium-based contrast agents. Ferromagnetic iron
oxide particles can be named as contrast agents with high T2 effect. The majority of contrast agents
being used in clinical field are based on gadolinium complexes, however there are some instances
of manganese- and iron-based contrast agents approved for clinical use. It has been reported that
there are more than 10 million MRI studies being performed with gadolinium every year [6].
The interaction of contrast agent with the water hydrogen will affect relaxation properties of
nuclei that creates the contrast which is different from contrast in other imaging modalities such
as X-ray and nuclear imaging agents where the effect observed is more related to the concentration
of the imaging agent. The concentration of water is much higher than the contrast agent, therefore,
the agent must act as a catalyst to relax the water protons for the effect to be observed. The
relaxivity is one of most important properties of a contrast agent which can be defined as the ability
of an agent to change relaxation rate, and it is represented as r1 or r2, where r1 refers to longitudinal
relaxation (1/T1) and r2 refers to transverse rate (1/T2). In other words, relaxivity is the change in
relaxation rate after a contrast agent (∆(1/T)1) is applied which is normalized to the concentration
of contrast agent or metal ion (M), Eqn (1-1).
(1-1)

Different contrast agents have different relaxivity values and therefore have different sensitivities.
Commercial and clinical contrast agents usually lack enough sensitivity and are effective at high
concentrations ( 0.1 mM), therefore there has been an unmet medical need to increase their
sensitivity [6].
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Clinical Gd3+-based MRI contrast agents: Advantages and limitations
Gadolinium-based contrast agent (GBCA) are used in approximately 25–30% of all MRI
scans [9, 10]. The contrast agent creates a brighter or darker image specifically in the area of
diseased tissue. The first approved contrast agent was Gd-DTPA (gadopentetate dimeglumine,
Magnevist®) introduced in 1988. The first generation of contrast agents produced were for
different purposes such as extracellular fluid (ECF) agents, liver imaging and agent that were given
orally for gastrointestinal imaging. Currently, several agents are in clinical trials and one has been
recently approved for MR angiography [11]. In preclinical stage, there has been continues efforts
to create gadolinium-based contrast agents in molecular imaging.
All GBCAs are used by intravenous (i.v.) administration. The route in which the contrast
agent is being administered plays an indispensable role on biodistribution and safety. The majority
of GBCAs are approved at a dose of ~ 0.1 mmol Gd/kg, however, for MR angiography two or
three times higher dosage is required. Some newly developed agents such as gadofosveset and
gadoxetic acid can be used at lower doses (0.03 mmol/kg and 0.025 mmol/kg, respectively). The
injection dosage of contrast agent is also important since it affects the Gd3+ levels the subject
receives. Furthermore, it can impact the exposure and how fast the compound is eliminated [11].
Since the first approval of clinical MRI contrast agent, gadopentetate dimeglumine (Magnevist),
in 1987, they have been successful in MR imaging of different types of tissues, diagnostics,
characterization of tumors and other diseased tissues. In different cases of diseases, the change in
permeability of blood vessels is crucial for the function of these MRI contrast agents. For instance,
stroke, liver fibrosis, neuron degenerative diseases and so on are all have change in permeability
of blood vessels. These clinical contrast agents can function as probes for organs such as liver,
kidney, and gall bladder [8].
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Currently, all clinically approved MRI contrast agents based on Gd3+, the primary structure
has a Gd3+ encapsulated by organic chelators, such as diethylenetriaminepentaacetic acid (DTPA)
and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (Table 1.1). Usually, the
coordination site of Gd3+ has up to 8 nitrogen and oxygen atoms contributed by the chelator to
function as Gd3+ binding ligands. Furthermore, there is one water molecule exist in Gd3+
coordination site in clinical MRI contrast agent which interacts with Gd3+ through the Gd-O
interactions. Charge and structure of chelators are important factors for Gd3+ coordination,
therefore as a result, clinically approved Gd3+ MRI contrast agents are categorized into four
groups: ionic linear contrast agents (examples: Magnevist, Multihance, Abalavar and Eovist),
non-ionic linear contrast agents (examples: Ominiscan and Optimark), ionic cyclic contrast agents
(examples: ProHance and Gadovist) and non-ionic cyclic contrast agents (example: Dotarem).
Multihance and Eovist are organ (liver) specific agents, however, most of the clinical MRI contrast
agents are extracellular contrast agents which are eliminated through kidney. Extracellular contrast
agents can be successfully used for imaging of the whole body, structural changes in blood vessels
and central nervous system (CNS). Since Eovist and Multihance are liver agents, hepatocytes in
liver are responsible for their uptake (~50 %) and 5 % is eliminated by biliary excretion. These
two contrast agents are widely used for liver imaging, such as primary liver cancer (hepatocellular
carcinoma), liver metastases from other organs, and liver fibrosis [8, 12].
With the advent of MRI contrast agents, contrast enhanced MRI attracted great attention
and became one of the most popular imaging modalities in the clinical field. For instance, the
diagnosis of different liver diseases such as liver metastases and fibrosis heavily depends on
imaging techniques, such as MRI, CT, ultrasound and PET, however, MRI is the best diagnostic
tool among them. With the use of contrast agents, MRI is able to detect small lesions in liver
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metastases with detection limit of ~ 2 cm or larger. Although other imaging modalities such as
ultrasound may detect lesions as small as 2 mm, it faces important challenges such as surgery and
limitations regarding the location of tumors since they need to be on the surface of the liver in
order to be detected [13]. In addition, for detection of diseases such as liver fibrosis, MRI has the
capacity to cover the whole liver in order to assess its heterogeneity [14]. Clinical MRI contrast
agents can also play critical roles in MRI assisted surgery and biopsy and MRI guided therapy for
different types of diseases, such as liver cancer [15].
Despite evolving the whole MRI field with their advantages, clinically approved contrast
agents have their own limitations. Since they are small-molecule chelators with small molecular
mass, clinical MRI contrast agents usually have a short half-life time (half-life of approximately
0.5-3 minutes in the blood of mice and elimination half-life of about 1.5 hours in humans [16, 17].
Optimization of MRI contrast agent’s properties are extremely important since it would directly
affect the time window of MRI data collection and eliminate repeated dose injections. In addition,
the application of these contrast agents can be widened to potential biological targets for molecular
imaging which would significantly increase and improve their detection limits. For instance, this
number is ~30 μM in mouse skeletal muscle for the contrast agent, [Gd(HPDO3A)(H2O)]. Overall,
clinical MRI contrast agents have the following limitations: low relaxivity, low metal selectivity,
high toxicity which causes Nephrogenic Systemic Fibrosis (NSF) due to high injection dosage,
and they are non-specific and lack targeting capability with short half-life. All of these limitations
have driven the need to develop contrast agents with significantly improved relaxivity, optimized
retention time, and high targeting capabilities [16, 18, 19].
Other important characteristic of contrast agents are their toxicity and pharmacokinetics
which have been well-studied in 1980s. Studies have shown that these contrast agents were proven
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to be safer than iodinated contrast agents used in CT and X-ray. Despite their good safety profiles,
clinical MRI contrast agents usually need high injection dosage of 0.025-0.3 mmol/kg and a
concentration in mM range to be considered effective for contrast in tissues. In principal, the
injection dosage and concentration can be lowered if the longitudinal relaxivity (r1) is increased or
optimized. Since high concentrations are being utilized, these agents are facing concerns regarding
the renal toxicity due to release of free Gd3+ from the most commonly used contrast agent,
gadolinium-diethylene-triaminepentaacetic acid (Gd-DTPA). There are increased reports of
nephrogenic systemic fibrosis (NSF) associated with Gd-DTPA, as well as a complication found
in patients with end-stage renal failure (GRF < 30 ml min-1) [20-23].
Table 1.1 Clinical MRI Contrast Agents Based on Gd3+ [1, 24-26].
Generic Name

Chemical Formula

Trade Name

Gadopentetate
dimeglumine
Gadodiamide

[Gd(DTPA)(H2O)]2-

Gadoversetamide
Gadoterate
meglumine
Gadoteridol
Gdobutrol

r2,Plasma
Relaxivity
1.5T,
37○C
(mM-1s-1)
4.6

Formulation
Concentration

Standard
dose
(mmol/kg)

Magnevist

r1,Plasma
Relaxivity
1.5T,
37○C
(mM-1s-1)
4.1

0.5 M

0.1

[Gd(DTPABMA)(H2O)]
[Gd(DTPABMEA)(H2O)]
[Gd(DOTA)(H2O)]-

Omniscan

4.3

5.2

0.5 M

0.1

Optimark

4.7

5.2

0.5 M

0.1

Dotarem

3.6

4.3

0.5 M

0.1

[Gd(HPDO3A)(H2O)]
[Gd(HP-

ProHance

4.1

5.0

0.5 M

0.1

Gadovist

5.2

6.1

1.0 M

0.1

[Gd(EOBDTPA)(H2O)]2[Gd(BOPTA)(H2O)]2-

Eovist
(Primovist)
Multihance

6.9

8.7

0.25 M

0.025

6.3

8.7

0.5 M

0.1

Diphenylcyclohexyl
phosphodiester-GdDTPA

Ablavar

27.7

72.6

0.25 M

0.03

butrol)(H2O)]
Gadoxetic acid
disodium
Gadobenate
dimeglumine
Gadofosveset
trisodium
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Important criteria of an MRI Contrast Agent
There are several criteria that need to be considered in order to have an ideal contrast agent.
One of the most important requirements for a contrast agent is to have minimum toxicity. In
addition, thermodynamic and kinetic properties should be taken into consideration to have good
stability and reasonable elimination half-life. Another important characteristic is the metal binding
affinity and selectivity to minimize the adverse effects of the release of free Gd3+ into the body.
Since other physiological metals such as Ca2+ and Zn2+ are present in high concentrations in the
body, they have the ability to compete with Gd3+ in the contrast agent and cause its release,
therefore, a high metal selectivity for paramagnetic metal ions (e.g. Gd3+ and Mn3+) against
physiological metal ions is needed [27, 28]. High relaxivity, especially longitudinal relaxation (r1),
is another important criterion required to achieve images with high dose efficiency and high
contrast-to-noise ratio (CNR). Proper vascular retention time, permeability and perfusion is also
crucial to allow the contrast agent to penetrate tissues in order to have enhancement, and monitor
capillary integrity changes.
Different methods have been used to improve the properties of MRI contrast agents based
on small chelators. For instance, small chelators are being non-covalently bound to plasma
proteins, such as albumin (MS-325), in order to greatly increase their relaxivity and blood retention
time, however, these contrast agents can only be used in magnetic resonance angiography (MRA)
[29, 30]. As it was mentioned previously, elimination or excretion time from the body is important
for the contrast agent and needs to be optimized in order to have optimal imaging and reduced
toxicity. Size of the contrast agent is therefore becoming important as molecules that are greater
than ~ 7 nm or ~ 60 kDa in diameter can pass through the glomeruli. The circulation half-life of
those molecules, compared to molecules with a diameter of less than 5 nm, can significantly
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increase to over 78 minutes in mice, as the molecular weight is larger than 60 kDa [31-33].
Eventually, targeting specific molecules or biomarkers can dramatically increase the specificity
and sensitivity of MRI contrast agents as powerful diagnostic and prognostic tools. Due to very
low expression of biomarkers in the disease area, creating contrast agents with this capability will
be beneficial. Moreover, high dose efficiency, low toxicity, optimal pharmacokinetics and
thermodynamics and targeting capability and perfusion are indispensable for concreate molecular
imaging. Understanding relaxivity as the most important criteria for designing an ideal contrast
agent with the mentioned characteristics needs a thorough understanding of its theory to assist in
development of MRI contrast agents [34]. In the next section, relaxivity and its theory and how it
can assist the design of contrast agents will be discussed.
Strategies for the design of Gd3+-based MRI contrast agents
In general, there are different approaches which will lead to increase in molecular relaxivity
of contrast agents. First step can be optimization of the parameters that affect relaxivity and second,
connecting multiple gadolinium complexes together. Linking multiple gadolinium complexes
together for MR imaging have attracted great attention recently. The linking can occur either
covalently (e.g. polymers, dendrimers) or non-covalently (e.g. liposomes). Many strategies have
been used to optimize the relaxivity of these complexes and also designing them to target specific
diseases.
As a summary, most important factors affecting relaxivity are external field, the electronic
properties of the gadolinium, water exchange, rotational diffusion, first and second coordination
sphere hydration, and the ion to water proton distance. Each factor will be discussed in the next
sections as well as the physical methods for the estimation of these parameters [6].
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Extracellular clinical MRI contrast agents like Magnevist ([Gd(DTPA)(H2O)]2- are cheap to
manufacture and have good safety profile. As it was mentioned earlier, doses as high as 0.3
mmol/kg are given clinically for applications such as angiography and cerebral perfusion. After
injection of the contrast agent at this dose, T1 becomes much shorter than T1 in any other tissue
without contrast agent, and provides good contrast. One approach to increase the relaxivity is to
increase the sensitivity of MRI for molecular targets instead of increasing the sensitivity of the
contrast agent itself or making a better Magnevist.
In order for a contrast agent to be effective in clinical exams with considerable and
observable contrast, a relaxation rate change of at least ~ 0.5 s-1 is needed. For commercial contrast
agents that are extracellular with a relaxivity of ~ 4 mM.s-1, ~125 µM of the agent is needed. If a
targeted contrast agent is developed with the assumption of 1:1 binding stoichiometry, a minimum
of 125 µM of the target needs to be present in order to observe the contrast. In order to assess the
sensitivity, a study was conducted and concluded that the limit of detection of
[Gd(HPDO3A)(H2O)] is around 30 µM in mouse skeletal muscle [19, 35].
It can be concluded that the amount of potential biological targets detected by the contrast
agent is limited. In order to have a reasonable and observable T1 change, relaxivity values and/or
the number of Gd/molecule should be increased. Since molecular motion can affect relaxivity and
the mobility will be dependent on molecular size, its rigidity, and possible tendency to bind other
proteins, relaxivity must be optimized based on each molecule. As a matter of fact, no gadolinium
complex exists which can be conjugated to a targeting molecule to necessarily create a targeted
contrast agent with high relaxivity. Another important point is about the rotational dynamics of
the final molecule which can be critical. With these parameters, there are several strategies to
achieve an effective molecular targeted MRI contrast agent [36].
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The interaction between Gd3+ and water proton which affects its relaxation happens through
a dipolar mechanism depending on 1/r6 which is the distance between the ion and the nucleus,
therefore, it is crucial to have at least one exchangeable water in the inner coordination sphere of
Gd3+ binding site. The number of water in the inner coordination sphere is represented by q and is
called hydration number, however if this hydration number is bigger than one then the complex
should be stable since the water can be displaced by ligands inside the inner coordination sphere
[37].
It is also very important for the complex to be stable and not reacting with any other
molecules for in vivo applications since the gadolinium can be released because of these
interactions. The rate in which the water is exchanging in and out of the first coordination sphere
should be fast, therefore the solvent surrounding the contrast agent becomes important and the
relaxation rate of bulk solvent should be increased. In order for that to happen, Gd3+ should relax
the water that has interaction with it, and the relaxed water should exchange fast enough with the
bulk water. For complexes like [Gd(DTPA)(H2O)]2- which has fast tumbling rate, the relaxation
rate of the bound water is the rate limiting process. When rotational motion is slow, then water
exchange rate becomes an important factor [37].
The impact of both water exchange and rotational motion can be observed in an example
where you compare the relaxivity of 0.1 mM MS-325 and MS-325-BMA in pH 7.4 phosphate
buffer with saline (PBS) and 0.67 mM human serum albumin (HSA) solution at 37 ○C and 0.47 T.
In this example, there are two contrast agents, one is one of the Gd-DTPA analogs called MS-325
and the other one is its bis(N methyl)amido derivative along with their relaxivities at pH 7.4
phosphate buffered saline (PBS) or in a PBS solution with human serum albumin (HSA) present.
Gd3+ complexes with amido oxygen donor atoms present in their structure usually have slower
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water exchange rates [6]. The complex of the bis (N-methyl) amide with Gd3+ which is the analog
of DTPA, [Gd(DTPA-BMA)(H2O)], possesses a water exchange rate of about 10 times slower
than [Gd(DTPA)(H2O)]2-along which has similar water exchange rates to their parent complexes.
In PBS buffer, the relaxivity is similar since the relaxation of the bound water is the rate-limiting
step [6, 37].
This effect can determine how fast the molecules tumble in solutions and because of the
similar size, their relaxivity values are similar. When there is serum albumin present in the solution,
both of the Gd3+ complexes will bind to serum albumin and therefore as a result, their tumbling
rate will be slower which will make the relaxation mechanism of the bound water more effective.
In this example, it is evident that the water exchange rate is important and the slow water exchange
in GdDTPA-BMA derivative complex affects its relaxivity. In some cases, increase in water
exchange can improve relaxivity further and increase it, however, this will happen only if the
process for relaxing the bound water is very efficient.
For imaging of the majority of biological targets, multiple Gd3+ ions are needed to provide
the required relaxation rate change. One option is linking multiple Gd3+ complexes to increase the
effective correlation time for motion, however, it is important to understand and control the
rotational flexibility which has a large impact on the relaxivity. Based on the way Gd3+ complexes
are linked together, they can have different rotational motions and therefore, a different relaxivity
value. Some complexes are linked in a linear oligomer way with anisotropic rotation, in this
fashion, the rotation along the short axis of the molecule is fast and limits relaxivity. Usually,
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dendrimers consist of Gd3+ complexes have higher relaxivity since the dendritic structure creates
a more isotropic rotational dynamic which in this situation the effect of the larger molecular weight

A

B

C

Figure 1.1. Different types of motions and linking strategies affecting relaxivity.

and size on relaxivity is more effective (Fig 1.1 A).
An example of a linear polymer is based on a modified dextran polymer with DO3Amonoamide chelates with molecular weight of 52 kDa. The relaxivity of this molecule is about
10.6 mM-1.s-1 (37○C, 0.47 T ) per Gd3+ [38]. Twenty-four of these Gd3+ chelates are linked together
to create a polyamide dendrimer with the name of Gadomer-17. With similar conditions (40○C,
0.47 tesla), Gadomer has a relaxivity of 16.5 mM-1.s-1 per gadolinium [36]. The Gd3+ chelates in
the dendrimer can also have internal motion within the connectors in the dendrimer core.
Another strategy to have the best effect of motion on relaxivity is to create a site for Gd3+
at the barycenter of a compound. For instance, Gadomelitol (also called P792 or Vistarem) which
is a Gd-DOTA with large hydrophilic groups attached to each of the -carbons on the acetate
branch follows this strategy. In this molecule, the Gd-H water vector rotates with the entire
molecule, however, there is some level of flexibility within the hydrophilic arms, (Fig. 1.1 B). This
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limitation in rotation can cause a significantly high relaxivity which has r1 of 39.0 mM-1s-1 (37○C,
0.47 T) for a molecule with the size of just 6.4 kDa. It has been reported that this rotational effect
can be tuned by changing the size of the hydrophilic arms [39-41].
Another strategy for controlling rotational motion is called metal templated self-assembly
approach [42, 43]. In this molecule, Gd3+ complexes are attached to rigid bidentate or tridentate
ligands, and then a transition metal is used to connect the Gd3+ complexes in a compressed space.
Another group has used this study with Gd3+ complexes with two water molecules [44]. In this
structure, there are two complexes that are covalently linked to a bipyridyl ligand which coordinate
Fe (II) in an octahedral structure leading to a high relaxivity per Gd3+ and per molecule. This
specific compound has high Gd3+ content and low molecular weight which makes it more
demanding as a contrast agent. The per Gd3+ relaxivity of the compound bipyridyl Gd3+ dimer is
12.5 mM-1s-1 at 40 MHz, 37○C compared to 3.8 mM-1s-1 for [Gd(DTPA)(H2O)]. In conclusion, the
high relaxivity can be attributed to two exchangeable water molecules and a large molecular
weight. In the presence of Fe2+ and bipy ligands, the Gd3+ ions are part of the whole molecule with
a longer correlation time which doubles the relaxivity to 26.5 mM-1s-1.
These were just a few examples to demonstrate how relaxivity can be tuned in contrast
agents of stable gadolinium complexes by changing the number of water molecules in Gd3+
coordination site, water exchange rate, and dynamics of the molecules related to their rotations. In
some cases, these parameters can be changed by introducing a new environment such as buffer in
the presence of serum albumin. Specifically, in this case, both water exchange rate and rotational
motion contributed to an increase in relaxivity, and only one of them could not change relaxivity
significantly by itself. Therefore, it would be very informative to know exactly what molecular
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parameters can contribute to relaxivity in more details and how can these specific parameters be
tuned. In order to answer these questions, we need to study the relaxivity theory more in details.
Relaxivity
The deterioration of an MRI signal which is the decay of water relaxation is analyzed in
terms of two separate processes: First, spin-lattice relaxation time (T1) and second, spin-spin
relaxation time (T2). When a proton is placed in a magnetic field, the overall magnetization will
be on the z axis. When an RF pulse is given, then the net magnetization will be oriented in different
directions as long as the RF pulse is in place. Immediately after that RF pulse is ended, the protons
will relax to their original position.
Spin–lattice relaxation is the mechanism by which the z component of the magnetization
vector comes into thermodynamic equilibrium with its surroundings (the "lattice") in nuclear
magnetic resonance and magnetic resonance imaging. It is characterized by the spin–lattice
relaxation time, a time constant known as T1. T1 characterizes the rate at which the
longitudinal Mz component of the magnetization vector recovers exponentially towards its
thermodynamic equilibrium, according to equation:
Mz (t) = Mz, eq - [ (Mz, eq –Mz (0)] e -t/T1

(1-2)

Or, for the specific case that Mz (0) = 0
Mz (t) = Mz, eq (1-e -t/T1)

(1-3)

It is thus the time it takes for the longitudinal magnetization to recover approximately 63% [1(1/e)] of its initial value after being flipped into the magnetic transverse plane by a 90°
radiofrequency pulse.
The spin–spin relaxation is the mechanism by which Mxy, the transverse component of
the magnetization vector, exponentially decays towards its equilibrium value in NMR and MRI. It
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is characterized by the spin–spin relaxation time, known as T2, a time constant characterizing the
signal decay. It is named in contrast to T1, the spin–lattice relaxation time. It is the time it takes
for the magnetic resonance signal to irreversibly decay to 37% (1/e) of its initial value after its
generation by tipping the longitudinal magnetization towards the magnetic transverse plane. Hence
the relation:
Mxy (t) = Mxy (0) e -t/T2

(1-4)

T2 relaxation generally proceeds more rapidly than T1 recovery.
The MRI signal enhancement in tissues are determined by T1 and T2 relaxation time. MRI
pulse sequences use different repetition time (TR) and echo time (TE) in order to observe the T1
and T2 effect on signal enhancement. Based on TR and TE parameters, different pulse sequences
can be applied such as T1-weighted MRI, T2 (or T2*)-weighted MRI, proton density-weighted,
T1 map and T2 map. Since T1 effect is being observed in T1-weighted MRI, it usually has a short
TR and very short TE to minimize the T2 effect, For T2 (or T2*)-weighted MRI, TR is very long
(usually more than 3 s) to minimize the T1 effect and TE is relatively long (at around 40 – 100
ms). Proton density imaging has both T1 and T2 effect which has long TR (more than 3 s) and
short TE. T1 and T2 maps are generally more sensitive than T1- and T2-wieghted sequences as
they reflect the actual T1 and T2 values rather than intensities. To generate T2 map, one single TR
is used and multiple TEs are applied. For T1 map inversion recovery, multiple inversion times (TI)
are being used. Using different TRs and TEs, MRI is able to show the differences of T1 or T2 (or
T2*) of the tissue. As it was mentioned before, Gd3+-based MRI contrast agents are mainly T1
agents because they can only shorten the T1 time of the water, however other contrast agents such
as iron oxide nanoparticles are T2 agents because of their ability to shorten T2 time, therefore they
are widely used in T2- or T2*-weighted MRI sequences. Generally, contrast agents have the ability
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to shorten either T1 or T2 not both of them and these contrast agents cannot be used in both T1weighted and T2-weighted MR imaging. Moreover, clinical Gd3+-based MRI contrast agents have
very low relaxivity and sensitivity which further limits their application in T1-weighted MRI.
An MRI contrast agent with both high r1 and r2 has the capability to change the MRI signal
in both T1- and T2-weighted images, and both T1 and T2 maps can be used for imaging with such
contrast agent. In addition, T1 inversion recovery with short TE which uses inversion time to
suppress the signal can be combined with such contrast agent. ProCA32.collagen1 has both high
r1 and r2 values and enables both T1 and T2 imaging. The application of a T1-T2 contrast agent
has not been widely reported in the literature since the majority of contrast agent are either T1 or
T2 agents and their relaxivity specially for small-molecule clinical contrast agents are low.
A gadolinium complex causes the relaxation of solvent water (bulk water) which is a
phenomenon with multiple variables involved. When water molecule is close to Gd3+ or any other
metal with similar properties, it will be relaxed and can be exchanged with water molecules in the
solvent. Therefore, three types of water molecules will be involved. First, there is inner-sphere
water. This type of water has directly coordinated Gd3+ in the binding site through its oxygen arms.
Second, there is 2nd-sphere water. In this type of water molecule, they have hydrated the Gd3+
complex, and they spend specific time with the complex which is longer than the translational
diffusion time of pure water. Third is outer-sphere water. Outer-sphere water can interact with the
waters that are with Gd3+ and they are guided only by translational diffusion and a distance of
closest approach [6].
The water hydrogen has a T1 relaxation by Gd3+ which happens through dipolar mechanism.
Generally, relaxation time will be affected by the number of water molecules, their distance to
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Gd3+, rate of exchange with bulk solvent, as well as rotational correlation time, τc which all of
them will be discussed in more details.
Constant changes in magnetic field strength can cause spin transitions and relaxation. In
order to quantify these changes, usually, a correlation time is defined as the time constant for
characterizing these fluctuations and 1/τc is the average rate constant to quantify the changes in
dipoles of magnetic field. The phenomena resulting in to fluctuation of magnetic dipoles are: 1.
Electronic relaxation (1/T1e) at the Gd3+ ion creates. 2. Rotational diffusion (1/τR) of the Gd3+
complex. 3. Water exchange in and outside of the first (1/τm) or 2nd (1/ τm´) coordination spheres
for the hydrogen nucleus. The shortest time constant or the fastest rate has the maximum effect on
the extent of relaxation. The lifetime of water in the second sphere and its corresponding
correlation time is usually ~ 10’s of picoseconds, however, the water in the first coordination
sphere has a much longer lifetime which is around 1 ns–10,000 ns, therefore, the correlation time
is

usually

rotational

diffusion

or

electronic

relaxation

[6].

Figure 1.2 Describing molecular parameters that are affecting inner- and 2nd-sphere relaxivity.
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Fig. 1.2 is demonstrating these effects. The hydrogen nuclei have magnetic dipoles shown
by the vectors. The water number that is shown by q are the waters in the inner-sphere which has
Gd–H distance of r and a residency time of τm, and q´ waters in the second-sphere at a Gd–H
distance of r´ and residency time τm´. Besides hydrogen, Gd3+ also has magnetic dipole which is
stronger and is shown by a large vector and quantified by spin S. The magnetic dipole can undergo
relaxation which is defined by T1e and T2e. If the complex tumbles in a isotropical manner, the
rotational motion resulting from this tumble is defined as rotational correlation time, τR.
Water in the outer-sphere is defined by a parameter called translational diffusion correlation
time τD and a distance of closest approach called a. Therefore, there are a total of 11 parameters
that can contribute to relaxation at a magnetic field of B0. In addition, electronic relaxation also
depends on magnetic field. It is important to mention that the simple measurement of relaxivity
cannot represent the effect of all these parameters. Some of these parameters and their effect on
relaxivity can be stimulated and some of these parameters can be determined independently. In
conclusion, a more complete perception of the molecular basis of relaxivity evolved the contrast
agent field and can result in improved agents with higher relaxivity [6].
1.5.1 Inner-Sphere Relaxivity
Relaxivity originating from the inner-sphere waters can be explained by equation (1-2). In
this equation, there are two sites for exchange where T1m is the T1 of the water hydrogen in the
inner-sphere and [H2O] is the water concentration in mM. In order to increase relaxivity, water
number q can be increased or T1m or τm can be decreased.

(1-5) [6]
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1.5.2 Hydration number, q
The safety of contrast agents used for human is the most important priority in developing
them and they should be stable enough so that the complex that is holding the Gd3+ does not release
it into the body, therefore due to safety concerns, the number of waters (q) that can be incorporated
into the complex to increase the relaxivity of the contrast agent is limited. Theoretically, when
there are more waters in Gd3+ coordination sites as ligands, the thermodynamic stability of the
complex is compromised and the Gd3+ is likely to be released from the complex. Another
disadvantage of increasing the water number is that other ligands such as endogenous phosphate
or bicarbonate can replace and displace water and coordinate Gd3+ instead which results in reduced
relaxivity. For instance, if an acetate group is removed from [Gd(DOTA)(H2O)]- to produce
[Gd(DO3A)(H2O)2], this will increase the hydration number but still results in a stable
complex[45]. The water molecules can be displaced by anion binding as well. A group of
compounds called hydroxypyridinone (HOPO) described in the literature have shown stability
with q = 2 and are resistant to anion coordination [46-48].
1.5.3 Inner-Sphere water relaxation
As it can be observed in eqn (1-5), both the relaxation time of the bound water (T1m), and
the water residency time (τm) should be as short as possible to increase the relaxivity. At the
beginning of development of MR contrast agents, T1m was larger than τm and therefore it was T1m
that was limiting the relaxivity of these agents. The compounds shown in Figure 1.1 followed the
same rule for their relaxivity in buffer. Dipolar relaxation originating from electron–nuclear spin
coupling can be described by Eqns (1-6) and (1-7):

(1-6) [6]
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(1-7) [6]

With respect to these equations, relaxation depends on the Gd–H distance, rGdH, Larmor frequency
of the proton H (in rad/s), the electron Larmor frequency S (S = 658H), and correlation times
τc1 and τc2. The 2τc22 are referred to as dispersive terms since 2 τc22 1, the relaxation rate
decreases and disperses with increase in frequency or magnetic field. Since the Larmor frequency
of the electron is 658 times bigger than the proton, the first term in square brackets disperses at a
lower magnetic field compared to the second term, however, if the correlation time is independent
of magnetic field, then the relaxation rate relies on proton Larmor frequency. Usually, at low fields
the rate decreases to almost 70% and then the rest will disperse at higher fields. For Gd3+
complexes, the correlation time depends on magnetic field and the NMRD behavior is more
complicated.
1.5.4 Gadolinium-water distance
In equation (1-6), the term outside the square brackets are physical constants. First, it is the
spin quantum number of Gd3+ which is S = 7/2, and Gd–H distance, which is shown by rGdH. Gd3+
is a suitable metal as a relaxation agent since it has large spin number and slow electronic
relaxation. Furthermore, Gd–H distance is important and if this distance is reduced, then it would
result in increase in relaxivity. The distance varies based on literature, however it ranges between
2.7 and 3.3 A° which is obtained indirectly. One of the direct determination methods of calculating
the Gd–H ion–nuclear distance is to use neutron diffraction on single crystals or using isotopic
exchange techniques. Electron–nuclear double resonance (ENDOR) spectroscopy is also possible
to use for measurement of Gd-H distance directly. 1H ENDOR studies make the determination of
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the hyperfine interactions between the Gd3+ and the water proton possible. One and two
dimensional ENDOR studies have illustrated that Gd-H distance is about 3.1 A° for 8- and 9coordinate complexes of Gd3+ and it is independent of ligand type or total charge. It is nearly
impossible to change this distance in order to have higher relaxivity values [49-51].
1.5.5 Rotational diffusion
Based on eqn (1-7), the correlation time can be most affected by the shortest correlation
time which are either rotation, electronic relaxation, or chemical exchange times. At the magnetic
field strength of 1.5 Tesla (64 MHz) which is the most commonly used magnetic field in clinical
imaging, the most effective correlation time is rotational diffusion in most of the cases. For
instance, in simple monomeric Gd3+ complexes, τR is in the range of 0.1 ns which have rotational
rate constant in the range of few GHz leading to small relaxation. Slowing down rotation leads to
higher relaxivity values at 1.5 tesla.
In higher fields, if a molecule’s rotation is too slow, then based on 2τc22  1, the relaxivity
decreases with increasing τR. Relaxivity can be simulated for three values of τR. For instance, r1
can be simulated over a range of magnetic fields between 0-3 Tesla for correlation times of 0.1 ns
(small molecule contrast agents, Gd-DTPA), 1 ns (intermediate motion), and 10 n (albumin bound
contrast agents). It can be concluded that by increasing the rotational correlation time from 0.1 ns
10 ns, the relaxivity will also increase, however, this effect is maximized at lower magnetic field
strengths. It is worth mentioning that r1 cannot obtain the zero value since there is also an outersphere parameter exists that contribute to relaxivity which has its own correlation time which is
very short.
Using various methods such as NMR relaxation, EPR, and fluorescence, rotational
diffusion can be estimated. Furthermore, it can also be calculated from the Stokes–Einstein
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equation as described in the literature. For larger molecules such as proteins, rotation may not be
isotropic. Correlation time can be reduced with anisotropic rotation or internal motion within a
molecule predicted by an isotropic model based on molecular weight. Anisotropy can be observed
when relaxation is determined as a function of magnetic field. It has been reported that there are
two types of motion in a complex molecule which the spectral density function can be simulated
by two correlation times corresponding to these motions, one for the global motion (τg) of the
molecule and another for the local motion (τ1) of the Gd–Hwater vector [6, 47, 48, 52].

(1-8)

(1-9)

Eqn (1-8) and (1-9) relates this parameter to dipolar relaxation of Gd3+ where C is a constant
consists of terms from eqn (1-7). The degree of isotropic motion is described by the order
parameter S2 (also shown by F to avoid confusion with the spin quantum number). At higher fields,
Sτ  1 and the spectral density is given by the second term in parentheses in eqn (1-8).
1.5.6 Electronic relaxation
Electronic relaxation for Gd3+ is a sophisticated process which relies on magnetic field. At
lower magnetic fields usually below 0.1 T, the electronic relaxation is short or fast and therefore
can dominate the correlation time, see eqn (1-8). With increase in magnetic fields, the electronic
relaxation decreases and therefore becomes slower than rotational motion, see eqn (1-11). As a
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result, the correlation time of nuclear relaxation depends on magnetic field and changes as a
function of field.

(1-10)

(1-11)

At lower magnetic fields, electronic relaxation is the dominant factor τc and as the relaxivity
increases so as the magnetic field since electronic relaxation slows down and τc increases. In
magnetic field strengths of about 0.7 T, relaxivity reaches its maximum and then starts to decrease
since τcH becomes larger than 1, therefore, affecting eqn (1-8) and making it larger [47, 53].
1.5.7 Water exchange rate
Water exchange is another important factor affecting the relaxivity. The water molecule
coordinating the Gd3+ in the complex must be exchanging rapidly with the bulk water in the solvent
so that it can transfer the relaxation effect to the solvent. The water exchange parameter can be
explained through 17O NMR transverse relaxation rate measurements at different temperatures at
high magnetic fields. There has been a significant body of data in the literature trying to address
this effect. For instance, replacing an acetato oxygen donor with an amido oxygen donor will lead
to a slower water exchange rate. In another case, for complexes experiencing dissociative water
exchange, increase in the steric bulk can increase the water exchange rate. Replacing an acetato
oxygen donor with the larger phosphonato oxygen donor can increase the exchange rate [54].
The water residency time τm (kex = 1/τm) plays a direct role for relaxivity in the equation as
well as through T1m. If water exchange value is short or very fast, then the τm can is the correlation
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time that dominates T1m. In addition, if water exchange is very slow, relaxivity will be affected
and decreased since the relaxation effect is not transferred to the bulk water sufficiently enough.
The very fast water exchange can also have a negative impact on relaxivity since if the water is
exchanging too fast then it does not have the ability to coordinate the Gd3+ and the time is not long
enough for the water to be relaxed. The dependency of relaxivity on τm can be observed where
inner-sphere relaxivity is simulated for a q = 1 in a 1.5 T system at different values of τR. The
relaxivity can be affected with water exchange rate being too slow or too fast, however, this effect
can observed if other important parameters such as τR are in their optimized conditions [55].
1.5.8 2nd-sphere and outer-sphere relaxivity
As it was mentioned before, 2nd-sphere and outer-sphere relaxivity can also contribute to
relaxivity coming from the bulk water surrounding the Gd3+ complex. Using hard-sphere model of
Hwang and Freed, the outer-sphere relaxivity can be simulated where relaxation is measured using
the diffusion coefficient of water as well as distance of closest approach. The hydrogens of water
that can be exchanged in the second coordination sphere of Gd3+ can also affect the relaxivity.
These protons originate from water in the second coordination sphere or the sites being protonated
on the molecule. As it was demonstrated, complexes even with q=0 can have high relaxivity. For
instance in [Gd(DTPA)(H2O)]2- approximately %50 of the effect originates from the inner-sphere
water. In addition, according to outer-sphere prediction model, protein binding does not have any
effect on relaxivity, however, the level and impact of 2nd-sphere on relaxivity is very difficult to
predict. For complexes with q  0, all the previously mentioned parameters will affect the
relaxivity as well as the number of hydrogens in the 2nd sphere that can be exchanged. Moreover,
the hydrogen distance from Gd3+, and their lifetimes become important. When each of the single
molecular parameters measured cannot contribute to the high relaxivity of a complex then the large
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2nd-sphere effect is very well observed. Sometime by fitting NMRD data, additional parameters
accounting for 2nd-sphere relaxivity can be modeled [56-58].
1.5.9 Effect of field strength and temperature
Relaxivity strongly depends on magnetic field strength. Moreover, since water exchange
rate and rotational diffusion are affected by temperature, then as a result relaxivity will be affected
by temperature as well. It is important to compare different relaxivity data at the same temperature
and field strength. Usually the ideal temperature in which the data are compared is 37○C as it is
the physiological temperature and all of the contrast agents are being applied in vivo at 37○C.
Although most of the clinical MRI contrast agents function at 1.5 T (64 MHz), the clinical field is
shifting towards higher magnetic fields as high as whole body 7.0 T (300 MHz) instruments. The
reason is that the higher field strengths provide higher signal to noise ratio and increased resolution.
At higher magnetic fields, the relaxivity is decreasing, therefore, clinical contrast agents should be
less useful, however relaxation time of different tissues will increase with increase in magnetic
field, therefore so less contrast agent with a fixed relaxivity is needed to produce the same level of
contrast. Higher magnetic fields can reduce the acquisition time and the presence of a relaxation
agent can make the acquisition time even shorter [59].
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Figure 1.3 A diagram demonstrating the parameters affecting relaxivity of a Gd3+-based MRI
contrast agent complex [6].
In conclusion, there has been a tremendous effort to develop and design new MRI contrast
agents with significant progress made. A more complete and thorough understanding of the
parameters affecting relaxivity such as coordination chemistry and biophysics can result in
improved contrast agents which will speed up the progress. among all of the parameters discussed,
the most important one is the rotational motion since it depends on rotational dynamics. There are
certain strategies being used to modulate the rotational dynamics in order to increase relaxivity.
For instance, linking multiple gadolinium complexes is one of those approaches. Perception of
how to modulate the water exchange rate at the Gd3+ coordination site and its complex can also
benefit the current progress in the development contrast agents. At 1.5 T which is the most common
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magnetic field for imaging with contrast agents, rotation, hydration, and water exchange rate are
the key parameters.
Current advancements in improving the relaxvity of Gd3+-based MRI Agents
Gadopentetate dimeglumine or Magnevist was the first gadolinium-based contrast agent
(GBCA) which become available for clinical use worldwide in 1988. After that eight more
gadolinium contrast agents based on chelates were introduced and approved in different countries
across the world. Progress in the field of contrast media and the MRI instrument itself has increased
the accuracy and application of contrast-enhanced-MRI (CE-MRI). Currently, CE-MRI as a
diagnostic imaging tool covers approximately 30 million procedures annually. There is a close
relationship between clinical diagnosis and the monitoring of specific therapies and research into
new MRI contrast agents [60].
Significant progress has been made in improving the relaxivity of MRI contrast agents and
there has been an ongoing effort. For instance, the relaxivity has been improved by covalently
linking Gd3+-chelates to nano-carriers, such as dendrimers, liposomes, nnanoparticle emulsions
viral capsids, and nanotubes. Moreover, non-covalent binding between Gd3+ chelators and
proteins, such as MS-325, have shown significant increase of relaxivity [61-66]. However, there
are limited number of publications which reported the use of proteins to function as ligands to bind
Gd3+ to improve the imaging capabilities.
Overall, there are two general approaches to use proteins Gd3+ ligands. First, Gd3+-chelates
will be covalently or non-covalently conjugated to proteins. Second, Gd3+ binding pockets are
directly designed inside the proteins or basically the protein itself functions as a chelator. The first
approach has been used numerously to create new class of MRI contrast agents. In these studies,
Gd3+ chelates were designed to non-covalently interact with proteins, and as a result they
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significantly increased the relaxivity of Gd3+ chelates [29, 30]. Furthermore, in a study proteins
such as albumin directly used to interact with DTPA-dianhydride to produce a DTPA-protein
complex loaded with Gd3+ [67]. Albumin labeled with Gd3+ has been extensively used in many
preclinical procedures such as assessment of tumor permeability and angiogenesis by CE-MRI of
cancer tissue, and monitoring vasculature changes of tumors [68, 69]. In another study, a class of
biodegradable contrast agents were designed by conjugating evenly distributed lysine residues on
protein polymers to Gd3+ chelates. Then the polymer length and lysine distribution were optimized
to produce an r1 of 14 mM-1s-1 per Gd3+ and 46.1 mM-1s-1 per particle at 1.5 T and 37 ˚C. These
contrast agents can be excreted rapidly in vivo [70]. As creating a Gd3+ binding pocket inside a
protein is challenging, the second approach has not been used frequently. When a protein is
designed to be used as chelator for Gd3+, several important parameters must be optimized for
relaxivity which will be discussed later in this chapter.
Design of protein-based MRI contrast agent with improved relaxivity
1.7.1 MRI contrast agents based on proteins
One of the interesting approaches for the development of new MRI contrast agents is to
use native or engineered proteins. Approximately one third of proteins have metal ions such as
calcium, magnesium, zinc, copper, iron, and manganese in their structure and these proteins that
exist naturally have Cu2+, Fe2+, Fe3+, Mn2+, and Mn3+ with spin quantum numbers ranging from
1/2 to 1/5. Some native proteins, such as hemoglobin, and engineered proteins like BM3h have
been used to monitor brain activities in human and animals [71-73]. In addition, studies have
shown that metalloproteins can be engineered to trap different metals such as manganese or iron
in ferritin with significantly high T2 property per particle (r2 = 5300 mM-1s-1) which can be applied
as T2 MRI agents [74-76]. Other proteins such as human protamine-1 expressed by live cells have
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been used as chemical exchange saturation transfer (CEST) MRI contrast agent. This protein is
based on a small arginine-rich protein, which functions through CEST mechanism [77]. In the next
section our protein design for development of MRI contrast agent will be discussed.
1.7.2 Choice of protein for designing Gd3+-based MRI contrast agents
Instead of conjugating proteins with small Gd3+ chelators, a very different approach was
chosen and used in which a Gd3+-binding pocket was designed and engineered into a protein
scaffold to change it to a protein chelator [78-80]. The design of protein-based contrast agent
(ProCA) was based on the discussions mentioned about the factors affecting relaxivity as well as
several other considerations. Proteins are in the category of biocompatible materials which will be
beneficial for in vivo applications. Other protein drugs such as insulin have been successfully used
in humans against different diseases [81, 82]. Moreover, there are some proteins that their wellfolded structures and proper sizes allow god circulation and tissue penetration. For instance, a
globular protein with molecular weight of 10–14 kDa has a size of 2–3 nm, therefore it can be
excreted from kidney. Many computational and protein engineering strategies were applied to
design Gd3+ binding sites in proteins with high coordination number and strong binding affinity.
Some of these proteins have well-studied structural and dynamic profiles by high-resolution NMR
which can be used for designing Gd3+ MRI contrast agents with improved metal binding and
relaxation properties. Finally, when a protein-based contrast agent was developed with high
relaxivity and metal-binding properties, its application can be extended to targeted contrast agents
with the addition of different moieties to target various disease biomarkers by protein modification.
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1.7.3 Design of MRI Contrast Agent based on -Parvalbumin
Based on important parameters affecting relaxivity such as water number, rotational
correlation time, water exchange rate, and etc as well as our strategy to design Gd3+ binding sites
into a protein as an MRI contrast agent with high relaxivity, high dose efficiency and strong metal
binding affinity, we have chosen -parvalbumin as a scaffold protein to host Gd3+-binding sites.
Our lab had previously developed a protein contrast agent (ProCA32) [83] , which was designed
and developed by creating one more negatively charged ligand S56D in the EF-hand motif 1 of rat
or human α-parvalbumin to create Gd3+ binding affinity and selectivity. Parvalbumin protein was
selected since it had strong calcium binding affinity (Kd = 8.35 ± 0.29 × 10−9 M; Fig. 1.4 a) and
stability. Furthermore, F103W mutation was made to introduce luminescence resonance energy
transfer (LRET) property to the protein to determine its metal binding affinity and water number
by Tb3+ luminescence life time decay. The protein was further modified with PEGylation of
ProCA32 by TMS(PEG)12 (named as ProCA32-P40) to increase blood retention time, liver
preference, solubility, as well as stability of the designed protein [84].
There are some unique factors that make α-parvalbumin one of the best candidates for the
design of a protein-based MRI contrast agent. Design of Gd3+ binding sites was based on our
analysis of metal binding sites in different small chelators and metal proteins. It is important to
mention that Gd3+, Tb3+ and Ln3+ have similar coordination to Ca2+. In addition, like Ca2+, they
prefer oxygen as ligands. Other small chelators used in generating contrast agents such as DTPA
have both oxygen and nitrogen atoms as ligands, however, proteins like α-parvalbumin use oxygen
as a ligand most of the times [85]. In α-parvalbumin, oxygen ligands from the side chain oxygens
of Glu and Asp are used at different stretches of the protein sequence to coordinate Gd3+. One
position of metal geometry is left open to allow fast water exchange between solvent and metal
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(Fig. 1.4 B). We have concluded that inserting a metal binding site without internal flexibility is
crucial to achieve a high relaxivity contrast agent based on a protein. In the next section, different
factors contributing to high relaxivity in ProCA32 will be discussed.

A

B

Figure 1.4 Model structure of rat -parvalbumin (a) and ProCA32 (b) with several
mutations

1.7.4 Factors Contributing to High Relaxivity in ProCA32
As it was mentioned before, there are different parameters such as correlation time and
inner, second, and outer sphere water number that can affect the significantly high relaxivity in
ProCAs compared to contrast agents based on small molecules. The first important parameter is
the optimized Correlation Time which is one of factors contributing to the high relaxivity of
ProCA32. As shown in previous equations, a protein contrast agent with τR of approximately 10
ns has a near optimized relaxivity at the most common magnetic field of 1.5 T. High-resolution
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NMR was used to study the dynamic properties of our designed protein contrast agent [86, 87].
Based on other proteins with the similar, the τc of a protein MRI contrast agent is approximately
9.08 ns in the presence of metal and 9.20 nsec in the absence of metal. Furthermore, the dynamic
NMR data demonstrate that the metal-binding pocket inside the protein contrast agent can rotate
along with the scaffold protein as a rigid complex.
The second parameter contributing to the high relaxivity value is the water number which
is also optimized in the protein-based MRI contrast agent. As shown in previous equations, the
relaxivity of a contrast agent directly corresponds to q. One can increase the relaxivity of a contrast
agent by increasing the water molecules coordinating the Gd3+ at the same time. In a study to
develop an enzyme responsive contrast agent named Egad, water access to Gd3+ (q = 0) was denied
by addition of a galactopyranose moiety to a Gd-DO3A chelate, however, after galactosidase
activation, galactopyranose sugar was cleaved from Gd3+, therefore exposing it to water molecules
which subsequently increased water number from 0.7 to 1.2 [88] and the r1 increased from 0.90
mM-1s-1 to 2.72 mM-1s-1 accordingly [89]. We have shown that ProCA32 has q=0.5 shared by the
two binding sites of Gd3+ which can increase the relaxivity. Moreover, larger surface of proteins
can also contribute to high relaxivity through second sphere relaxivity that could reach as high as
3.3 and 8.8 mM-1s-1 at 20 and 60 MHz, respectively (τR = 10 ns, τm = 10 ns, q = 4, rGdH = 5 A°).
According to all the parameters, it is highly likely that ProCA32 high relaxivity benefits from
coordination water from the inner, second, and outer spheres of which cause the increase of
relaxivity in ProCA32.

33

Table 1.2 The relaxivity of some of the research-based Gd3+ MRI contrast agents [67, 84, 87, 89106].

Category of Contrast Agent

Contrast Agent

r1 (mM-1s-1)

r2 (mM-1s-1)

Paramagnetic Nanoparticles

Gd@C82(OH)22±2

61.1

4.7

Nanodiamond

Nanodiamond

58.82

1.5

Trimetallic Nitride
Metallofullerene CA
Dendrimer Nanoclusters

Gd3N@C80[DiPEG(OH)x]

79

2.4

Dendrimer Nanoclusters

12.3

Hydroxypyridonate Viral
capsid conjugates
Lipid Nanoparticles

Gd-TREN-bis-HOPOTAM-CO2H
GdDOTA(GAC12)2

41.7

0.7

40

0.47

Gold Nanoparticles

Au@DTDTPA-Gdx

4.1

7.0

Nanoassembled Capsules

NACs

24

0.54

Ca2+-Binding Proteins

α-lactalbumin

4.2

5

3

Nanoparticle emulsion

34

50

1.5

Nanoglobular MRI CAs

Gd-perfluorocarbon
nanoparticles
G3 nanoglobular

10

3

Porous Polymersomes

porous polymersomes

7.2

1.5

Liposome

ACPL

12

11

1.5

Collagen peptide conjugated
with Gd-DTPA
Multimeric CAs

EP-3533

15.6

32.5

1.5

Protein Carriers

Albumin

11.5

HOPO derivatives

Gd-TREN-1,2-HOPO

10.5

0.47

Cell-permeable CAs

Gd3+-DTPA-Arg8

7.8

1.5

12.2

B0 (T)

1.5
12.4

0.25
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Small Chelators

Gd-DTPA

5.4

Dendrimers

Gadomer-17

13

8

1.5
1.5

1.7.5 Design of a Targeted Contrast Agent for Imaging of Biomarkers
In order to image biomarkers with MRI, targeted contrast agents are needed to be
developed with high specificity as well as sensitivity. Currently, many attempts have been made
to design and develop targeted MR agents to obtain molecular imaging by MRI (Table 1.2).
Different molecules such as antibody, peptide or small ligands, and small protein domains such as
affibodies have been applied for targeting [61, 63, 107-117]. To have contrast agents with higher
sensitivity, biomarker-targeting moieties are usually linked to these MRI contrast agents, such as
nanoparticles. In a study, fibrin antibody was conjugated to emulsion nanoparticles and they were
successfully used to image vulnerable plaques [62]. Furthermore, in a different study, arginineglycineaspartic acid (RGD) peptide was conjugated to emulsion nanoparticles for successful
application in imaging integrin, which is expressed in high levels in many diseases such as cancer
and atherosclerosis [114, 115, 118], however, nanoparticles have limited applications to imaging
biomarkers on the blood vessel due to the large size and low tissue penetration. Many approaches
have been used to solve the issues with macromolecules in terms of extravasation and diffusion
barriers. Caravan and coworkers used conjugation approaches with targeting and labeling
strategies to create antibody-tagged magnetic particles as well as peptides targeting collagen type
I conjugated with multiple Gd-DTPAs named EP-3533 [109, 119, 120]. In these studies, a small
collagen targeting peptide was conjugated with Gd3+-chelates and eventually was capable of
targeting collagen type I in different diseases such as liver, lung and heart fibrosis [110, 121, 122].
In addition, small molecules such as peptoid-(Gd)8-dendron were synthesized and used for
molecular imaging of vascular endothelial growth factor receptor 2 (VEGFR2) which is an
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angiogenesis biomarker expressed in different tumors [113]. Although significant progress has
been made in generating targeted MRI contrast agents, the development of these agents for
molecular imaging by MRI is largely hampered by their low sensitivity compared to other agents
in PET/SPECT. In addition, inadequate perfusion to diseased tissue, instability of the peptide-

based targeting moieties, and targeting specificity and selectivity are other major limitations of the
current MRI agents.
Figure 1.5 Top 5 final modeled structures predicted by I-TASSER for
ProCA32.collagen1

Fig. 1.6 demonstrates the modeled structures generated by I-TASSER for
ProCA32.collagen1. C-score is a confidence score for estimating the quality of predicted models
by I-TASSER [123]. It is calculated based on the significance of threading template alignments
and the convergence parameters of the structure assembly simulations. C-score is typically in the
range of -5 to 2], where a C-score of higher value signifies a model with a high confidence and
vice-versa.

Therefore, model 1 with C score of -1.18 was chosen as our final model for

ProCA32.collagen1.
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Figure 1.6 The model structure and development of ProCA32.collagen1
ProCA32 was generated from rat -parvalbumin by incorporating the S56D and F103W
mutations, then ProCA32 was further developed to ProCA32.collagen1 by linking collagen type I
targeting moiety at its C-terminal, then ProCA32.collagen was further modified with covalently
linking PEG by PEGylation. The model structures were generated based on the structure of αparvalbumin (Protein Data Bank ID code 1RWY) and I-TASSER.

Based on our previous design of ProCA32 discussed in section 1.7.3 [83], ProCA32 was
chosen to design a protein-based MRI contrast agent with biomarker targeting capacity, therefore,
a collagen type I peptide targeting moiety was designed based on previous studies [120] and linked
to the C-terminal of ProCA32 through a flexible linker. We have named this protein contrast agent
ProCA32.collagen1. The protein was further modified with PEGylation, a representation of this
process can be seen in Fig. 1.6. Collagen type I is an important biomarker in different diseases
such as liver fibrosis and metastasis. It is an important target for molecular imaging of liver fibrosis
and metastasis since its accumulation is a characteristic of most types of chronic liver diseases
(CLD), further details will be discussed in the next chapters. In order to meet the requirements for
MR imaging of different liver diseases, the targeting peptide was added to the C-terminal to avoid
any alterations in the protein structure and its metal binding affinities which is very different from
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other approaches. We have demonstrated that it is possible to increase relaxivity by addition of a
targeting moiety to a protein MRI contrast agent without sacrificing relaxation and metal binding
properties, such as affinity and metal specificity.
In vitro properties of MRI contrast agents
1.8.1 Optimizing peptide targeting capability of MRI contrast agents
The basis of biomaterial science and drug design is to have a good understanding and
knowledge of the key protein–protein interactions occurring in cell–matrix, macromolecular
organization of the extracellular matrix (ECM), and pathogen-induced and degenerative diseases
[124]. The recognition of adhesion moieties used in biomaterials usually occurs via methods that
are based on techniques such as phage display [125] or by using trial and error strategies such as
screening different sequences from ECM components [126, 127]. In drug design, however, a more
efficient strategy is applied which provides structural information from complexes of the binding
partners. Furthermore, computational and experimental procedures can be extremely beneficial for
the identification of binding epitopes [128]. Similar methods can be used to the rational design of
collagen-binding peptides that have relevance to biomaterial applications. Although substantial
progress has been made in medicinal chemistry, chemical biology, and biochemistry, biomaterial
scientists largely dependent on a few peptide motifs in biomimetic design, such as RGD peptides
or enzyme-sensitive peptide sequences [129]. In order to investigate an ideal targeting moiety for
collagen type I, more diverse and specific motifs are required, similar to the ECM [130]. The ECM
is a hydrogel based on reversible supramolecular interactions and its most abundant protein is
collagen. [131-135]
Targeted Gd3+-based contrast agents can become great diagnostic tools combined with
MRI to positively enhance images with the contrast they provide since MR has an order of
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magnitude better spatial resolution than nuclear imaging modalities such as positron emission
tomography (PET) and single photon emission computerised tomography (SPECT), however the
first challenge facing these targeted MR agents has always been sensitivity [6]. Usually, Gd3+ in
M levels are needed to be in the detectable range of MRI. One strategy can be generating a
macromolecule which includes large numbers of metal complexes and targeting moiety (such as
peptide or antibody). Different molecules such as polymers, dendrimers, liposomes and
nanoparticles have been used successfully in animal models [63, 136-138], however nanoparticles
have limitations for vascular targets as they have long half-life in blood leading to slow targeting
capability as well as incomplete elimination from the body which usually leave Gd3+ behind.
Another strategy is to use a chelate or multiple chelates of Gd3+ with a targeting moiety attached
to them such as a peptide conjugated to one or more small molecule-chelates of Gd3+ such as GdDTPA [139-142].
Linking or conjugating short peptide fragments with affinity to biomarkers (peptide
targeting) is a common approach used in molecular imaging because of its small size and advances
in peptide synthesis [143], however application of peptides in targeting has some disadvantages
such as their instability and degradation by enzymatic cleavage, having a short half-life in the
body, and their undefined structure which could result in decreasing the binding specificity and
affinity to the target biomarker. As discussed in previous section, we have used a protein chelate
(ProCA32) to chelate two Gd3+ and conjugated a collagen type I targeting peptide to its C-terminal
to produce ProCA32.collagen1 to overcome the mentioned challenges. Then, based on literature
reviews and studying certain amino acid residues responsible for collagen binding,
KKWHCYTYFPHHYCVYG sequence was chosen to be linked at the C-terminal via three glycine
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linker so that the peptide can freely move for targeting. Using this approach, we have successfully
imaged collagen type I with ProCA32.collagen1 in liver fibrosis and liver metastasis.
1.8.2 Thermodynamic stability of MRI contrast agents
Clinical contrast agents such as Gd-DTPA have long term toxic systemic effects (the LD50
of Gd3+ is 0.2-0.3 mmol/kg and the LD50 of Na3Ca-DTPA is 5 mmol/kg) which is caused by free
Gd3+ and the chelators. Since Gd3+ has an ionic radius (0.93 Å) very similar to Ca2+ (0.99), it is
very likely that it can compete with Ca2+ in the biological systems and cause disruptions in the
Ca2+ signaling pathways by interacting with calcium binding proteins such as calcium sensing
receptor, and voltage-gated calcium channels. Therefore, it is crucial that contrast agents have
enough stability in order to prevent Gd3+ from being released from their structure. Generally, the
stability of contrast agents to Gd3+ is defined by thermodynamic, conditional, and kinetic stability.
Since these contrast agents are used in medical diagnosis field, it is of great importance that Gd3+based chelators remain in the complex in vivo, and they need to have high metal binding stability
and selectivity [144-147]. The chemical instability of the chelate can lead to exchanges with other
metal ions (Zinc, copper, and calcium) which can, in turn, have biological consequences.
Accumulation of Gd3+ in bones, interference with colorimetric serum determination of calcium
and hence spurious hypocalcaemia, interaction with scintigraphic procedures, increased zincuria,
interaction with metal-dependent biological systems such as metalloenzymes, are some these
consequences, etc.
Basically, two structurally distinct categories of gadolinium chelates are currently used: a)
The ‘macrocyclic’ chelates such as Gd-DOTA, where Gd3+ is ‘caged’ in the pre-organized cavity
of the ligand. (b) The ‘linear’ chelates such as Gd-DTPA or Gd-DTPA-BMA. The toxicity of
gadolinium complexes actually depends on their ability to release free Gd3+ ions. Transmetallation
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is a type of organometallic reaction that involves the transfer of ligands from one metal to another.
Several cations such as Fe3+, Cu2+, Zn2+ or Ca2+ compete with the Gd3+ cation and a number of
other anions such as PO43- , CO32- , OHcan compete with the ligand for the Gd3+. Thermodynamic stability can be described by eqn 1-12.
(1-12)

where M is the endogenous bivalent cation which exchanges with Gd3+ in the chelate. Factors
affecting the stability of contrast agents are their linear or cyclic structure and their overall charge
of the molecule. The thermodynamic stability of contrast agents can be summarized as:
Macrocyclic Ionic > Macrocyclic Non-ionic > Liner Di-ionic > Liner Non-ionic [148]. In addition,
thermodynamic can be described by these following equations:

(1-13)

(1-14)
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where KML is thermodynamic stability constant, [GdL] is the concentration of metal ligand
complex and [Gd] and [L] are the concentrations of free Gd3+ and ligand in the solution. Clinical
MRI contrast agents have thermodynamic stability constants ranging from 16.6-25.8 (log KML).

Figure 1.7 Structure of some commonly used clinical contrast agents [149].
ProCA32.collagen1, with two Gd3+ binding sites, has a thermodynamic stability constant
of 22.3, which is greater than Gd-DTPA-BMA (log KML= 16.6). The conditional stability constant
determines the stability of the metal-chelator complex at physiological pH, which is the
protonation of the chelator at pH 7.4 [150]. To investigate the metal binding affinity and selectivity
of ProCA32.collagen1, we have used different fluorescence spectroscopic methods such as dye
competition and Tb3+ energy transfer. ProCA32.collagen1 has a metal selectivity for Gd3+ over
physiological metal ions log (KGd/KCa) = 14.4 and log (KGd/KZn) = 16.2. Furthermore, the Gd3+
binding constant (log KGd) for ProCA32.collagen1 is comparable to DTPA and the metal
selectivities of ProCA32.collagen1 for Gd3+ over Zn2+ and Ca2+ are much greater than other clinical
contrast agents.
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We also have investigated the stability of Gd3+ binding to ProCA32.collagen1 under the
conditions of extracellular environment where there are other biological metal ions present and
can compete with Gd3+ and subsequently affect the relaxivities of ProCA32.collagen1. The
relaxivities (r1 and r2) of ProCA32.collagen1 were not significantly affected in the presence of Zn2+
and Ca2+, more details will be discussed in Chapter 2 and 4.
Table 1.3 Thermodynamic stability of some of clinical contrast agents compared to
ProCA32.collagen1 and ProCA32-P40 [151].
Contrast Agent

* Log
(KTb)
22

Log
(KGd)
22.46

Log
(KCa)
10.75

Log
(KZn)
18.6

Log(KGd)
/ Log (KCa)
12.24

Log(KGd)
/ Log (KZn)
4.13

Eovist (EOBDTPA)
Dotarem (DOTA)

N/A

23.6

11.82

18.78

12.22

5.18

N/A

24.7

17.23

21.05

7.46

3.65

MultiHance
(BOPTA)
ProHance (HPDO3A)
ProCA32-P40

N/A

21.91

N/A

17.04

N/A

4.87

N/A

23.8

14.83

19.37

10.07

4.37

21.08

22.44

9.55

8.77

13.1

14.3

ProCA32.collagen1

22.80

22.30

8.70

6.12

14.4

16.2

Magnevist (DTPA)

N/A, not available, * Values from NIST at pH 14
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Table 1.4 General data for all currently marketed Gd3+-based MRI contrast agents [1].

1.8.3 The kinetic stability and metal selectivity of MRI contrast agents
Metalloproteins such as Ca2+-binding proteins are important in biological systems as they
play a variety of roles in cell proliferation, migration, protein-protein interactions, protease
activation, signal transduction, and immune-responses [152, 153]. These Ca2+- and Zn2+- binding
proteins can potentially bind to free Gd3+ released from contrast agents in the body. Moreover,
blood plasma and interstitial fluids in the body have multiple ions such as Ca2+ and Zn2+ and Fe3+
which can compete with Gd3+ in the contrast agent to release free Gd3+. There are also certain
anions in the body that can compete with contrast agent itself such as phosphate (0.6 M) and
bicarbonate (0.36 M) in the biological systems form which in turn further drives the disassociation
of Gd3+ from the metal contrast agent complex. Kinetic stability properties determine the rate of
this dissociation in a contrast agent in which an agent with high kinetic stability will release less
Gd3+ per unit time [154]. In order to assess the kinetic stability, the dissociation rate of Gd3+ from
the complex can be measured at pH=1, at which the dissociation rate of a contrast agent is
significantly increased compared with physiological pH. As it was mentioned previously, linear
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contrast agents have higher dissociation rates or lower kinetic stability compared to cyclic contrast
agents. As can be seen in Fig. 1.7, clinically approved contrast agents such as Gd-DTPA-BMA
has the lowest kinetic stability, however Gd-DOTA has highest kinetic stability. It has been
demonstrated that the dissociation rate of the Gd-chelator complex correlates with the Gd3+
retention in mouse 14 days after injection of these agents [35].
1.8.4 Size is essential for contrast agent distribution and excretion
Disease biomarkers have diverse locations based on the stage of the disease. For instance,
Collagen type I is a biomarker expressed in higher levels in a variety of cancers such as liver and
breast cancer as well as liver fibrosis and its progression to cirrhosis [155]. Collagen is also present
in blood vessels and inside and on the surface of tumors, while other biomarkers such as HER-2
is deeply expressed in a tumor outside of the blood vessel. Therefore, it is important to have an
ideal half-life for targeting different biomarkers. Theoretically, longer circulation times might
provide more time for Gd3+ release and toxicity, therefore, the contrast agent should have a
moderate and optimized blood circulation time tailored towards the specific targeted biomarker.
For molecular imaging of a liver metastasis and fibrosis, the contrast agent should have sufficient
blood half-life to allow the contrast agent to penetrate deeply into the tumor and then quickly be
excreted out of the body to reduce the toxicity. The half-time of ProCA32.collagen1 in mouse is
about 9 hours depending on the surface modification [84] and exhibits enhancement in various
organs but mainly in the liver. Since the collagen concentration increases (M levels) as fibrosis
progresses and its extracellular location makes it readily accessible by the probe, therefore
relatively longer half-life is needed.
The half-life of clinical contrast agents that are based on small chelators are very different
from other agents such as nanoparticles that have uptake by macrophages and have accumulations
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in the liver and spleen. In a study regarding the distribution of gold nanoparticles with a diameter
ranging from 10, 50, 100, and 250 nm, after 24 h, the 10 nm gold nanoparticles distributed in
different organs such as blood, liver, kidney, spleen, heart, lung, and brain, however the majority
of 50 nm gold nanoparticles distributed in blood, lung, liver, and spleen [156]. Usually, the agents
that are larger than 50 nm mainly distribute in blood, liver, and spleen. In addition to tumor
penetration and organ distribution, the size of the contrast agents can also affect renal excretion.
For instance, a molecule with a size of larger than 7 nm in diameter (approximately 60 kDa) is not
readily able to pass through the glomeruli, and the blood half-live of these molecules in mouse is
longer than 80 min [31]. Lysozyme with a molecular weight of 15 kDa and diameter of 3.4 nm,
has the blood half-life of 12 min. On the other hand, IgG has the molecular weight of 152 kDa has
the blood half-life of 330 min. The toxicity of nanoparticles with a size larger than 15 nm has
grown concern since the renal excretion is prevented for these large macromolecules due to the
risk of accumulation in the human body [31].
1.8.5 Transmetallation studies of MRI contrast agents
One of the important studies in MRI contrast agent field and their development is
transmetallation of Gd3+ chelates by other physiological ions such as Fe3+, Cu2+, and Zn2+.
Protocols based on relaxivity have been used to compare the transmetallation of the approved
clinical contrast agents (2.5 mM) in the presence of 2.5 mM Zn2+ in the phosphate buffer. In these
studies, the highest kinetic stability was achieved for Gd-DOTA [35]. In addition, further studies
demonstrated the kinetic profile of Gd3+ dissociation from Gd3+-based MRI contrast agents in
serum for the duration of 15 days using HPLC-ICP-MS. More unstable contrast agents such as
nonionic linear ones like Gd-DTPA-BMA, demonstrated 10 times higher Gd3+ release than ionic
linear contrast agents, such as Gd-DTPA. In contrast, macrocyclic contrast agents as the most
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stable type of agents did not show any Gd3+ release such as Gd-DOTA. These studies demonstrate
that cyclic contrast agents have good kinetic stability compared to linear contrast agents [157].
1.8.6 Toxicity studies of MRI contrast agents
The major organs in the body which have Gd3+ deposits are usually bone, lung, and liver.
The dissociation rate in which Gd3+ is released from the contrast agents has direct effect on its
deposition in bones. Studies have reported Gd3+ retention in mice 14 days after injection of
different Gd3+-based chelates with different dissociation rates. Results demonstrated that mice
injected with Gd-DTPA-BMA or Gd-NP-DO3A had much higher Gd3+ deposition in the whole
body, mainly in bone and liver, compared to mice injected with Gd-DOTA or Gd-HP-DO3A [35].
In another study, Gd3+ concentration in the bones of patients who had hip replacement was
analyzed after injection of 0.1 mmol/kg Gd-HP-DO3A or Gd-DTPABMA. The analysis showed
that Gd3+ retention was 1.77 and 0.447 μg per gram of bone for Gd-DTPA-BMA and Gd-HPDO3A, respectively as revealed by ICP-AES [158]. Furthermore, the use of these contrast agents
in patients with kidney problems is reported to cause NSF. Biopsy results of patients with NSF
have confirmed the presence of insoluble Gd3+-phosphate deposits in their skin [159, 160].
The acute toxicity of ProCA32.collagen1 was studied with clinical chemistry tests and
different components of plasma samples were measured such as liver enzymes (ALT, ALP, AST,
LDH), urea nitrogen, bilirubin, and total protein content from CD1 mice 5-7 days post tail veil
injection of 0.0013 mmol/kg of ProCA32.collagen1. The results showed negligible toxicity
compared to control subjects (CD-1 mice).
The serum stability experiment is another useful tool for monitoring unstable compounds
in vitro. To test the stability of ProCA32.collagen1 in human serum, the protein was incubated in
complex with an equal concentration of GdCl3 in human serum at 37 ˚C. The degradation of the
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protein was monitored by both SDS-PAGE. The results showed that the protein remained intact
for at least 48 hours in the absence of serum as well as in the presence of 70% human serum up to
14 days of incubation. Long term Gd3+ retention and pharmacokinetics of ProCA32.collagen1 will
be discussed in detail in the Chapter 4.
Molecular imaging by MRI using a biomarker-targeted contrast agent
Monitoring different disease biomarkers in patients with invasive methods such as biopsy
has so many disadvantages such as its invasiveness, high costs and sampling error, intra/interobserver variability, hospitalization in 1–5% of cases, mortality in 0.01–0.1% of cases, lack of
accuracy due to substantial sampling error, cost associated morbidity, pain and bruising at the
biopsy site, prolonged bleeding, infection of the biopsy site, and pneumothorax and hemothorax.
For instance, there is a 33% error in diagnosis of liver cirrhosis which severely affect the patient
outcomes [109, 161]. With its unique capacity to generate reproducible and non-invasive
assessment of biological/disease processes of different organs at various time points, molecular
imaging of disease biomarkers using MRI can be an important and ideal diagnostic tool to facilitate
the understanding of the disease, monitoring disease progression and drug treatment and activity
during preclinical and clinical application. Since MRI is cheaper compared to some other imaging
modalities, its application for molecular imaging can dramatically lower the costs by reducing the
number of animals required for a specific study. However, one of the major limitations of MRI to
investigate specific disease biomarkers for diagnosis and drug treatment monitoring is the lack of
sensitive contrast agents with high relaxivity, targeting capability, and tissue permeability.
The majority of disease biomarkers have very low expression levels. Approximately,
5×106 Gd3+ per cell are needed to acquire a good and sufficient contrast in MRI using current
clinical contrast agents based on small chelators since they have low relaxivity of ~5 mM-1s-1[162].
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Studies have shown that endocytosis is a useful process for contrast agents in tissues since it helps
them to accumulate in a local area, however recent studies showed otherwise and that the relaxation
enhancement is suppressed when the local concentration of Gd3+ is higher than 1010 Gd3+ per cell
[163-165]. The decrease in relaxivity can be attributed to insufficient water exchange across the
plasma membrane.
Targeted molecular imaging by MRI is now under development to increase sensitivity
[109, 166]. The majority of these MRI contrast agents target biomarkers expressed on the surface
of blood vessels and not so many have tried to target the biomarkers outside of the blood vessels.
In order to improve the dose efficiency of MRI contrast agents, peptide fragments with high
affinity to biomarkers are extensively applied for conjugation. For instance, two-component Gd3+based MRI contrast agents have been generated by binding of avidin-Gd3+ complexes to tumor
cells which was labeled with a biotinlyated antibody [167, 168]. These contrast agents have the
disadvantage of slow diffusion when targeting tumors in vivo. Moreover, antibodies demonstrate
improper distribution and penetration in tumor blood vessel [80]. Peptides on the other hand have
small size compared to the antibodies, therefore they have good tumor penetration [119, 169],
however, these peptide-based MRI agents need further improvement in targeting capability and
resistance to protease cleavage. Overall, the development of targeted MRI agents has long way to
go despite the significant amounts of research. In conclusion, there is still unmet medical needs
for the development of MRI contrast agents with higher relaxivity and improved targeting
capability to image spatial distributions and patterns of biomarkers by MRI.
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Magnetic resonance imaging (MRI) demonstrates several technical advantages such as
deep tissue penetration, high spatial resolution, complete coverage of the entire liver, detailed
structural and anatomical information, evaluation of organ morphology, and it is relatively
inexpensive. Most importantly, MRI does not use ionizing radiation which makes it suitable for
monitoring disease progression and treatment when repeated imaging is required for a long period
of time [161]. More than 35% of MRI scans use MRI contrast agents, particularly paramagnetic
gadolinium (Gd3+)-based contrast agents [83], which shorten T1 and increase MRI signal [7],
however MRI lacks sensitive contrast agents. All clinically approved Gd3+-based contrast agents
are based on small chelators with relaxivity (r1 and r2) ranging from 4–6 mM−1·s−1. Their low
relaxivities severely limit their sensitivity to be applied in detection of early stages of chronic
diseases, their progression and treatment monitoring. In addition, they do not have the targeting
capability for any disease biomarker. For instance, gadolinium–ethoxybenzyl– diethylenetriamine
pentaacetic acid (Gd-EOB-DTPA) (Eovist, United States; Primovist, Europe; Bayer) and
gadobenate dimeglumine (Gd-BOPTA) (Multihance; Bracco) are among the most popular and
common clinical contrast agent which are T1-weighted liver contrast agents, and have 50% and
5% hepatocyte uptake, respectively [8]. However, these contrast agents cannot detect early stages
of many diseases where biomarkers expression play an important role in early diagnosis and
progression. Therefore, development of targeted and sensitive MRI contrast agents with improved
sensitivity, higher metal binding affinity and selectivity is needed to overcome MRI limitations
and enable the earlier detection of different chronic diseases such as liver fibrosis, and monitor its
progression as well as its treatment, which results in earlier diagnosis, treatment and subsequent
reversion of the disease.
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Collagen type I: An appealing target for many chronic diseases
Extracellular matrix (ECM) is a dynamic and complex environment characterized by
biophysical, mechanical and biochemical properties specific for each tissue and able to regulate
cell behavior. The ECM is composed of a large collection of biochemically and structurally diverse
components. Biochemically, these components can be divided into proteins, proteoglycans, and
glycoproteins, each of which has diverse sub-categories of components and varying physical and
biochemical properties[170]. Collagen type I is the most abundant component of ECM. Collagen
is abundant in humans accounting for one-third of total proteins. The fibrous, structural protein
contains three polypeptide α-chains, displaying a polyproline-II conformation, a right-handed
supercoil and a one-residue stagger between adjacent chains [171]. Each polypeptide chain has a
repeating Gly–X–Y triplet, and the three polypeptide α-chains in the triple helix held together by
inter-chain hydrogen bonds can be identical, but heterotrimeric triple helices are more prevalent
than homotrimeric triple helices.
Recent studies have highlighted the role of the ECM and shown the importance of
deregulated ECM dynamics in molecular etiology of disease development. Excess ECM
production or reduced ECM turnover, for example, are a salient feature in tissue fibrosis of many
organs and collagen type I as the most abundant component of EMC plays an indispensable role
in these processes [170].
Collagen type I is an appealing target for molecular imaging of a variety of diseases such
as liver fibrosis, liver metastasis, breast cancer, pancreatic cancer and aortic aneurysms. In organ
fibrosis and different cancers, collagen accumulation as well as its concentration increases by the
disease progression. In addition, collagen type I is an extracellular protein which makes it
accessible for any agent.
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Collagen targeted MR imaging contrast agent could act as an agent to image these diseases,
and these agents may have higher efficacy for fibrosis and cancers assessment than the clinically
available contrast agents. [30, 109]. Furthermore, MRI contrast agent providing a measure of
collagen levels as well as its capability to bind cross-linked collagen would have utility in detection
of early stages of diseases such as fibrosis, cirrhosis and drug treatment monitoring. Although
other groups such as Caravan et al, conducted extensive research on developing contrast agents
for detection of fibrosis, or pancreatic cancer, sensitivity and specificity is still a challenge in
development of contrast agents for early detection [109, 110, 121, 122, 161, 172].
Using rational protein design, we have developed a protein-based MRI contrast agent
ProCA32.collagen1 that targets collagen type I. ProCA32.collagen1 has high relaxivity values for
r1 and r2 per Gd3+ at both 1.5 and 7.0 T. In addition, ProCA32.collagen1 is able to detect both early
and late stage (Ishak score of 3 and 5) of mouse liver fibrosis in multiple mouse models which has
not been achieved by any clinical contrast agent such as Eovist and non-targeted contrast agent,
ProCA32 previously developed by S. Xue. et al [83]. Moreover, ProCA32.collagen1 is able to
detect small tumor lesions in uveal melanoma liver metastasis.
Motivation and challenges to be addressed
Early diagnosis for many diseases has always been a challenge for scientists and clinicians.
It can play an indispensable role in treatment efficiency and strategies. Development of MRI
contrast agents is an evolving field, however clinical MRI contrast agents have faced major
limitations in terms of application in early diagnosis for many chronic diseases due to lack of
sufficient sensitivity and targeting capability. Our lab has been working on development of novel
Gd3+ protein-based MRI contrast agents (ProCA) to overcome the challenges associated with
current MRI contrast agents in clinics.
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In order to apply our contrast agent in diagnosis of chronic diseases, there are several
challenges the need to be addressed. First, can we develop a new MRI contrast agent with improved
sensitivity to target a specific biomarker for early stage diagnosis of chronic diseases? Can we
improve the safety of an MRI contrast agent by reducing its dose and toxicity? Third, can we
develop a new MRI contrast agent capable of monitoring diseases progression and treatment?
Forth, can we stage chronic diseases with the use of a noninvasive technique and absent of biopsy?
Fifth, can we improve accuracy and specificity of chronic disease diagnostics by taking advantage
of a T1-T2 dual mode contrast agent combined with imaging methodologies?
Overview of the dissertation
In this Ph.D. dissertation, in order to address these mentioned challenges and questions, I
have developed a collagen type I targeted protein-based MRI contrast agent, ProCA32.collagen1
with improved sensitivity and targeting capability compared to other previously developed contrast
agents in our lab and clinically available contrast agents.
Chapter 2 details experimental methods and protocols that we used for the dissertation.
Chapter 3 describes our rationales for design of a novel collagen type I targeted protein
contrast agent (ProCA32.collagean1) and its expression, purification and characterization.
Chapter 4 describes the biophysical properties of ProCA32.collagen1 such as its metal
binding affinities, relaxivities, pharmacokinetic, transmetallation, collagen type I affinity, serum
stability and toxicity studies.
Chapter 5 details the successful application of ProCA32.collagen1 in early detection of
liver fibrosis in TAA/alcohol induced mouse liver fibrosis using both r1 and r2 property. Moreover,
ProCA32.collagen1 ability to map liver cirrhosis heterogeneity in DEN- and TAA/alcohol-induced
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mouse models is elaborated as well as its capability in revealing vascular structural changes,
intrahepatic angiogenesis and portal hypertension.
Chapter 6 reports the successful application of ProCA32.collagen1 for early detection of
human uveal melanoma tumors metastasis to mouse liver. In addition, ProCA32.collagen1
capability in distinguishing different uveal melanoma growth patterns (Nodular vs Infiltrative) in
liver is described.
Chapter 7 reports the studies of hepatocellular carcinoma (HCC) tumor detection in liver
in DEN-induced mouse model using ProCA32.collagen1. ProCA32.collagen1 is able to
distinguish cirrhotic regions in liver from HCC tumors.
Chapter 8 describes our attempt in extending the application of ProCA32.collagen1 in
imaging collagen in mouse model of thoracic and abdominal aortic aneurysm (TAA/AAA) with
subcutaneous infusion of angiotensin II (AngII) from implanted osmotic pump.
Chapter 9 provides our studies in application of ProCA32.collagen1 in early detection of
Nonalcoholic steatohepatitis (NASH) in Nonalcoholic fatty liver disease (NAFLD) in mouse
models on a NASH diet.
Chapter 10 describes and summarizes the major findings of this dissertation and future
direction.
In Appendix, my studies on a different topic involving Connexin43 (Cx43) gap junction
regulation by Ca2+/Calmodulin will be discussed. We have identified several Calmodulin binding
sites in Cx43, and fluorescence spectroscopy was used to study the interaction between Cx43 and
calmodulin in the presence of Ca2+.
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2

MATERIALS AND EXPERIMENTAL METHODS

Molecular cloning, expression, purification and Lysine PEGylation.
In

the

contrast

agent

design,

collagen

type

I-targeting

peptide

(KKWHCYTYFPHHYCVYG) for type I human collagen) was linked to the C-terminal of
ProCA32 by a flexible linker (GGG). The protein contrast agent was named ProCA32.collagen
and then it was purified according to Henzl’s and Xue et al procedure with some modifications
[83, 173]. First, ProCA32.collagen was expressed in Escherichia coli BL21 (DE3) cell strain, and
then it was induced by 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when the optical
density at 595 nm (OD595) reached 0.6. After induction, the culture temperature was reduced from
37 °C to 28 °C for expression overnight. The bacterial pellets were re-suspended and sonicated in
10 mM Tris.HCl buffer for 12 times at pH 7.2 with 1 μL of benzonuclease (Novagen). The
supernatant of the cell lysate was incubated at 85 °C for 20 min, cooled to 4 °C in an ice-water
bath, and centrifuged (41,100 × g, 20 min, 4 °C). Impurities including DNA, were then precipitated
by addition of 3% (wt/vol) streptomycin sulfate and placed at 4 °C overnight. On the next day, the
precipitate DNA was removed by centrifuge and the supernatant was dialyzed at least in 4 changes
of buffer in 4 °C for 24 h against 10 mM Tris.HCl at pH 8.0 then the protein mixture was further
purified using a HiTrap Q column (GE Healthcare) by fast protein liquid chromatography (FPLC)
. After removing unbound proteins with 3 column volumes of 10 mM Tris at pH 8.0, the column
was eluted with a 0–1 M NaCl gradient in 10 mM Tris·HCl at pH 8.0. Purified ProCA32.collagen
was confirmed by SDS-PAGE and UV spectrum. Gd3+ was loaded to ProCA32.collagen at a 2 : 1
ratio. Other metals in ProCA32.collagen such as Ca2+ was removed by chelex-100 and the metal
content in ProCA32.collagen was analyzed by ICP-OES. The protein was PEGylated by the
following steps: First, it was dialyzed three times against 10 mM Hepes at pH 7.0–7.2. Second,
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ProCA32.collagen was mixed with Methoxy Succinimidyl Carboxymethyl Ester (M-SCM-2000)
reagent with molecular weight of 2 kDa (JenKem Technology), with a molar ratio of 1:5, and then
incubated at room temperature for 4 h or 4 °C overnight. Third, unreacted free M-SCM-2000 was
quenched by adding 100 mM Tris·HCl with a final concentration of 10 mM. Fourth, PEGylated
ProCA32.collagen was further purified using HiTrap Q column and then concentrated about 4
times using concentrator with 3kDa membrane to remove the unreacted free PEG (MW 2 kDa).
After removing unbound fractions with 3 bed volumes of 10 mM HEPES at pH 8.0, the proteins
bound to the column were eluted with a 0–1 M NaCl gradient in 10 mM HEPES at pH 8.0.
PEGylated products were analyzed by SDS/PAGE with protein staining by Coomassie Brilliant
Blue and PEG staining by I2.
Liver fibrosis and metastasis animal models
2.2.1 Thioacetamide (TAA)/alcohol induced fibrosis
Balb/c mice (6 - 7-week-old male) were I.P. injected with 100 mg/kg TAA and gradually
increased to 200 mg/kg TAA in two weeks. 10% alcohol was also fed to mice along with the TAA
treatment. For rPKM2 experiment, 5 mg/kg of rPKM2 was mixed with TAA for injection starting
at two and a half weeks, and lasted for total of seven weeks. TAA mixed with buffer or rPKM1
was the control.
For the PKM2 antibody experiment, TAA was continuously treated for twelve weeks. After
that, TAA and alcohol was stopped and 4mg/kg of PKM2 antibody was I.P. injected every other
day for ten doses. Buffer and rabbit IgG were the control.
The body weights were recorded every week or every four days. At the end of the
experiments, animals were sacrificed. Livers, other organs, and blood samples were collected.
Liver weights were measured and liver pictures were taken. Tissue sections were prepared and
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analyzed by IF, IHC, or H&E stains using commercially available antibodies as indicated. Serum
samples were prepared from collected blood samples. The serum samples were analyzed by the
service of Comparative Clinical Pathology.
Liver fibrosis was induced with Balb/C mice by administration of TAA and 10% ethanol
in drinking water for 12 weeks. At the end of cirrhosis induction, the animals were treated via
buffer. After the treatments, animal body weights, liver weights, and out-surface of livers were
examined. All animal experiments in this study complied with the Association for Research in
Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research
and complied with an approved animal protocol from the Institutional Animal Care and Use
Committee at Georgia State University and the University of Georgia.
2.2.2 DEN induced Cirrhosis and HCC
For all of our studies, we employed female and male mice with C57BL/6 genetic
background. Experiments involving animals were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and were approved by the Georgia State University
IACUC. Animals were housed in a pathogen-free animal facility under a 12 h light/dark cycle and
fed a standard rodent chow and water ad libitum. In order to induce liver tumor development, 14day-old mice were treated with a single dose of DEN (Sigma–Aldrich # N0756) given dissolved
in saline at a dose of 25 mg/kg body weight by i.p. injection on day 12. Mice in one randomly preassigned group were killed 10 months after DEN administration for histological and biochemical
analyses. Mice were randomly distributed in various groups having equal males and females.
Immediately after euthanizing, livers were removed, weighed and the numbers of visible
tumors on the liver surface were counted macroscopically. The largest lobes were fixed in formalin
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and embedded in paraffin. Sections were stained with hematoxylin and eosin and examined
microscopically.
2.2.3 Uveal melanoma liver metastasis model
All animal procedures performed in this study complied with the Association for Research
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision
Research and complied with an approved animal protocol from Institutional Animal Care and Use
Committee at Georgia State University and University of Georgia. To generate hepatic melanoma
implantation model, C57BL/6 female mice, 7–10 wk old, were anesthetized with i.p. ketamine
hydrochloride, 90 mg/kg, and xylazine, 10 mg/kg. After anesthesia, a small horizontal abdominal
incision (1 cm) was made in the left upper quadrant such that the left lobe of the liver will be
exposed. A total of 5 × 106 of mouse B16LS9 melanoma cells were drawn into a Hamilton syringe
with a 29-gauge needle creating a 5-μL slurry that were injected into the parenchyma of the
exposed liver under an operating microscope. Gentle pressure was applied to the hepatic injection
site for 1 min with a cotton-tipped applicator after tumor cell injection. The left lobe of the liver
was repositioned into the peritoneal cavity, and the abdominal wall was then closed with 5.0
sutures. To generate the uveal metastasis model, aliquots of 5 × 105 cells of B16LS9/2.5 μL were
inoculated into the choroid of the right murine eye of 7- to 10- week-old PEDF-null C57BL/6
female mice (8), using a transscleral technique that allows the inoculated cells to remain in the eye.
The mice were anesthetized and a tunnel was prepared from the limbus within the sclera to the
choroid with a 30 1/2-gauge needle under the guidance of a dissection microscope. The tip of a
10-μL glass syringe with a blunt metal needle (Hamilton) was introduced into the choroid through
the needle track, and no cells were inoculated until the needle tip was inside the eye. A 2.5-μL
suspension of cells was inoculated. No tumor cell efflux from the eye occurred, and the
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subconjunctival space remained free of tumor cells. The inoculated eyes were enucleated after 1
wk, fixed in 10% (vol/vol) formalin, and routinely processed for light-microscopic examination.
Serially adjacent 5-μm-thick sections were stained with hematoxylin and eosin (H&E) and
evaluated for the presence and location of melanoma. Hepatic tissue was collected at 3 wk after
MRI.
Human uveal melanoma 92.1 cells were inoculated into the supra choroid space of the right
eye using a transcorneal technique. For each inoculation, a million cells were delivered in a volume
of 2.5 uL. The mice were anesthetized with intraperitoneal injection of ketamine and xylazine
mixture. A tunnel was prepared from the limbus within the cornea, sclera and ciliary body to the
choroid with a 301/2-gauge needle under a surgical microscope. The tip of a 10 uL glass syringe
with a 31-gauge /45-degree point metal needle (Hamilton, Reno, NV) was used to introduce cell
suspension into the supra choroid space through the needle track. The right eye was enucleated at
2 weeks after tumor cell inoculation [174, 175].
Metal binding affinity measurements of ProCA32.collagen1
In order to investigate the Gd3+ binding affinity of PEGylated ProCA32.collagen, a buffer
system is used in which Tb3+ binding affinity can be measured since Gd3+ is spectroscopically
silent. Then the Gd3+ binding affinity was calculated using a competition assay [83]. Determining
Tb3+ binding affinity of ProCA32.collagen1 was based on the Tb3+ luminescence resonance energy
transfer (LRET) experiment in which 30 μM ProCA32.collagen1 was prepared in 5 mM DTPA,
50 mM HEPES, and 150 mM NaCl at pH 7.2. The ratio of Tb-DTPA concentration ([Tb-DTPA])
and free DTPA concentration ([DTPA]free) were controlled by titration of TbCl3 in the system. The
protein-Tb3+ LRET emission spectra were collected between 520 and 580 nm using an excitation
wavelength of 280 nm. The free Tb3+ concentrations ([Tb]free) in each titration point were
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calculated by eqn (2-1). The dissociation constant between Tb3+ and ProCA32.collagen1
(KdTb,ProCA) is calculated by the Hill equation (2-2).

(2-1)

(2-2)
[Tb3+]free is the free Tb3+ concentration calculated from the buffer system, KdTb, DTPA is
the dissociation constant of Tb3+and DTPA, the dissociation constants of Tb3+ to DTPA were
obtained from National Institute of Standards and Technology Standard Reference Database [75].
[Tb-DTPA] is the concentration of Tb-DTPA complex that is formed during titrations, [DTPA]free
is the free DTPA in the buffer, f is the fractional change of the LRET signal at each titration point
and n is the hill number, KdTb,

ProCA

is the dissociation constant between Tb3+and

ProCA32.collagen1.
After achieving the binding constant of Tb3+ for ProCA32.collagen1, a competition assay
was performed to measure the binding affinity of ProCA32.collagen1 for Gd3+. The Tb3+
fluorescence spectra were recorded by tryptophan excitation at 280 nm and emission from 500 to
650 nm. 10 μM of ProCA32.collagen1 was used and 20 μM of Tb3+were incubated with different
concentrations of GdCl3 from 0 to 1000 μM at room temperature overnight. The Tb3+-FRET
changes were measured by the emission at 545 nm. The apparent dissociation constants (Kdapp)
were calculated by fitting the plot of LRET peak intensities over different concentrations of Gd3+
(eqn (2-3)) and the dissociation constants of Gd3+ to ProCA32.collagen1 (KdGd,ProCA) were
calculated by eqn (2-4).
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(2-3)

(2-4)

where f is the fractional change of the LRET signal, [Tb]T is the total Tb3+ concentration,
[Gd]T is the total Gd3+ concentration in each titration point, and KdGd,ProCA is the dissociation
constant between Gd3+ and ProCA32.collagen1 determined by eqn (2-2).
The Kdapp for ProCA32.collagen1 was calculated first and then this value was used to
calculate the actual dissociation constant using the equation 4.
For determining the calcium binding affinity of ProCA32.collagen1, a calcium equilibrium
buffer system was used where, 10 μM of ProCA32.collagen1 was added to the calcium–EGTA
buffer system containing 50 mM HEPES, 150 mM NaCl, and 5 mM EGTA at pH 7.2. The system
was titrated with different concentrations of CaCl2 to alter the concentration ratio between the CaEGTA ([Ca-EGTA]) and free EGTA ([EGTA]free). The tryptophan (Trp) fluorescence changes
were monitored under the emission spectra between 300 and 390 nm as excited at 280 nm. The
free calcium concentration at each titration point was calculated by eqn (2-5)

(2-5)
Furthermore, free calcium concentrations in the buffer were tightly monitored and
calculated using equation derived from Tsein’s equation [176] with some modifications and the
Kd of EGTA-Ca2+ =1.51×10-7 M was obtained from NIST. The Kd of Ca2+ to ProCA32.collagen1
(KdCa,ProCA) was determined by eqn (2-6).
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(2-6)

where f is the fractional change of Trp fluorescence intensity, [Ca]free is the free Ca2+
concentration in each titration point determined by eqn 5. The same data points were fitted using
Adair equation [173] which will result in two separate association constants Ka for each binding
site.
The Zinc binding affinity of ProCA32.collagen1 was determined using a similar assay by
competition titration using Fluozin1 dye [79, 177]. The fluorescence of 2 µM Fluozin-1 was
excited at 495 nm and the emission spectra were collected between 500 and 600 nm in the presence
of 2 µM Zn2+ and different concentrations of ProCA32.collagen1. The apparent dissociation
constant (Kdapp) was calculated by eqn 2-7.

(2-7)

where f is the fractional change of the fluorescence intensity of Fluozin-1, [Zn]T is the total
Zn2+ concentration, and [ProCA]T is the total concentration of protein contrast agent at each
titration point. The dissociation constants between ProCAs and Zn2+ (KdZn,ProCA) were then
calculated by eqn (2-8).

(2-8)
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where Kdapp is determined by eqn (2-7), KdZn,Fluozin is the Zn2+ affinity to Fluozin-1 and
[Fluozin]T is the total Fluozin-1 concentration.
Histology analysis
2.4.1 Immunohistochemistry and Hematoxylin and Eosin analysis
For immunohistochemistry, paraffin-embedded liver sections were cut (4 μm) and mounted
on slides (ProbeOn; Fisher Scientific). The sections were dried, deparaffinized, and hydrated with
xylene and graded ethanol. Formalin-fixed samples were then stained with Sirius Red according
to standard procedures. Sirius Red stained slides were analyzed by a pathologist, at Emory
University School of Medicine, to score the amount of liver disease based on Ishak scoring system
[178, 179] . Furthermore, CPA which is % area stained with Sirius Red, was calculated from the
histology images using ImageScope.
For H&E Staining, livers were fixed in 10% (vol/vol) formalin. Then they were dehydrated
in increasing concentrations of alcohol, cleared in xylene, and embedded in paraffin. Serial 5-μm
sections were prepared, stained with H&E, and processed for light-microscopic examination.
2.4.2 Immunofluorescence staining
Immunofluorescence staining was performed on fibrotic tissues collected from the mice
liver post injection of ProCA32-P40 and ProCA32.collagen1 for 48 hours. Tissues were
immediately frozen in liquid nitrogen after dissection and stored in -80C. After that the tissues
were embedded in optimal cutting temperature (OCT) cryostat sectioning medium and cut with a
thickness of 5 μm. ProCA32-P40 and ProCA32.collagen1 were stained by home-made rabbit
antibody against ProCA32 and Alex Fluo 555-conjugated secondary antibody (red) against the
rabbit antibody. The nuclei of the cells were stained by DAPI (blue).
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Mouse MRI imaging
All mice were imaged on a 7-T Agilent MRI scanner at the University of Georgia. Animals
were anesthetized using isoflurane and their respiration rate was monitored with a small animal
physiological monitoring system. Anesthesia was adjusted to maintain a respiration rate of 65 ± 5
breaths per minute. T1 map (inversion recovery) and T2 map MRI images were collected before
and after intravenous (I.V.) administration of 5 mmol/L of ProCA32.collagen1 or ProCA32-P40.
T1 map images were acquired with inversion recovery times of 10, 222, 435, 648, 861, 1074, 1287,
and 1500 ms. Other acquisition parameters include: repetition time of TR = 5000 ms, Effective
TE=32.67 ms, field of view FOV = 35×35 mm, matrix = 256×256, slice thickness = 1.0 mm, and
12 image slices with no gap. T2 map images were collected before and after the contrast agent I.V.
injection of 5 mM ProCA32-P40 or ProCA32.collagen1 with different time points using the
MSME sequence with the following parameters: TR = 2000 ms, different echo times, TE (8, 16,
24, 32, 40, 48, 56, 64, 72, 80, 88, 96 ms), matrix = 256×256, FOV = 35×35 mm, and slice thickness
= 1 mm and 12 image slices with no gap. The final T2 and R2 map images were generated by
using a ImageJ plugin MRI T2 calculator, and the T1 and R1 map images were generated with
MATLAB. After MRI experiment, animals were sacrificed and different organs including liver
were collected for biodistribution, and histology experiments.
T1-wieghted MRI images were recorded with TR of 500 ms and TE of 15 ms with matrix
resolution of 256×256, FOV = 35×35 mm, and slice thickness = 1 mm and 12 image slices with
no gap. T2-weighted images were recorded with TR=2000 ms and TE of 8 ms with matrix
resolution of 256×256, FOV = 35×35 mm, and slice thickness = 1 mm and 12 image slices with
no gap. Heavy T2-weighted images were recorded with longer TE times in order to completely
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remover the T1 effect. The TE used is 4000 ms and TE=10 ms. Other parameters remained the
same.
Statistical analysis
Statistical analysis of signal to noise ratio (SNR) was performed using two-tailed Student’s
t test. The statistical analysis of contrast-to-noise ratio (CNR) of T1- and T2-weighted imaging
were analyzed by one-way ANOVA. Statistical analysis was performed in GraphPad Prism 5
(GraphPad Software). Longitudinal relaxation rate (R1) maps and their associated histograms were
generated from the images using a custom written MATLAB (Mathworks, Natick, MA) program
for voxel wise fitting of the inversion recovery signal intensities as a function of inversion recovery
time. The mouse group sizes were set to support statistically valid data and to minimize the use of
the animal. Mice were randomly assigned to groups for the experiments. The animal studies were
not blinded, because the same investigators performed the grouping, experiments, and analysis,
rendering blinding of these studies unfeasible. An experienced pathologist was blinded to the
groups of H&E and Sirius red staining to evaluate the staging of fibrosis as well as organ toxicity
of contrast agents.
In addition, the change in liver longitudinal relaxation rate ∆R1 which is defined as R1postR1pre as well as Increase Rates of Liver R1 values (%) defined as

(2-9)

Was calculated. Receiver Operating Characteristic (ROC) analysis used to demonstrate our
developed contrast agent ability in staging liver fibrosis
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Determination of r1 and r2 relaxivity values
The ability of a contrast agent to change a relaxation rate is represented quantitatively as
relaxivity, r1 or r2, where the subscript refers to either the longitudinal (1/T1) or the transverse rate
(1/T2). Relaxivity is simply the change in relaxation rate after the introduction of the contrast agent
(Δ(1/T)1) normalized to the concentration of contrast agent or metal ion (M):

(2-10)

The relaxation rates of contrast agents (r1 and r2) were determined using different
concentrations of GdCl3 and protein (2:1) at 37 °C with 1.4 T Bruker Minispec using saturation
recovery and CPMG sequence, respectively. Using the equation below the relaxation rate for both
T1 and T2 were measured. The slope of the curve will be longitudinal (r1) and transverse (r2)
relaxivities. Furthermore, the T1 and T2 of Gd-DTPA and ProCA32.collagen1 were also measured
by using a 7 T Agilent scanner using saturation recovery and spin echo sequence. r1 and r2 were
calculated by eqn 10.

(2-11)

Enzyme-linked immunosorbent assay (ELISA) assay
Collagen type I solution from rat tail (Sigma-Aldrich) was coated in 96-well plates at 4 °C
overnight. After being blocked with 5% bovine serum albumin (BSA), a series of different
concentrations of ProCA32.collagen1 was incubated with the collagen type I solution. After
incubation at 4 °C overnight, the unbounded ProCA32.collagen1 was washed away with 1× TBST.
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The homemade polyclone rabbit-anti-ProCA32 antibody was applied with 1: 1000 dilution as the
primary antibody against protein contrast agent. A stabilized goat-anti-rabbit HRP-conjugated
antibody (Pierce) was used as the secondary antibody. After a robust wash with 1× TBST, the
remaining secondary antibody in the 96 well plate was visualized by using 1-Step™ Ultra TMBELISA Substrate Solution (Thermo Fisher Scientific). The absorbance intensity was detected by
the FLUOstar OPTIMA plate reader at an absorbance wavelength of 450 nm.
Pharmacokinetics, distribution and toxicity studies
All the animals were injected with 5 mM of Gd-DTPA, ProCA32-P40, and
ProCA32.collagen1. Different organ tissue samples from the mice were collected after euthanasia.
The collected tissues (~ 0.2 g) were digested with 70% (wt/vol) ICP-grade HNO3 at 40 °C
overnight. The HNO3 solution containing the digested tissues were collected the next day, filtered,
and diluted with 2% (wt/vol) HNO3 to 8 mL. Then each sample containing different organ was
analyzed by ICP-OES to measure the Gd3+ concentration at wavelength of 342.246 nm. YCl3 at 2
ppm was used as internal reference and different Gd3+ standard solutions with different
concentrations ranging from 5 ppb to 1000 ppb were made.
For pharmacokinetics studies, the blood concentration-time profiles after intravenous
injection of ProCA32.collagen1, ProCA32-P40, and Eovist in mice were analyzed using twocompartmental analysis using WinNonlin ™ 5.0.1 software (Pharsight Corp., Palo Alto, CA).
Mean blood concentration values from 3-6 mice at each sampling time point were used for the
mice pharmacokinetic analysis. The area under the blood concentration-time curve (AUC) was
calculated using the log-linear trapezoidal rule. The elimination half-life (t1/2) was calculated by
the equation t1/2 = 0.693/K, where K was estimated from the terminal slope of the blood Gd3+
concentration versus time curve. The systemic clearance (CL) was determined from dose/AUC,
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with AUC (area under the curve to infinity) by linear interpolation and extrapolation to infinity y
from Clast x t1/2β/0.693 (where Clast was concentration at each last sampling point). The volume of
distribution at steady-state (Vss) was determined by the equation Vss = CL × (AUMC/AUC),
where AUMC is the area under the first moment curve. The mean residence time (MRT) was
calculated from AUMC/AUC.
For clinical chemistry test studies of ProCA32.collagen1, mice with an average body
weight of 30 g were I. V. injected with 0.0012 mmol/kg of ProCA32.collagen1. The bloods of the
mice were collected five days post injection using heparin-coated capillary. Then the serum of
blood was obtained by centrifuge at 3000 rpm at 4 ˚C for 10 min. Approximately 300 μL of mice
serum were collected for clinical chemistry tests conducted in IDEXX Laboratories. The clinical
chemistry tests assessed the liver, kidney, and heart functions based on the levels of different liver
enzyme, proteins, glucose and ions in the serum.
Serum stability and transmetallation of ProCA32.collagen1
About 300 μM of ProCA32.collagen1 complexed with Gd3 was mixed with human serum
with 1:1 ratio, and then incubated at 37 ˚C for different time points. SDS-PAGE gel was used to
to detect the presence of Gd3+-ProCA32.collagen1 after incubating in the serum for each time
point. The protein separated by SDS-PAGE is stained by Coomassie brilliant blue or Ponceau S
solution to monitor its stability. Transmetallation of ProCA32.collagen1 and clinical MRI contrast
agents were evaluated by measuring the relaxivity changes in the presence of Zn2+ and phosphate
over time. The relaxivity of ProCA32.collagen1 was monitored with 55 or 110 μM
ProCA32.collagen1, 100 μM Gd3+, 100 μM Zn2+, and 1.2 mM PO43−.
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Measurement of water coordination number in ProCA32.collagen1
The number of water ligands coordinated to ProCA32.collagen1 complexed with Gd3+
complex was determined by measuring Tb3+ luminescence decay in H2O or D2O using the
previously published methods with some modifications [180]. Tb3+ was excited at 265 nm with a
Xenon Flash lamp and the Tb3+ emission was collected at 545 nm at a series of time points in both
H2O and D2O solutions. Luminescence decay lifetime of Tb3+ or Tb3+ complex with different
chelators and ProCA32.collagen1 in H2O and D2O solution were determined by fitting
monoexponential decay equation. A standard curve of water number (q) over ΔKobs (the difference
of the decay constant between H2O and D2O) was plotted using Tb- NTA (q=5), Tb-EDTA (q=3),
Tb-DTPA (q=1) and Tb3+ in aqueous solution (q=9). The water number of ProCA32.collagen1
was calculated based on the standard curve.
3

DESIGN, EXPRESSION AND PURIFICATION OF PROCA32.COLLAGEN1
Introduction
As it was mentioned in Chapter 1, currently used MRI contrast agents are not sensitive

enough for patient’s needs in diagnosis and treatment monitoring, therefore development of new
and more sensitive MRI contrast agents with targeting capability is urgently required. To design
contrast agents based on proteins with improved in vivo and in vitro applications, there are several
important criteria that need to be taken into consideration. First, protein- based MRI contrast agent
should be stable and resistant to factors such as protease cleavage to prevent degradation in the
body. Furthermore, protein-Gd3+ complex should be stable with protein binding strongly to Gd3+
to avoid competition with other physiological cations such as Ca2+ and Zn2+ and inions. Since free
Gd3+ is toxic with LD50 of 0.2 mmol/kg [144], Gd3+ must bind to protein contrast agent to avoid
free Gd3+ being released before excreted out. Second, the contrast agent should have high
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sensitivity and therefore higher relaxivity to increase the dose efficiency. If relaxivity is higher,
then the total injection dosage of Gd3+ will be decreased to reduce to the toxicity caused by free
Gd3+ release. High relaxivity of contrast agent also improve the sensitivity of MRI for imaging
biomarkers. Third, protein contrast agent should have a proper size to optimize organ/tissue
distribution and blood retention time. It is recommended for contrast agents to have fast
accumulation in the organ/tissue and fast excretion to reduce the toxicity. Fourth, immunogenicity
of protein-based MRI contrast agent must be decreased, therefore, PEGlytion is one of the factors
to reduce this effect. Fifth, protein contrast agent should have targeting capability, therefore,
targeting moieties should be grafted inside or conjugated to improve the imaging specificity and
enable quantitative biomarker imaging.
Previous members in our lab have designed two Gd3+ binding sites into a scaffold protein
called rat -parvalbumin and were able to increase relaxivity by tuning τc and secondary
coordination shell contributors as well as improving metal binding affinities [83]. However,
targeting specific biomarkers to image in different diseases was still a challenge and needed further
investigation [78]. Design of ProCA32.collagen1
Design of ProCA32.collagen1 with collagen type I targeting capability
In order to design a protein contrast agent with targeting capability, collagen targeted
protein MRI contrast agent, ProCA32.collagen1 was designed by covalently linking a collagen
type I targeting peptide (KKWHCYTYFPHHYCVYG) moiety consisting natural amino acids to
the C-terminal of protein contrast agent ProCA32 (with two Gd3+ binding sites). A flexible hinge
was used to optimize the targeting capacity of the peptide [83] (Fig. 1.6). The collagen type I
targeting peptide was chosen in way that residues in the peptide are contributing both to the binding
and relaxivity by tuning correlation time. Cysteine residues can form a cyclic peptide to interact
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with collagen I and Lysine residues are improving in vivo MR imaging through PEGylation.
Lysine PEGylation of the whole contrast agent can improve protein solubility, blood retention time
and reduce immunogenicity [84]. The designed ProCA32.collagen1 was bacterial expressed,
purified, and modified and confirmed to form a 1:2 Gd-ProCA32.collagen1 complex using ICPOES (Methods) [83] [177].
Results
3.3.1 Expression and purification of ProCA32.collagen1
Fusion of a collagen-targeting peptide to ProCA32 can generate collagen-targeted MRI
contrast agent, ProCA32.collagen1 since ProCA32 has multiple Gd3+ binding sites and our proteinbased MRI contrast agent will be able to quantitatively evaluate the collagen expression in
different diseases such as uveal melanoma tumor in the liver and liver fibrosis. Therefore, this
protein was expressed and purified. The transformation was carried out using B21 (DE3) plyss cell
line. Then, small scale (250 mL of LB medium) and Large scale (1000 mL): 1 L of LB medium
was used for expression. The temperature was 37°C for small scale and then the medium was
transferred to large scale (1 L). After optical density of bacteria reached 0.6, 500 μL of IPTG was
added to induce the expression of the protein and then the temperature was decreased to 25°C for
overnight expression. Cell pellets are collected by centrifugation, and then HEPES (10 mM) buffer
with pH=7.4 was added into the cell pellets. For cell pellets coming from 1 L of LB medium, 10
mL of PBS buffer was used plus 100 μL of PMSF and 1 μL of benzonulease (for DNA cleavage).
Sonication was performed for 12 times until a homogenous solution was reached. The solution
was centrifuged at 17000 rpm speed for 10 min and the supernatant was collected, and then boiled
for 10 min. Again the solution was centrifuged for 6000 rpm for 10 min and supernatant was
collected. 3% streptomyosin was added into the mixture and incubated at 4°C overnight to
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precipitate the DNA and remove it from the protein. Centrifugation was carried out for another 10
min and the supernatant was collected (6000 rpm). The solution was then heated to 80-85°C for
10 min and then centrifuged down at 6000 rpm and supernatant was obtained. In the next step, the
protein was dialyzed overnight in 10 mM HEPES buffer at pH=8.0. to be negatively charged (500
uL of PMSF was added). Then before injection of supernatant to FPLC for further purification,
EGTA is added to the final concentration of 20 mM to remove any extra calcium and then the
supernatant is filtered and injected to FPLC.
For purification using FPLC, an ion exchange column was used. A resin is chosen so that
the protein binds to resin by a charge interaction. In the final step of FPLC, the concentration of
salt in the buffer is increased in order to elute the protein out of the column. Figure 3.1
demonstrates the SDS-page results for expression and purification of ProCA32 with collagen
targeting moiety.
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A

B

C

Figure 3.1 Modeled structure of ProCA32.collagen1 and its expression and purification.
A. Model structure of ProCA32.collagen1 based I-TASSER. B. Expression of ProCA32.collagen1
in BL21 (DE3) plys (BI: Before Induction, AI: After Indcution). C. Different steps of
ProCA32.collagen1 purification.

The results in Fig. 3.1 demonstrates that the protein has been successfully purified using
our established purification protocol and furthermore, boiling the sample helps the purification and
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elimination of unwanted proteins. As can be seen in Fig. 3B, after boiling, most of the undesired
proteins were removed from our target protein. Figure 3.2 illustrates the FPLC spectra of the
purified protein. As it can be seen in the figure, four major peaks can be observed. The first peak
corresponds to undesired proteins and maybe some of our target proteins at very low amount.
However, both peak 2 and 3 in the FPLC spectra belongs to our ProCA32.collagen1 with a slight
difference. The second peak is the Holo form of our protein-based contrast agent (Ca2+-bound) and
the third peak is the Apo form of our protein (Ca2+-free). Since our contrast agent binding sites are
supposed to be occupied with Gd3+, the Ca2+-free form is desired for future experiments in order
to avoid any effects on Gd3+ binding affinity of ProCA32.collagen1.

Figure 3.2 Diagram of ProCA32.collagen1 purification using FPLC.
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The majority of Peak 1 include unwanted proteins, and peak 2 is the Ca2+-bound form of
ProCA32.collagen1 and peak 3 include the Ca2+ free form which is the desired form and peak 4
has DNA.
In the last peak, DNA will elute out as peak number four. At the end, all fractions for peak 3
were collected and combined, and a SDS-page gel electrophoresis was run to make sure the protein is
completely pure. Then the concentration of the protein was measured using UV-Vis instrument. Figure
3.3 shows the UV-Vis spectrum of pure ProCA32.collagen1. A small shoulder right before 280 nm
wavelength can be observed which is another indication for the presence of our protein.

A

B

Figure 3.3 UV-Vis spectrum of ProCA32.collagen1 after FPLC purification
A. shows the Apo form of ProCA32.collagen1 after concentration of peak 3 and B. demonstrates
the Holo form of ProCA32.collagen1 after concentration of peak 2 (No.1 and 2 correspond to
different concentrations of the protein).
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Two different batches of the protein were purified with different concentrations. To further
confirm the purity of the protein, a sample was sent to mass spectrometry facility in order to obtain
the electro spray ionization (ESI) spectrum.

3.3.2 Lysine PEGylation of ProCA32.collagen1
To optimize the protein solubility, blood circulation time, and avoid possible enzymatic
degradation and reduction of immunogenicity; Poly ethylene glycol (PEG) conjugation with
protein has been often used in pharmaceutical and biotechnical applications. The desired protein
can be modified using several PEG conjugation strategies such as amino group modification, thiol
group modification. For this purpose, ProCA32.collagen1 has been PEGylated with NHS-Ester on
lysine residues.
The contrast agent was modified using Methyl-POEn-NHS ester, PEG-40 with molecular
weight of 2 kDa and 40 repeating units of ethylene glycol. At first, ProCA32.collagen1 and PEG40 were mixed with 1:5 ratios in 10 mM HEPES buffer (pH 7.2) and allowed to shake at room
temperature for about 2 hours or at 4 °C overnight. Then, 100 mM Tris/HCL was added to the
reaction mixture to stop the reaction by quenching the unreacted free PEG-NHS ester. The mixture
was then concentrated about 4 times using concentrator with 3-6kDa membrane to remove the
unreacted free PEG (MW 2 kDa). PEGylated protein was identified by Iodine staining and SDSPAGE. Iodine can stain the free PEGylated protein along with free PEG in the solution while
Coomassie brilliant blue can stain the protein that is already conjugated with PEG. Figure 3.4
shows the SDS-page results with Coomassie brilliant blue stain (left) and iodine stain (right) before
and after PEGylation. As it can be seen most of the protein has been PEGylated.
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PEGylation on Cysteine resides is also possible, however, due to possible role of cysteine
in binding to collagen type I, Lysine PEGylation was chosen, further details will be discussed in
the next chapter.

Figure 3.4 SDS-page results for Lysine PEGylation of ProCA32.collagen1.
Left (Coomassie blue stain) and right (BaCl2/I stain) gels show ProCA32.collagen1 before and
after Lys PEGylation. Multiple bands after PEGylation is showing that multiple Lys residues in
the protein are PEGylated.
Figure 3.5 demonstrates the structure of the contrast agent after PEGylation with PEG. As it
can be seen in the figure, multiple sites have been PEGylated since there are multiple Lys residues in
both the protein and targeting peptide.

77

Figure 3.5 Structure of ProCA32.collagen1 after PEGylation

Discussion
3.4.1 Optimization of ProCA32.collagen1 purification
In order to improve the yield of ProCA32.collagen1, several modifications were made in
the original purification protocol of parvalbumin to remove DNA contamination more efficiently
and simplify the purification procedure. To remove DNA, additional step before FPLC for DNA
precipitation was added. We added 3 % streptomycin sulfate and incubated at 4○C overnight. After
centrifugation at 13000 rpm for 10 min, the supernatant was heated at 85○C for 5 min. After
centrifugation, the supernatant was dialyzed against 10 mM Tris/HCl at pH 8.0 before injecting
into FPLC column. Moreover, the buffer pH was increased from 7.5 to 8.0. Since the Q column is
anion exchange column, increasing the pH of buffer improves the binding of ProCA32.collagen1
to the column. It was observed that our protein can be eluted out from Q column at 200 mM NaCl,
therefore, the percentage of buffer B (containing 1 mM NaCl) during elution was decreased from
70% to 25%. In addition, the flow rate of FPLC was decreased from 5 mL/min to 2 ml=L/min to
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improve the binding of ProCA32.collagen1 to Q column. Nine column volumes are usually used
to let buffer B slowly increase from 0% to 25%. The very slow increase of salt gradient further
helps the separation between ProCA32.collagen1 and DNA. After FPLC purification step, the
remaining DNA can be further eliminated by concentrating protein using through 3-6 kDa
membrane.
The FPLC purification curve is shown in Fig. 3.2. The UV absorbance at 280 nm from
FPLC detector shows four peaks during the elution with buffer B. Each peak was collected and
then measured by UV spectroscopy, SDS PAGE and agarose gel. The third fraction (peak 3)
showed a single band at 14.3 kDa, which is consistent with the molecular weight of
ProCA32.collagen1. UV spectrum of this fraction (Fig. 3.3A) is the same as parvalbumin (PV) in
the old purification techniques. The first and second peaks have the Holo form of
ProCA32.collagen1 and the last peak contains protein with a molecular weight of 30 kDa. DNA
and UV absorbance data demonstrated that peak 1 and peak 4 has a lot of DNA/RNA since they
showed high absorbance at 260 nm. The final yield of ProCA32.collagen1 is about 50-70 mg per
liter bacteria expression in LB medium.
Summary
To design novel protein-based MRI contrast agent with collagen type I targeting ability
(ProCA32.collagen1), PV was selected as the scaffold protein based on the criteria discussed for
an ideal contrast agent. This developed protein is well folded, highly stable and soluble, tolerant
to mutations, have a rigid structure and strong metal binding sites for Gd3+. There is also no
reported interaction between this protein and PV. We have chosen a collagen type I targeting
peptide to create a targeting capacity and improve its relaxivity by altering PEGylation locations.
We have constructed vectors for the bacteria expression. We have also optimized the bacterial
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expression and tag-less purification procedures of ProCA32.collagen1 by selecting expression
strains and removal of DNA contaminations. After purifying ProCA32.collagen1, different
biophysical properties of the contrast agent such as metal binding affinity and selectivity,
relaxivity, metal coordination ligands, and serum stability were examined. ProCA32.collagen1
was also PEGylated for in vivo studies, such as MR imaging, biodistribution, pharmacokinetics
and toxicity.
4

STUDIES OF BIOPHYSICAL PROPERTIES OF PROCA32.COLLAGEN1
Introduction
Safety is one of the most important criteria in development of contrast agents, therefore,

the contrast agent must have superior biophysical properties such as high Gd3+ stability, high metal
selectivity as well as relaxivity. As it was mentioned before, long term toxicity of the contrast
agent usually originates from the free Gd3+ release in the body because of the competition of other
physiological cations and onions, such as Zn2+, Mg2+ and PO43-. The ionic radius of Gd3+ is 0.93
Å, which is similar to the ionic radius of Ca2+. Therefore, Gd3+ has the ability to bind to the
physiological Ca2+ and occupy binding sites in Ca2+ binding proteins. It is very likely that this
interaction can disrupt and affect the dynamic function of calcium binding proteins. Moreover,
Gd3+ accumulation could cause NSF (Nephrogenic systemic fibrosis) in long terms, which is a
lethal disease in patients with the impaired kidney function [181, 182]. A safe MRI contrast agent
with high metal stability and Gd3+ selectivity is urgently required to reduce the toxicity caused by
MRI contrast agent injection. Traditional techniques such as pH titration were applied to measure
the meal binding affinities for the small-chelator based clinical contrast agents [183]. Small
chelators, such as DTPA, has a Gd3+ binding affinity of 1.8 × 10-21 M. In proteins however, since
there are multiple protonations of residues, traditional methods such as pH titration cannot be
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applied to measure the dissociation constant (Kd) between ProCA32.collagen1 and Gd3+ or other
metals. FERT methods that are based on Tb3+ or Eu3+ can be applied to determine protein-metal
binding affinity measurement but one of the major limitations of these methods is the lack of
sensitivity which they can only determine a Kd of around 1 μM or above. Due to this limitation,
the metal binding affinity for Tb3+ reported for our previous contrast agents such as ProCA1 was
around 10-7 M. With several other methods being developed such as the Ca45 flow dialysis,
equilibrium dialysis, florescence dye titration and NMR for determination of metal binding
affinities for calcium binding proteins [72, 184], the Gd3+ binding affinity of EF-hand binding
proteins is still not accurately reported. The Ca2+ binding affinity of all EF-hand proteins for
instance PV can reach to 10-9 M. Therefore, a more accurate method is required to measure Gd3+
binding affinity in the range between 10-22 and 10-18 M for our contrast agent, ProCA32.collagen1.
Relaxivity is another key parameter for MRI contrast agents as discussed thoroughly in
Chapter 1. The MRI signals are generated based on the different relaxation properties of protons.
However, such differences are very small among organs in vivo. The contrast and sensitivity of
MRI can be improved by administrating the contrast agents. MRI contrast agent works as
“catalyst” to catalyze the relaxation properties of each water molecule. By differential distribution
in vivo, MRI contrast agents make the relaxation properties different in each organ. The relaxivity
of clinical MRI contrast agent is around 5 mM-1s-1. The theoretical maximum relaxivity, however,
is about 100 mM-1s-1, therefore, there is a strong need to develop MRI contrast with high relaxivity.
Since ProCA32.collagen1 is a targeted contrast agent, therefore, it needs to have proper
binding affinity to collagen type I, in order to generate the targeting effect.
In this chapter, we first report a sensitive technique previously developed by our lab to
measure metal binding affinities (Tb3+, Gd3+, Ca2+, and Zn2+) and selectivity of
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ProCA32.collagen1. We then report our studies on determining relaxivity and water number of
ProCA32.collagen1 designed in Chapter 1 and 2. In addition, using ELISA method, we report the
collagen type I binding affinity of ProCA32.collagen1. At the end, we will report the detailed
pharmacokinetic studies of ProCA32.collagen1 required for in vivo studies.

Contrast-enhanced magnetic resonance imaging is evolving rapidly with different clinical
applications in imaging various diseases, therefore several important characteristics of MRI
contrast agents such as their biodistribution, safety profile and pharmacokinetics have been well
studied over the past few years. Based on their distribution, clinical MRI contrast agents can be
categorized into three classes. First class is non-specific MRI contrast agents or Extracellular Fluid
Agents (ECF), second class is liver specific MRI contrast agents, and third class is blood pool MRI
contrast agents. Some clinical contrast agents such as Magnevist, Omniscan, ProHance, Optimark,
and Dotarem are part of the non-specific MRI contrast agents. Due to their small size and low
molecular weight and no interaction with biomarkers in the body, there are mainly distributed in
blood vessels and extracellular-extravesicular spaces with very short blood half-life which is less
than 5 min in mouse and less than 30 min in humans. The organ that these contrast agents are
mainly accumulated is kidney which is their way of excretion from the body. Therefore, they can
be used for kidney imaging.
In addition, this type of MRI contrast agents can accumulate in lesions and disease tissues
with blood vessel damage, therefore, they can be used for cancer, and stroke imaging. Second
class which are liver specific MRI contrast agents such as MultiHance and Eovist are also small
chelator-based contrast agents, however, the major difference between these and non-specific MRI
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contrast agents is that they are covalently incorporated with one hydrophobic moiety, which
facilitates liver accumulation of these contrast agents. Clinical studies demonstrated that, 10%
MultiHance and 50% of Eviost is excreted from the liver [185]. Mn-DPDP is another liver specific
MRI contrast agent with similar structure as vitamin A which has uptake by liver cells. The
accumulation of Mn-DPD in liver increases the MRI signal significantly, however, there are some
stability concerns associated with DPDP in the liver which can cause Mn2+ release [21]. A blood
pool MRI contrast agent, MS-325 is a new FDA approved drug which can reversibly binds to
serum albumin. The binding of MS-325 to albumin can increase its relaxivity as well as its blood
half-life which increases its circulation time. Due to its unique blood distribution properties, MS325 has been approved for imaging blood vessel abnormalities [21]. In addition to clinical MRI
contrast agents, nano-sized MRI contrast agents, such as dendrimers liposome, nanotubes, and
emulsions have been developed with dramatically different pharmacokinetic and distribution
properties. The pharmacokinetics, distribution and excretion of these contras agents are largely
affected by the size, charge and targeting moieties of the contrast agents. One of the disadvantages
of these contrast agents is that with a size larger than 7 nm, they cannot be eliminated from renal
filtration, and therefore their blood retention time are much longer. Liver and spleen are the major
sites of accumulation of these agents due to the phagocytosis of immune-cells. Nanoparticles with
molecular weight larger than 30 kDa is accumulated in the tumor tissue due to EPR effects [31,
78].
4.1.1 Gadolinium deposition
These approved compounds were all designed to be completely excreted after injection.
The pharmacokinetic studies in humans noted that recovery of gadolinium decreased in patients
with severe renal insufficiency. From studies on NSF patients it is clear that some gadolinium is
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retained. Several reports show Gd to be present in skin biopsies of NSF patients [186-191].
Recently Kay et al. [192] described a case report of a female patient who died with NSF.
Gadolinium was found in all tissues surveyed and there were very high levels of Gd reported in
the kidney and the heart. Swaminathan et al. [186] also noted high concentrations of Gd in the
heart and vessels on postmortem analysis of NSF subjects. It is not yet established whether Gd is
also retained in patients with renal impairment but who do not develop NSF. It is still not
established what the form of Gd is in these patients. For instance, is the Gd3+ still part of the
contrast agent? Is it present as some insoluble inorganic deposit like the carbonate or phosphate
salt, since these are very insoluble. Or is the Gd removed from the chelate but bonded to the
calcium binding site of a calcium binding protein since it is known that gadolinium can replaced
calcium in proteins. If the Gd is released from the contrast agent, what is the mechanism for
release? Frenzel et al. [157] recently reported the serum stability of approved contrast agents and
found that about 20% of Gd was released from gadoversetamide and gadodiamide after 15 days in
human serum at pH 7.4, 37 °C compared to <2% release for the linear ionic chelates, while the
macrocyclic chelates showed no detectable Gd release. Gd release in serum was increased when
phosphate concentration was increased [157]. This would suggest that in renally insufficient
patients where the plasma half-life increases to days, there would be significant Gd release from
gadodiamide and gadoversetamide. Factors influencing Gd release are the presence of metals that
have high affinity for the Gd-binding ligand like Zn2+, Cu2+, or Fe3+ and/or the presence of
ligands with high affinity for Gd such as phosphate and carbonate. Another potential mechanism
for Gd release would be low pH in a lysosome if the contrast agent is taken up intracellularly, e.g.
in the renal proximal tubules. It is well established that the rate of Gd release increases with
decreasing pH.
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Gibby and coworkers compared Gd levels in the bone of patients that were scheduled for
hip transplant following a contrast enhanced MRI [21, 158]. Bone was taken about 4 days after Gd
administration. Patients received either gadodiamide (N=9) or gadoteridol (N=10) at the standard
0.1 mmol/kg dose. They found 4-fold higher levels of Gd in the bone of subjects who received
gadodiamide (1.77±0.704 μg Gd/g bone) than for those who received gadoteridol (0.477±0.271 μg
Gd/g bone). Assuming a similar distribution to all bone and depending on the fractional weight of
bone in the individual, this would equate to about 1 – 2% of the injected dose of gadodiamide
being present in the bone after 4 days. This study did not identify whether the Gd was still
associated as the contrast agent. However, since both gadodiamide and gadoteridol have similar
clearance rates, the excess Gd remaining after gadodiamide injection is presumed to be dissociated
Gd. It is unknown how fast the Gd will clear from the bone. In animal studies (see below), bone
levels of Gd decreased with time after contrast agents were injected. For “free” Gd, which localizes
mainly to liver and bone, elimination of Gd was on the order of 1–3% per day in rodents.
On the one hand it is straightforward to detect and quantify Gd in biopsy or autopsy
samples. Since Gd is not an essential element and is not ubiquitous in the environment, there is no
background signal to contend with. Elemental analysis techniques like inductively coupled plasma
(ICP) with mass spectrometry (MS) or optical detection are sensitive means to quantify Gd.
However, this is a destructive technique that reports only on the elemental composition and not on
form of the Gd, i.e. whether it is still present as contrast agent. Scanning electron microscopy
(SEM) with x-ray spectroscopy is also used. This can detect Gd and can also indicate the
distribution of other heavy elements that are spatially localized with the Gd. However, SEM cannot
indicate in what form the Gd exists in tissue. There is also potential bias in the SEM technique
because this technique is sensitive to heavy atoms. For instance, a microcrystalline deposit of
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gadolinium phosphate, with its high local concentration of Gd and P atoms, would be much more
visible than a diffuse distribution of Gd still present as contrast agent or Gd bound to calciumbinding proteins. There remains a need for additional biophysical studies to determine the
speciation of Gd in skin and other organs.
Although the ECF agents generally behave very similarly, there are some differences
among their physical properties. The diamide complexes gadodiamide and gadoversetamide have
considerably lower thermodynamic stability (log K~17 vs log K >21 for other Gd complexes)
[193]. The linear complexes tend to be more reactive to metal substitution (transmetallation) or
decomplexation. The incidence of NSF seems to reflect these physical chemistry findings. Most
cases have been reported with gadodiamide, the least stable and least inert compound. Other cases
have been reported with gadopentetate and gadoversetamide, while no non-confounding cases
have yet been reported with the other contrast agents. In terms of market share, gadopentate >
gadodiamide > gadoteridol > other agents.
4.1.2 Gadolinium deposition in animals in approved contrast agents
There have been concerns about Gd deposition in tissue since Gd-based contrast agents
were first reported. A fundamental product criterion was full elimination of the Gd. In rodent
studies the bone and the liver are target organs for Gd deposition. Tweedle and colleagues
published a series of studies comparing Gd retention in rats and mice after injection of Gd-DTPA,
GdHP-DO3A, Gd-DOTA, and Gd-DTPA-BMA as well as some other compounds, including “free
Gd” administered as GdCl3 or gadolinium acetate [35, 194]. When “free Gd” is administered i.v.
most of the dose is deposited in the liver and the bone of rodents. Very little is excreted and
clearance has been reported to be on the order of 1 to 3% per day. When contrast agents are
administered, the biodistributions of Gd-DTPA, GdHP-DO3A, Gd-DOTA, and Gd-DTPA-BMA
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are very similar for the first 24 hrs. At 7 and 14 days the data begins to separate. The organs with
remaining Gd are kidney, liver, and bone. In a direct comparison of 4 compounds the order of
tissue retention was Gd-DTPA-BMA > Gd-DTPA ~ Gd-DOTA ~ GdHPDO3A [28]. There was
no statistical analysis performed in that study but it is apparent from the values and standard
deviations reported that there is significantly more Gd remaining in the whole body, liver, or femur
of mice or rats treated with Gd-DTPA-BMA compared to the other agents. This difference was
interpreted as being due to greater Gd release from the chelate. This hypothesis is supported by a
double label study by Kosokat and Urich who used [153Gd] and [14C] labeled Gd-DTPA in rats
and found a 153Gd:14C ratio of 6:1 in liver and 9:1 in bone. Tweedle et al. [28] also noted that
formulated Omniscan which is a mixture of gadodiamide with 5% sodium caldiamide (Na[CaDTPA-BMA]) showed less whole body retention than gadodiamide injected alone. Animal studies
with MS-325, Gd-EOB-DTPA, and Gd-BOPTA all showed very low values of Gd in bone at 7 or
14 days post injection similar to those reported for Gd-DTPA [195-200].
In renally impaired patients the exposure to Gd is increased; the longer plasma half-life
results in a large AUC. Since the terminal plasma half-life in rats is 15–20 min compared to about
90 minutes in healthy humans for ECF agents, one way to mimic the increased Gd exposure in
renally compromised subjects is to administer high doses of agent daily to rats. Sieber and
colleagues recently reported a series of studies taking this approach. They administered formulated
Omniscan, Optimark, Magnevist, Multihance, Gadovist, or Dotarem at 2.5 mmol/kg daily (except
weekends) for four weeks to rats [198-200]. This daily dose is 25 times the standard 0.1 mmol/kg
dose and resulted in a cumulative dose of 50 mmol/kg. They examined Gd levels in the skin, liver
and femur at the end of the study. In all three organs the order of Gd deposition was the same with
Omniscan > Optimark > Magnevist > Multihance ~ Gadovist ~ Dotarem in terms of how much
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Gd was deposited. Although there were differences among the contrast agents, Sieber et al. [198200] only reported statistical analysis to show the amount of Gd deposited after Omniscan injection
was significantly higher compared to the other contrast media. No other comparisons were made.
Interestingly the relative concentrations of Gd in the skin, liver, and femur differed. For instance,
there was about 8 times more Gd in the skin following Omniscan compared to Magnevist, but
about 3 times more in the femur or 2 times more in the liver. Interestingly liver levels were similar
for the linear Magnevist complex and the macrocycles Dotarem and Gadovist, although there were
clear differences in the skin or the bone (Magnevist higher).
In this same repeat dose model, Sieber et al. [198] also investigated the influence of excess
ligand. Formulated Omniscan contains gadodiamide and 5% excess ligand as the calcium complex
(caldiamide) while Optimark contains gadoversetamide and 10% excess ligands. They repeatedly
gave either the gadolinium complex (gadodiamide or gadoversetamide), gadolinium complex +
5% excess ligand, or gadolinium complex + 10% excess ligand for 20 days to rats. The Gd
concentration in the skin was significantly higher after treatment of the gadolinium complex alone
compared with 5% excess ligand. By increasing the excess of ligand from 5% to 10%, the Gd
concentrations in the skin were further reduced by a factor of three. The addition of 5% excess
ligand in both contrast agents reduced Gd levels significantly in the femur and the liver, but
additional excess ligand had no further benefit in these organs.
Approved gadolinium-based contrast agents have 3 categories of biodistribution
extracellular with renal elimination, extracellular with mixed renal and hepatobiliary elimination,
and intravascular with renal elimination. After intravenous injection the distribute in the blood and
the extracellular space and transiently through the excretory organs. Preclinical animal studies and
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the available clinical literature indicate that all these compounds are excreted intact Elimination
tends to be rapid and for the most part, complete.
In renally insufficient patients the plasma elimination half-life increases substantially from
hours to days depending on renal function. In patients with impaired renal function who then
developed NSF, administration of the ECF agents gadodiamide, gadoversetamide, and
gadopentetate dimeglumine have been shown to result in Gd deposition in the skin and internal
organs. It is unknown whether Gd deposition results in non-NSF subjects as well and if so, whether
such deposition correlates with impaired renal function. In one study of hip replacement recipients,
at 4 days post Gd administration, patients that received gadodiamide had 4-fold higher Gd levels
in bone than those who received gadoteridol which suggests that there may be Gd deposition in
non-NSF subjects. In the cases of Gd deposition in NSF patients, it is likely that the Gd is no longer
associated with its chelator, but this has still not been definitively shown. The speciation of Gd in
human tissue remains an open question – is the Gd still bound to the chelate and if not, what is it
bonded to? Is the form of Gd the same in skin deposits compared to internal organs? From the
limited Gd distribution data available in NSF subjects, there appears to be differences in
distribution compared to the preclinical rodent studies. For instance, high myocardial uptake of
Gd in post-mortem analysis is not consistent with the rodent studies. Besides the speciation of Gd,
the trafficking of Gd in NSF subjects is another open question, i.e. if dechelation occurs, then
where does it occur and how is the Gd transported to other organs?
Finally, the route of administration is critical to understanding the biodistribution and
potential Gd deposition of these GBCA. Despite this low incidence of NSF, GBCA have proven
to be very safe especially when administered intravenously at approved dosages. The package
insert should always be consulted for up to date safety information. Alternate routes of
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administration (e.g. subcutaneous, intrathecal, etc), formulation (e.g. in a liposome or other
nanoparticle), or cell labeling will likely alter the biodistribution and may impact Gd tissue
deposition and/or toxicity. Such studies should be undertaken with caution.
Results
4.2.1 Metal binding affinity of ProCA32.collagen1
With a previously developed metal-buffer system in our lab, we were able to apply this
system to measure metal binding affinities of ProCA32.collagen1. This metal-buffer system can
control the free metal concentration in the solution, therefore, an accurate measurement of Kd can
be achieved successfully for ProCA32.collagen1 and metal ions such as Ca2+, Zn2+, Gd3+ and Tb3+.
4.2.1.1 Measurement of ProCA32.collagen1 binding affinity to Tb3+
Since Gd3+ is a spectroscopically silent element, we first determined the binding affinity of
ProCA32.cllagen1 to Tb3+ and then used a competition assay to measure the affinity to Gd3+. To
determine the accurate affinity of ProCA32.collagenl to Tb3+, Tb3+-DTPA buffer system
previously developed was used. This system has 5 mM DTPA, 30 μM ProCA32.collagen1, 0.06
μM Rhod-5N, 5 mM HEPES, and 100 mM NaCl at pH 7.2 to mimic the physiological conditions.
The Kd of DTPA to Tb3+ is 9.55 × 10-22 M. Tb-DTPA can generate a buffer ranging from 10-24
and 10-18 M of free Tb3+. There is Rhod-5N present in the buffer system, which is a low-affinitymetal indicator with fluorescence properties which can increase the fluorescence signal when free
[Tb3+] is higher than 10-6 M. The Rhod-5N was introduced into the system as an internal standard
and it is important to make sure that DTPA is not saturated by Tb3+. Fig. 4.1 shows TbProCA32.collagen1 LERT signal changes after Tb3+ titration. In a similar experiment performed
in parallel, 5 mM DTPA without ProCA32.collagen1 was titrated with Tb3+ to monitor its
background signal and Rhod-5N at each titration point. As it can be seen in Fig. 4.1 A, Tb3+-
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ProCA32.collagen1 LERT signal occurs in the Tb-DTPA buffer system, which demonstrates that
ProCA32.collagen1 can bind to Tb3+ in concentrations between 10-23 and 10-19 M. Using Hill
equation described in Chapter 2 (equation 2-2), we can calculate the Kd (Fig. 4.1 B).
ProCA32.collagen1 has a Kd of 6.14 × 10-22 M to Tb3+.

Figure 4.1 Resonance energy transfer process between Tb3+ and Trp in
ProCA32.collagen1

A

B

Figure 4.2 Determination of Tb3+ binding affinity of ProCA32.collagen1.
Determination of Tb3+ binding affinity of ProCA32.collagen1 using Tb-DTPA chelator buffer
system in which Free [Tb3+] was kept in a range between 10−23 and 10−17 M using a tightly
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controlled concentration ratio between Tb3+-DTPA and free DTPA. The interaction between Tb3+
and ProCA32.colagen1 was quantified by fluorescence intensity increase due to luminescence
resonance energy transfer between Trp in ProCA32.colagen1 and Tb3+.

It is worth mentioning that, PEGylated and non-PEGylated protein had similar binding
affinities which shows that PEGylation did not affect the binding affinity, Moreover,
ProCA32.collagen1 had similar Tb3+ binding affinity to non-targeted contrast agent, ProCA32P40 which is an indication that addition of targeting moiety of collagen type I to the contrast agent
did not change the affinity to Tb3+ (Table 4.1). As it is shown in Fig. 4.2 A, Terbium fluorescence
spectrum changes after adding Tb3+ into 5 mM DTPA with 30 μM ProCA32.collagen1 in 50 mM
HEPES with 100 mM NaCl at pH 7.2. Rhodamin 5N fluorescence changes also after adding Tb3+
into 5 mM DTPA with 0.06 Rhodamin 5N in 50 mM HEPES with 100 mM NaCl. In addition,
fluorescence intensity does not change during Tb3+ titration in Rhodamin 5N and DTPA.
4.2.1.2 Measurement of ProCA32.collagen1 binding affinity to Gd3+
After measuring Tb3+ binding affinity, Gd3+ binding affinity to ProCA32.collagen1 was
measured using competition assay.

In this experiment, 10 μM of Tb3+ and 5 μM

ProCA32.collagen1 were incubated with different concentrations of Gd3+ at room temperature
overnight in a similar buffer as the Tb3+ binding experiment. The next day, Tb-FRET fluorescence
signal was measured at excitation 280 nm and emission at 545 nm. As shown in Fig. 4.3 A, Gd3+
can compete Tb3+ out of ProCA32.collagen1 with a decrease of FRET upon the gradual addition
of Gd3+ with an apparent Kd (Kapp) of 6.4 × 10-6 M. Using the apparent Kd and FRET signal
decrease, we then calculated Kd between Gd3+ and ProCA32.collagen1 using equation (2-3 and 24). As shown from Table 4.1, the Gd3+ binding affinity of ProCA32.collagen1 is 1.96 × 10-22 M
which was similar to ProCA32-P40. This result shows that ProCA32.collagen1 has very similar
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Gd3+ stability and affinity compared to most clinical MRI contrast agents, such as Gd-DTPA,
Multihance, Eovist and Dotarem. and much better Gd-stability than Ominiscan and Optimark (Tale
4.2).

A

B

Figure 4.3 Determination of Gd3+ binding affinity of ProCA32.collagen1.
Gd3+ binding affinity was calculated using competition assay. Different concentrations of Gd3+
were incubated with Tb3+- loaded ProCA32.colagen1. The fluorescence intensity decreases due to
luminescence resonance energy transfer between Trp in ProCA32.colagen1 and bounded Tb3+
was quantified when Gd3+ competed Tb3+ out of the metal binding pocket.
4.2.1.3 Measurement of ProCA32.collagen1 binding affinity to Ca2+
Development of metal-chelator buffer system can control the free metal concentration in
solution which can then help us successfully measure the accurate Kd between ProCA32.collagen1
and metal ions such as Ca2+ and Zn2+. As a contrast agent, it is extremely important that is has
selectivity to Gd3+ and cannot be competed out by physiological ions such as Ca2+ and Zn2+ in the
body.
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Since ProCA32.collagen1 is based on α-parvalbumin, which is a calcium-binding protein,
it has been reported that is has strong Kd around 10-9 M to Ca2+ [201] which is even stronger than
EGTA, therefore we predicted that ProCA32.collagen1 should have similar Ca2+ binding affinity.
This strong Kd cannot be accurately measured by regular fluorescent titration methods because of
limitation in free metal background in solution as well as the sensitivity of these methods.
Theoretically, in order to have an accurate method for Kd measurement, one needs to use protein
and metal concentration close to the Kd. Development of metal-chelator buffer system can
overcome these limitations and keep the free Ca2+ concentration between 10-13 M to 10-8 M, and
then Trp fluorescence change in ProCA32.collagen1 which is close to the binding site can be used
to monitor the Ca2+ binding affinity at very low concentrations of free Ca2+. Fig. 4.4 demonstrates
the experimental procedure of Ca2+-EGTA buffer system. This buffer system has 5 mM EGTA,
100 mM KCl, 50 mM HEPES at pH 7.2. ProCA32.collagen1 was added into this system to a final
concentration of 5 μM before the experiments. As it is observed, the system has 1000-times higher
concentrations of EGTA compared to ProCA32.collagen1. This is to make sure that the majority
of ProCA32.collagen1 can stay in the apo form or Ca2+ free form. Different concentration of Ca2+
was titrated into the system. The free Ca2+ concentration can be calculated based on Equation (25). Ca2+ binding to ProCA32.collagen1 can cause the fluorescent intensity changes and
conformational change in the protein since Trp signal is being monitored. Based on this
fluorescence signal change in each titration point, the fraction of the Ca2+ bound to
ProCA32.collagen1 can be derived (Fig. 4.4 B). Then the data can be fit using the titration points
(Fig. 4.4 A) and Hill Equation (Equation (2-6)).
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Figure 4.4 Determination of Ca2+ binding affinity of ProCA32.collagen1.
Determined Ca2+ affinity to ProCA32.collagen1 using the Ca2+-EGTA buffer system. Free [Ca2+]
was kept in a range between 10−10 and 10−4 M by the tightly controlled concentration of Ca2+ and
EGTA. The interaction between Ca2+ and ProCA32.colagen1 was monitored by the Trp
fluorescence intensity increase by increasing Ca2+ concentration.
It is important to point out that upon addition of Ca2+ to ProCA32.collagen1, not only the
fluorescence signal increases but also Trp peak shifts to lower wavelengths which is an indication
of conformational change in ProCA32.collagen1 upon Ca2+ binding. Fig. 4.5 illustrates how free
Ca2+ concentration can be calculated based on total concentration of Ca2+ in the Ca2+-EGTA buffer
system. Generally, the total Ca2+ of the buffer system comes from three sources (1) basal Ca2+ in
the buffer, even after dialysis with Chelex-100 bag to remove excess Ca2+; (2) Ca2+ which has
bound to ProCA32.collagen1 and introduced to the system upon addition of ProCA32.collagen1
before titration; (3) Known Ca2+ concentration titrated in to the system. The total basal Ca2+
concentration, [Ca2+ ]basal can be measured by Fura-2 dye, which is around 10-7-10-6 M after chelex-
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100 treatment. According to Equation (2-5), [Ca2+]basal is responsible for 10-12 - 10-11 M of free
Ca2+ when total EGTA concentration is 5 mM. Concentration of ProCA32.collagen1 added in this
experiment is 5 μM. If Kd of ProCA32.collagen1 to Ca2+ is 10-9 M, then we can generate 10 μM
of total Ca2+ into the system, which further contribute 7.37 × 10-10 M of free Ca2+ in the system.
The total Ca2+ concentration in each titration point is tightly controlled, and the exact total Ca2+
concentration titrated into the system is known. For instance, if we titrated 100 μM of total Ca2+
in the system, it generates 7.51 × 10-9 M free Ca2+ in the system according to Equation (2-5).

Figure 4.5 Schematic demonstration of free Ca2+ calculation in Ca-EGTA buffer system
After all the calculations, the Kd of ProCA32.collagen1 was 4.93 × 10-8 M which is similar
to ProCA32-P40. In addition, each individual association constant (Ka) of ProCA32.collagen1 to
Ca2+ can also be calculated using Adair equation. It has been hypothesized that binding affinity is
not a fixed term, but dependent on ligand saturation. Having demonstrated that hemoglobin
contained four Hemes (and therefore binding sites for oxygen), Adair equation works from the
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assumption that fully saturated hemoglobin is formed in stages, with intermediate forms with one,
two, or three bound oxygen molecules. The resulting fractional occupancy can be expressed as:

(4-1)

Or, for any protein with n ligand binding sites:
(4-2)

After using equation 4-2, the data were fit and each individual Ka was calculated. Average
Ka1=3.45×10 7M, Average Ka2=1.13×10 7 M.

Figure 4.6 Determination of Ca2+ binding affinity of ProCA32.collagen1 using Adair
equation.
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4.2.1.4 Measurement of ProCA32.collagen1 binding affinity to Zn2+
Another physiological metal ion which can compete with Gd3+ in contrast agents is Zn2+
causing transmetallation in contrast agents. The binding affinity of ProCA32.collagen1 to Zn2+
was determined using Fluozin-1 competition methods [79]. In this experiment, Zn2+ and Fluozin1 were incubated together in 50 mM HEPES, 100 mM NaCl, pH 7.2. After that ProCA32.collagen1
was titrated into the solution. The fluorescence signal of Fluozin-1 was monitored in each titration
point. Due to competition of ProCA32.collagen1, Zn2+ will be removed from Fluozin-1 during
titration which causes the fluorescence signal of Fluozin-1 to decrease until it reaches a plateau
(Fig. 4.7 A). After fitting the titration points with 1:1 binding equation (2-8), Zn2+ binding affinity
of ProCA32.collagen1 was calculated to be 1.33×10-6 M (Table 4.1).

A

B

Figure 4.7 Determination of Zn2+ binding affinity of ProCA32.collagen1.
Zn2+ binding affinity was determined using Fluozin-1 competition assay in which
ProCA32.collagen1 is competing with Fluozin-1 for Zn2+.
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Table 4.1 Summary of metal binding affinities of ProCA32.collagen1 and clinical contrast
agents

4.2.2 Relaxivity measurements of ProCA32.collagen1
Relaxivity of ProCA32.collagen1 as the most important property of a contrast agent was
measured in the buffer containing 50 mM HEPES, 100 mM NaCl, pH 7.2 at 37 ˚C. Since relaxivity
depends on the field strength, and MRI instruments are evolving fast to higher magnetic fields for
higher resolution, ProCA32.collagen1 relaxiviy was measured at both 1.4 T which is the most
widely used clinical magnetic field and 7.0 T which is higher field strengths. We incubated
different concentrations of Gd3+ with different concentrations of ProCA32.collagen1 in order to
plot a curve for relaxivity. Four points were used plus zero point without any Gd3+. These four
points are: 80 µM ProCA32.collagen1:160 µM Gd3+, 40 µM ProCA32.collagen1:80 µM Gd3+, 20
µM ProCA32.collagen1:40 µM Gd3+, and 10 µM ProCA32.collagen1:20 µM Gd3+. We then plot
the curve with Gd3+ concentration in the x axis in mM and relaxation rate in the y axis in s-1. Bruker
bench top 1.4 T relaxometer was used to measure T1 and T2 in ms.
We calculated the per Gd3+ relaxivity of ProCA32.collagen1. The final relaxivity was
calculated with 1:2 ratio between Gd3+ and ProCA32.collagen1 at 37 ˚C 1.4 T. Fig. 4.8 shows the
r1 and r2 measurements of PEGylated and non-PEGylated ProCA32.collagen1 at 1.4 T and 7.0 T.
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Since ProCA32.collagen1 has two Gd3+ binding sites, 1:2 ratio was chosen to make sure that all
sites have been occupied with Gd3+. Interestingly, the per Gd3+ r1 and r2 of non-PEGylated
ProCA32.collagen1 is 30 ± 0.3 and 42 ± 0.3 mM-1s-1, respectively and these values for PEGylated
ProCA32.collagen1 were 34 ± 0.12 mM-1s-1 and 50 ± 0.16 mM-1s-1 for r1 and r2, respectively. It is
important to point out that relaxivity of ProCA32.collagen1 increased after PEGylation.
Moreover, these values are larger than ProCA32-P40 which is an advantage for this targeted
contrast agent. Relaxivity values were also calculated for ProCA32.collagen1 at 7.0 T field
strength. The results (Fig. 4.8 C) show a significant increase in r2 (108 ± 1.2 mM-1s-1) value and a
slight decrease of r1 (21.3 ± 0.5 mM-1s-1). As Table 4.2 demonstrates, these values for
ProCA32.collagen1 are significantly higher than clinical contrast agents and even higher than
ProCA32-P40.

A

B

C

Figure 4.8 Relaxation rate of ProCA32.collagen1 at different magnetic fields.
(A) Relaxation rate of non-PEGylated ProCA32.collagen1 at 1.4 T, 37 ○C. Changes in r1 and r2
relaxation rates were plotted over various concentrations of [Gd3+]. (B) Relaxation rate of
PEGylated ProCA32collagen at 1.4 T, 37 ○C. (C) Relaxivity values (r1 and r2) of PEGylated
ProCA32.collagen1 at 7.0 T, 37 ○C.
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Table 4.2 Summary of r1 and r2 relaxivity of ProCA32.collagen1 and clinical contrast
agents

4.2.3 Serum stability of ProCA32.collagen1
Since ProCA32.collagen1 will be applied for in vivo studies with good metal stability and
relaxivity, it needs to have good serum stability as well. Therefore, it is extremely important that
PEGylated ProCA32.collagen1 will not be cleaved by the enzyme in the serum and maintain intact
structure before secreting out of the body. In order to assess the stability of ProCA32.collagen1
with PEGylation, the contrast agent was incubated in the 50% serum and then detected by SDSPAGE. As Fig. 4.9 shows, ProCA32.collagen1 is very stable in the serum for at least 13 days.
After a couple of days, the native proteins in the serum start to degrade, however,
ProCA32.collagen1 was still present in the blood serum. All of these data further confirm that
ProCA32.collagen1 is as stable as ProCA32-P40 and can be a suitable contrast agent for in vivo
studies.
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Figure 4.9 ProCA32.collagen1 stability in human serum.
ProCA32.collagen1 is stable after incubation in serum at 37 °C for up to 12 days as raveled by
Coomassie Brilliant Blue Ponceau S solution staining.
4.2.4 Transmetallation studies of ProCA32.collagen1
Metal stability and selectivity is one of the important criteria for designing contrast agents
and they are extremely needed for the development of contrast agents. Other physiological ions
such as Zn2+ can compete with Gd3+ and force them out of the binding pocket of contrast agents.
After measurement of the binding affinities of ProCA32.collagen1 to different metal ions such as
Zn2+, Ca2+ and Gd3+, the results demonstrated higher selectivity of ProCA32.collagen1 compared
to clinical contrast agents (Table 4.1). These results led us to assess the transmetallation property
of ProCA32.collagen1 since it was going to be applied in vivo.
Zn2+ and PO43- are the major competitors of Gd3+ in physiological conditions. To study the
transmetallation of ProCA32.collagen1, relaxation rate changes of the contrast agent was measured
over time in the presence of Zn2+ and PO43-. As reported in the literature, different clinical contrast
agents had different transmetallation rates in this solution. (Fig. 4.10). The linear contrast agents
with no charge such as Omniscan experienced the highest transmetallation effect, however,
macrocyclic non-charged MRI contrast agents such as ProHance, had no transmetallation in the
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presence of Zn2+ and PO43- for at least 4 days based on the study [202]. For other clinical contrast
agents, although the number of negative charge and ligand type are very similar, different ionic
linear MRI contrast agents has different transmetallation rate.
We used the similar procedure to assess the transmetallation properties of
ProCA32.collagen1 in the presence of Zn2+ and PO43-. Due to the higher relaxivity, 25 times lower
Gd3+ concentration, and 25-50 times lower chelator concentration was used in this study. To better
compare the transmetallation properties of ProCA32.collagen1 with clinical MRI contrast agent,
this experiment was applied using 25 times lower concentrations of Zn2+ and PO43-. As shown in
Fig. 4.10, the relaxation rate of ProCA32.collagen1 is not changed in the presence of Zn2+ and
PO43- for about 4 days, demonstrating that ProCA32.collagen1 is very selective to Gd3+ at these
conditions.

Figure 4.10 Stability of ProCA32.collagen1 and clinical contrast agents.
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The relaxation rates change of clinical contrast agents (♦ Eovist; ● Magnevist; □
MultiHance; △ Ominiscan; ■ ProHance; ○ Dotarem; and ProCA32.collagen1 (◊, loaded with
Gd3+ to at approximately 1:1 ratio) in phosphate buffer in the presence of ZnCl2 at different time
points up to 4 days.
Transmetallation of ProCA32.collagen1 and clinical MRI contrast agents were evaluated
by measuring the relaxivity changes in the presence of Zn2+ and phosphate over time. The
relaxivity of ProCA32.collagen1 was monitored with 55 or 110 μM ProCA32.collagen1, 100 μM
Gd3+, 100 μM Zn2+, and 1.2 mM PO43−. In this experiment, when Zn2+ is competing Gd3+ out of
the structure of contrast agents, Gd3+ will form a precipitate with PO43− in the buffer which is an
indication of instability of the contrast agent.
4.2.5 Water number determination of ProCA32.collagen1
Water number was one the factors discussed in Chapter 1 affecting the relaxivity of contrast
agents. The number of water molecular interacting with Gd3+ at the same time is important.
Furthermore, determination of water number can illustrate the special arrangement of the Gd3+
binding ligands. Tb3+ luminescence life time experiment was performed in order to test that the
relaxivity and metal binding affinity of ProCA32.collagen1 can be tuned by changing water
number [173, 176]. Generally, the fluorescence decay of the Tb3+ is caused by the radiative decay
(Г) and non-radiative decay (K). Non-radiative decay has many factors, such as molecular
collation, quenching, energy transfer. H2O molecule is one of the major factors which creates the
non-radiative decay of the Tb3+ fluorescence, however, D2O cannot generate non-radiative decay
of Tb3+ fluorescence. As a result, the difference of the decay rates of Tb3+ in the presence of H2O
and D2O (ΔKobs) represents the number of water molecules interacting with Tb3+ProCA32.collagen1.
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In order to measure the exact number of water number of ProCA32.collagen1, different
organic chelators (NTA, EDTA, DTPA) and Tb3+ in aqueous solution were used to create a
standard curve. The water number for NTA, EDTA, DTPA and Tb3+ and aqueous solution have
been reported in the literature. X-ray diffraction was used to determine the water numbers of these
chelators [173, 176]. To create a standard curve, Tb-DTPA, Tb-EDTA, Tb-NTA and free Tb3+ are
prepared in H2O and D2O solution. Then Tb3+ fluorescence was excited at 280 nm and the
fluorescence decays were monitored at 545 nm. The fluorescence decay was fitted by single
exponential decay Equation. The decay rate (Kobs) and life time (τ) of Tb3+ in H2O and D2O were
then calculated. After that the standard curve was plotted on the reported water number of these
chelators and difference of Kobs in H2O and D2O (ΔKobs) (Fig. 4.11). Water number of
ProCA32.collagen1 was calculated and q=0.5 which is the same as ProCA32-P40.

A
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Figure 4.11 The luminescence decay of Tb3+ in H2O (blue) or D2O (white) in solution of
ProCA32.collagen1. (A) Tb3+ and ProCA32.collagen1 were mixed with 1 to 2 ratios. (B) Water
number of Magnevist, Eovist, ProCA32-P40, ProCA32.collagen1.

105

4.2.6 Collagen type I binding affinity of ProCA32.collagen1
Since ProCA32.collagen1 is a collagen type I targeted MRI contrast agent, its binding
affinity to this biomarker needs to be measured. Collagen type I is the most abundant component
of extracellular matrix (ECM), therefore it is more accessible to contrast agents than other
biomarkers that are expressed on the membrane. Indirect ELISA (enzyme-linked immunosorbent
assay) was used to determine the binding affinity of ProCA32.collagen1 to collagen type I. ELISA
(enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and
quantifying substances such as peptides, proteins, antibodies and hormones. Other names, such as
enzyme immunoassay (EIA), are also used to describe the same technology. In an ELISA, an
antigen must be immobilized on a solid surface and then complexed with an antibody that is linked
to an enzyme. Detection is accomplished by assessing the conjugated enzyme activity via
incubation with a substrate to produce a measurable product. The most crucial element of the
detection strategy is a highly specific antibody-antigen interaction. Figure 4.12 shows the basic
principles of ELISA.
In our experiment, collagen type I solution from rat tail with stock concentration of 4
mg/mL was coated in ELISA plate mixed with coating buffer (0.2 M sodium
carbonate/bicarbonate, pH 9.4) overnight at 4°C. Approximately 30 µL of collagen type I was
mixed with 80 µL of coating buffer. Coating buffer is used to activate the plate. It is important to
pay attention to the capacity of the plate and how much protein is coated. In the next step, the plate
is washed with 100 µL of 1×TBST (10×TBS +Tween 20) three times, each time for about 5-10
minutes under constant shaking at room temperature. Next, the blocking buffer (%5 of Bovine
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Serum Albumin in 1×TBST) is prepared and 100 µL is added to the plate with constant shaking at
room temperature for about 1.5-2 hours.

Figure 4.12 Basic principles of ELISA.

Different concentrations of ProCA32.collagen1 starting from 0 nM up to 164000 nM were
added to the plate in the blocking buffer and incubated for either 2 hours at room temperature or
4°C overnight. Then the plate is washed again with 100 µL of 1×TBST (10×TBS +Tween 20)
three times, each time for about 5-10 minutes under constant shaking at room temperature. Primary
antibody (rabbit anti mouse) was added with 1:1000 dilution to the blocking buffer and then 100
µL was added to the plate with constant shaking at room temperature for 1.5-2 hours.
The plate was washed again with the same procedure, and the secondary antibody (goat
anti rabbit) was added with 1:2000 dilution in the blocking buffer with shaking at room
temperature for about 45 minutes. Then the plate was washed again and 1-Step Ultra TMB-ELISA
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solution (100 µL) was added. It is important that each well in the plate has the same exposure time
to the ELISA substrate solution for better results. In the last step, a stop solution (2M sulfuric acid)
is added to stop the reaction. Then the absorbance in each well is read by plate reader.

A

B

Figure 4.13

The dissociation constant

of Lysine

and Cysteine

PEGylated

ProCA32.collagen1 to collagen type I using indirect ELISA. ProCA32-P40 without any targeting
moiety did not show any specific binding.
After measuring the absorbance of multiple concentration points, the data were fit with one
to one binding equation and a dissociation constant of 1.4 ± 0.2 µM was calculated (Fig 4.13 A).
It is important to point out that residue PEGylation affect the binding affinity of the contrast agent
significantly as Cysteine residues reported to play a crucial role in the binding [120]. Cysteine
PEGylated ProCA32.collagen1 showed much lower binding affinity to collagen type I (Kd=71.8
± 2 µM) due to prevention of forming a cyclic peptide in the targeting moiety to bind to collagen
I (Fig 4.13 B).
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4.2.7 Pharmacokinetic studies of ProCA32.collagen1
In addition to metal affinity and relaxivity properties of ProCA32.collagen1, detailed
pharmacokinetic characteristic of ProCA32.collagen1 was also studied. There is an excellent
correlation between relaxivity, Gd3+ binding affinity and selectivity, and in vivo pharmacokinetics
required for detection of different stages of liver fibrosis and metastasis as well disease
heterogeneity. In order to obtain pharmacokinetic parameters, ProCA32.collagen1 (0.016
mmol/kg) was intravenously injected into mice (n=3-6) and blood was collected from saphenous
vein at different time points before and after injection up to 7 days. After collection, serum of each
sample was obtained and the Gd3+ concentration was measured using ICP-OES at a wavelength of
342 nm (Gd). Then the data were fit using two-compartment distribution model and
pharmacokinetic parameters such as terminal half-lives (blood/plasma), volumes of distribution,
and total clearance were calculated.
The blood concentration-time profiles after intravenous injection of ProCA32.collagen1 in
mice were analyzed using two-compartmental analysis using WinNonlin ™ 5.0.1 software
(Pharsight Corp., Palo Alto, CA). Mean blood concentration values from 3-6 mice at each
sampling time point were used for the mice pharmacokinetic analysis. The area under the blood
concentration-time curve (AUC) was calculated using the log-linear trapezoidal rule. The
elimination half-life (t1/2) was calculated by the equation t1/2 = 0.693/K, where K was estimated
from the terminal slope of the blood Gd3+ concentration versus time curve. The systemic clearance
(CL) was determined from dose/AUC, with AUC (area under the curve to infinity) by linear
interpolation and extrapolation to infinity y from Clast x t1/2β/0.693 (where Clast was concentration
at each last sampling point). The volume of distribution at steady-state (Vss) was determined by
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the equation Vss = CL × (AUMC/AUC), where AUMC is the area under the first moment curve.
The mean residence time (MRT) was calculated from AUMC/AUC.
ProCA32.collagen1 has the terminal elimination half-life of 9.93 h. In addition, volume of
distribution (Vc) and volume of distribution at steady state (Vdss) were 1.53 and 1.77 L/kg,
respectively. Total body clearance (CL) for ProCA32.collagen1 was 0.36 mL/min/kg. Table 4.3
summarizes the pharmacokinetic parameters of ProCA32.collagen1 compared to ProCA32-P40
and Eovist.
The pharmacokinetic characteristics of ProCA32.collagen1 in the mouse showed a
relatively high volume of distribution and vascular confinement of the contrast agent, which is
superior than clinical contrast agents like Magnevist, where the agent is largely distributed to the
extravascular extracellular space (outside the central nervous system) after intravenous
administration. Blood ProCA32.collagen1 concentrations dropped to a significantly lower level by
2 days (Fig. 4.14) after its administration and mean residence time (MRT) for ProCA32.collagen1
was 14.51 h. ProCA32.collagen1 had an increased elimination half-life compared to Eovist and
ProCA32-P40.
The systemic clearance of ProCA32.collagen1 was about 3 times higher than ProCA32P40 which is a non-targeted contrast agent. The difference could be attributed to a potentially
higher renal glomerular filtration rate or higher hepatic clearance of the agent. Biodistribution in
mouse showed accumulation of ProCA32.collagen1 in the liver and spleen, consistent with
reticuloendothelial system (RES) clearance of macromolecular contrast agents. The volume of
distribution at steady state (Vss) was two times higher than that of ProCA32-P40 which is an
indication of contrast agent distribution in tissues.
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Figure 4.14 Pharmacokinetics of ProCA32.collagen1.
Gd3+ concentration in serum collected after injection of ProCA32.collagen1 (n = 3-6) at different
time points measured by ICP-OES at 342 nm up to 7 days, however the data up to 72 h are shown.
After injection, the Gd3+ concertation in serum decreased until it was below the detection limit of
ICP-OES. The concentration of Gd3+ in serum samples were fit with exponential model in order
to extrapolate the necessary PK parameters.

As Table 4.3 demonstrates, ProCA32.collagen1 has improved pharmacokinetic properties
compared to non-targeted contrast agent, ProCA32-P40. ProCA32.collagen1 has slightly longer
elimination half-life compared to ProCA32-P40 which is due to its targeting capability. However,
its show much faster clearance rate with increased exposure time which is important for a targeted
contrast agent.
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Table 4.3 Summary of PK parameters for ProCA32.collagen1 and ProCA32-P40.

4.2.8 Safety studies of ProCA32.collagen1
Due to safety issues related to Gd3+ toxicity of MRI contrast agents, ProCA32.collagen1
distribution in different mouse organs was studied. The Gd3+ concentration in each organ was
measured using ICP-OES in order to assess the possible Gd3+ deposition in organs. Furthermore,
clinical chemistry tests were performed after injection of high concentration of ProCA32.collagen1
and different enzymes and analytes reflecting the functions of liver and kidney were measured to
investigate the toxicity of ProCA32.collagen1.
At the end, tissues of mice injected with ProCA32.collage1 were collected and H&E
staining was performed on each tissue and assessed by a pathologist blinded to our studies and the
results were then compared with control mice.
4.2.8.1 Distribution of ProCA32.collagen1 in different organs
As Fig. 4.15 demonstrates, each mouse organ was collected and Gd3+ concentration was
measured 14 days after 0.025 mmol/kg injection of ProCA32.collagen1. For this procedure,
approximately, 0.2 g of each tissue was sectioned and digested in 1 mL of ICP-grade concentrated
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nitric acid overnight at room temperature until a clear solution was achieved then the solution was
diluted with %2 nitric acid to 6-8 mL and then the Gd3+ concentration was measured.
As the results show, our contrast agent has very negligible accumulation in bone, skin and
brain, however Eovist which is a clinical contrast agent showed high depositions of Gd3+ in bone,
skin and brain as well as other organs.

Figure 4.15 Biodistribution analysis of ProCA32.collagen1.
Long term organ toxicity demonstrates the biodistribution of ProCA32.collagen1 and Eovist 14
days after injection in mice in different organs using ICP-OES. As it can be seen, different organs
such as brain, skin and bone have high accumulations of Gd3+ which is an indication of free Gd3+
being released.
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4.2.8.2 Clinical chemistry tests
Clinical chemistry tests performed by an independent company. For this purpose, serum
samples after injection of 0.025 mmol/kg ProCA32.collagen1 was collected and shipped. The mice
clinical chemistry profiles were collected by analyzing mice serum samples 5 days after injection
of saline (gray, n = 5), or 0.023 mmol/kg ProCA32.collagen1 (black). Data are expressed as mean
± SD. Different tests performed for clinical chemistry profile studies.
Alanine Transaminase (ALT) test is used by the body to metabolize protein. If the liver is
damaged or not functioning properly, ALT is released into the blood. This causes ALT levels to
increase. A high result on this test can be a sign of liver damage.
Aspartate Aminotransferase (AST) Test: Aspartate aminotransferase (AST) is an enzyme
found in several parts of the body, including the heart, liver, and muscles. Since AST levels aren’t
specific for liver damage, it’s usually measured together with ALT to check for liver problems.
When the liver is damaged, AST is released into the bloodstream. A high result on an AST test
might indicate a problem with the liver or muscles.
Alkaline Phosphatase (ALP) Test: Alkaline phosphatase (ALP) is an enzyme found in your
bones, bile ducts, and liver. An ALP test is typically ordered in combination with several other
tests. High levels of ALP may indicate liver damage, blockage of the bile ducts, or a bone disease.
Creatine Kinase (CK) Test: Measurement of serum creatine kinase (CK) activity is
essential in the evaluation of suspected neuromuscular disease. In skeletal muscle CK plays a
major role in energy generation, buffering cellular ATP and ADP concentrations by catalyzing the
reversible exchange of high-energy phosphate bonds between phosphocreatine and ADP,
regenerating ATP from ADP produced during muscle contraction. A diagnosis of liver disease
should not be made with elevations of AST and ALT alone in the absence of concurrent
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measurement of serum CK activity. If serum CK activity is not measured, misdiagnosis of a liver
disease may be made when the actual problem is a myopathy.
Total Proteins test: Albumin is the main protein made by liver. It performs many important
bodily functions. For example, albumin: Stops fluid from leaking out of your blood vessels
Nourishes the tissues, Transports hormones, vitamins, and other substances throughout the body
An albumin test measures how well the liver is making this particular protein. A low result
on this test indicates that the liver isn’t functioning properly. Globulin is a set of sixty proteins
including the antibodies or gamma globulins and protein-carbohydrate compounds known as
glycoprotein. There are four basic groups of globulin proteins known as the alpha-1, alpha-2, beta
and gamma proteins.
These are used to help transport proteins through the lipoproteins and assisting the blood
in clotting. They also act as plasma cells which indicate whether there is an antibody deficiency in
the blood stream. The liver produces much of the alpha and beta globulins used for this purpose.
The level of these proteins is measured against the levels of albumin, the other major type
of protein in the bloodstream. Albumin and globulin are two types of protein in body. The total
protein test measures the total amount albumin and globulin in your body.
Bilirubin and Creatinine Test: Bilirubin attached by the liver to the glucose-derived acid,
glucuronic acid, is called direct, or conjugated, bilirubin. Bilirubin not attached to glucuronic acid
is called indirect, or unconjugated, bilirubin. All the bilirubin in the blood together is called total
bilirubin. Bilirubin is a waste product ordinarily processed by the liver. The breakdown of red
blood cells creates this waste product. It passes through the liver before being excreted through
stool. A damaged liver can’t properly process bilirubin. This leads to an abnormally high level of
bilirubin in the blood. A high result on the bilirubin test indicates that the liver isn’t functioning
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properly. If bilirubin is not being attached to the glucose-derived acid (conjugated) in the liver or
is not being adequately removed from the blood, it can mean that there is damage to your liver.
Testing for bilirubin in the blood is a good way of testing for liver damage.
Creatinine Test: Creatinine is a chemical waste molecule that is generated from muscle
metabolism. Creatinine is produced from creatine, a molecule of major importance for energy
production in muscles. Creatinine is transported through the bloodstream to the kidneys. The
kidneys filter out most of the creatinine and dispose of it in the urine. The kidneys maintain the
blood creatinine in a normal range. Creatinine has been found to be a fairly reliable indicator of
kidney function. Elevated creatinine level signifies impaired kidney function or kidney disease.
As Fig 4.16 shows, liver and kidney function tests appeared to be normal after injection of
ProCA32.collagen1 and the results were the same as control mice, therefore, ProCA32.collagen1
did not cause any toxicity after injection.
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Figure 4.16 Toxicity studies of ProCA32.collagen1.
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(A, B, C, D, E) Clinical chemistry tests after injection of 0.023 mmol/kg, ProCA32.collagen1. The
mice clinical chemistry profiles were collected by analyzing mice serum samples 5 days after
injection of saline (gray, n = 5), or 0.025 mmol/kg ProCA32.collagen1 (black). Data are expressed
as mean ± SD.
4.2.8.3 Tissue toxicity of ProCA32.collagen1
The 0.0013 mmol/kg ProCA32.collagen1 or saline (control) was i.v. injected in CD-1 mice.
H&E staining was used to evaluate the toxicity of the ProCA32.collagen1 to these tissues after
injection. An experienced pathologist was blinded to the groups of H&E staining to evaluate the
organ toxicity of ProCA32.collagen1. ProCA32.collagen1 shows no toxicity in all kinds of mice
tissues and organs studied, including liver, kidney, muscle, spleen, brain, and heart. The images
are representative of three independent experiments. As results show in Fig. 4.17, all the tissues in
all viral organs appeared to be normal after injection of ProCA32.collagen1 which shows that the
contrast agent does not cause any tissue damage due to Gd3+ deposition.
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Figure 4.17 Tissue toxicity studies of ProCA32.collagen1.
The 0.0013 mmol/kg ProCA32.collagen1 or saline (control) was i.v. injected in CD-1 mice. H&E
staining was used to evaluate the toxicity of the ProCA32.collagen1 to these tissues after injection.
An experienced pathologist was blinded to the groups of H&E staining to evaluate the organ
toxicity of ProCA32.collagen1. ProCA32.collagen1 shows no toxicity in all kinds of mice tissues
and organs studied, including liver, kidney, muscle, spleen, brain, and heart. The images are
representative of three independent experiments.
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Discussion
4.3.1 Design of ProCA32.collagen1 with collagen targeting capability and dual high relaxivity
Collagen targeted protein MRI contrast agent, ProCA32.collagen1 was designed by
covalently linking a collagen type I targeting peptide moiety consisting of natural amino acids to
the C-terminal of protein contrast agent ProCA32 (with two Gd3+ binding sites). An intra-disulfide
bond formed by two cysteine residues to stabilize conformation required for collagen I binding. In
the modeled structure, Lysine residues are positioned to bind collagen type I while its PEGylation
also increase relaxivity by tuning correlation time. A flexible linker was used to maximize
targeting capacity and relaxivity yet maintaining metal binding capability [83]. PEGylation of the
contrast agent can improve protein solubility, blood retention time and reduce immunogenicity
[84]. The designed ProCA32.collagen1 was bacterial expressed, purified, and modified and
confirmed to form a 1:2 Gd-ProCA32.collagen1 complex using ICP-OES (Methods) [83] [177].
We determined collagen I binding affinity of PEGylated ProCA32.collagen1 using enzyme
linked immunosorbent assay (ELISA). The contrast agent exhibits high affinity to collagen type I
with dissociation constant of Kd=1.42  0.2 M (fitted by 1:1 binding model) [135, 203]. On the
other hand, PEGylated ProCA32 without addition of a collagen targeting moiety did not show any
specific binding to collagen I.
The determined relaxivity of r1 and r2 of PEGylated ProCA32.collagen1 were 34 ± 0.12
mM-1s-1 and 50 ± 0.16 mM-1s-1 per Gd3+, respectively at 37 °C and 1.4 T or 68  0.25 mM-1s-1 and
100  0.32 mM-1s-1 per particle, respectively. Interestingly, at high magnetic fields of 7.0 T, 37 °C,
PEGylated ProCA32.collagen1 exhibits the highest r1 (21.3 ± 0.5 mM-1s-1 per Gd3+ or 42.6 ± 1
mM-1s-1 per participle) and r2 (108.5 ± 1.2 mM-1s-1 per Gd3+ or 217 ± 2.4 mM-1s-1, per particle)
compared to reported contrast agents (Table 4.2). ProCA32.collagen1’s r1 and r2 relaxivity values
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are 5-10 and 12-17 times greater than those of clinical contrast agents at 1.4 and 7.0 T, respectively.
Therefore, this targeted contrast agent can be applied to both low and high magnetic field strengths
with both T1 and T2 weighted molecular imaging. Such large value of r1 and r2 are likely due to
secondary shell water contribution since water number q in the first coordination shell determined
by luminescence resonance energy transfer (LRET) using Tb3+ luminescence life time decay is
0.5.
4.3.2 High Gd3+ binding affinity and metal selectivity, and low toxicity of ProCA32.collagen1
To address one of the major causes of nephrogenic systemic fibrosis (NSF) associated with
free Gd3+ toxicity, we next examined metal binding affinity and selectivity of ProCA32.collagen1.
We determined the dissociation constant (Kd) of ProCA32.collagen1 to Tb3+ to be 6.14 ± 0.2 × 1022

M using Tb3+-DTPA buffer system and Tb3+ luminescence resonance energy transfer (Tb3+-

LRET) between Tb3+ and Trp adjacent to the metal binding sites. Addition of Gd3+ results in
decrease of the LRET signal between Tb3+ and Trp due to competition of metal binding sites. The
Gd3+ binding affinity of ProCA32.collagen1 is 2.0 ± 0.25 × 10-22 M which is comparable to the
approved clinical contrast agents (Table 4.1). Since competition of physiological metal ions such
as Zn2+, Mg2+ and Ca2+ [6, 11] is considered to be one of the most important risk factors for Gd3+
release in vivo, we then determined metal binding constants for these metal ions [83, 176]. Table
4.1 shows that ProCA32.collagen1 exhibits 1014-1016-fold increases in metal selectivity (kinetic
stability) for Gd3+ over Ca2+ and Zn2+ compared with all approved agents including macrocyclic
“safe” agents Dotaram and ProHance. To the best of our knowledge, like ProCA32-P40,
ProCA32.collagen1 has the greatest metal selectivity among all other approved Gd3+-based
contrast agents.
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4.3.3 Additional improved safety properties of ProCA32.collagen1
ProCA32.collagen1 has several additional improved safety properties. Transmetallation
studies demonstrate the relaxation rates of clinical contrast agents (Eovist; Magnevist; Ominiscan;
ProHance) gradually decrease upon incubation with 2.5 mM Zn2+ in 30 mM PO43- [83].

In

contrast, the relaxation rates of ProCA32.collagen1 remain unchanged suggesting that
ProCA32.collagen1 has strong capability against transmetallation, similar to approved “safe”
contrast agents Dotarem and ProHance. Further, ProCA32.collagen1 remains intact without
cleavage upon incubation with human serum at 37C for 13 days. Recent brain deposition has
underlined the importance of metal safety [204, 205]. Importantly, ProCA32.collagen1 does not
have brain deposit possibly due to lack of penetration to blood barrier.

Moreover,

ProCA32.collagen1 did not show any acute toxicity as clinical chemistry test values are within
the normal range demonstrating the normal function of organs specially kidney and liver. No
tissue and organ toxicity was observed. More importantly, the projected required injection dosage
of ProC32.collagen1 in human for significant MRI enhancement in liver is ~ 20-230-fold lower
than clinical contrast agents such as MultiHance (Table 4.2).
Our developed ProCA32.collagen1 represents a major leap in addressing concerns about
metal toxicity and Gd3+ deposition associated with current contrast agents in several aspects.
Administration of contrast agents helps with visualization of diseases at MRI. Specifically,
majority of clinical Gd3+-based MRI contrast agents cause T1 shortening and signal enhancement
on T1 map images, however most of these agents have been linked to the occurrence of
nephrogenic systemic fibrosis (NSF) in renal impaired patients due to release and accumulation of
Gd3+ from the agent because of transmetallation [157, 206] . Furthermore, they are all based on
small-molecule chelates and have very low relaxivity (both r1 and r2) and sensitivity without
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targeting capability, therefore, they are only able to detect moderate and advanced stage of
diseases. The clinical contrast agents also use a high clinical injection dosage due to their low
sensitivity with a short imaging window without the capability of enhancing the entire organ such
as Eovist. ProCA32.collagen1 with high r1 and r2 relaxivity has very low injection dosage (Table
4.1) of 0.0013 mmol.kg-1 projected in humans which is 20-200-fold lower than clinical contrast
agents. In addition, its high selectivity towards Gd3+ makes it a safer agent.
Summary
In summary in this chapter, some of the most important properties of a contrast agent was
reported. ProCA32.collagen1 has very strong binding affinity to collagen type I and superior r1
and r2 relaxivity. The contrast agent has very high binding affinity and selectivity towards Gd3+
and is very resistant to transmetallation. ProCA32.collagen1 is also very stable in the human serum
up to 13 days without any degradation. It is worth mentioning that PEGylation not only increases
the stability and solubility of the contrast agent but also increase its relaxivity and sensitivity for
in vivo applications which will be discussed in the coming chapters. ProCA32.collagen1 did not
show any tissue and long-term organ toxicity based on low and negligible Gd3+ accumulations.
5

APPLICATION OF PROCA32.COLLAGEN1 IN IMAGING OF LIVER FIBROSIS
Introduction

5.1.1 Organ fibrosis
Fibrosis is a common feature in many different pathologies. It is characterized by the
accumulation of extracellular matrix (ECM) components and is associated with up to 45% of
deaths in industrialized countries [207]. In general, fibrosis mechanisms include exacerbated
injury-related responses that are dysregulated versions of conventional tissue repair processes
[208]. Core elements in disease progression can be acute, recurrent or persistent epithelial and
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endothelial injuries that can both initiate and sustain fibrosis [209]. These pathogenic pathways
furthermore involve changes in numerous inflammatory, endothelial and mesenchymal cells,
resulting in increased production of fibronectin, osteopontin, hyaluronan, proteoglycans, laminins
and a variety of collagen subtypes [210]. The abnormal ECM deposition which is typical of fibrosis
leads to a disruption and distortion of the tissue architecture and function [211]. These fundamental
fibrotic processes are shared across a variety of tissues and organs, including connective tissue,
gastrointestinal tract, liver, kidney, lung and heart (Fig. 5.1). While the mechanisms of fibrogenesis
are similar, the regenerative capacity and the ability to reverse advanced fibrosis vary
tremendously. Resolution of fibrosis is for example possible in the liver when the underlying cause
is removed; this is for instance the case in complete suppression of hepatitis B virus replication
and curative treatment of hepatitis C [212].
The desmoplastic reaction and increased ECM production in tumors is remarkably similar
to organ fibrosis [213]. Cancer-associated fibroblasts (CAF) are one of the most crucial
components of the tumor microenvironment and have been implicated in angiogenesis,
immunosuppression and metastasis [214, 215]. Fibrotic stroma affects disease progression in
various tumors, e.g. breast cancer, in colon/colorectal cancer and in pancreatic tumors, as well as
in head and neck cancer [216, 217]. In contrast to fibrosis as a common endpoint for all of the
above organs and tissues, the etiologies causing fibrosis are highly diverse, encompassing an array
of different triggers such as acute injury, chronic inflammation, autoimmune reactions and genetic
alterations. In some cases, the exact etiology may even remain unknown. While a detailed
description of these triggers and their disease-initiating mechanisms is beyond the scope of this
review, several prototypic examples can be provided, to exemplify the high prevalence and farreaching consequences of fibrotic processes in human diseases. Among the most obvious
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etiologies for induction of fibrosis are exposure to ionizing irradiation and mechanical obstruction,
resulting from e.g. myocardial infarction, surgical intervention, gall- and kidney-stones.
Frequently accountable chronic illnesses with fibrotic elements include psoriasis, Crohn's disease,
pneumoconiosis subtypes, steatohepatitis, viral hepatitis and glomerulosclerosis. Also, many
autoimmune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, Sjörgen's
syndrome, progressive systemic sclerosis, Hashimoto's thyroiditis and ankylosing spondylitis are
associated with fibrosis.
Underlying genetic predispositions that make individuals susceptible to fibrosis are
neurofibromatosis, cystic fibrosis, alpha 1-antitrypsin deficiency, tyrosinosis, Wilson's disease and
hemochromatosis, as well as hypertrophic and restrictive cardiomyopathy. There are multiple
fibrosis related diseases, in which the exact triggers are unknown, such as sarcoidosis, idiopathic
pulmonary fibrosis, retroperitoneal fibrosis, acute interstitial pneumonitis and dilated
cardiomyopathy.
Accurate diagnosis and staging of fibrosis is essential for proper prognosis and progression
monitoring. The presence and the severity of fibrosis actually are the best predictors for disease
progression in chronic kidney disorders and in fatty liver disease [218]. Traditionally, needle-based
biopsies have been the gold standard for fibrosis diagnosis and staging. Biopsies, however, are
faced with multiple limitations, including their invasive nature, procedure-associated risks, limited
representativeness for the entire organ, and inter- and intra-observer sampling variability [219].
In the recent years, increasing numbers of studies have focused on the development of noninvasive imaging techniques for fibrosis diagnosis, staging and treatment monitoring. Noninvasive imaging techniques such as X-ray imaging, computed tomography (CT), ultrasound (US),
magnetic resonance imaging (MRI), photoacoustic imaging (PAI), optical imaging (OI), positron
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emission tomography (PET) and single-photon emission computed tomography (SPECT) have all
been employed for this purpose [220-223]. Biopsies and liquid biomarkers to assess fibrosis
An accurate determination of fibrosis stage is crucial for the prognosis, for determining
surveillance strategies and for selecting a suitable therapeutic approach. Traditionally, needlebased biopsies are considered the gold standard and they often are the only available means for
specific fibrosis assessment and exact disease differentiation. In the case of systemic lupus
erythematosus (SLE), for instance, a renal biopsy is crucial to diagnose the specific form of lupus
[224]. In general, multiple stainings can be employed for visual inspection, such as hematoxylin
and eosin staining or more specifically trichrome or Sirius Red staining (marking collagenous
fibers) or immunohistochemistry specific for certain types of collagens or other ECM components
[225].

Figure 5.1 Pathological characteristics of fibrosis in different tissues.
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To achieve optimal accuracy in the diagnosis of fibrosis, the biopsy bias has to be
minimized, starting with the excised sample, which should have specific properties. An adequate
kidney biopsy is 10 mm in length and at least 1.2 mm in width, and it should contain 10–15
glomeruli [226]. A liver biopsy is considered adequate if it has a length of at least 20 mm and
contains at least 11 portal tracts (some experts even prefer 16 portal tracts) [227]. However, such
“optimal” liver biopsies only represent 1/50,000 of the total liver volume. For the diagnosis of
arthritic diseases, a biopsy sample of the synovial fluid is considered equally informative as a
sample of the synovial tissue. The diagnosis of connective tissue disease is commonly performed
on the basis hematological tests (complete blood count, erythrocyte sedimentation rate),
biochemical analysis (C-reactive protein, hepatic function, renal function) and immunologic
investigations (autoantibodies, rheumatoid factors, antinuclear antibodies, antibodies to DNA,
antiphospholipid antibodies) [228].
In case of tumors, a biopsy is the standard diagnostic procedure to determine the nature
and stage of the tumor, as well as its malignant potential. Although the essential role of
desmoplastic processes for tumor growth and metastasis has been recognized [229], they are not
considered in routine pathological assessments. Many studies have suggested that especially in
invasive colorectal cancer [230-232] and in pancreatic ductal adenocarcinoma [233-235], the
desmoplastic reaction is a key hallmark determining therapeutic outcome. Thus far, however,
histopathological information on e.g. myxoid stroma as an indicator for epithelial-to-mesenchymal
transition [230], has not yet managed to become broadly accepted and implemented for disease
differentiation, prognosis assessment and treatment selection [236].
While needle-based biopsies inevitably play an important role in the diagnosis and staging
of fibrotic diseases, they suffer from several drawbacks, including invasiveness with the risk of
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life-threatening complications, sampling errors, and intra- and inter-observer variability [237,
238]. Moreover, repeated biopsy procedures are difficult and impractical, due to the increased risk
of complications [121]. Nevertheless, because of the lack of reliable tools and technologies to
obtain information noninvasively, up to 4 biopsies are still routinely taken in large phase III trials,
e.g. in patients suffering from non-alcoholic steatohepatitis (NASH) [239].
In tumors, biopsy-based diagnosis is particularly complicated, because of intrinsic
heterogeneity in the primary tumor, as well as heterogeneity between the primary tumor and
metastases [240]. In such situations, also the accessibility of the pathological site(s) and the risk
of spreading/seeding cancer cells play an important role [241]. In light of these limitations, liquid
biopsies are increasingly emerging in the field of cancer diagnosis as a refined and non-invasive
alternative (and/or as an add-on) to needle-based biopsies [242]. A liquid biopsy, in the form of a
blood sample, can provide information on the genetic profile of cancerous lesions (and the
heterogeneity therein) by means of analyzing circulating tumor cells or circulating cell-free tumor
DNA [243, 244].
Because of their high applicability, reproducibility and widespread availability, liquidbased biopsies not only hold great promise for cancer diagnosis, but also for the assessment of
classical fibrotic diseases. For the assessment of liver fibrosis, for instance, several serum
biomarkers are available that are composite scores of not strictly liver-specific parameters as well
as some that have been associated with fibrosis stage, but both types have been mainly proposed
for patients with chronic hepatitis C [245]. The most commonly used tests include the FibroTest®
(which combines alpha-2 macrolobulin, haptoglobin, apolipoprotein, bilirubin, gamma glutamyl
transferase, age and gender into an algorithm), the aspartate-to-platelet ratio index (APRI) and the
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Enhanced Liver Fibrosis score (ELF; which includes amino-terminal propeptide of procollagen
type III (PIIINP), TIMP metallopeptidase inhibitor 1 and hyaluronic acid) [246, 247].
Shortcomings of liquid-based biomarkers are that they may not be organ-specific (enough),
that they may be limited to the indication of impaired organ function or inflammatory state, and in
particular that they may not specifically reflect fibrosis or discriminate between different stages of
fibrosis [248, 249]. The abovementioned new biomarkers may help to provide more fibrosisspecific information, since they mostly assess molecules of the ECM. These novel markers now
require validation in large cohorts of patients and in long-term studies [249]. In the future, such
liquid biopsy techniques may be used in combination with other modalities, such as imaging, to
improve the accuracy of fibrosis diagnosis and staging.
5.1.2 Non-invasive imaging of fibrosis
In the last decade, non-invasive imaging techniques have received a lot of attention for the
assessment of fibrosis. Such set-ups and strategies typically include anatomical, functional and/or
molecular imaging approaches that allow for the examination of the affected organ (or even the
whole body) in a readily repeatable manner. In the case of fibrosis, this makes non-invasive
imaging not only attractive for initial diagnosis, but also for staging and progression monitoring.
Several imaging protocols have been evaluated for this purpose over the years, ranging from the
basic assessment of anatomical/morphological changes, via the quantification of differences in
functional properties, to the identification of molecular adaptations and disease-specific changes.
Importantly, non-invasive imaging can also be employed for treatment monitoring, thereby
potentially facilitating the clinical translation of novel anti-fibrotic therapies. In the following
sections, using selected examples from the literature, we will provide an overview of the
noninvasive imaging techniques that are commonly used in the context of fibrosis, and we will
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discuss their (pre-) clinical application in systemic autoimmune diseases, in parenchymal organs,
such as liver, kidney, lung and heart, and in desmoplastic tumors [249].
5.1.3 Liver fibrosis
The global burden of liver disease is already enormous [250-252] and an exponential
increase is predicted for the next couple of decades [253]. A recent meta-analysis showed that
fibrosis (in a stage-dependent manner) closely correlates with liver-related mortality, as well as
with overall mortality [254, 255]. Consequently, the degree of liver fibrosis is of great importance
for proper diagnosis, prognosis assessment and therapeutic intervention in chronic liver disease.
Up to now, the histologically determined stage of fibrosis is the strongest independent risk factor
for predicting liver-associated complications and the need for liver transplantation, as well as for
liver-related and overall mortality [256]. Non-invasive assessment of liver fibrosis has thus far
only been established for chronic hepatitis B and C virus infections, via the combination of two
concordant tests, i.e. serum biomarkers plus transient elastography [245]. To distinguish between
benign fatty liver disease and progressive non-alcoholic steatohepatitis, invasive biopsies are still
required [257]. This biopsy procedure comes with multiple drawbacks, including the associated
risks, sampling errors and intra and inter-observer variability. The latter is especially obvious,
when semi-quantitative scoring systems are applied, which include grading (steatosis, ballooning,
portal inflammation) and staging (fibrosis) [245, 247, 257].
In terms of anatomical imaging, standard gray-scale US is routinely used in the clinic for
the assessment of liver disease. It provides baseline information on liver morphology and texture
[247]. As an example, Choong and colleagues used gray-scale US to show that the liver surface
progressed from being smooth to extremely nodular as the severity of the disease increased. The
authors also reported coarsened echotexture and blunting of liver edges in patients with liver
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fibrosis. However, this type of anatomical US imaging is limited to the detection of advanced stage
fibrosis and does not provide sufficient accuracy for ruling out early-stage liver fibrosis [258].
Besides US, non-contrast enhanced CT has also been shown to be able to depict liver surface
nodularity, and it does so with high accuracy and high intra- and inter-observer independency
(upon assistance of an automated computer algorithm). So far, this technique has only been tested
retrospectively for the differentiation of cirrhotic from non-cirrhotic livers, and further evaluations
are needed to assess its reproducibility, as well as its (prospective) performance in intermediatestage liver fibrosis [259].
Functional imaging of liver fibrosis has encompassed a variety of elastography modalities,
which assess liver stiffness and which have had a massive impact on the non-invasive diagnosis
of liver fibrosis. These elastography methods include transient elastography (TE), acoustic
radiation force impulse imaging (ARFI), shear wave elastography (SWE) and MR elastography
(MRE) [260]. FibroScan® was the first TE device which was approved for the rapid and user
friendly quantification of fibrosis at the bedside [261]. The FibroScan® system consists of an US
transducer combined with a vibrator that enables the direct relation of shear wave propagation to
tissue stiffness [262, 263]. Initial inaccuracies and even application failures of TE devices in obese
patients were partially overcome with an adapted XL probe that allows for deeper tissue
penetration [264]. As opposed to TE, both ARFI and SWE use focused US pulses to estimate shear
wave velocities in the liver which are related to tissue stiffness. ARFI is based on the elasticity
information from the axis of the pushing beam that creates a 2D stiffness map, whereas SWE
depends on the shear waves propagating sideways from the axis of the US beam [265, 266]. In
liver SWE scans, fibrotic liver tissue is characterized by a higher stiffness as compared to healthy
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liver tissue [267]. The elastic modulus of the depicted fibrotic liver is - with an average of 28 kPa
- almost 5 times higher than the one measured in a healthy liver.
In comparison to the above-mentioned US elastography techniques, in which transient
elastography in obese patients is compromised, MRE has been shown to have superior diagnostic
performance not only for the detection of advanced fibrosis, but also for differentiating the
individual progression states from simple steatosis to steatohepatitis [248, 268, 269]. In a recent
prospective trial, MRE was found to be more accurate in identifying liver fibrosis (stage 1 or
higher) than TE in patients with non-alcoholic fatty liver disease [270]. In this context, Chen and
co-workers investigated the precision of MRE for discriminating patients with simple steatosis,
steatohepatitis and hepatic fibrosis. A clear difference in hepatic stiffness manifested in all three
conditions, and the highest stiffness was observed in patients with hepatic fibrosis followed by
steatohepatitis and simple steatosis [271]. These results indicate that the use of MRE allows for
separating patients with simple steatosis from the ones with steatohepatitis, which would allow for
earlier and more specific therapeutic interventions. The MRE procedure can be incorporated into
a routine liver MRI protocol with only a few minutes added to the total scan time [272, 273]. The
postprocessing procedure is simple, but the hardware and software additions to the MRI are
expensive and might impede clinical translation and implementation [274]. Recently, the
feasibility of a cost-effective and portable photoacoustic imaging system (PAI) and US dual
modality imaging setup has been evaluated in a preclinical CCl4- induced murine fibrosis model
and it turned out to be an interesting addition to the currently available elastography techniques
[214]. This alternative set-up relies on hemoglobin as a chromophore that absorbs light and the
combination with US for proper selection of the liver region to be evaluated [275]. The PAI signal
is increased in fibrotic livers due to the more heterogeneous tissue structure caused by ECM
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deposition and angiogenesis. Analogously, PAI - in the form of a multispectral optoacoustic
tomography set-up (MSOT) - has recently also gained interest for application in several other
fibrosis-related diseases, including Crohn's disease [276, 277].
Moreover, a number of tools and technologies have been proposed for molecular imaging
of liver fibrosis. These include MRI and nuclear imaging techniques that are used in combination
with targeted contrast agents. The liver-specific contrast agent gadolinium ethoxybenzyl
dimeglumine (Gd-EOB-DTPA), also known as Primovist® in Europe or Eovist® in the USA, is a
MRI contrast agent that was originally developed for the detection of liver metastasis and
hepatocellular carcinoma (HCC) [278, 279]. After intravenous injection Gd-EOB-DTPA
progressively distributes into the hepatocytes via the organic anion transporter polypeptides
OATP1B1 and OATP1B3 and excretes into the bile ducts via the multi drug resistance protein 2
(MRP2) [280]. The uptake and excretion of Gd-EOB-DTPA by the hepatocytes is also impaired
in liver fibrosis, which enables the detection of severe fibrosis and cirrhosis in patients [281].
Molecular MRI has also shown promise in case of imaging of ECM components, such as
elastin and collagen. Evidence for the use of ECM-targeted MR contrast media has been obtained
in several liver fibrosis animal models. Elastin has been used as a target for molecular MRI, a
significantly higher contrast enhancement in the perivascular regions in CCl4- treated fibrotic mice
was observed as compared to healthy mice upon the administration of the Gd-containing elastin
specific contrast agent, ESMA [282]. Similarly, Farrar and colleagues demonstrated that the Gdcontaining collagen I-specific contrast agent EP-3533 not only allowed for staging of liver fibrosis
via 3D molecular MRI, but also enabled accurate therapy monitoring in mouse and rat models
[110, 283].
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Besides MRI, also radionuclide-based imaging techniques such as SPECT and PET have
been used for molecular imaging of liver fibrosis in preclinical setups. In case of SPECT, Li and
colleagues reported on the use of 99mTc-labeled cyclic RGD penta-peptide for imaging hepatic
stellate cells (HSC) in fibrotic rats [284]. The RGD peptide is known to have a high binding affinity
to αvβ3 integrins, which are upregulated in hepatic fibrosis [285, 286]. Specifically, it was shown
that the expression levels of αvβ3 integrins on HSC correlate with fibrosis stage, and that noninvasive SPECT-based staging of liver fibrosis is possible with 99mTc-labeled cRGD [284]. In
line with this, PET in combination with CT has been used for the imaging of translocator protein
(TSPO) expression in progressive liver fibrosis. The TSPO is a convenient biomarker since it is
mainly expressed by macrophages and HSC. The accumulation of the TSPO specific radiotracer
18F-FEDAC correlated well with the severity of liver damage in rats exposed to CCl4 [287]. In
order to facilitate clinical translation, further studies are needed to optimize molecular imaging
probes and protocols which are specific for HSC [288] and other fibroblast-like cells, which e.g.
express the platelet-derived growth factor receptor-β [289].
In summary, significant progress has been made at the clinical level in anatomical and
functional imaging of liver fibrosis. However, the abovementioned techniques and protocols entail
multiple disadvantages and they do not really permit accurate fibrosis staging and treatment
monitoring. At the preclinical level, molecular imaging of liver fibrosis via MRI, PET and SPECT
has hinted towards more specific detection of changes in biomarker levels that correlate with
disease progression and/or treatment responses, indicating that such probes and protocols may start
impacting the diagnosis and treatment of liver fibrosis in the clinic in the near to distant future.
Collagen type I is an important target for molecular imaging of liver fibrosis since its
accumulation is a characteristic of most types of chronic liver diseases (CLD) [290]. In this paper,
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we report the development of a protein MRI contrast agent for molecular imaging of the collagen
level (ProCA32.collagen1) extending the targeting capability of our recently reported ProCA32P40, a protein MRI contrast agent [83]. ProCA32.collagen1 with high dual relaxivity values for r1
and r2 per Gd3+ at both 1.5 and 7.0 T as well as strong collagen targeting capability enables the
first robust detection of early and late stage of liver fibrosis as well as heterogonous expression of
collagen by multiple molecular dynamic imaging. The development of collagen-targeted protein
MRI contrast agent is expected to overcome the major clinical barriers in early diagnosis,
noninvasive detection and staging of liver fibrosis, and have strong application in facilitating
effective treatment and stop further progression toward major clinical consequences including
cirrhosis, impaired liver function, and hepatocellular carcinoma.
Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide[110,
121, 161, 283]. Hepatic fibrosis can develop in patients with any type of chronic liver disease
(CLD), including alcoholic liver disease (ALD), hepatitis C, hepatitis B, nonalcoholic fatty liver
disease (NAFLD) and autoimmune hepatitis. The Centers for Disease Control (CDC) estimates
that 19,388 people died in the US from alcohol related liver disease in 2014 [291]. Chronic liver
disease originates from a variety of causes such as viral hepatitis, metabolic dysfunction, as well
as alcohol abuse and autoimmune disease and almost all chronic liver injuries can cause liver
fibrosis [291, 292].
Biopsy coupled with histological analysis is the gold standard for diagnosis and staging of
liver fibrosis as it relies on stage-dependent characteristic patterns of collagen expression. Collagen
type I is heterogeneously accumulated in liver fibrosis depending on etiology which leads to
fibrosis that disrupts liver cytoarchitecture and function [293]. Sequential histological grading of
inflammation and staging of fibrosis based on collagen 1 are used to decide the risk of disease
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progression. However, biopsy has many limitations such as sampling errors, high inter-observer
variability with 33-50% error rate even for diagnosis of advanced stages of liver fibrosis such as
cirrhosis likely due to heterogeneity [283]. Tremendous effort have been devoted into development
of noninvasive imaging techniques based on stiffness associated with fibrosis such as ultrasound
apparent diffusion coefficient (ADC), magnetic resonance elastography (MRE), T1, T2, relaxation
in the rotating frame (T1ƿ) [294], magnetization transfer [295], and proton density fat fraction
(PDFF). However, these techniques cannot provide accurate detection of early stage liver fibrosis
and visualization of heterogeneity.
A prerequisite for early detection and efficient treatment of liver fibrosis is a reliable noninvasive diagnostic method to accurately stage fibrosis progression and response to therapy. MRI
offers several unique advantages compared to other clinical imaging modalities with its deep tissue
penetration, high spatial resolution, and coverage of the entire liver. Since MRI does not require
the use of ionizing radiation, it is well suited for screening and monitoring the progression and
regression of fibrosis [296, 297]. However, an early stage of patient liver fibrosis with regional
heterogeneity cannot be ambiguously detected by MRI due to limitations of currently available
MRI contrast agents.
To differentiate “invisible” fibrotic cells from heterogeneous tissue background without
clear boundary requires novel MRI contrast agents and imaging methodology to have a strong
specificity for both organ and diseased cells as well as much improved relaxation properties. Iron
oxide-based contrast agents such as ferumoxides create negative (dark) T2 /T2* effects that are
reported to yield images with signal voids with very limited accuracy[278, 298]. Like all other
approved Gd3+ MRI contrast agents, Gd-BOPTA (Multihance) and Gd-EOB-DTPA (Eovist US;
Primovist, Europe) have Gd3+ r1 relaxivity strong enough to lead to a positive (bright) imaging.
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[299]. These two clinical agents have liver distribution and able to detect late stage fibrosis in vivo
with r1 increase using T1-weighted sequence at a short arterial phase and a short hepatobiliary
uptake phase [300, 301]. In addition, severity or the stage of fibrosis assessment is also necessary
when making decision in diseases diagnosis, prognosis of chronic liver diseases and even while
screening for various forms of HCC. Recent developments of collagen targeted contrast agent
using approved DTPA (Magnivest) have shown to be able to image liver fibrosis with improved
sensitivity and specificity but largely depending on the animal models[121], however, safety
concerns about Magnevist underscore the pressing need of a safe MRI contrast agent with strong
capability in detecting early stage fibrosis and delineating liver heterogeneity [302].
We reasoned that precision dual imaging capability (r1 and r2) of stage-dependent
characteristic expression patterns of collagen type I will lead us to differentiate “invisible” fibrotic
cells from heterogeneous tissue background without clear boundary in early stage and extracellular
matrix heterogeneity associated with late liver fibrosis depending on etiology, liver
cytoarchitecture and function [293]. In this chapter, we report the development of a protein MRI
contrast agent (ProCA) for molecular imaging of the collagen level (ProCA32.collagen1) in two
models of liver fibrosis extending the targeting capability of our recently reported ProCA32-P40
[83] (Fig. 5.2). ProCA32.collagen1 with high dual relaxivity values for r1 and r2 per Gd3+ at both
1.5 and 7.0 T as well as strong collagen targeting capability enables the first robust detection of
early and late stage liver fibrosis as well as heterogonous expression of collagen by multiple
dynamic molecular imaging properties. In addition, ProCA32.collagen1 is able to demonstrate
vascular and architectural alterations during late stage fibrosis which has not been achieved before.
The development of collagen-targeted protein MRI contrast agent is expected to overcome the
major clinical barriers in early diagnosis, noninvasive detection and staging of liver fibrosis, and
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have strong application in facilitating effective treatment and stop further progression toward
major clinical consequences including cirrhosis, impaired liver function, and hepatocellular
carcinoma.

Figure 5.2 Development of ProCA32.collagen1 for molecular imaging of liver fibrosis.
ProCA32.collagen1 was developed by linking collagen type I targeting moiety at its C-terminal to
be applied in early detection of liver fibrosis as well as late stage liver cirrhosis.
Results
5.2.1 Robust detection of early and late stages liver fibrosis with dual contrast property
We tested whether molecular MR imaging with ProCA32.collagen1 is able to
unambiguously and quantitatively detect early stage and late stage of liver fibrosis in vivo taken
advantage of high r1 and r2 values (Fig. 5.3). Early and late stages of liver fibrosis of BALB/c mice
were induced by injection of thioacetamide (TAA) and fed with 10% alcohol in drinking water
either for 6 weeks or 12 weeks, respectively (Fig. 5.4). Fig. 5.3 shows R1 map inversion recovery
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MRI images collected before and 24 hrs after intravenous (I.V.) injection of contrast agents (100
µL, 5 mM) of ProCA32.collagen1, ProCA32-P40 (non-targeted), and Eovist. After 24 hours post
injection, ProCA32.collagen1 demonstrates a dramatic increase in R1 to 2.4 (∆R1~ 0.78 s-1, about
50% increase in liver area) in early stage fibrotic liver in mouse. Such change is increased with R1
enhancement to ~ 2.85 s-1 (78 % increase) and ∆R1 to approximately 1.40 s-1 compared to preinjection for late stage fibrotic liver in mice. The R1 increase at 24-hour post injection is highly
specific since it gradually decreased 48 hrs post injection due to excretion (Fig. 5.5). In contrast,
this targeting agent does not result in a significant change for the mouse with normal liver (< 0.2
s-1 and 10% increase in liver area) at 24-hour time point (Fig. 5.3). In addition, ProCA32-P40
without collagen binding capability does not result in any significant enhancement at this time
point. On the other hand, clinical approved liver contrast agent, Eovist for the fibrotic liver, at the
same stage (1A-Mild) and Ishak=3 did not result in any increase in R1 or ∆R1, 24 hrs after
injection. Consistent with R1 map, T2 map results also exhibit the same pattern at 24 hours for
both early and late stages of fibrosis with higher changes for late stage than early stage of
TAA/alcohol model (Fig. 5.6). Further quantitative analysis of R1 map and T2 map can be
observed in Fig, 5.7.
Taken together, these results demonstrate that the dual contrast property of
ProCA32.collagen1 enables the first robust detection of early stage Ishak=3 mouse liver fibrosis
with unprecedented sensitivity and quantification of both early and late stage liver fibrosis with
significant enhancement in both ∆R1 and ∆R2 that correlate well with the severity of fibrosis (Fig.
5.9).
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Figure 5.3 Early and late stage liver fibrosis detection using ProCA32.collagen1.
Demonstrates the R1 map of fibrotic (Ishak=3), normal (Ishak=0) and cirrhotic liver (Ishak=5)
before and 24 hrs after injection of ProCA32.collagen1, ProCA32-P40 and Eovist. ΔR1 values of
fibrotic (Ishak=3, and 5) and normal (Ishak=0) liver 24 hours after injection of
ProCA32.collagen1,

ProCA32-P40,

and

Eovist

shows

the

targeting

capability

of

ProCA32.collagen1 in differentiating different stages of liver fibrosis as the late stage shows the
highest ΔR1 compared to early stage and normal liver.
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Figure 5.4 TAA/alcohol-induced liver fibrosis animal model procedure

Figure 5.5 R1 changes of liver over different MRI time points after injection of
ProCA32.collagen1, ProCA32-P40 and Eovist. It shows the dynamic enhancement by
ProCA32.collagen1 based on stage of fibrosis and its targeting capability.
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Figure 5.6 T2 map MRI images of normal and fibrotic livers.
T2 map MRI results are consistent with R1 map showing a significant decrease in T2 value
(increase in R2) of late stage fibrotic liver (Ishak=5) after 24 hours post injection of
ProCA32.collagen1, in addition, early stage fibrotic liver (Ishak=3) also shows decrease in T2
which is more than normal liver but decrease is not as high as late stage. ΔR2 values shows that
24 hrs is the time which demonstrates the significant difference between normal liver (Ishak=0),
late (Ishak=5) and early stage (Ishak=3) fibrotic liver.
5.2.2 Histological validation of early and late stage fibrosis and correlation with MRI
Detailed histological analysis including H&E, alpha smooth muscle actin (SMA) levels
(brown) and Sirius Red staining for collagen content (red) as well as quantitative analysis of CPA
confirmed stage 3 in Ishak scoring system and late stage (Ishak=5). (Fig. 5.8).
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Figure 5.7 Quantitative analysis of T1 and T2 map.
(A) Increase rates of liver (R1) values (%) for R1 map in TAA/alcohol induced mouse liver fibrosis
compared to control showing different degree of increase based on contrast agent and time point.
(B) T2 map values of normal and fibrotic livers with quantitative analysis. T2 map MRI results
are consistent with R1 map showing a significant decrease in T2 value (increase in R2) of late
stage fibrotic liver (Ishak=5) after 24 hours post injection of ProCA32.collagen1, in addition,
early stage fibrotic liver (Ishak=3) also shows decrease in T2 which is more than normal liver but
decrease is not as high as late stage.
Furthermore, collagen proportional area (CPA) for TAA/alcohol and DEN model by
pathologist confirmed early stage liver fibrosis (Mild-1A, zone 3, perisinusoidal) based on the
NASH/CRN scoring. ProCA32.collagen1 distribution in normal and fibrotic liver is wellcorrelated with the stage of the disease. The late stage of liver cirrhosis. SMA levels (brown) are
much higher in later stage of liver fibrosis and CPA is 16% for Ishak= 5 (Fig. 5.8).
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Figure 5.8 Histology validation of different stages of TAA/alcohol-induced liver fibrosis.
Sirius red, H&E and αSMA staining of early and late stage fibrotic liver compared to normal liver
confirms the stage of liver fibrosis, as more collagen and αSMA content and dead hepatocytes are
the indications of the disease stage.
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Figure 5.9 Correlation of MRI with histology analysis in detection of different stages of
liver fibrosis.
(A, B) Demonstrate the ability of ProCA32.collagen1 to distinguish early and late stages
of liver fibrosis with ΔR1 and ΔR2 and its correlation with collagen proportionate area (CPA).
(C) Collagen proportionate area analysis using ImageScope and its correlation with Ishak scoring
system shows the stage of both early (Ishak=3) and severe fibrosis (Ishak=5) in TAA/alcohol
induced mouse model. (D) Demonstrates a correlation between Gd3+ concentration in liver with
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Ishak score. As the fibrosis becomes more severe, more Gd3+ as an indication of more
ProCA32.collagen1 is in the fibrotic liver (* P < 0.05, student’s t-test).
As Fig. 5.9 demonstrates, ProCA32.collagen1 is capable of distinguishing early stage
fibrosis (Ishak=3) from normal liver (Ishak=0) and late stage fibrosis (Ishak=5) based on both R1
and R2 mapping. With both ∆R1 and ∆R2 increasing based on the stage of the fibrosis,
ProCA32.collagen1 can detect different stages with more confidence. Moreover, there is a strong
correlation between Gd3+ concentration in liver with Ishak score. As the fibrosis becomes more
severe, more Gd3+ as an indication of more ProCA32.collagen1 is in the fibrotic liver.
5.2.3 Biodistribution and pharmacokinetics of ProCA32.collagen1
Biodistribution analysis of ProCA32.collagen1 (Fig. 5.10) further supports the MRI results
showing the targeting capability of the contrast agents. Severe fibrotic liver (Ishak=5) showed the
highest concentration of Gd3+ and after that fibrotic liver (Ishak=3) supporting that the contrast
agent targets based on collagen levels. Moreover, other organs did not show significant levels of
contrast agent, all of them had less than %2 injection dosage per gram of tissue (Fig. 5.10).
Detailed pharmacokinetic characteristic of ProCA32.collagen1 revealed that clearance of
ProCA32.collagen1 was low and 0.36 mL/min/kg (less than 1% of liver blood flow of 90
mL/min/kg) but more than 3 times higher than ProCA32-P40 and showed very high exposure (>
100000 ng.h/mL blood). ProCA32.collagen1 has the terminal elimination half-life of 9.9 h that
was slightly higher than ProCA32-P40 (8.09 h) with mean residence time of 14.51 h that was
higher than 13.9 h of ProCA32-P40. In addition, volume of distribution (Vc) and volume of
distribution at steady state (Vdss) were 1.53 and 1.77 L/kg, respectively, which were more than 27 times higher than ProCA32-P40. Taken together, these results demonstrate that the dual contrast
property of ProCA32.collagen1 enables the first robust detection of early stage Ishak=3 mouse
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liver fibrosis with unprecedented sensitivity and quantification of both early and late stage liver
fibrosis with significant enhancement in both ∆R1 and ∆R2 that correlate well with the severity of
fibrosis.

A

B

C

Figure 5.10 Biodistribution analysis of contrast agents using ICP-OES.
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(A, B) Shows percent injection dosage and [Gd3+] of contrast agents, in different diseased livers.
Sever fibrotic liver (Ishak=5) shows the highest Gd3+ concentration and injection dosage/g of
tissue among other livers. (C) Shows percent injection dosage of ProCA32.collagen1 based on
[Gd3+], in other organs. ProCA32.collagen1 does not have a brain deposit possible due to lack of
penetration to blood barrier.
5.2.4 Detection of vascular and architectural alterations with dynamic molecular imaging
Here we report the first dynamic molecular imaging (DMI) as a function of time of collagen
for both early and late stages of fibrosis to reveal intrahepatic angiogenesis (Fig. 5.11). The
dynamic molecular imaging curve of collagen as a function of time for both early and late stage of
fibrosis are very different at 3 and 24 hours (Fig. 5.5) despite the similarity for pre-injection and
later time points 48-72 hrs due to excretion and washout of ProCA32.collagen1 at 48-hour post
injection which both R1 and R2 enhancement for both early stage and late largely reduced to their
initial values. Strikingly, at early blood pool phase 3-hour post injection of ProCA32.collagen1,
R1 of cirrhotic liver increased dramatically to > 3.5 s-1 with ∆R1 > 2.0 s-1 (Fig. 5.11). Furthermore,
the R1 increase rate of fibrotic liver was more than 120 % suggesting vascular distortion (Fig. 5.7
A, 5.12, 5.13). Detailed histogram analysis of R1 map MRI images further shows in late stage
fibrosis, different areas of the liver have heterogeneous enhancement reflecting these vessel
changes at both 3 and 24 hrs post injection of ProCA32.collagen1 (Fig. 5.14). Normal liver has a
symmetric Gaussian distribution of relaxivity plot consistent with sinusoid arrangement in the
normal liver. On the other hand, several bi-mode or multiple-mode distributions of relaxivity also
consistent with the addition of intrahepatic angiogenesis with enlarged extracellular space (Fig.
5.14). Consistently, the early stage liver fibrosis exhibits a small addition of R1. Significantly
increased vessel formation stained by CD31 with quantitative analysis have also been observed
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for late stage fibrosis supporting the first visualization of large vessel structure changes due to
formation of severe fibrosis (Fig. 5.12, and 5.13). We further show (Fig. 5.12) the existence of the
portal hypertension associated with severe fibrosis in mouse liver (Ishak=5) reflecting the targeting
ability of ProCA32.collagen1 with slow washout from the liver. Thus, we have achieved the first
characterization of dynamic molecular contrast profiles to distinguish different stages of liver
fibrosis with differential vessel structures and distortion of the hepatic vasculatures as well as
collagen expression.

Figure 5.11 Detection of vasculature structural changes during late stage fibrosis with
ProCA32.collagen1.
Demonstrates the R1 map of fibrotic (Ishak=3), normal (Ishak=0) and cirrhotic liver
(Ishak=5) before and 3 hrs after injection of ProCA32.collagen1 and Eovist. ΔR1 values of fibrotic
(Ishak=3, and 5) and normal (Ishak=0) liver 3 hours after injection of ProCA32.collagen1 and 30
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min for Eovist shows the capability of ProCA32.collagen1 in detecting and revealing the vascular
distortion occurring in severe fibrosis as ΔR1 has the highest value compared to early stage and
normal liver.
As it is observed from Fig. 5.12, normal liver sinusoidal endothelial cells (SEC) have
fenestrae and express SE-1 marker but not CD31, however, in late stage of fibrosis, SEC upon
activation lose fenestrae and these defenstrated SECs do not express SE-1 and they express CD31
(Fig. 5.13). Defenestration of SECs lead to portal hypertension since the blood entering to the liver
cannot go to central vein as the blood flow out of the liver is significantly lowered. In late stage
fibrosis, intrahepatic angiogenesis occurs which does not increase blood flow, but blood has to
flow through more capillaries to reach same central vein which still does not increase portal flow
but creates more resistance, therefore after 3 hrs post injection, ProCA32.collagen1 is revealing
sinusoidal remodeling, and portal-vein blood flow resistance which has not been reported by any
MRI contrast agent before.

Figure 5.12 Representative SEM images and ultrasound of sections from mice with normal
and severe fibrotic liver (Figure provided by Ravi Chakra).
Representative SEM images of sections from mice with late stage cirrhotic liver (Ishak=5).
Quantitation of number and size of fenestrations of liver sinusoids in mice with late stage cirrhotic
liver (Ishak=5) measured by manually counting/measuring number and the diameters of
fenestration in the SEM images confirm vasculature structural changes detected by

150

ProCA32.collagen1. Fenestration size is average diameters (in micro Meter) of fenestrate from
the SEM image analyses. Velocity of portal vein blood flow is measured by Doppler ultrasound
imaging shows high portal hypertension detected at 3 hrs after injection of ProCA32.collagen1.
The flow velocity is presented as mm per second.
In Fig. 5.13, it is shown that CD31 is highly expressed in late stage fibrosis which is a
confirmation for intrahepatic angiogenesis.

Figure 5.13 Representative images of IHC stains of CD31 and quantitation of CD31.

IHC stains of liver tissue in mice with late stage cirrhotic liver (Ishak=5) confirming intrahepatic
angiogenesis. The quantity of CD31 IHC is presented fold changes in CD31 stains compared to
that of non-fibrotic mice (normal) (Figure provided by Ravi Chakra).
As Fig. 5.14 demonstrates, histogram analysis performed by MATLAB is showing
different patterns of enhancement in normal liver and early and late stage fibrotic livers based in
different time points (3 hrs, and 24 hrs) post injection of ProCA32.collagen1. Furthermore, it
shows heterogenous distribution of voxels across livers demonstrating a wide range of R1 values.
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Figure 5.14 R1 map histograms analysis of mouse livers.
R1 map histograms analysis of early stage (Ishak=3), late stage fibrosis and normal liver
(Ishak=0) pre (blue) and 3 hrs (red) and 24 hrs (green) post injection of ProCA32.collagen1 in
TAA/alcohol-induced

fibrosis

mouse

model

demonstrates

the

dynamic

ability

of

ProCA32.collagen1 in revealing both heterogeneity and vascular distortion of severe liver fibrosis
5.2.5 Quantitative mapping of liver fibrosis heterogeneity
Liver fibrosis heterogeneity can be regarded as one of the major limitations of liver biopsy
and other imaging modalities since it has differential special distribution and also dependent on
animal models and causes [303-306]. We then address liver fibrosis heterogeneity induced by
both TAA and DEN byProCA32.collagen1 enabled molecular imaging (Fig. 5.15). This DENinduced late stage cirrhosis mouse model exhibits strong liver heterogeneity mimicking patient
cirrhosis [307, 308]. Fig. 5.16 show that right segment of the mouse liver has CPA of 12% (Sirius
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red staining) while left segment has CPA of 6.7%. Consistent with TAA/alcohol model, both T1, T2-weighted and T1 inversion recovery images have enhancement of cirrhotic liver 3 and 24
hours post injection of ProCA32.collagen1 with the maximum enhancement at 3 hours post
injection specifically at the right segment of the liver confirming the histology data (Fig. 5.17).
Histogram analysis of the MRI images show different heterogeneous distribution of voxels in MRI
based on different pulse sequences (Fig. 5.18). In addition, R1 map data demonstrate further
heterogeneity in the liver (Fig. 5.19.)

Figure 5.15 Mapping liver cirrhosis heterogeneity with ProCA32.collagen1.
T1, T2-weighted and T1 inversion recovery images of DEN-induced cirrhotic mouse liver before
and 3 and 24 hrs post injection of ProCA32.collagen1 demonstrating heterogeneity of liver in the
right segment.

153

Figure 5.16 Sirius red staining and collagen proportionate area analysis.
Sirius red staining and collagen proportionate area analysis confirm that the right segment is
more cirrhotic than the left region which correlates with MRI.
Contrast to noise ratio (CNR) analysis of different pulse sequences demonstrate the right
segment enhancement compared to left segment which is in agreement with histology and CPA
analysis. Moreover, as shown in Fig. 5.18, histogram analysis also confirms the heterogenous
distribution of voxels in the liver correlating with MRI data.
R1 map analysis of DEN-induced liver cirrhosis also demonstrates heterogeneity of liver
as shown in Fig. 5.19. In addition, histogram analysis performed for R1 map further confirms the
data.

Figure 5.17 Quantitative analysis of contrast to noise ratio of liver.
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T1, T2-weighted and T1-inversion recovery images all demonstrate a higher contrast to noise ratio
(CNR) of right segment of cirrhotic liver after 3 hours of ProCA32.collagen1 injection compared
to left segment.

Figure 5.18 Histogram analysis of DEN-induced cirrhotic liver.
Histogram analysis of DEN-induced cirrhotic liver pre (blue), 3 hrs (red) and 24 hrs (green) post
injection of ProCA32.collagen1.
Taken together, further analysis of DEN-induced cirrhotic liver shows that
ProCA32.collagen1 is capable of a time-dependent heterogenous enhancement of liver with
specific areas of liver highlights at 3 hrs and 24 hrs and specific areas that remained enhanced or
washed out at different time points. Similarly, detailed analysis of R1 map MRI images of
TAA/alcohol model in late stage fibrosis, different areas of the liver have heterogeneous
enhancement reflecting vessel changes at both 3 and 24 hrs post injection of ProCA32.collagen1.
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Figure 5.19 R1 map analysis of DEN-induced liver cirrhosis.

(A) R1 map results showing heterogeneity in DEN-induced liver cirrhosis 3 and 24 hours post
injection of ProCA32.collagen1. (B) Quantitative analysis of R1 values showing a significant
increase in 3 hours post injection as well as showing heterogeneity. (C) Histogram analysis of
DEN-induced cirrhotic liver pre (blue), 3 hrs (red) and 24 hrs (green) post injection of
ProCA32.collagen1 (* P < 0.05, student’s t-test).
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Figure 5.20 Combination of STIR with long TE methodology with a T1-T2 MRI contrast
agent.
(A) T1 inversion recovery at different inversion times showing different heterogeneity of cirrhotic
liver. (B) Schematic demonstration of STIR with long TE methodology with ProCA32.collagen1.
ProCA32.collagen1 has high accumulation in the liver. As a result, liver has shortened T1, first,
inversion time was used to suppress liver signal. Second, since liver also has short T2, we then use
long TE to further suppress the liver signal. (C) Contrast to noise ratio (CNR) of cirrhotic liver
before, 3 and 23 hours after injection of ProCA32.collagen1 at different inversion times (*P <
0.05, student’s t-test).
Figure 5.20 shows one of the advantages of combining T1 inversion recovery with a dual
mode contrast agent like ProCA32.collagen1. We applied this pulse sequence which is STIR (short
tau inversion recovery) with long TE and combined it with ProCA32.collagen1 and studied its
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effects in contrast to noise ratio in DEN-induced mouse model of cirrhotic liver. It is observed that
ProCA32.collagen1 combined with this imaging methodology can enhance different regions of
cirrhotic liver at different time points (3 hrs and 24 hrs) by changing inversion times (TI) which
can suppress the liver signal.
5.2.6 Immunofluorescence staining of fibrotic liver
In order to further confirm the targeting capability of ProCA32.collagen1, the contrast
agent was co-stained with collagen type I in fibrotic liver. For this purpose, frozen sections of
liver tissues were collected. Then the tissues on slides were fixed with either ethanol or methanol
in -20°C for 20 minutes to remove OCT which is a gel-like medium for embedding the tissues.
After the tissues were dried, the blocking buffer is added for 2 hours at room temperature.
Then the slides are washed with 1×TBST for once, and the primary antibody is added (Collagen
type I) with 1:50 or 1:200 dilution and left for incubation in 4°C overnight. The slides are washed
again with 1×TBST for three times, each time for 5 min. The second primary antibody is then
added (ProCA32.collagen1) with 1:50 dilution for 2 hours at room temperature.
In the next step, the slides are washed again three times, and secondary antibody is added
for both of the primary antibodies (anti goat) and left for 1 hour at room temperature. Then DAPI
is added to the slides and they are covered with glass and left at 4°C until they are dried.
As Fig. 5.21 demonstrates, left picture shows fibrotic liver which was injected with
ProCA32.collagen1. It is observed that ProCA32.collagen1 (red) is targeting collagen type I
(green) in the liver, however, on the right picture, the fibrotic liver injected with ProCA32-P40 is
shown. In this picture, there is no sign of the contrast agent which confirms its lack of targeting
collagen type I.
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Figure 5.21 Immunofluorescence staining of ProCA32.collagen1 and collagen type I in
fibrotic liver tissues. Fibrotic liver injected with ProCA32.collagen1 clearly demonstrates that
ProCA32.collagen1 (red) can target collagen type I (green) in liver, however, ProCA32-P40 does
not show any targeting capability as it cannot be detected by Immunofluorescence staining in
fibrotic liver.
5.2.7 Treatment monitoring of liver fibrosis with ProCA32.collagen1
Since liver fibrosis can be treated and reversed if detected early and several drugs are under
development for treatment of liver fibrosis, and clinical contrast agents cannot follow up and
monitor treatments, it is extremely crucial to design MRI contrast agents capable of treatment
monitoring.
Therefore, ProCA32.collagen1 was tested for treatment monitoring of late stage liver
cirrhosis using ProAgio drug. ProAgio is a protein-based drug derived from domain 1 of CD2
protein developed by our collaborator Dr. Zhi-Ren Liu, and it has shown promising results for
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reversal of late stage cirrhosis. We injected ProCA32.collagen1 to mice treated with ProAgio and
mice with normal liver to assess the capability of the contrast agent in distinguishing drug treated
liver from normal liver (Fig. 5.22).

Figure 5.22 Liver cirrhosis treatment monitoring using ProCA32.collagen1.
(A) ProAgio structure with M26C mutation for treatment of liver cirrhosis. (B) ProAgio can
reverse liver cirrhosis as observed by decrease in liver weight. (C) R1 map MRI results before and
3 and 24 hrs post injection of ProCA32.collagen1 is able to show the difference between ProAgio
treated liver and normal liver at 3 hrs time point. (D) Quantitative analysis of ΔR1 at 3 and 24 hrs
after injection of ProCA32.collagen1 is showing that normal liver has significant increase at 3hour time point, however ProAgio treated liver does not show any enhancement.
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As Fig. 5.22 C and D are showing, at 3-hour time point, ProCA32.collagen1 is able to show
the different between ProAgio treated liver and normal liver. At 3 hours post injection,
ProCA32.collagen1 is causing a dramatic increase in ΔR1 values, however, drug treated liver does
not show any increase suggesting that the contrast agent is being washed our rapidly from the liver.
The normal liver R1 value increased to more than %25 at 3 hours but ProAgio treated liver
increased only %2.
5.2.8 Dynamic multi-color mapping of liver cirrhosis heterogeneity with ProCA32.collagen1
Since we observed a dynamic property in ProCA32.colllagen1 in enhancement of DENinduced mouse liver cirrhosis, a multi-color heterogenous cirrhotic mouse liver was created in
order to better reflect the liver enhancement at different time points (3 hrs and 24 hrs). For this
purpose, MATLAB was used to create a multi-color map with voxel by voxel quantitative analysis.
Since ProCA32.collagen1 has both r1 and r2 property and we scanned multiple pulse sequences,
and this approach was used in both T2-weighted and T1 inversion recovery sequences. Two
general color maps were generated for T2-weighted pulse sequence. First, a color map was created
to summarize and demonstrate the voxels that enhanced 3 hrs and 24 hrs post injection of
ProCA32.collagen1 and then a percentage of relative enhancement was calculated using this
equation: Intensity (post) – Intensity (pre) / Intensity (pre). Figure 5.23 shows the T2-weighted
color map 3 and 24 hrs post injection enhancement of ProCA32.collagen1. Then a separate color
map was generated to show the regions that stayed enhanced after 24 hrs and the areas that washed
out after 24 hrs (Fig.5.24). In figure 5.24, the color bar shows the percentage of areas that
maintained up to %200 and the regions that washed out completely within 24 hrs.
The same procedure was performed for T1 inversion recovery and T1-weighted pulse
sequences.
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Figure 5.23 T2-weighted Multi-color map of 3 and 24 hrs enhancement in DEN-induced
cirrhotic mouse liver.
The color map demonstrates the dynamic enhancement of cirrhotic regions 3 (blue) and 24 (red)
hrs post injection of ProCA32.collagen1. Right segment of liver is enhanced more at 3 hrs and left
segment was enhanced more at 24 hrs. The bar on the right shows the percentage of relative
enhancement.
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Figure 5.24 T2-weighted Multi-color map of maintained vs washed out within 24 hrs of
contrast agent injection in DEN-induced cirrhotic mouse liver.
The color map demonstrates the dynamic enhancement of cirrhotic regions within 24 hrs, and the
areas that the contrast agent remained in the liver are shown in a red color and the areas that the
contrast agent is washed from the liver are shown in more blue color. The bar on the right shows
the percentage of relative enhancement.
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Figure 5.25 Quantitative analysis of T2-weighted cirrhotic liver enhancement post
injection of ProCA32.collagen1.
The bar on the right represents the voxel number which different parentage of increase at different
time points. For instance, at 3 hrs, approximately, 1600 voxels had enhancement of less than %10.
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Figure 5.26 T1-weighted Multi-color map and quantitative analysis of maintained vs washed out
regions within 24 hrs of contrast agent injection in DEN-induced cirrhotic mouse liver.
This is the summary of T1-weighted images demonstrating dynamic property of
ProCA32.collagen1. At each time point, different regions of liver are enhanced.

165

Figure 5.27 T1 inversion recovery Multi-color map and quantitative analysis of 3 and 24
hrs post injection of ProCA32.collagen1.
The color map demonstrates the dynamic enhancement of cirrhotic regions 3 (blue) and 24 (red)
hrs post injection of ProCA32.collagen1. In contrast to T2-weighted sequence, areas of
enhancement at each time point are limited more to right or left segments of liver and are spread
across the liver.
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Figure 5.28 T1 inversion recovery Multi-color map of maintained vs washed out within 24
hrs of contrast agent injection in DEN-induced cirrhotic mouse liver.
The color map demonstrates the dynamic enhancement of cirrhotic regions within 24 hrs, and the
areas that the contrast agent remained in the liver are shown in a red color and the areas that the
contrast agent is washed from the liver are shown in more blue color. The bar on the right shows
the percentage of relative enhancement.
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Discussion
Liver fibrosis heterogeneity currently cannot be accurately detected by any methods.
Spatial heterogeneity in fibrosis is one of the major limitations and challenges of liver biopsy and
elastography-based techniques as they sample a small volume of liver which does not accurately
reflect the overall extent and stage of fibrosis [306]. Collagen type I is an important target for
molecular imaging of liver fibrosis since its accumulation is a characteristic of most types of
chronic liver diseases (CLD) [290].
5.3.1 Implication for early detection: Our developed contrast agent enabled novel imaging
methodology for early detection of liver fibrosis.
Early fibrosis can be reversed if it is detected early [309, 310]. However, current techniques
including Fibroscan and MRE as well as MRI with clinical contrast agents in the market failed to
detect fibrosis at early stage despite of rapid progress [311]. To overcome the limitation of small
chelator-based contrast agents for detection of early stage fibrosis, targeting extracellular matrix
(ECM) proteins with probes in molecular imaging techniques has attracted great attention for
detection, monitoring disease progression as well as treatment [312]. Type I collagen is
immediately secreted into the ECM as soon as the hepatic stellar cells are activated at the very
early stage. Its expression level and spatial distribution patterns play important role for the ECM
remodeling and directly reflect fibrosis progression. Elastin, on the other hand, is more involved
in the late stage fibrosis and cirrhosis [313]. Collagen targeting molecular magnetic resonance
imaging demonstrates a unique application of MR technology to view biological processes at the
cellular and molecular level. [314], [122], [315]. However, recent works reported that collagen
targeting MRI contrast agents have more sensitive than other MRI techniques including using
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endogenous relaxation times, diffusion, and magnetization transfer measurements [283], however,
have limited capability in monitoring early stage of fibrosis in a rat DEN model.
We have shown that early stage liver fibrosis (stage 3 based on Ishak and CPA analysis)
can be detected using both R1 map and R2 (24 hours post injection). The detected MRI signals for
both early and late stages are correlated well to those from histology analysis from CPA and further
validated by Gd3+ contention detection with ICP-OES.
Our developed protein-based MRI agent with collagen type I targeting moiety
ProCA32.collagen 1 can have robust detection of early stage of liver fibrosis with large dynamic
range with dramatic increased sensitivity.
We have shown that ProCA32.collagen1 exhibits 5-fold increase in r1 relaxivity that
clinical approved ones including Magnevist, and liver specific reagents such as MultiHance and
Evoist. More importantly, ProCA32.collagen1 also has a high r2 value that enables application of
several imaging methodologies including both T1 and T2 imaging to overcome the subtle changes
of liver morphology without defined boundary at early stage liver fibrosis. More importantly, the
precision is doubled. In contrast to the risk to trade off targeting capability and relaxivity reported
by previously reported studies, here we demonstrate that we can further increase relaxivity
properties for both r1 and r2 since ProCA32.collagen1 has higher relaxivity compared to ProCA32P40. Previously we have shown that the addition of targeting moiety to ProCA32 does not have a
reduction of the relaxivity, a problem associated with the addition of targeted capability [316].
Here, we attribute the additional contribution of water from outer-sphere to the relaxivity by
PEGylation at nearby Lys sites to the increase of relaxivity of ProCA32.collagen1 compared to
ProCA32-P40. Second, ProCA32.collagen1 also exhibits the highest binding affinity to collagen
type I (Kd of 1.4 µM) among all other imaging agents available [121] likely due to the proper
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design of the targeting moiety. This strong binding affinity to collagen type I provides required
sensitivity to detect early stage of secreted collagen in liver (1–20 nmolg-1) [313]. Third,
ProCA32.collagen1 has a unique tissue penetration as revealed by its capability in distinguishing
early and late stage fibrosis at 24-hour time point which correlates well with CPA quantification
in histology.
ProCA32.collagen1 has the organ distribution and retention time required by the new
dynamic molecular imaging capability for temporal and spatial resolution of intrahepatic
angiogenesis, portal hypertension and liver heterogeneity. The PK/PD studies have shown
ProCA32.collagen1 has a relatively high volume of distribution and vascular confinement and very
high exposure (> 100000 ng.h/mL of blood) which is superior than clinical contrast agents like
Magnevist and even ProCA32-P40 demonstrating its targeting capacity.
5.3.2 Implication for detection of heterogeneity, intrahepatic angiogenesis and portal
hypertension
Liver fibrosis heterogeneity and the process for the formation of liver fibrosis currently
cannot be accurately detected by any methods. Spatial heterogeneity in fibrosis is one of the major
limitations and challenges of liver biopsy and elastography-based techniques as the lack of whole
liver volume coverage cannot accurately reflect the overall extent and stage of fibrosis[306].
Collagen type I is heterogeneously accumulated in liver fibrosis depending on etiology which leads
to fibrosis that disrupts liver cytoarchitecture and function [293].
Normal liver sinusoidal endothelial cells (SEC) have fenestrae and express SE-1 marker
but not CD31, however, in late stage of fibrosis, SEC upon activation lose fenestrae and these
defenestrated SECs do not express SE-1 and they express CD31. Defenestration as can be seen
from SEM images lead to portal hypertension in late stage fibrosis since the blood entering to the
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liver cannot go to central vein as the blood flow out of the liver is significantly lowered. In late
stage fibrosis, vascular remodeling leading to capillarization of the sinusoids with generation of
intrahepatic shunts creates hepatic angiogenesis which contributes to the progression of the
disease[317]. Angiogenesis is also a key event in the emergence and recognition of early HCC and
development of recurrence after potentially curative therapy and for the progression of liver cancer
[318-320]. Observation of such process has only reported via histological staining and is not
possible to be detected by any noninvasive methods. Early studies reported that in most cases MRI
can detect morphological characteristics of liver cirrhosis including surface nodularity, widening
of fissures, expansion of the gallbladder fossa, notching and atrophy of the right lobe, and relative
enlargement of the lateral segments of the left lobe and caudate lobe, in some cases however,
cirrhotic liver can appear completely normal with confirmation of the diagnosis requiring biopsy
[307, 308].
Here we report that ProCA32.collagen1 is also able to detect intrahepatic angiogenesis,
portal hypertension and map heterogeneity via DMI. Dynamic contrast enhancement (DCE) is
largely applied to report the cellular and tissue changes of various diseases and the responses upon
drug treatment [321-323]. However, dynamic molecular contrast imaging was not achieved due
to several major limitations of reported contrast agents. In addition to lack of targeted contrast
agents with required sensitivity, DMI also requires targeted contrast agents to have adequate
penetration and retention time to liver tissue to report the formation of new vascular structures.
Detailed histological and PK/PD analysis revealed that ProCA32.collegen1 exhibits required
targeting capability, sensitivity as well as the penetration capability. Thus, vascular changes
results from shunting of the portal and arterial blood supply directly into the hepatic outflow
(central veins), compromising exchange between hepatic sinusoids and the adjacent liver
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parenchyma causing fibrous portal-tract expansion, central-vein fibrosis and capillarization of the
sinusoids [324] have been unambiguously detected by dual contrast property of
ProCA32.collagen1. We further provided dynamic map of regions of cirrhotic liver with three
distinguished vascular features. ProCA32.collagen1 reveals sinusoidal remodeling, and portalvein blood flow resistance that has not been reported by any MRI contrast agent before. We show
that DEN- and TAA/alcohol-induced models exhibit differential map. Such information is
essential for understanding molecular mechanism for fibrosis formation and treatment. It will also
be very helpful for image-guided biopsy. Detection of angiogenesis as a promising therapeutic
target by MRI contrast agents may be a useful noninvasive approach in follow-up of both disease
progression and response to anti angiogenic therapies and even choosing treatment strategies
[325].
In this chapter, two different late stage cirrhosis models were used to test the contrast agent.
First, late stage cirrhosis in TAA/alcohol model was tested to compare the ∆R1 values with early
stage fibrosis. In late stage liver cirrhosis, the contrast agent shows its maximum effect in shorter
time point of 3 hrs compared to 24 hrs of early stage. The increase in ∆R1 is more than 2.0 s-1 and
the R1 increase rate is more than %100 which shows the huge difference between ∆R1 and R1
increase rate for early stage fibrosis at both 3 and 24-hour time point. This bigger enhancement
displays the great capacity of ProCA32.collagen1 in staging different degrees of fibrosis from early
to moderate to late stage. After 24 hrs post injection, ∆R1 is decreasing due to fast washout of the
contrast agent. It is worth mentioning that, ICP-OES analysis shows the highest accumulation of
Gd3+ in late stage cirrhotic liver. In DEN-induced model, the highest enhancement in the liver was
observed again at 3-hour time point after injection of the contrast agent. After injection of the
contrast agent, a clear heterogeneity of cirrhotic liver due to heterogeneous increase in CNR of T1-
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and T2-weighted and T1 inversion recovery images was observed. This result is significant
compared to homogenous enhancement of liver in TAA/alcoholic model. Before injection of
contrast agent, the liver looks homogenous which makes biopsy difficult in stage determination
and even detection of the disease due to sampling error and small sample collection. Detecting
liver heterogeneity after the injection ProCA32.collagen1 can facilitate the biopsy process and
stage determination.
ProCA32.collagen1 not only detects late stage fibrosis but also reveals vascular changes
results from shunting of the portal and arterial blood supply directly into the hepatic outflow
(central veins), compromising exchange between hepatic sinusoids and the adjacent liver
parenchyma causing fibrous portal-tract expansion, central-vein fibrosis and capillarization of the
sinusoids [324]. Furthermore, with dual contrast property of ProCA32.collagen1 different regions
of cirrhotic liver is enhanced which helps the efficiency and facilitation of biopsy.
5.3.3 Safety: Advantages of ProCA32.collagen1 Compared with Imaging Agents of Liver
Fibrosis
Increased evidences have demonstrated that the occurrence of nephrogenic systemic
fibrosis (NSF) in renal impaired patients is associated with the release and accumulation of Gd3+
from the agent because of transmetallation [157, 206]. Recent concerns about Gd3+ depositions in
animals and patients have led to withdrawn of four Gd3+ contrast agent from Europe by European
Medicines Agency (EMA) [326]. Due to necessity for liver applications, Eovist and MultiHance
remain in use. Our developed ProCA32.collagen1 represents a major leap in addressing concerns
about metal toxicity and Gd3+ deposition associated with current contrast agents in several aspects.
First, we have demonstrated that ProCA32.collagen1 can mitigate metal toxicity with largely
reduced dose and strong resistance against transmetallation (104-1012-fold higher metal selectivity
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for Gd3+ over Ca2+ and Zn2+) compared to existing contrast agents. In addition, we have not
observed any brain depositions possibly due to its incapability in blood-brain barrier (BBB)
penetration. Further, ProCA32.collagen 1 has strong liver preference and is able to specifically
target molecular biomarkers, a property that lacks in all approved Gd3+ contrast agents. More
important, ProCA32.collagen1 with high r1 and r2 relaxivity has very low injection dosage of
0.0013 mmol.kg-1 projected in humans which is 20-200-fold lower than clinical contrast agents.
Indeed, detailed clinical chemistry and tissue analysis demonstrate that no acute tissue toxicity
have been observed.
Our developed ProCA32.collagen1 represents a major leap in addressing concerns about
metal toxicity and Gd3+ deposition associated with current contrast agents in several aspects.
Administration of contrast agents helps with visualization of fibrosis at MRI. Specifically, majority
of clinical Gd3+-based MRI contrast agents cause T1 shortening and signal enhancement on T1
map images, however most of these agents have been linked to the occurrence of nephrogenic
systemic fibrosis (NSF) in renal impaired patients due to release and accumulation of Gd3+ from
the agent because of transmetallation [157, 206] . Furthermore, they are all based on smallmolecule chelates and have very low relaxivity (both r1 and r2) and sensitivity without targeting
capability, therefore, they are only able to detect moderate and advanced stage of fibrosis, cirrhosis.
The clinical contrast agents also use a high clinical injection dosage due to their low sensitivity
with a short imaging window without the capability of enhancing the entire liver such as Eovist.
ProCA32.collagen1 with high r1 and r2 relaxivity has very low injection dosage of 0.0013 mmol.kg1

projected in humans which is 20-200-fold lower than clinical contrast agents. In addition, its high

selectivity towards Gd3+ makes it a safer agent.
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Potential Application and Significance
ProCA32.collagen1 with collagen type I targeting moiety was successfully developed and
used in detection of liver fibrosis. Based on our results, the contrast agent is able to detect and
distinguish different stages of the disease from early stage 3 (Ishak system) to late stage 5 liver
fibrosis with high sensitivity. This sensitivity can be well demonstrated by increase in ∆R1 of
fibrotic liver 3 and 24 hours after injection of ProCA32.collagen1 using R1 map MRI.
Furthermore, this increase in ∆R1 is approximately 5-fold higher than Eovist, a clinical contrast
agent. The early and late stage of fibrosis was further confirmed with histology analysis.
Furthermore, ProCA32.collagen1 is capable of detecting cirrhosis heterogeneity in DEN-induced
model which can significantly help other procedures such as biopsy for more accurate sample
collection. To the best of our knowledge, this study describes the first early detection of liver
fibrosis in the literature. This is a significant achievement since early fibrosis can be reversed if it
is detected early, however, clinical contrast agents in the market have failed to detect fibrosis at
early stage. Targeting capability of the contrast agent was further confirmed with ICP-OES and
immunofluorescence staining as well as ELISA studies. The development of collagen targeting
contrast agent is expected to have broad applications in detection and staging of fibrosis in chronic
diseases and liver metastasis from various types of cancer and probing heterogeneous
microenvironment changes upon disease progression and treatment. Furthermore, less injection
dosage can be used to avoid toxicity as our results demonstrate. ProCA32.collagen1 combined
with MRI can be used as a quantification and promising method for diagnosing stage specific
chronic liver diseases. More results based on DEN-induced cirrhosis and HCC will be
demonstrated in Chapter 7. Please visit Chapter 9 for results regarding nonalcoholic steatohepatitis
detection.
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Summary
Early diagnosis and noninvasive detection of liver fibrosis and its heterogeneity remain as
major unmet medical needs for stopping further progression toward severe clinical consequences.
We have developed a collagen type I targeting protein-based contrast agent (ProCA32.collagen1)
(Kd of 1.4 M). ProCA32.collagen1 possesses high relaxivities (r1 and r2 are 68 and 100 mM-1⋅s1

at 1.4 T and 42.6 ± 1.0 and 217 ± 2.4 mM-1s-1 at 7T) per particle with a T1-T2 dual mode action.

ProCA32.collagen1 enables the first robust detection of early (Ishak=3) and late stage of liver
fibrosis and mapping liver fibrosis heterogeneity in animal models by its dynamic molecular
imaging property by revealing vascular distortion during the late stage cirrhosis with largely
reduced dose and strong resistance against transmetallation (104-1012-fold higher metal selectivity
for Gd3+ over Ca2+ and Zn2+) compared to existing contrast agents.
Based on our results, ProCA32.collagen1 with collagen type I targeting moiety can detect
early stage 3 (Ishak system) with high sensitivity with dual mode r1 and r2 property and high
collagen affinity which has not been achieved before. This sensitivity can be well demonstrated
by increase in ∆R1 and ∆R2 of fibrotic liver 24 hours post injection of ProCA32.collagen1.
Furthermore, during late stage fibrosis, ProCA32.collagen1 is capable of detecting heterogeneity,
portal hypertension and intrahepatic angiogenesis in different animal models 3 hours post injection
which can significantly help biopsy and treatment strategies for more accurate theranostics. It has
no toxicity as demonstrated by clinical chemistry tests, tissue staining and injection dosage. To the
best of our knowledge, this study describes the first early detection of liver fibrosis with high
sensitivity as well as sinusoidal remodeling and portal hypertension during the late stage of the
disease by any MRI contrast agent. The development of collagen-targeted protein MRI contrast
agent is expected to overcome the major clinical barriers in early diagnosis, noninvasive detection
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and staging of liver fibrosis, and have strong application in facilitating effective treatment and stop
further progression toward major clinical consequences including cirrhosis, impaired liver
function, and hepatocellular carcinoma.
Furthermore, ProCA32.collagen1 is capable of detecting cirrhosis heterogeneity in DENinduced model which can significantly help other procedures such as biopsy for more accurate
sample collection. To the best of our knowledge, this study describes the first early detection of
liver fibrosis in the literature. This is a significant achievement since early fibrosis can be reversed
if it is detected early, however, clinical contrast agents in the market have failed to detect fibrosis
at early stage. Targeting capability of the contrast agent was further confirmed with ICP-OES and
immunofluorescence staining as well as ELISA studies. The development of collagen targeting
contrast agent is expected to have broad applications in detection and staging of fibrosis in chronic
diseases and liver metastasis from various types of cancer and probing heterogeneous
microenvironment changes upon disease progression and treatment.
The development of collagen-targeted protein MRI contrast agent is expected to overcome
the major clinical barriers in early diagnosis, noninvasive detection and staging of liver fibrosis,
and have strong application in facilitating effective treatment and stop further progression toward
major clinical consequences including cirrhosis, impaired liver function, and hepatocellular
carcinoma.
6

APPLICATION OF PROCA32.COLLAGEN1 IN IMAGING OF UVEAL
MELANOMA LIVER METASTASIS

Introduction
Liver as a vital organ in human body and determinant of survival from cancer is one of the
major sites of metastasis such as gastrointestinal and extragastrointestinal cancers, melanoma,
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breast, pancreatic, and renal cancer. The liver as the largest organ of the body has unique
architecture for its diverse functions such as protein biosynthesis and detoxification of portal
blood[327, 328]. Uveal melanoma as the most common intraocular malignancy typically
metastasizes through blood and occurs in adults with an age-adjusted average of 5.1 per million
[329]. Uveal melanoma accounts for 3.7% of all reported melanoma cases in the United
States[330]. Approximately half of the patients with a primary uveal tumor will have
metastasis[331]. Typically there is 40% chance of uveal melanoma to metastasize to the liver
however, in hepatic metastasis cases, this chance is more than 90-95% in patients [329, 332].
Although the reported 5-year relative survival rate from diagnosis of a primary uveal melanoma is
approximately 80% [329], the prognosis for patients with uveal melanoma liver metastases is poor,
with a median survival of less than 6 months [333, 334]. Currently, the life expectancy of patients
with metastatic UM is only 4-6 months since there are no highly effective treatments for these
metastasis[332, 335].
Previous studies have shown that there are three stages of uveal melanoma metastasis to
liver: In stage I: 50-μm-diameter micrometastasis occurs within the sinusoidal space; stage II:
51- to 500-μm-diameter metastasis forms expanded collections of cells within the sinusoidal space;
and stage III: 500-μm-diameter collections of cells will generate two distinctive patterns. These
two patterns in stage III are called the “nodular” or “portal” and “infiltrative” or “lobular” patterns.
The infiltrative pattern is an expansion of stage I to III intrasinusoidal growth, which has penetrated
the portal lobule and is surrounded by fibrous septae (Fig. 6.1). In contrast, the nodular pattern
appeared to efface, rather than infiltrate, the surrounding liver; it has been reported that the nodular
pattern originates from the perivascular area of the portal triad with distinct clusters of tumor cells
located around the portal venules [336].
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In the infiltrative pattern, tumor cells are supplied by blood vessels in the sinusoidal or
pseudosinusoidal spaces, and angiogenesis is minimal [332], however, in the nodular pattern, the
tumors are adjacent to portal venules and demonstrate angiogenesis as the metastatic focus grows
with new tumor blood vessels formed and extend from branches of the hepatic arteriole [337].
It is vital to distinguish different UM tumor growth pattern characteristics in the liver in
terms of diagnosis and therapy since their recognition in the liver has important clinical
implications [334, 336]. In histological point of view, nodular and infiltrative pattern show
differences in the host immune response. In infiltrative pattern, there are natural killer cells but in
the nodular form cytotoxic T lymphocytes are the major cells [332].
In previous studies, infiltrative and nodular patterns of metastatic UM have been
distinguished by hepatic angiography and it was concluded that it can be used to predict response
to hepatic arterial chemoembolization [338]. In addition, it has been reported that
radioembolization can be effective in treating nodular liver metastases, but not infiltrative
sinusoidal metastases[334]. In that particular study, nodular tumors in liver decreased in size with
radioembolization without the infiltrative tumors responding to treatment[334]. Furthermore, it
has been shown that patients with angiographically determined nodular tumor appearances
survived longer than patients with infiltrative lesions (overall survival, 621 vs. 114 days) [339],
therefore, distinguishing these patterns on any imaging modality is an important consideration
when determining the treatment plan for patients with metastatic UM [339].
Current clinical imaging techniques have significant limitations in the early detection,
diagnosis and differentiation of UM micrometastasis to liver as well as their different growth
patterns. Magnetic resonance imaging (MRI) is a powerful technique for high-resolution
visualization of the anatomic structure and function of soft tissues, including tumors without the
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use ionizing radiation [340-342]. MRI offers several unique advantages compared to other clinical
imaging modalities with its deep tissue penetration, high spatial resolution, and coverage of the
entire liver. Since MRI does not require the use of ionizing radiation, it is well suited for screening
and monitoring the progression and regression of different diseases [296, 297]. Existing methods
such as apparent diffusion coefficient (ADC), magnetic resonance elastography (MRE), T1, T2,
relaxation in the rotating frame (T1ƿ) [294], magnetization transfer [295], and proton density fat
fraction (PDFF) cannot provide accurate detection of liver lesions, their patterns and heterogeneity.
More than 35% of MRI scans require contrast agents [341]. Differentiation of
micrometastasis from heterogeneous tissue background without clear boundary requires even more
sensitive contrast agents and imaging methodology to have specificity for diseased cells as well as
improved relaxation properties. Iron oxide-based contrast agents such as ferumoxides create
negative (dark) T2 /T2* effects that are reported to yield images with signal voids and very limited
accuracy[278, 298]. Two Gd3+-based contrast agents approved for liver imaging, Gd-BOPTA
(Multihance) and Gd-EOB-DTPA (Eovist US; Primovist, Europe) have positive (bright) imaging.
Along with all other approved Gd3+ MRI contrast agents, they have per Gd3+ relaxivity (r1) values
~5 mM-1.s-1 which is ~20-fold lower than a theoretical value [299]. Such low relaxivity limits their
sensitivity for detecting small liver lesions. In addition, these agents are extracellular with r1
increase using T1-weighted sequence at a short arterial phase and a short hepatobiliary uptake
phase. Furthermore, a high injection dose of 0.025-0.3 mmol/kg is required to generate detectable
contrast. Such high injection doses contribute to metal toxicity and have resulted in a black box
warning.
Small molecular Gd3+ agents that are routinely used for clinical cancer imaging to enhance
image contrast by shortening the relaxation times of the surrounding water protons [47] are non-
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specific contrast agents and cannot differentiate tumor growth patterns or provide efficient
detectable contrast in small tumors and micrometastasis. As a result, biomarker-specific molecular
imaging reflecting tumor microenvironment can be an effective and sensitive approach towards
the early detection and differential diagnosis of UM liver micrometastasis [343].
Tumor microenvironment plays a vital role in tumor progression and metastasis [344, 345].
Extracellular matrix (ECM) is a major part of the microenvironment and collagen type I is the
most abundant component [155]. Furthermore, Collagen as the major part of tumor
microenvironment can affect its regulation of ECM remodeled by collagen degradation and redeposition, as well as promotion of tumor infiltration, angiogenesis, invasion and migration[155].
Collagen has been extensively used as both imaging and therapeutic agents such as delivery
systems for many kinds of bioactive proteins and drugs and engineered collagen hydrogels for the
sustained release of biomolecules and imaging agents in various collagen-related diseases [346,
347].
Since there are significant differences in the formation of collagen in these two distinctive patterns
of UM micrometastasis [332] and differentiation can affect the choice of treatment regimens in the
future, in this paper, we report the development of protein MRI contrast agents for molecular
imaging of the collagen level (ProCA32.collagen1) extending the targeting capability of our
recently reported ProCA32-P40, a protein MRI contrast agent [83]. ProCA32.collagen1 with high
dual relaxivity values for r1 and r2 per Gd3+ at both 1.5 and 7.0 T as well as strong collagen targeting
capability enables the first robust early detection of stage II UM micrometastasis to the liver.
Furthermore, for the first time, ProCA32.collagen1 is capable of differentiating nodular vs
infiltrative pattern at this stage which has been achieved before (Fig. 6.2). The development of
collagen-targeted protein MRI contrast agents are expected to overcome the major clinical barriers
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in early diagnosis, noninvasive detection and staging of UM micrometastasis to liver, and have
strong application in facilitating effective treatment toward major clinical consequences.

Figure 6.1 . Schematic cartoon of metastatic UM to the liver [332].
Melanoma arises in the choroid of the eye, extravasates into tumor blood vessels, and then travels
via the systemic circulation as circulating melanoma cells with tumor stem cell–like properties,
where it enters the liver as single cells. These single cells likely arise from hepatic arterioles and
seed the sinusoidal space causing the infiltrative pattern of growth, which progresses to stage I
(0-50 μm) micrometastases, stage II (51-500 μm) intermediate metastases, which are bathed by
serum in the sinusoidal space, and eventually stage III (500 μm) metastases, which replace the
hepatic lobule.
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Figure 6.2 Precision imaging with progressive molecular MRI contrast agent,
ProCA32.collagen1.
Schematic illustration of ProCA32.collagen1 capability in early detection and differentiation of
UM tumor growth patterns micrometastasis in liver. Nodular pattern showing different pattern
and higher levels of collagen compared to infiltrative.

Results
In order to assess the application of ProCA32.collagen1 with collagen type I targeting
moiety in detection of small lesions of micrometastasis, the contrast agent was used in different
animal models of uveal melanoma liver metastasis.
6.2.1 Molecular imaging of implanted mouse Uveal Melanoma in liver
In order to test our contrast agent capability for in vivo imaging of the tumor, mouse uveal
melanoma (B16LS9) was implanted in the liver. Then, the PEGylated contrast agent (100 µL, 5
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mM) has been injected in the mice in the tail vein. Fig. 6.4 A illustrates the tumor in the liver of
the mice. T1-weighted, T2-weighted and inversion recovery MRI images of the tumor in the liver
were collected using a 7.0 T MRI instrument. T1-wighted images showed approximately 6-fold
enhancement in the relative contrast of the tumor 40 hours post injection of ProCA32.collagen1.
Fig. 6.4 A and B show the T1-weighted images and quantitative analysis of the tumor enhancement
after injection. T2-wieghted images also showed about 4-fold enhancement in the relative contrast
of the tumor 40 hours post injection of ProCA32.collagen1 compared to pre-injection. Fig. 6.4 A
demonstrated the T2-wieghted images.
An inversion recovery pulse sequence was also used for molecular imaging of the tumor
in the liver. In this method, both liver and tumor signal were suppressed in order to achieve a high
contrast between liver and tumor. As can be seen in Fig. 6.4 A and B summarize the results using
different techniques. In these techniques, tumor images can appear as both bright and dark spots
depending on the type of signal suppression. Fig. 6.3 demonstrates the procedure in which the liver
signal is suppressed with the use of inversion recovery pulse sequence combined with
ProCA32.collagen1.
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Figure 6.3 Demonstration of STIR with long TE sequence for the double suppression of
liver signal for tumor imaging.
After injection of ProCA32.collagen1 for about 3 hours, contrast agent has high accumulation in
the liver than tumor. As a result, liver has shortened T1, while tumor T1 doesn’t change much.
This sequence has two steps to suppress liver signal. First, we will use inversion time to suppress
liver signal. Second, since liver also has short T2 compared with tumor, we further using TE to
further suppress the liver signal, while tumor signal still can be detected due to long T2.
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Figure 6.4 MRI images of B16LS9 mouse implanted UM tumor before and after injection
of ProCA32.collagen1 in liver.
(A) T1-weighted, T2-weighted, and T1 inversion recovery images (B) Quantitative analysis of
relative contrast of tumor before and 40 hours after injection of ProCA32.collagen1 demonstrates
a great enhancement in tumor post injection of the contrast agent in T1-weighted, T2-weighted,
and T1 inversion recovery with different inversion times.

Figure 6.5 T2 map MRI images of B16LS9 mouse implanted UM tumor.
(A) T2 map MRI images of B16LS9 mouse implanted UM tumor before and 24 and 40 hours post
injection of ProCA32.collagen1. (B) T2 map analysis of tumor before and 24 and 40 hours post
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injection of ProCA32.collagen1 shows the contrast agent is penetrating into the tumor causing a
noticeable decrease in T2 post 24 hrs.
In addition to those three mentioned pulse sequences, T2 maps of liver with implanted
tumor was also collected before and 24 and 40 hours post injection of ProCA32.collagen1. Fig.
6.5 A and B demonstrate the results with quantitative analysis of T2 values. As it is observed from
Fig. 6.5 B, tumor T2 value was significantly decreased from 0.13 s (pre) to 0.08 s (24 hours) post
injection of ProCA32.collagen1. This result is an indication of targeting capability and tumor
penetration of ProCA32.collagen1. The T2 value then gradually increased at 40 hours since the
contrast agent is being washed out. The liver T2 value slightly decreased at 24 hours post injection
and deceased more at 40 hours post injection but the majority of T2 reduction occurs at tumor site.
6.2.2 Immunofluorescence and collagen staining
In order to further confirm the targeting capability of ProCA32.collagen1, the liver frozen
sections with tumor were stained for collagen and contrast agent with Sirius red and rabbit
antibody, respectively. For this purpose, for contrast agent staining, frozen sections of liver tissues
were collected. Then the tissues on slides were fixed with either ethanol or methanol in -20°C for
20 minutes to remove OCT which is a gel-like medium for embedding the tissues.
After the tissues were dried, the blocking buffer is added for 2 hours at room temperature.
Then the slides are washed with 1×TBST for once, and the primary antibody is added
(ProCA32.collagen1) with 1:50 dilution and left for incubation in 4°C overnight. The slides are
washed again with 1×TBST for three times, each time for 5 min.
In the next step, the slides are washed again three times, and secondary antibody is added
for the primary antibody (anti goat) and left for 1 hour at room temperature. Then DAPI is added
to the slides and they are covered with glass and left at 4°C until they are dried.
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As Fig. 6.6 demonstrates, A is showing heart tissue without any collagen present and B is
liver with tumor exhibiting large packs of collagens in pink color and C is showing the liver with
implanted tumor. D and E are uveal melanoma tumors in the liver showing two distinctive patterns
demonstrated by collagen (blue). F is immunofluorescence staining of ProCA32.collagen1
showing the contrast agent is targeting the liver with tumor.

Figure 6.6 Immunofluorescence and collagen staining
(A) Heart as a negative control showing no signs of collagen. (B) Liver tissues with tumor show
collagen packs in pink color. (C) Image of liver with implanted uveal melanoma tumor. (D, E)
Liver with two different uveal melanoma tumor growth patterns showing different in collagen
pattern as well. (F) Immunofluorescence staining of ProCA32.collagen1 in liver with uveal
melanoma implanted tumor shows the heterogenous distribution of the contrast agent.
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6.2.3 Molecular imaging of M15 Uveal Melanoma metastasized to the liver
Human UM M20 orthotopic mouse model metastasized to the liver was generated and
PEGylated contrast agent (100 µL, 5 mM) was injected in mice in the tail vein. T1-weighted, T2weighted and inversion recovery MRI images of the tumor in the liver have been collected using
a 7.0 T MRI instrument. Fig. 6.7 shows the T1 inversion recovery of mouse liver before and after
injection of ProCA32.collagen1 at different inversion times. The mouse model is M20 with human
uveal melanoma tumor metastasized to the liver from the eye. As it can be seen from MRI images,
tumors are showing up 24 hours after injection of ProCA32.collagen1 based on the inversion time
used. The same results can be observed in T1- and T2-wieghted MRI images. Inversion recovery
pulse sequence was also used in this experiment with different inversion times. The best MRI
image with tumors lighting up in the dark background of the liver can be obtained in the optimized
inversion time of 0.01s (Fig. 6.7). Inversion time of 0.12 s surprisingly did not show any tumors
in the liver. Different inversion times at 48-hour time point was also tested to identify the best
inversion time for better contrast of the tumor.
Therefore, inversion time of 0.01 s can provide the best enhancement of tumors 24 hours
post injection of ProCA32.collagen1. Other contrast agents such as non-targeted agent, ProCA32P40 and Eovist were tested later in 0.01 s inversion time to assess the targeting ability of
ProCA32.collagen1.
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Figure 6.7 Imaging of UM Tumor with different inversion times.
Different invasion times of 0.01, 0.12 and 0.23 seconds were tested in inversion recovery pulse
sequence in order to obtain the best enhancement for tumors. Inversion times of 0.01 s and 0.23 s
were able to show tumors; however, inversion time of 0.12 s did not show any tumors, therefore,
0.01 s was used for further analysis.
We have used other contrast agents such as ProCA32-P40, and Eovist to test the targeting
efficiency of ProCA32.collagen1. As Fig. 6.8 demonstrates, Eovist, a liver specific clinical
contrast agent cannot show any tumors in the liver although histology analysis confirmed the UM
metastasis to the liver. Moreover, ProCA32-P40 which has also good relaxivity and sensitivity but
lacks collagen type I targeting capability failed to show any tumors. These results exhibit the
advantage of having a targeting moiety in ProCA32.collagen1.
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Figure 6.8 T1 inversion recovery (IT=0.01 s) MRI images of mouse livers with M15 UM
metastasis model.
Only ProCA32.collagen1 can show UM micrometastasis 24 hrs post injection confirmed with
histology. Eovist and ProCA32-P40 cannot show any tumors in the liver after injection despite the
presence of tumors in histology.
6.2.4 Correlation of MRI with histology of Uveal Melanoma
Hematoxylin and eosin stain or hematoxylin and eosin stain (H&E stain or HE stain) is one
of the principal stains in histology. It is the most widely used stain in medical diagnosis and it is
often the gold standard. In M20 model, the liver tissues were stained with H&E and tumors were
correlated with MRI image (inversion recovery at 24-hour time point). As it can be seen in Fig.6.9
A, total number of six isolated tumors with nodular and infiltrative patterns along the portal vein
were detected by H&E staining. The same tumors were detected in MRI by injecting
ProCA32.collagen1 contrast agent considering that tumors with nodular pattern have high levels
of collagen type I surrounding them. Most importantly, the contrast agent is able to detect the
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nodular pattern of tumors which has significant clinical implications. The tumors in the MRI can
be well correlated with H&E staining of liver tissue. Fig 6.9 B shows the good correlation between
tumor size in histology and tumor size in MRI. Moreover, the limit of detection has been
significantly lowered with the use of ProCA32.collagen1 as tumor as small as 0.250 mm 2 was
detected. Tumor heterogeneity can also be observed after injection of the contrast agent as shown
in Fig 6.9 C. Contrast to noise ratio analysis of tumors show the significant enhancement of tumors
24 hours post injection of ProCA32.collagen1. A 14-fold increase was observed in the CNR (24
hour) compared to pre (Fig. 6.9 D).
In addition, the tumors were stained with collagen type I antibody to confirm that collagen
type I is surrounding the tumors. Collagen type I in Fig.6.10 A can be seen in brown color and can
be correlated with H&E staining at the same time.
In Fig. 6.10 A, brown colors can be seen that are surrounding the UM tumor in dark purple.
In addition, the tumors in the liver were stained with S100 antibody staining to confirm the Uveal
Melanoma tumor in the liver. The result can be seen in Fig. 6.10 B. Fig. 6.10 C and D are
demonstrating Sirius red staining for collagen in uveal melanoma tumors. These images are
showing two different patterns of UM with different collagen levels and patterns (red). It can be
seen that nodular pattern has more collagen levels compared to infiltrative pattern, furthermore,
collagens in nodular pattern are present both inside and outside of the tumor, however, in
infiltrative pattern collagens are surrounding the tumor.
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Figure 6.9 MRI and histology correlation of UM tumor detected by ProCA32.collagen1.
(A) H&E staining of 6 tumors with different patterns corresponds with MRI image demonstrating
the high sensitivity of ProCA32.collagen1 in early detection and distinguishing of UM patterns.
Tumor numbers 1-4 showing infiltrative pattern and tumor number 5 and 6 are representing the
nodular pattern. Based on histology, stage II, nodular and infiltrative patterns can be detected by
the contrast agent using T1 inversion recovery (TI=IT=0.01 s). (B) Histology results showing
correlation with MRI image. Tumors area in mm2 in MRI is very close to the area of tumors in
H&E. (C) Contrast to noise ratio (CNR) calculations showing a 14-fold increase in tumor after
injection of ProCA32.collagen1.
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Figure 6.10 Histology confirmation of UM tumor and collagen expression.
(A) UM nodular tumor in liver with collagen type I surrounding it in brown color. (B) S100
antibody staining confirms the Uveal Melanoma tumor in the liver. (C) Sirius red staining of
infiltrative pattern UM tumor in liver showing collagen (red) surrounding the tumor. (D) Sirius
red staining of nodular pattern UM tumor in liver showing collagen (red) surrounding the tumor
as well as inside the tumor. The collagen pattern is clearly different based on tumor pattern.
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6.2.5 ICP-OES organ distribution
The Gd3+ concentration in different organs were measured post injection of contrast agents
using ICP-OES. Based on the measurements, the Gd3+ concertation in liver with uveal melanoma
48 hours post injection of ProCA32.collagen1 was approximately 0.08 mol/g. Overall, liver 48
hours after injection of ProCA32.collagen1 showed the highest Gd3+ concentration among other
organs including the liver injected with non-targeted contrast agent, ProCA32 (ProCA32-P40),
which demonstrates the targeting capability of ProCA32.collagen1 towards collagen type I in liver
with uveal melanoma. The Gd3+ injection dosage per gram of tissue in liver with
ProCA32.collagen1 was approximately 3-fold higher than ProCA32-P40. Further results in Fig.
6.11 A and B show that the Gd3+ content is much lower in other organs compared to liver.

Figure 6.11 Gd3+ concentration measurements showing contrast agent distribution in
different organs 48 hours post injection of ProCA32.collagen1.
(A) Gd3+ concentration measurements in (µmol/g) in different organs using ICP-OES. (B)
Injection dosage of contrast agents per gram of tissues in different organs using ICP-OES.
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Discussion
We have developed a protein-based MRI agent with collagen type I targeting moiety
attached to its C-terminal. In order to meet the requirements for MR imaging of liver metastasis,
the targeting peptide was added to the C-terminal to avoid any alterations in the protein structure
and its metal binding affinities which is very different from other approaches. We have
demonstrated that it is possible to increase relaxivity by addition of a targeting moiety to a protein
MRI contrast agent without sacrificing relaxation and metal binding properties, such as affinity
and metal specificity.
ProCA32.collagen1 as an MRI contrast agent has several advantages over clinical contrast
agents based on small chelators such as Gd-DTPA in functional and molecular imaging
applications. First, it greatly increases the CNR and SNR. Second, it improves dose efficiency with
reduced metal toxicity. Three, it prolongs the tissue retention time, which enables imaging of
different stages of the disease that requires prolonged tissue enhancement; and fourth, it functions
as a protein carrier that can conjugate target-specific ligands to collagen 1 for targeted molecular
MR imaging. Although the diffusion rate of a protein with proper size (3-5 nm) is slower than that
of small chelators, ProCA32.collagen1 has the capability to diffuse to the target.
One of the most important characteristic of an MRI contrast agent specifically for liver
metastasis is its sensitivity. An MRI contrast agent with high relaxivity determines the sensitivity
and limit of detection of the agent capable of detecting a disease. This is extremely crucial for liver
metastasis since the early stage of the disease cannot be detected by MRI due to small sizes of
micrometastasis. In addition, clinical contrast agents do not have the capacity to detect UM tumor
growth patterns (nodular vs infiltrative) in order to make a difference in treatment strategies. Given
the fact that collagen type I is an important biomarker in assessing the growth patterns of UM
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tumors, ProCA32.collagen1 was designed and developed to overcome the major limitations of
clinical contrast agents. ProCA32.collagen1 with targeting capability is able to not only detect
small UM micrometastasis in liver at early stage but also has the ability to distinguish nodular and
infiltrative tumor patterns and therefore, facilitate the treatment of these tumors.
6.3.1 Advantages of ProCA32.collagen1 Compared with Imaging Agents of Liver Metastasis
Administration of contrast agents helps with visualization of tumors using MRI.
Specifically, majority of clinical Gd3+-based MRI contrast agents cause T1 shortening and signal
enhancement on T1 map images, however most of these agents have been linked to the occurrence
of nephrogenic systemic fibrosis (NSF) in renal impaired patients due to release and accumulation
of Gd3+ from the agent because of transmetallation [157, 206] . Furthermore, they are all based on
small-molecule chelates and have very low relaxivity (both r1 and r2) and sensitivity without
targeting capability, therefore, they are only able to detect late stages of UM when the tumor sizes
are in cm. The clinical contrast agents also use a high clinical injection dosage due to their low
sensitivity with a short imaging window without the capability of enhancing the entire liver such
as Eovist.
Several research-based probes and Gd3+-based contrast agents targeting extracellular
matrix (ECM) proteins have been evaluated in animal models of breast cancer in the past several
years. Zhou et al has developed penta-peptide conjugated to Gd-DOTA to target fibrin–fibronectin
complexes in tumor microenvironment[343]_ENREF_49. All of these MRI contrast agents have
low relaxivity values for both r1 and r2 and rely only on their T1 property. ProCA32.collagen1 with
high r1 and r2 values allow both T1 and T2 imaging to increase the confidence of MRI scans.
ProCA32.collagen1 enhances the entire liver for at least 3 h, which substantially widens the MRI
detection window for high-quality imaging of liver, allowing us to introduce both T1 and T2
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property of the contrast agent since the small tumor micrometastasis are usually not well visualized
during the arterial and early venous phases, upon the administration of clinical contrast agents. In
addition, tumor growth pattern cannot be visualized either.
6.3.2 Noninvasive Biomarkers of Uveal Melanoma Liver Metastasis
Uveal melanoma (UM) has high tendency to metastasize to the liver [348, 349]. Although
the local treatment of the intraocular tumor has progressed, the survival rate of UM patients
remained unchanged or changed little over the past few decades. Since UM metastatic tumor
burdens are typically high when detected by changes in liver function tests or even different
imaging modalities, there is no reliable and effective treatment [350, 351]. In the past,
oncologists were dependent on the measurement of liver enzymes levels in order to raise
the suspicion of metastases, however a significant tumor size is sometimes needed to increase liver
enzymes, therefore, sometimes patients have normal liver enzymes with diffuse hepatic metastases
[352]. As a result, there is an unmet medical need to develop sensitive biomarkers to detect early
metastatic UM as well as its growth patterns.
A broad variety of molecules synthesized or in the blood have been proposed as markers
of cutaneous melanoma tumor progression [353]. These markers include melanin-related
metabolites and enzymes (Alpha-MSH, tyrosinase), adhesion molecules (ICAM-1, PECAM-1,
CD-44) and cytokines (IL-8, IL-10, IL-2R). The currently available diagnostic tests to detect
cutaneous melanoma- associated molecules include LDH as introduced by the AJCC (American
Joint Committee on Cancer), S-100β [354], NSE (neuron specific enolase ), LASAP (lipid bound
sialic acid) and melanoma-inhibitory activity (MIA) [355].
In cutaneous melanoma, a study demonstrated that serum S-100β can be an independent
prognostic maker for Stage II of the disease [356, 357]. It was reported that S-100β serum level
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changes can be of predictive value for a positive response to chemotherapy and immunotherapy
[357], however, there is not enough information about the clinical value of S-100β in patients with
UM. In addition, two serum markers reported to correlate with the presence of hepatic metastases
from uveal melanoma are tumor-associated antigen known as melanoma inhibitory activity (MIA)
and osteopontin (OPN) [355, 358-360].
Collagen type I as a tumor stroma-derived biomarker is important in variety of cancers
since it reflects the tumor microenvironments changes, therefore, as a direct marker is a perfect
target for molecular MR imaging compared to other ECM components such as elastin.
Specifically, in UM, collagen type I is not only present in early stages of the disease and small
micrometastasis but also an indication of tumor growth pattern difference in the liver which is
indispensable for treatment choices. Furthermore, collagen targeting molecular magnetic
resonance imaging demonstrates a unique application of MR technology to view biological
processes at the cellular and molecular level.
Development of an MRI contrast agent to target collagen type I can be an ideal way to take
advantage of combination of an imaging modality with a direct biomarker to detect UM in liver at
early stage and the growth pattern differences. ProCA32.collagen1 with high binding affinity of
1.4 M to collagen type I among agents targeting the ECM is an ideal contrast agent since it is
well within the range of the natural collagen type I concertation in liver (1–20 nmolg-1), in addition,
this concentration will increase as the tumor develops or changes its pattern. ProCA32.collagen1
with high relaxivity it very sensitive to these changes for early detection and pattern distinction in
UM in liver.
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6.3.3 Nodular vs infiltrative growth pattern distinction using ProCA32.collagen1
Patients with UM metastasis rarely survive more than a few years after initial detection of
the metastasis. The median survival time after diagnosis of metastasis in the largest published
series of unselected patients with metastatic uveal melanoma was 3.6 months [361]. Cumulative
actuarial survival in this series was 20% at 1 year, 13% at 2 years, 5% at 3 years, 2% at 4 years,
and less than 1% at 5 years [335]. The liver is usually the first site of metastasis of UM, and is the
only single organ involved in 60%–80% of UM patients[362]. The median survival of patients
with liver metastasis is 2–7 months despite aggressive therapy, [363] and the clinical course of
these patients is highly dependent on disease progression in the liver [364, 365].
Recognizing the different growth patterns of metastatic UM in the liver has important
clinical implications. Histologically, nodular and infiltrative types exhibit differences in the host
immune response: there are natural killer cells in the infiltrative form, whereas the nodular form
contains cytotoxic T lymphocytes [332]. There are also discrepancies in the formation of collagen,
angiogenesis, and other factors that distinguish these 2 histologic growth patterns [366]. The
choice of treatment regimens in the future may be altered because of these differences. Dayani et
al distinguished between infiltrative and nodular patterns of metastatic UM on hepatic angiography
and noted that it can be used to predict response to hepatic arterial chemoembolization. Halenda
et al[338] also noted that radioembolization was effective in treating nodular liver metastases, but
not infiltrative sinusoidal metastases[334]. In that particular study, a patient had a mixture of
nodular and infiltrative liver metastases demonstrated by MRI. The nodular liver metastases
decreased in size with radioembolization, but the infiltrative metastases did not respond to
treatment and the patient’s condition ultimately progressed. Sharma et al[339] showed that patients
with angiographically determined nodular tumor appearances survived longer than patients with
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infiltrative lesions (overall survival, 621 vs. 114 days)[339]. Differentiating between these patterns
on scans is an important consideration when determining the treatment plan for patients with
metastatic UM. It is possible that the nodular pattern on imaging may represent an earlier pattern
of disease that transforms into the infiltrative pattern as the tumor escapes from the portal triad.
ProCA32.collagen1 is the only contrast agent developed so far with the capability of differentiating
UM growth patterns in liver which is significant when choosing treatment strategies for patients
to prolong the survival.
6.3.4 Transmetallation of ProCA32.Collagen and Clinical MRI Contrast Agents
The chemical instability of a Gd3+-based contrast agent can lead to exchanges with other
metal ions such as zinc, copper, and calcium which can, in turn, have biological consequences.
These consequences include accumulation of Gd3+ in bones, interference with colorimetric serum
determination of calcium and hence spurious hypocalcaemia, interaction with scintigraphic
procedures, increased zincuria, interaction with metal-dependent biological systems such as
metalloenzymes, etc. Free gadolinium is highly toxic and the ionic radius of Gd3+ (107.8 pm) is
close to that of Ca2+ (114 pm) and this element is an inorganic blocker of many types of voltagegated calcium channels at nano- to micromolar concentrations, therefore, it cab inhibit those
physiological processes which depend upon Ca2+ influx.
Generally, there are two structurally distinct categories of gadolinium chelates exist: (a)
The ‘macrocyclic’ chelates such as Gd-DOTA (Dotarem), where Gd3+ is ‘caged’ in the preorganized cavity of the ligand. (b) The ‘linear’ chelates such as Gd-DTPA (Magnevist) or GdDTPA-BMA. The toxicity of gadolinium complexes actually depends on their ability to release
free Gd3+ ions. Transmetallation: is a type of organometallic reaction that involves the transfer of
ligands from one metal to another. Several cations such as Fe3+, Cu2+, Zn2+ or Ca2+ compete with
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the Gd3+ cation and a number of other anions such as PO43- , CO32- , OH- can compete with the
ligands for the Gd3+. Generally the stability of contrast agents has the following order: Macrocylic
ionic  Macrocylic non-ionic  linear di-ionic  linear non-ionic  cyclic-linear-charge.
In order to further support the kinetic stability and metal selectivity of ProCA32.collagen1
for Gd3+ over Zn2+ compared to other clinical contrast agents, 55 µM and 110 µM of
ProCA32.collagen1 was used along with 100 µM Gd3+, 100 µM Zn2+ in 1.2 mM PO43- buffer. For
clinical contrast agents, 2.5 mM of contrast agents (Omniscan, Eovist, Mganevist and MultiHance)
with 2.5 mM Zn2+ in 30 mM PO43- was used in buffer. The relaxation rate (R1) was measured for
each contrast agent over time. To normalize the data, R1(t)/R1(0) was calculated. Figure 3f
demonstrates the relaxation rates change of clinical contrast agents (Eovist, Magnevist, Ominiscan;
ProHance, MultiHance and Dotarem) and ProCA32.collagen1 (loaded with Gd3+ to at
approximately 1:1 ratio and 1:2 ratio) in phosphate buffer supplemented with ZnCl2 for different
length of time. As it can be concluded form Fig. 3f, Omniscan has the highest decrease in relaxation
rate after 4000 min incubation with zinc (91.2%). ProCA32.Collagen (1:1) along with Dotarem
and ProHance did now show significant decrease in relaxation rate.
In addition, 250 µM of contrast agent as the final concentration was used in the human
serum and incubated at 37C for 13 days. Ponceau S solution and Coomassie brilliant blue were
used for staining. As it can be seen in Fig. 8c, ProCA32.collagen1 is stable up to 10 days. These
experiments further support the conclusion that ProCA32.colagen1 has significantly higher kinetic
stability and metal selectivity for Gd3+ over Zn2+ than those of Omniscan, Eovist, Magnevist and
MultiHance. In addition, ProCA32.collagen1 has a strong proteolytic stability, as revealed by its
structural integrity for 10 days of incubation in human serum. These two experiments also showed
that high concentration of Zn2+ is not able to compete with Gd3+ in ProCA32.collagen1.
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Potential Application and Significance
Based on the results described in this study, ProCA32.collagen1 is capable of detecting
early stage II UM tumor liver metastasis with high sensitivity which has not been achieved before
by any clinical or research-based MRI contrast agent. In addition, for the first time, an MRI
contrast agent is able to differentiate UM tumor growth patterns (nodular and infiltrative) in the
liver resulting in important clinical consequences in terms of choosing the best treatment for UM.
Detection of liver metastasis can make significant difference in patient treatment outcome and
survival. In addition, noninvasive detection of tumor heterogeneity using ProCA32.collagen1 can
provide important information regarding the population of different cell types (inflammatory or
tumor cells).
Since of ProCA32.collagen1 has higher relaxivity values for both r1 and r2 compared to
other contrast agents, different imaging sequences can be applied to increase the detection
confidence. Furthermore, less injection dosage can be used to avoid toxicity as our results
demonstrate.
Summary and Conclusion
The MRI images suggest that the contrast agent has the capability of enhancing the tumor
signal in much longer times post injection (24 hours) in both T1- and T2-weighted images. In
addition, inversion recovery technique was successfully applied for the deigned contrast agent
which led to 6-fold increase in the relative contrast of the mouse implanted tumor compared to
pre-injection image. Furthermore, MRI images in metastatic model (M20) studies showed the
heterogeneous distribution of the contrast agent in tumors which further prove the targeting
capability. Gd3+ biodistribution results strongly correlates with tissue staining studies. Picro-Sirius
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Red staining results suggest that collagen pattern and level difference based on tumor pattern
difference and the capacity of ProCA32.collagen1 in distinguishing them.
Transmetallation data suggest that ProCA32.collagen1 with (1:1) ratio of Gd3+ and protein
has the highest kinetic stability among other clinical contrast agents. Furthermore, the contrast
agent is stable in human serum up to 10 days. ProCA32.collagen1 can be considered as a promising
agent in early detection of uveal melanoma metastatic liver tumor as well as distinguishing pattern
difference. In addition, based on the literature, collagen has different expression levels depending
on the type of the tumor, therefore, our contrast agent can be used to distinguish the originality of
the metastatic tumor.
Collagen expression and changes are major diagnostic biomarker and therapeutic target for
many chronic diseases including chronic liver diseases, many types of cancers and metastasis,
heart failure, and pulmonary fibrosis. Uveal melanoma, the most common primary intraocular
tumor, has a 40% risk of metastasizing to the liver that results in death in almost all cases. To date,
there is no reliable noninvasive imaging method for early detection and staging of primary liver
cancer and hepatic metastases with high sensitivity and specificity. MRI has several unique
advantages for monitoring slow progression and detection of metastasis with high resolution
without using radiation. There is a pressing unmet medical need to develop MRI contrast agents
with desired sensitivity and collagen specificity to overcome high heterogeneous background as
well as proper in vivo properties and reduced toxicity.

In this study, we report the success in

designing a protein-based MRI contrast agent, ProCA32.collagen1 with collagen type I targeting
capability to diagnose and stage the metastasis of uveal melanoma. ProCA32.collagen1 exhibits
the highest relaxivity values for r1 and r2 per Gd3+ at both 1.5 and 7.0 T and are 14-20-fold higher
than clinically used contrast agents. The uniqueness of both high r1 and r2 relaxivity values enable
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us to achieve both T1 and T2 imaging after a single injection of ProCA32.collagen1. More
important, we can significantly improve dynamic range in detection with a 6-fold enhancement in
the relative contrast for the implanted liver uveal melanoma tumor in mouse taken advantage of
both relaxation property and imaging methodology. In addition, ProCA32.collagen1 is able to
differentiate M15 uveal melanoma metastasized to the liver with nodular pattern from infiltrative
with 14-fold increase in contrast to noise ratio (CNR) which has not been achieved using clinical
contrast agent. Distinguishing different patterns of uveal melanoma has significant clinical
implications in terms of choosing the most effective treatment. Based on MRI correlation with
histology analysis, ProCA32.collagen1 is capable of detecting tumors as small as 0.250 mm2 which
is much smaller than not only the current detection limit of 10–20 mm but also tumors previously
detected by ProCA32-P40. We have further shown that the addition of targeting moiety does not
reduce its strong metal binding affinity to Gd3+ and 1011-fold higher selectivity towards Gd3+ over
Zn2+ than Eovist. The development of collagen targeting contrast agent is expected to have broad
applications in detection and staging of liver metastasis from various types of cancer and probing
heterogeneous microenvironment changes upon disease progression and treatment.
7

APPLICATION OF PROCA32.COLLAGEN1 IN DETCTION OF
HEPATOCELLULAR CARCINOMA (HCC)

Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver.
Worldwide, approximately 500,000 new patients are diagnosed with HCC each year, often
associated with poor prognosis [367]. It is the fifth most frequent neoplasm and ranks third on the
list of most lethal cancers [368, 369]. The highest incidence of HCC is found in Asia and sub-
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Saharan Africa. Most cases of HCC develop in a background of chronic liver damage such as
cirrhosis or hepatitis [370].
Cirrhosis from any cause predisposes to hepatocellular carcinoma (HCC) and hence can be
considered a premalignant condition. Indeed, the majority of patients worldwide with HCC have
underlying cirrhosis [371]. With the exception of some areas of the world where hepatitis B virus
(HBV) infection is endemic and the role of other oncogenic agents (ie, aflatoxin) may be important,
[372] it is uncommon to find HCC in the absence of cirrhosis. On a global basis, longitudinal
studies indicate that cirrhosis related to either hepatitis C virus (HCV) or hepatitis B virus (HBV)
infections represent the major known risk factors for HCC [370, 373, 374].
7.1.1 HCC in Cirrhosis
HCC is a common cause of death among patients with compensated cirrhosis. European
cohort studies have reported that, among persons who died of a liver- related cause, HCC was the
responsible cause in 54% 6 to 70% [375] of patients with compensated cirrhosis of different
etiologies and in 50% of patients with HCV-related cirrhosis [376]. Data from one of the
longitudinal studies, which involved 112 cirrhotic patients with HCC detected during ultrasound
surveillance, showed that tumor progression was the cause of death of 63% of patients with HCC
who died during the first 4 years of surveillance (1987–1991), of 69% who died during the second
4-year period (1992–1996), and of 83% who died during the third period (1997–2001) [374].
Recent epidemiologic data indicate that, in the United States as well as in some European
countries, the mortality rate from HCC is increasing [377-379]. Conversely, cirrhosis-related
mortality not due to HCC declined into the early 1990s in the same areas, [380-382] although,
subsequently, remained stable in the United States between 1995 and 1998 [383]. A similar trend
was noted in Italy, between 1969 and 2000, where the mortality rates of cirrhosis showed a clear
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decline while the mortality rates for HCC slowly increased. A possible explanation for these
findings is that medical management of non-HCC complications of cirrhosis, such as prevention
and treatment of variceal bleeding and management of ascites, has improved, as has the availability
of alcoholism treatment, leading to longer survival of patients with cirrhosis, who in turn are at
greater risk over time of developing HCC. A recent report of a decrease in the mortality rate of
alcohol-related cirrhosis supports this hypothesis [384, 385].
7.1.2 Benign versus malignant hepatic nodules in HCC
According to the currently used nomenclature, there are only two types of hepatocellular
nodular lesions: regenerative lesions and dysplastic or neoplastic lesions. Regenerative nodules
include monoacinar regenerative nodules, multiacinar regenerative nodules, cirrhotic nodules,
segmental or lobar hyperplasia, and focal nodular hyperplasia. Dysplastic or neoplastic nodules
include hepatocellular adenoma, dysplastic foci, dysplastic nodules, and hepatocellular carcinoma
(HCC) [386-388].
Many of these types of hepatic nodules play a role in the de novo and stepwise
carcinogenesis of HCC, which comprises the following steps: regenerative nodule, low-grade
dysplastic nodule, high-grade dysplastic nodule, small HCC, and large HCC (Fig. 7.1).
During the past 2 decades, MR imaging has emerged as an important imaging modality for
assessing cirrhosis and its complications, such as hepatic nodules [386]. For assessment of hepatic
nodules, MR imaging is more useful than any other imaging modality currently available [386].
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Figure 7.1 Different steps in generation of carcinogenesis for HCC in cirrhosis[387].

Although arterial enhancement with delayed washout, increased T2-weighted signal
intensity, delayed capsular enhancement, restricted diffusion, and tumor thrombus are typical
features, not all lesions demonstrate these findings. The radiologist must be familiar with these
typical imaging characteristics, and less common appearances and associated findings of HCC,
and must be able to differentiate them from those of lesions that mimic HCC. Knowledge of
therapeutic options and how those are related to imaging findings is imperative to assist clinicians
in managing these patients [386].
Accordingly, researchers have aimed to derive target genes and drug candidates for HCC;
however, the development of targeted drugs has not yet significantly improved outcomes [389,
390]. Lately, the paradigm in cancer biology has shifted from the study of the genetics of tumor
cells alone to the complicated crosstalk between cancer and the tumor microenvironment (TME)
[391, 392]. The TME is the cellular environment in which the tumor exists, including the
surrounding blood vessels, immune cells, fibroblasts, other cells, signaling molecules, and the
extracellular matrix (ECM). Recent studies have shown that the stromal cells in HCC have a
dynamic and flexible function in tumor proliferation, invasion, and metastasis, and that the cells
of the TME can regulate the response of cancer cells to chemotherapy [393-395]. Hepatic stellate
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cells (HSCs) play critical roles in diverse aspects of liver physiology, including liver organogenesis, regeneration, and HCC. HSCs are found in the space of Disse between the sinusoidal
endothelial cells and hepatic epithelial cells [396].
Hallmarks of HSC activation are reduced levels of intracellular lipid drop- lets, increased
expression of α-smooth muscle actin (α-SMA) and ECM production, as well as morphological
changes [397, 398]. Additionally, the interaction between HCC and activated HSCs forms a proangiogenic microenvironment by the overexpression of VEGF-α and matrix metallopeptidase 9
(MMP9) [399-401].
ECM-related proteins in the TME play important roles in liver function in health and
disease. Abnormal ECM composition and structure in solid tumors are the major obstacles for the
penetration of anticancer drugs. Among ECM proteins, collagens and specially collagen type I are
the most abundant structural protein in the liver. A disproportionate concentration of collagen type
I results in altered cell phenotypes and architectural distortion with abnormal blood flow in the
liver. Moreover, a high collagen type I content is a key barrier for interstitial drug penetration
among ECM-related proteins [402] and thereby reduces the efficacy of chemotherapeutics.
Because HCC is developed from chronically damaged tissue that contains a large amount of
inflammation and fibrosis, further knowledge of the crosstalk between HCC and their TME is
essential for achieving a better understanding of tumor development, progression, and
chemoresistance in HCC [402, 403].

7.1.3 The challenges in diagnosis of hepatocellular carcinoma
The aim of early detection plans in patients at risk of hepatocellular carcinoma (HCC) is to
detect the tumor at an evolutionary phase, when a cure with long-term disease-free survival is
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highly likely [404]. Accordingly, the goal is to detect and diagnose tumors when they are smaller
than 2 cm in size, the so-called BCLC stage 0. Beyond this cutoff, the prevalence of satellites
and/or microvascular invasion is significantly increased and treatments such as resection,
transplant, and ablation will be plagued by recurrence due to dissemination prior to treatment
[404].
While this goal is easy to frame, establishing accurate diagnosis in such small nodules is a
major clinical challenge. Tumor markers, including alpha-fetoprotein and novel ones such as
glypican or PIVKA, have no major usefulness for screening and diagnosis [404], and thus, as in
most other cancer types, diagnosis would require a positive biopsy. Nevertheless, biopsy is known
to have a suboptimal sensitivity (around 60–70 %) [405]. It provides a limited amount of tissue,
and the fact that such small HCCs are usually well differentiated makes it difficult to confidently
distinguish HCC from dysplastic or regenerative nodules. Even expert pathologists would not have
a 100 % agreement without false positives and false negatives in such small malignant nodules.
Immunohistochemical staining for glypican 3, heat-shock protein 90, or survivin may reinforce
HCC suspicion, but they do not increase the diagnostic rate. Diagnostic signatures based on gene
expression have also been proposed but have not been validated, and such molecular diagnosis is
not yet in clinical practice. Even if biopsy would have 100 % sensitivity, it would not be feasible
in some patients because of the location or the presence of clotting disorders.
All these comments explain the development of imaging criteria for the non-invasive
diagnosis of HCC [405]. The increased arterial blood supply that characterizes HCC provides the
basis for the increased contrast uptake in the arterial phase of dynamic techniques, such as
computed tomography and magnetic resonance. This is a hallmark of malignancy and, if it is
followed by hypointensity in the venous/delayed phases, the profile is specific for HCC [405].
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This hypointense appearance of the hypervascular focal lesions known as ‘‘wash-out’’ is due to
the venous supply being less prominent in HCC as compared to the surrounding liver, and, thus,
the arrival of contrast through the portal vein, so that the liver intensity is enhanced as compared
to the tumor. Several studies have validated such a profile as almost 100 % specific for HCC [406,
407]. Interestingly, while intrahepatic cholangiocarcinoma may display increased arterial blood
supply, it does not show washout and this is key for the distinction between these two entities,
which have a sharply different prognosis and treatment [5, 6]. It is important to note that
intrahepatic cholangiocarcinoma (ICC) incidence is on the rise and cirrhosis is a major risk for it.
Thus, differentiation between HCC and ICC is not futile. Nevertheless, as happens with biopsy,
the diagnostic sensitivity of CT or MR for small HCC (~2 cm) is far from 100 %. Increased arterial
blood supply appears along tumor growth and, currently, just 60–70 % of HCC\2 cm can be
confidently diagnosed by imaging techniques [407].
7.1.4 Limitations of current clinical contrast agents in HCC diagnosis
All these limitations explain the need to further improve the diagnostic accuracy of imaging
techniques in order to set a non-invasive diagnosis avoiding the request for a positive biopsy. The
use of organ-specific contrast agents such as gadoxetic acid (GA or Eovist) or aims to fulfill this
goal.
Eovist is a combined hepatobiliary (HB) and Gadolinium-chelates contrast agent, suitable
for regular dynamic multiphasic studies, that offers the possibility to obtain both the conventional
arterial and venous phases, but also a 20-min delayed HB phase. At this delayed time point, the
hepatocytes have taken up the 50 % of the administered dose [278, 408-410]. Therefore, nonhepatocyte focal lesions and those with non-functional hepatocytes, such as most HCCs, should
not accumulate contrast. This results in low signal intensity foci relative to the intensity of the liver
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parenchyma in the HB phase of Eovist-enhanced MR. While this background would make EovistMRI an optimal technique, there are a number of issues that need active research.
Several studies suggest a potential diagnostic value [411-415], but no robust prospective
study has defined its added diagnostic value in the clinical setting. Very early HCC with wellpreserved hepatocyte function may show GA uptake and offer false negative results. In addition,
as previously mentioned, ICC may also emerge in a cirrhotic liver, and likely this opens a potential
for false positive diagnosis. Finally, the technicalities for the optimal use of GA for an adequate
reading of the arterial and venous phases of MRI as done currently with gadolinium chelates are
not well established. The injection rate of the small amount of contrast injected for GA-MRI may
limit the proper recognition of the contrast uptake in the arterial phase and, thus, impair the use of
the already validated criteria based on the recognition of arterial uptake followed by wash-out.
Even wash-out recognition in such nodules may be impaired, as uptake of GA in the biliary phase
may overlap with the delayed venous one. Accordingly, the injection of higher volumes or the use
of different injection rates have been proposed to optimize the information offered by GA-MR.
Prior studies have evaluated the impact of injection rate and the amount of contrast injected
with controversial results. Zech et al. [416] compared in an experimental study the influence of
regular to double doses and different rates of injection (1–2 mL/s) on the enhancement of liver
vasculature in GA-MR and Gd-DTPA. They found that the arterial enhancement in GA-MR
injected at 1 mL/s was comparable to Gd-DTPA. Haradome et al. [417] reported in a retrospective
study on 216 patients that fluoroscopic triggering GA-MR and slow rate injection provide proper
arterial phase images. Schmid-Tannwald et al. [418]compared two injection rates (1 and 2 mL/s)
for GA-MR dynamic studies in 80 patients and reported higher enhancement in the aorta in the
arterial phase with the lower injection rate. Feuerlein et al. [419] compared the enhancement
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characteristics of liver parenchyma, portal vein, and the portal vein to liver contrast with two HB
contrast agents in 70 patients. The authors found that contrast in the arterial and portal venous
phases was lower when GA was used compared to Gd-BOPTA.
It is important to note that such studies do not include patients with liver tumors. Such
information is the focus of the manuscript by Chen et al. [420] published in this issue of
Hepatology International. The authors describe that, in hypervascular HCCs, the enhancement in
the arterial and portal phases is lower than that observed when using the conventional non-specific
gadolinium. The authors found that the relative contrast difference between the liver and HCC was
significantly less when using GA as compared with a nonspecific gadolinium, but, interestingly, it
was increased in the portal phase. This resulted in a better definition of the hypointense lesions
that may be due to the overlap of the delayed venous phase and the early HB uptake of GA by the
nontumoral liver.
All these studies suggest that clinical MRI contrast agents have considerable weaknesses
for the diagnosis and staging of patients with suspected or proven HCC and major clinical research
is needed to develop more sensitive MRI contrast agents for the proper management of patients
diagnosed with HCC. In this Chapter, our efforts to apply ProCA32.collagen1 in MR detection of
HCC tumors in DEN-induced mouse model will be discussed.
Results
7.2.1 DEN-induced HCC
For these studies first, the HCC animal model was generated. For all of our studies, we
employed female and male mice with C57BL/6 genetic background. Experiments involving
animals were conducted in accordance with the NIH Guide for the Care and Use of Laboratory
Animals and were approved by the Georgia State University IACUC. Animals were housed in a
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pathogen-free animal facility under a 12 h light/dark cycle and fed a standard rodent chow and
water ad libitum. In order to induce liver tumor development, 14-day-old mice were treated with
a single dose of DEN (Sigma–Aldrich # N0756) given dissolved in saline at a dose of 25 mg/kg
body weight by i.p. injection. Mice in one randomly pre-assigned group were killed 10 months
after DEN administration for histological and biochemical analyses. Mice were randomly
distributed in various groups having equal males and females.
Immediately after euthanizing, livers were removed, weighed and the numbers of visible
tumors on the liver surface were counted macroscopically. The largest lobes were fixed in formalin
and embedded in paraffin. Sections were stained with hematoxylin and eosin and examined
microscopically.
Two mice with HCC were selected for MRI scan and after scan they were sacrificed, and
livers were collected and weighted for HCC assessment (Fig. 7.2). As it can be seen from the
images multiple tumors have developed in the liver which shows the large volume of the liver
compared to normal liver.

Figure 7.2 HCC mouse livers after treatment compared to normal liver.
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7.2.2 MRI results of DEN-induced HCC mouse
The mice with HCC tumors were tail-vein injected with ProCA32.collagen1 and T2wighted, T1-weighted, T1 map inversion recovery and T2 maps were collected before and 3 and
24 hrs post injection of ProCA32.collagen1. As Figures 7.3 to 7.6 show, after injection of
ProCA32.collagen1 at both 3 and 24 hrs, there is enhancement in the tumor areas as well as
cirrhotic regions.

Figure 7.3 T2-weighted images of HCC mouse post injection of ProCA32.collagen1
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Figure 7.4 T2-weighted images of HCC mouse post injection of ProCA32.collagen1 in a
different slice of liver

Figure 7.5 T2-weighted MRI images in slice 12 of HCC mouse liver
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Figure 7.6 T2-weighted MRI images in slice 13 of HCC mouse liver.
Areas in orange circle shows the enhancement in tumor and areas in blue circle is showing the
cirrhotic areas. ProCA32.collagen1 is able to detect both tumors and cirrhotic areas.
Figure 7.6 is a clear demonstration of mixture of HCC and cirrhosis in the mouse liver
observed by ProCA32.collagen1. In 3 hrs post injection of the contrast agent, a significant
enhancement is observed in the cirrhotic areas (blue circle), and after 24 hours the contrast agent
is washed out, therefore the enhancement is decreasing. Moreover, ProCA32.collagen1 can
demonstrate HCC tumor 3 and 24 hrs post injection as shown by orange circle.
Further analysis of another HCC mouse (Fig. 7.7) confirms the results and show the same
phenomenon.

217

Figure 7.7 T2-weighted MRI images of another HCC mouse liver before and 3 and 24
hrs post injection of ProCA32.collagen1
As Fig. 7.7 demonstrates, the left segment of liver is more cirrhotic and right segment has
possibly two large tumors as defined by their boundaries. After injection of ProCA32.collagen1 at
3 hrs, a significant enhancement is observed in the two large tumors as well as left segment of liver
showing cirrhotic region.
Fig. 7.8 shows the R2 map analysis after injection of ProCA32.collagen1. As it is observed
from the figure, T2 map results further confirm the T2-weighted results (Fig. 7.7). After
quantitative analysis of T2 values, both left and right tumors in the right segment of liver showing
decrease in T2 and increase in R2 (MRI image). Furthermore, left down segment of liver showing
increase in R2 and decrease in T2 as indication of cirrhotic regions.
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Figure 7.8 T2 map analysis of HCC tumors and cirrhotic areas in DEN-induced HCC
mouse liver. R2 map MRI images showing enhancement in tumors and quantitative analysis of T2
values showing decrease in both tumors and cirrhotic regions in the liver.
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Figure 7.9 T2-weighted MRI images of slice 2 of DEN-induced HCC mouse liver before
and 3 and 24 hrs post injection of ProCA32.collagen1.
Left segment of liver has significant enhancement 3 hrs post injection of ProCA32.collagen1 (blue
circle) demonstrating cirrhotic regions and after 24 hours the contrast is washed out. Right
segment of liver which was significantly enhanced after 3 hours showing HCC tumor (orange
circle).
These results are consistent with results from previous HCC mouse (Fig. 7.7) which show
that results are reproducible with the injection of ProCA32.collagen1. Moreover, R2 map MRI
results are complimentary to T2-weighted results showing the same pattern for cirrhotic areas and
tumor regions (Fig. 7.10).
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Figure 7.10 R2 map MRI images and quantitative T2 analysis of slice 2 of DEN-induced
HCC mouse liver before and 3 and 24 hrs post injection of ProCA32.collagen1.

Figure 7.11 T2-weighted MRI images of slice 4 of DEN-induced HCC mouse liver before
and 3 and 24 hrs post injection of ProCA32.collagen1.
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Since our ProCA32.collagen1 has both r1 and r2 property, we scanned these HCC mice
with multiple pulse sequence to further increase the confidence level of detection. Therefore, T1weighted MRI was also used assess the tumor and cirrhotic regions of HCC mice.

Figure 7.12 T1-weighted MRI images of another HCC mouse liver before and 3 and 24
hrs post injection of ProCA32.collagen1.
T1-weighted MRI images showing different regions of liver enhanced consistent with T2-weighted
images in Fig. 7.7 in the same slice.
Figures 7.13 and 7.14 show the significant enhancement of liver and cirrhotic regions 3
hrs post injection of ProCA32.collagen1 in T1-weighted MRI image.
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Figure 7.13 T1-weighted MRI images of slice 4 of HCC mouse liver before and 3 and 24
hrs post injection of ProCA32.collagen1.

Figure 7.14 T1-weighted MRI images of slice 5 of HCC mouse liver before and 3 and 24
hrs post injection of ProCA32.collagen1.
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7.2.3 Histology results of DEN-induced HCC mouse liver
In order to confirm the presence of tumors and collagen in HCC mouse livers, H&E and
Sirius red staining were performed on paraffin embedded section of mouse liver.

Figure 7.15 Sirius red (left) and H&E (right) staining of mouse HCC liver.
Left picture showing Sirius red staining of collagen (red) in liver and right picture demonstrating
H&E. The areas with darker pink show HCC tumors as it is observed from their boundaries.
Further analysis is required to completely correlate each specific tumor from histology
with MRI and it is currently being studied.
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Figure 7.16 Sirius red (left) and H&E (right) staining of mouse HCC liver.

Figure 7.17 Sirius red (left) and H&E (right) staining of mouse HCC liver.
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Summary
In summary, ProCA32.collagen1 was successfully applied in detection of DEN-induced
HCC mouse model in the liver. ProCA32.collagen1 is able to enhance both cirrhotic and tumor
areas in the model as confirmed by several pulse sequences. One of the advantages of using
ProCA32.collagen1 in detection of HCC is that because of both r1 and r2 property, T1- and T2weighted and T1 and T2 maps can be used to increase the level confidence for the detection and
avoid observing artifacts in the MRI. Moreover, based on MRI images, ProCA32.collagen1 is able
to show heterogeneous enhancement in both cirrhotic and tumors areas which reflect the
heterogeneous collagen expression in these areas. Distinguishing collagen patterns and
arrangement in HCC tumor from collagen patterns in cirrhotic areas can be a significant
achievement in the clinical imaging field. These differences can shed light on how cirrhosis can
progress to HCC and help with treatment strategies and even distinguishing different tumor
subtypes in HCC. Further studies and correlation between MRI images and histology results are
needed to achieve this goal.
8

APPLICATION OF PROCA32.COLLAGEN1 IN DETECTION OF THORACIC
AORTIC ANEURYSM (TAA)
Introduction
Aortic aneurysms exhibit permanent luminal expansion of the aorta that portends rupture

and usually leads to death. This disease occurs in both abdominal and thoracic aortic regions,
which are termed as abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs),
respectively. Due to an incomplete understanding of molecular mechanisms and pathophysiologic
processes, there is no proven medical therapy that can prevent expansion or rupture of either type
of aortic aneurysms.
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Patients with suspected dissection of the thoracic aorta require immediate diagnostic
evaluation so that urgent therapeutic interventions can begin. Detailed information on associated
findings, such as the extent of the dissection, the location of the entry site, the formation of
thrombus in the false lumen, and evidence of pericardial effusion or aortic regurgitation may be
helpful in selecting the best management plan and assessing the patient's prognosis [421-425]. The
established diagnostic procedures, including aortography, [426, 427] contrast-enhanced x-ray
computed tomography (CT), [428-433] and two-dimensional transthoracic color-flow Doppler
echocardiography (TTE), [434-438] all have inherent procedural or diagnostic shortcomings.
Transesophageal echocardiography (TEE) [439-441] and magnetic resonance imaging (MRI)
[442, 443] are recent advances in noninvasive imaging technology that have been useful in
assessing the thoracic aorta [444, 445].
The degradation of the extracellular matrix (ECM) in the medial wall in aorta is key in the
formation, progression and rupture of TAA [446]. Particularly, the turnover of collagen, an
essential component of the ECM, is known to be responsible for the remodeling that occurs in the
adventitia. Recent studies indicate that perturbations in collagen micro-architecture and networks,
probably as a result of collagen degradation and inappropriate collagen deposition, may alter vessel
wall response to mechanical load and lead to vessel wall failure [447]. Therefore, imaging collagen
in AAA and TAA might provide valuable information about the state of aneurysm development
and the identification of AAAs and TAAs prone to severely progress or rupture.
8.1.1 Animal model of TAA and AAA
Since it is difficult to acquire patient samples and perform experiments in humans directly,
research focusing on defining mechanisms of AAAs has been frequently extrapolated from animal
models. A commonly used animal model is subcutaneous infusion of angiotensin II (AngII) into
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mice. Compared to other surgical approaches for inducing AAAs in mice, such as intra-aortic
elastase perfusion or peri-aortic application of calcium chloride that require laparotomy [448, 449],
this method does not require entry into the body cavity and requires minimal surgical expertise
[450, 451].
Subcutaneous infusion of AngII through osmotic pumps to induce AAAs and TAAS was
initially reported in low density-lipoprotein (LDL) receptor -/-mice fed a saturated fat-enriched
diet [450], and subsequently in apo E -/- mice fed a normal laboratory diet [451]. Many recent
studies have also demonstrated that AngII induces AAAs in normolipidemic mice [452-454]. The
approach of infusing AngII has been applied to induce AAAs and explore molecular mechanisms
as well as development of potential therapeutic strategies [455] since this model recapitulates many
features observed in human AAAs. For example, risk factors of human AAAs such as smoking,
aging, and male gender also augment AngII-induced AAAs in mice [456, 457]. The association of
hypercholesterolemia with AAAs in humans requires clarification. However, it has been consistent
that hypercholesterolemia augments AngII-induced AAAs in mice [458, 459]. Pathologies of
AngII-induced AAAs in mice are highly heterogenous and are characterized by profound
macrophage infiltration, collagen degradation, thrombotic formation and resolution, and
neovascularization [460]. In contrast to the most common infrarenal aortic location of AAAs in
humans, AngII-induced AAAs in mice occur in the suprarenal aortic region. Another ubiquitous
feature of AngII-induced AAAs is the transmural medial break, leading to transmural thrombosis.
It is unclear whether transmural elastin rupture occurs in humans since pathological development
of AAAs in humans has not been exclusively studied due to lack of aneurysmal tissues from earlier
stages. AngII infusion into mice also leads to profound expansion of the thoracic aortic region,
that is predominantly restricted to the ascending aorta which is the most common region for TAAs
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in humans [461, 462]. Similar to AngII-induced AAAs, TAAs induced during AngII infusion also
recapitulate many features of human TAAs [463]. However, in contrast to AngII-induced AAAs,
AngII-induced TAAs are not associated with hypercholesterolemia and do not have gender
differences. The overall goal of subcutaneous AngII infusion into mice is to study pathological
features and molecular mechanisms of AAAs and TAAs.
In this Chapter, we first explored the use of multi-sequence high-field MRI to study the
development of TAA in the animal model with subcutaneous infusion of angiotensin II (AngII)
into mice. Then, we applied our recently developed protein-based collagen targeted MRI contrast
agent, ProCA32.collagen1 with collagen-targeting capability to identify presence of collagen in
the aneurysmal wall in aorta with molecular MRI.
Results
8.2.1 MRI procedure for cardiac gating
The fundamental challenges of cardiac MRI imaging is that movement of the heart
throughout the cardiac cycle and the movement of the lungs during the respiratory cycle produce
motion artifacts in the image. Respiratory motion can be alleviated with breath holding during
imaging. The problem of heart motion can be solved with the use of ECG gated imaging. ECG
gating allows for stop motion imaging by acquiring data only during a specified portion of the
cardiac cycle, typically during diastole when the heart is not moving. The R wave of the ECG is
used as a reference point with data acquisition being initiated following a given delay after the R
wave. Images are created from data collected over a series of cardiac cycles (R to R intervals) (Fig.
8.1 and 8.2) [464].
ECG electrodes are placed over the mouse’s chest right under the skin in both hands (Fig.
8.1) using either a three or four lead configuration. Lead are positioned such to accentuate the R
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wave and minimized the T wave. If the procedure is being used in humans, patients with a
prominent T wave often prove difficult to image as misgating can occur from triggering off the T
wave rather than the R wave. Artifacts also occur when there are differences in the length of the R
to R interval, such as occurs in cardiac dysrhythmias. ECG gating may be impaired in people with
a low ECG signal. A low ECG signal results from geometries that decrease signal to the ECG
leads, such as in barrel chested patients with COPD. Large pericardial effusion can also decrease
the ECG signal. A common gating artifact, known as the magnetohydrodynamic effect, occurs
when ions within the blood are transported through a magnetic field, inducing a voltage and
distorting the ECG recording. This artifact can often be overcome by vectorcardiogram gating
(VCG), which can distinguish electrical activity of the heart from ions in the blood. In cases where
ECG gating is unsuccessful, pulse triggering can be employed using a pulse oximeter with the
systolic upstroke as the trigger for the pulse sequence. This technique is not very successful in
patients with a delayed pulse upstroke relative to heart contraction [464].
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Figure 8.1 ECG gating procedure in mouse with TAA

Figure 8.2 Cardiac and respiratory gating diagrams and module in mouse with TAA

As it is observed in Fig. 8.2, there are two diagrams conducting the gating in 7.0 T MRI,
one indicating the ECG gating by monitoring the mouse beat per minute (BPM) number and the
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other one that is monitoring the mouse respiratory by breath per minute number. The MRI is signal
is collected in between these signals.
8.2.2 MRI pulse sequence
For MRI scan of heart, several pulse sequences were used. Black blood T1-weighted and
black blood proton density are one of the most common pulse sequences used for heart imaging
as they show blood vessels as dark images. In black blood T1-weighted, TR of 13.82 ms and TE
of 3.11 ms were used. For black blood proton density which has both T1 and T2 property, TR of
250 ms and TE of 7 ms were used. For both of the pulse sequences, a total of 7 slices were collected
with matrix size of 128×128, FOV= 35 mm with no gap.
Dark Blood MR is vascular imaging strategy wherein the signal from flowing blood is
suppressed (rendering it "black") rather than enhanced as it is in conventional Bright Blood MRI
techniques. Rapidly flowing or turbulent blood has a naturally low signal because of phasedispersion and time-of-flight signal losses. These effects may be further accentuated by application
of flow-spoiling gradients, saturation bands, and/or inversion pulses. The well-recognized vascular
"flow voids" seen on routine MR imaging represent a crude form of dark-blood MRI.
8.2.3 MRI images of mouse with TAA
After performing the ECG and respiratory gating and using the mentioned pulse sequences,
MRI images of TAA and control mice were collected before and 16 and 24 hours post injection of
ProCA32.collagen1. Several slices of MRI were collected focused on the aortic arch or thorax-I as
shown in Fig. 8.3. Figure 8.4 shows the whole field of view of MRI which has the aorta shown in
black hole at the center of the image (red circle).
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Figure 8.3 Graphic image of different sections of aorta

Figure 8.4 Black blood T1-weighted images of TAA mouse before and post injection of
ProCA32.collagen1.
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Figure 8.5 MRI images of black blood proton density-weighted of TAA-1 mouse before
and post injection of ProCA32.collagen1.
The black hole encircled in red in all images represent the aorta in the thorax region and the white
area surrounding the aorta shown by red arrows is collagen surrounding the wall of aorta.
Figure 8.5 shows the focused images on the aorta region before and 16 and 20 hrs post
injection of ProCA32.collagen1 in mouse with TAA in black blood proton density-weighted
images.

Figure 8.6 MRI images of black blood T1-weighted of TAA-1 mouse before and post
injection of ProCA32.collagen1.
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Figure 8.7 MRI images of black blood proton density-weighted of normal mouse before
and post injection of ProCA32.collagen1.

Figure 8.8 MRI images of black blood T1-weighted of normal mouse before and post
injection of ProCA32.collagen1.
As it is observed from the above figures, white regions surrounding the aorta is enhanced
20 hrs post injection of ProCA32.collagen1 which might be an indication of collagens surrounding
the aorta.
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Figure 8.9 MRI images of black blood proton density-weighted of TAA-2 mouse before
and post injection of ProCA32.collagen1.
As Fig. 8.9 demonstrates, clearly there is an enhancement in proton density MRI images
16 hrs post injection of ProCA32.collagen1 which is possibly due to presence of collagen outside
of aorta walls.

Figure 8.10 MRI images of black blood T1-weighted of TAA-2 mouse before and post
injection of ProCA32.collagen1.
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Figures 8.9 and 8.10 are showing black blood MRI images of another TAA mouse which
shows the areas of enhancement aroud16 hours post injection of ProCA32.collagen1. This might
be an indication of presence of collagen around the aorta walls.
8.2.4 Histology results of TAA and normal mice
After MRI data collection, the mice were sacrificed and whole aorta was collected as
shown in Fig. 8.11 and then they were sliced in paraffin embedded sections.

Figure 8.11 Aortic images (ex vivo) from mice infused with AngII (TAA) and normal mouse
(control). The area pointed with red arrow is where the MRI images where collected.
Trichrome Stains (Masson) was used to study the presence of collagen fibers in the aorta
walls. This procedure is intended for use in the study of connective tissue, muscle and collagen
fibers. Trichrome Stain reagents are for ‘‘In Vitro Diagnostic Use’’. Trichrome stains are used
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primarily for distinguishing collagen from muscle tissue. In general, they consist of nuclear,
collagenous and cytoplasmic dyes in mordants such as phosphotungstic or phosphomolybdic acid.
The procedure described here is using aniline blue as a collagen stain instead of a green dye. Tissue
sections are treated with Bouin’s solution to intensify the final coloration. Nuclei are stained with
Weigert’s iron hematoxylin, and cytoplasm and muscle are then stained with Beibrich scarlet-acid
fuchsin. After treatment with phosphotungstic and phosphomolybdic acid, collagen is
demonstrated by staining with aniline blue. Rinsing in acetic acid after staining renders the shades
of color more delicate and transparent.

Figure 8.12 Masson's trichrome stain of aorta in normal mouse.
In the slide, nuclei are shown in black, cytoplasm is shown in red, muscle fibers are shown in red
and collagen fibers are shown in blue.
Fig. 8.12 is showing the control mouse have some collagen fibers (blue) surrounding the
muscle of aorta. Masson's trichrome stain was also performed for two TAA mice. The results are
shown in Fig. 8.13 and 8.14.
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Figure 8.13 Masson's trichrome stain of aorta in TAA-1 mouse.

Figure 8.14 Masson's trichrome stain of aorta in TAA-2 mouse.

As shown in Fig. 8.14, the amount of collagen fibers is relatively higher compared to TAA1 mouse and control mouse which confirms the enhancement in Figures 8.9 and 8.10.
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Summary
In conclusion, ProCA32.collagen1 was used to image collagen fibers surrounding aorta
wall in both normal and two Ang II mice with TAA. Black blood T1-weighted and proton densityweighted MRI images were used to suppress the bright signal from the blood vessels to facilitate
the visualization of aorta and its surroundings. Based on literature, collagen should appear as a
bright signal in black blood pulse sequences. MRI images before and 16 and 20 hrs post injection
of ProCA32.collagen1 demonstrate signal enhancement post injection around the aorta wall.
Furthermore, based on histology analysis, TAA-2 mouse has more collagen fibers (blue) as shown
by Masson's trichrome stain. Therefore, it can be concluded that ProCA32.collagen1 is capable of
imaging collagen in mouse with thoracic aortic aneurism. It is worth mentioning that, TAA and
AAA models in a much later stage will have significant collagen expression and fibrosis which
will be used in our future studies.
9

APPLICATION OF PROCA32.COLLAGEN1 IN DETECTION OF
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Introduction
Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat is stored in
the liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes
fat to build up in the liver, this condition is called alcoholic liver disease. Two types of NAFLD
are simple fatty liver and nonalcoholic steatohepatitis (NASH). Simple fatty liver and NASH are
two separate conditions. People typically develop one type of NAFLD or the other, although
sometimes people with one form are later diagnosed with the other form of NAFLD.
Non-alcoholic fatty liver disease (NAFLD), defined as excess accumulation of fat in the
liver, has become the most common cause for chronic liver disease in the Western world and is
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estimated to impact at least 30% of Americans [465, 466] or Chinese [467] with the prevalence
appearing to rise in recent years [468, 469]. Non-alcoholic steatohepatitis (NASH) is a subset of
NAFLD, estimated to affect 2–5% of Americans, in which increased liver fat is accompanied by
cellular injury, inflammatory infiltrate and, subsequently, liver fibrosis, which can progress to
cirrhosis with it associated complications [470].
Nonalcoholic fatty liver disease is characterized by hepatic steatosis, without a history of
excessive alcohol use, in the absence of other known liver diseases [471-474]. Nonalcoholic fatty
liver disease is categorized into 2 subtypes: nonalcoholic fatty liver (NAFL), which is usually
nonprogressive, and NASH, which is often progressive and can lead to cirrhosis and HCC [475].
Nonalcoholic fatty liver and NASH have traditionally been considered 2 separate clinical entities,
rather than 2 points on a disease continuum [476]. Recent studies evaluating sequential liver
biopsies are challenging this notion [477] .A systematic review and meta-analysis of paired biopsy
studies found that both patients with NAFL and NASH have the potential to develop progressive
liver disease [478]. The fibrosis progression rate from stage 0 to stage 1 for NAFL vs NASH is 14
years vs 7 years, providing suggestive evidence that NAFL, NASH, and fibrosis progression are a
continuum rather than separate diagnoses [478].
Patients with NAFL and mild lobular inflammation, without ballooning, had an increased
risk of disease progression as compared with those without inflammation. Another retrospective
study evaluated serial liver biopsies in 108 patients and found no significant difference in the
proportion of fibrosis progression between patients with NAFL and those with NASH at index
biopsy (37% vs 43%; P=.65). Similarly, a recent study analyzing paired liver biopsies over time
found that even patients with bland steatosis can progress to NASH, especially in the setting of
metabolic risk factors [479].
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For reasons that are not completely clear, NAFLD is more common in men than women
and precise estimates of incidence rates for NAFLD are uncertain (because of difficulties with
establishing a precise diagnosis during sequential follow-up) current incidence rates are
approximately 20/10,000 person-years, peaking in the sixth decade of life. Current populationbased prevalence of NAFLD is approximately 30–40% in men and 15–20% in women and is even
higher in people with type 2 diabetes mellitus (T2DM), occurring in up to 70% of this group of
patients [480].
Establishing an accurate diagnosis of NASH is of major clinical importance. A histologic
diagnosis of NASH is associated with cardiovascular disease and more rapid progression of liver
disease. To accurately distinguish NASH from NAFL requires liver biopsy. Nonalcoholic fatty
liver is defined as bland steatosis with minimal or no inflammation, whereas NASH is
characterized by macrovesicular steatosis, ballooning, and mixed lobular inflammation with or
without zone 3 perisinusoidal fibrosis [481, 482].
Although fatty liver by itself is associated with other features of the metabolic syndrome
such as obesity, diabetes mellitus type 2, hypertension and dyslipidemia, increased liver-related
mortality is essentially limited to patients with NASH [483].
Increased triglyceride deposition in the liver reflects an input/output imbalance of hepatic
free fatty acid (FFA) metabolism. In obesity-associated NAFLD, there is an increase of FFA
delivery to the liver, especially during the fed state, due to adipose tissue insulin resistance [484,
485]. In addition, de novo lipogenesis is increased, [486] driven by the hyperinsulinemia as well
as excess availability of carbohydrates. Compensatory increase in very low-density lipoprotein
(VLDL) secretion is not sufficient to overcome the excess formation of triglycerides [487] while
it is unclear whether β-oxidation is increased or decreased in these subjects [488].
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The accumulated triglycerides in steatosis appear to be relatively inert with benign
outcome; hepatocellular injury is driven by lipotoxicity from FFAs and their derivatives, [489] as
well as overloading of mitochondrial capacity. This initial metabolic stress activates multiple cell
stress pathways, including generation of reactive oxygen species, endoplasmic reticulum stress
and apoptosis. Injury signals from stressed or dying hepatocytes, lipids and chemokines activate
an immune response, including recruitment and activation of variety of immune cells, further
increasing cellular injury. Key mediators are the Kupffer cells and macrophages, which are further
activated by bacterial products from the gut microbiome. Hepatocellular injury and immune cell
activity converge to activate hepatic stellate cells, causing a change in their phenotype and
deposition of collagen, resulting in increased fibrosis and hepatic architectural distortion.
Although the injury patterns are common and conserved, there is variability between
patients with NAFLD in the degree of activation of each individual pathway, likely accounting for
the heterogeneity of clinical phenotypes and severity. This may be secondary to different external
stimuli (ie, dietary composition), genetic components and modulation by the gut microbiome,
among other factors.
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Figure 9.1 Schematic representation of the putative mechanisms underlying the
contribution of NAFLD to the increased risk of cardiovascular and kidney chronic diseases.
Although there are no Food and Drug Administration-approved medications for NASH,
there are several medications that have shown benefits in clinical trials. Prompt diagnosis, timely
referrals, and effective treatments are necessary to improve the long-term outcomes of patients
with NAFLD and NASH in the setting of primary care and general gastroenterology
practices[490].
NAFLD affects a substantial proportion of the population worldwide. Only a minority of
subjects who have the condition develop liver-related complications. Predicting which patients
will develop progressive disease is problematic. Currently, there is no available noninvasive test
demonstrated to be simple, reproducible, and valid for disease staging in patients with NAFLD.
Liver biopsy remains the gold standard investigation to distinguish between patients with NASH
and those without NASH or bland steatosis, and to determine disease prognosis based on fibrosis
staging [491].
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Figure 9.2 Epidemiology of NAFLD.

In this chapter, our efforts in extending the application of ProCA32.collagen1 in early
detection of NASH will be discussed. Furthermore, liver cirrhosis induced by NASH diet has been
imaged with ProCA32.collagen1. Based on our results, we have demonstrated that
ProCA32.collagen1 can detect liver fibrosis even at a much earlier stage of nonalcoholic
steatohepatitis where liver has a mixture of steatosis and fibrosis. Based on histology analysis,
ProCA32.collagen1 can detect Ishak stage 1 of 6 or 1A Mild in NASH/CRN scoring systems.
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Results
9.2.1 NASH animal model
Two different groups of mice (n=4 in each group) on NASH diet were chosen for our
studies in detection of NASH in NAFLD mice. First group, they had a liver-specific Comparative
Gene Identification-58 (CGI-58) knocked out (LivKO) and second group were wild type (WT)
mice. Both groups were fed with a western diet (D12079B) and fructose in drinking water (42g/L)
starting from 6-week old. They were also fed with ASO with dose of 25g/kg per injection. IP
injection was done twice a week. Fructose in drinking water was autoclaved and changed twice a
week. They were on western diet all the time.
9.2.2 Analysis of LivKO group
ProCA32.collagen1 was injected through tail vein and MRI images of mouse livers of
LivKO group were collected before and 3 and 24 hrs post injection of the contrast agent. Then the
mice were sacrificed and their livers were collected and examined for histology analysis.

Figure 9.3 Liver images of four LivKO mice with severe NASH and fibrosis.

As it is seen from Fig. 9.3, livers are fatty and weights are much larger than normal livers.
The liver weights were ranging from 5.0-5.9 grams.
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9.2.3 MRI results of LivKO mice
Similar to our previous MRI experiments, several pulse sequences were used to image
LiveKO mice livers. Heavy T2-wrighted, T1 weighted, T1 map, and T2 map sequences were
collected for all four mice and quantitative analysis was performed on the liver signal. Figures 9.4
to 9.7 demonstrates the heavy T2-weighted MRI images of liver before and 3 and 24 hrs post
injection of ProCA32.collagen1.

Figure 9.4 Heavy T2-weighted MRI images of mouse 1 with significant fibrosis due to fatty
liver before and 3 and 24 hrs post injection of ProCA32.collagen1.
Regions shown in green, yellow and red are livers which show significant enhancement after
injection of the contrast agent.
MRI images are shown in both gray scale and color map to illustrate the amount of increase
in the liver after injection of ProCA32.collagen1. The regions in the border of the images are fat
that show a high intensity signal under MRI (red color).

247

Figure 9.5 Heavy T2-weighted MRI images of mouse 2 with significant fibrosis due to
fatty liver before and 3 and 24 hrs post injection of ProCA32.collagen1.

Figure 9.6 Heavy T2-weighted MRI images of mouse 3 with significant fibrosis due to
fatty liver before and 3 and 24 hrs post injection of ProCA32.collagen1.
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Figure 9.7 Heavy T2-weighted MRI images of mouse 4 with significant fibrosis due to
fatty liver before and 3, 19 and 24 hrs post injection of ProCA32.collagen1.

Figure 9.8 Contrast to noise ratio (CNR) analysis of fibrotic livers pre- and 3 and 24 hrs
post injection of ProCA32.collagen1.
A significant increase in CNR of livers was observed post injection of ProCA32.collagen1. The
value almost doubled after the injection (n=4, * P < 0.05, student’s t-test).
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9.2.4 Analysis of WT group
ProCA32.collagen1 was injected through tail vein and MRI images of mouse livers of WT
group were collected before and 3 and 24 hrs post injection of the contrast agent. Then the mice
were sacrificed and their livers were collected and examined for histology analysis.

Figure 9.9 Liver images of four WT mice with mild NASH and fibrosis.

As it is seen from Fig. 9.9, livers are fatty and weights are larger than normal livers. The
liver weights were ranging from 2.1-3.4 grams which are lighter than KO mice which is an
indication of milder NASH and fibrosis.
9.2.5 Comparison of heavy T2-weighted MRI results of WT and KO groups
In order to study the ability of ProCA32.collagen1 in distinguishing between different
stages of fatty liver, heavy T2-weighted MRI images of KO and WT mice were collected and
compared before and 3 and 24 hrs post injection of the contrast agent. Contrast to noise ratio (CNR)
analysis was also used to show the MRI signal enhancement different between livers after injection
of ProCA32.collagen1. The results can be observed in Fig 9.10. As it is observed, CNR of both
WT and KO mice increased 3 hrs post injection of the contrast agent, however, this increase is
much higher for KO mice which might be an indication of portal hypertension existence in this
group. In 24 hrs, the targeting ability of the contrast agent is visible as the KO mice with severe
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NASH and fibrosis have larger CNR compared to WT mice. Moreover, CNR of WT mice has
increased significantly compared to CNR at 3 hrs which confirms the targeting capability of
ProCA32.collagen1.

Figure 9.10 Heavy T2-weighted MRI images of WT and KO livers before and 3 and 24
hrs after injection of ProCA32.collagen1 along with CNR their corresponding CNR.
CNR of both WT and KO mice increased 3 hrs post injection of the contrast agent, however, this
increase is much higher for KO mice which might be an indication of portal hypertension existence
in this group. In 24 hrs, the targeting ability of the contrast agent is visible as the KO mice with
severe NASH and fibrosis have larger CNR compared to WT mice. Moreover, CNR of WT mice
has increased significantly compared to CNR at 3 hrs which confirms the targeting capability of
ProCA32.collagen1.
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9.2.6 Comparison of R1 map MRI results of WT and KO groups
Since ProCA32.collagen1 has both r1 and r2 properties, T1 map MRI images of mouse
livers from these two groups were also scanned to further confirm the results observed by heavy
T2-wighted images. Using MATLAB software, T1 map data were processed and analyzed (Fig.
9.11). Consistent with results in Chapter 5 where late stage liver cirrhosis (Ishak=5) and portal
hypertension was detected in TAA/alcohol-induced mice, R1 has significantly increased at 3 hrs
for KO group which has severe fatty liver. In addition, targeting process of ProCA32.collagen1
was observed in 24 hrs time point.

Figure 9.11 R1 map analysis of KO and WT Mice with fatty liver before and after
injection of ProCA32.collagen1.
R1 of both WT and KO mice increased 3 hrs post injection of the contrast agent, however, this
increase is much higher for KO mice which might be an indication of portal hypertension existence
in this group. In 24 hrs, the targeting ability of the contrast agent is visible as the KO mice with
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severe NASH and fibrosis have larger R1 compared to WT mice. Moreover, CNR of WT mice has
increased significantly compared to CNR at 3 hrs which confirms the targeting capability of
ProCA32.collagen1. Moreover, ∆R1 analysis shows the highest enhancement for KO mice at 3 hrs
and targeting at 24 hrs.
9.2.7 Histology results of NASH mice
After MRI analysis, detailed histology consisting of Sirius red stain for collagen and
hematoxylin and eosin (H&E) for fat cells were performed to confirm the stage of fatty liver for
these two groups. As the results demonstrate in Fig. 9.12 and 9.13, there is a distinctive difference
in liver structure among WT and KO groups showing the WT mice have mild fatty liver and KO
mice have sever fatty liver disease.

Figure 9.12 Sirius red staining collagen (red) of fatty mouse liver in KO and WT groups.
Collagen networks in red color can be observed for both KO and WT groups, however, in KO mice
much higher collagen levels can be observed which is an indication of the severity of fatty liver
compared to WT which has milder fatty liver.
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Figure 9.13 Hematoxylin and eosin (H&E) staining of fatty mouse liver in KO and WT
groups. Microvesicular steatosis can be observed in both images, however KO mice has much
higher degree of steatosis.
Summary
ProCA32.collagen1 has proved that it has the capacity to detect early stage fatty liver
disease and distinguish late stage from early stage NASH using both r1 and r2 property with high
confidence. Moreover, at 3 hrs time point, ProCA32.collagen1 is able to show the vascular
structural changes during late stage of NASH white at 24 hrs time point, the targeting capability
occurs. Both R1 map and CNR analysis exhibit the higher enhancement in KO group liver
compared to WT mice. Sirius red and H&E staining both confirmed the early stage of NASH in
WT mice and late stage of NASH in KO mice.
10 MAJOR FINDINGS AND FUTURE DIRECTION
To achieve “Precision Diagnostics” in molecular imaging of chronic liver and heart
diseases, first, we need to identify and validate biomarkers of early disease which may likely to be
different than those of late stage disease. Second, we need to develop new high throughput methods
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to develop imaging agents targeted to these new biomarkers. Third, we need to develop more
sensitive, high-resolution imaging technologies that can multiplex signals.
Monitoring different disease biomarkers in patients with invasive methods such as biopsy
has so many disadvantages such as its invasiveness, high costs and sampling error,
intra/interobserver variability, hospitalization in 1–5% of cases, mortality in 0.01–0.1% of cases,
lack of accuracy due to substantial sampling error, cost associated morbidity, pain and bruising at
the biopsy site, prolonged bleeding, infection of the biopsy site, and pneumothorax and
hemothorax. For instance, there is a 33% error in diagnosis of liver cirrhosis which severely affect
the patient outcomes. With its unique capacity to generate reproducible and non-invasive
assessment of biological/disease processes of different organs at various time points, molecular
imaging of disease biomarkers using MRI can be an important and ideal diagnostic tool to facilitate
the understanding of the disease, monitoring disease progression and drug treatment and activity
during preclinical and clinical application. However, one of the major limitations of MRI is lack
of sensitive contrast agents with targeting capability.
Disease biomarkers, are important indicators of disease formation and progression. Disease
biomarkers have been extensively applied in the disease diagnosis for the identification of disease,
prediction of disease progression and follow the effects of drug treatment. Image and quantify
these biomarkers provides valuable information for the disease evaluation and treatment. Although
huge progress has been made during the past few decades, immunohistochemistry after biopsy is
still the major approach to evaluate biomarkers. Unfortunately, biopsy is an invasive technique;
patient suffers huge pain during this process. Moreover, only limited samples can be collected by
biopsy which could easily lead to false positive and false negative results. Therefore, non-invasive
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imaging techniques, which enables image the biomarker in the whole disease tissue, are in urgent
need for the disease diagnosis, especially cancer diagnosis and evaluation.
Collagen type I is an appealing target for molecular imaging of a variety of diseases such
as liver fibrosis, liver metastasis, breast cancer, pancreatic cancer and aortic aneurysms. In organ
fibrosis and different cancers, collagen accumulation as well as its concentration increases by the
disease progression. In addition, collagen type I is an extracellular protein which makes it
accessible for any agent. Collagen type I meets the criteria for an ideal biomarker since its
concentration can increase with disease progression to provide a quantitative level for disease stage
(Early vs Late). In addition, its extracellular location can make it readily accessible by the probe.
Collagen has different patterns which can reflect the disease cause and stage as well as providing
information on the disease microenvironment to reflect the mechanism. Collagen type I is also
responsive to treatment (Monitoring treatment) and it is specific in determining the disease state.
In order to address major barriers in the field of clinical diagnostics, we have developed a
collagen type I-targeted MR contrast agent, ProCA32.collagen1 to act as an agent to image chronic
heart and liver diseases. We have successfully applied the contrast agent in a variety of mouse
models with liver and heart disease.
As discussed in Chapter 1, there is pressing need to develop more sensitive imaging agents
for early diagnosis of different chronic liver and heart diseases. We have shown in Chapter 4 that
ProCA32.collagen1 has improved sensitivity and targeting capability and superior biophysical
characteristics compared to other previously developed contrast agents in our lab and clinically
available contrast agents.
The contrast agent has very high relaxivity at both 1.4 T (clinical magnetic field) and 7.0
T compared to all clinically used contrast agents and majority of research-based agents. It has very
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good Gd3+ binding affinity as well as high selectivity in the presence of other physiological metal
ions such as Ca2+ and Zn2+. ProCA32.collagen1 has shown no signs of toxicity and has improved
safety properties. It is very stable in serum and has strong resistance against transmetallation.
ProCA32.collagen1 has low injection dosage given its high relaxivity as well as good collagen
type I binding affinity, the highest reported for a collagen-targeted MRI contrast agent (Figure
10.1). ProCA32.collagen1 has better collagen I affinity compared to EP-3533 (Kd = 1.4 µM) which
is a research-based contrast agent based three Magnevists.

Figure 10.1 Collagen type I binding affinity comparison between ProCA32.collagen1
and EP3533.
In Chapter 5 and 9, we have successfully applied ProCA32.collagen1 in early detection of
alcohol induced mouse liver fibrosis and nonalcoholic steatohepatitis using both r1 and r2 property.
ProCA32.collagen1 enables the first robust detection of early stage (Ishak stage 3 of 6) liver
fibrosis and nonalcoholic steatohepatitis (Ishak stage 1 of 6 or 1A Mild) in animal models via dual
contrast modes. ProCA32.collagen1 also provides the first non-invasive mapping of intrahepatic
angiogenesis associated with vascular distortion during late-stage cirrhosis and heterogeneity via
dynamic molecular imaging (DMI).
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Figure 10.2 Animal Models of Liver Fibrosis.

In Chapter 6, ProCA32.collagen1 was successfully used for early detection of human uveal
melanoma tumors metastasis to mouse liver. ProCA32.collagen1 can detect UM tumors in liver in
both implanted and metastatic mouse models. ProCA32.collagen1 can demonstrate tumor
heterogeneity in metastatic model with 14-fold increase in contrast to nose ratio and has improved
sensitivity compared to non-targeted agent (ProCA32-P40) and Eovist which could not detect any
tumors. The contrast agent is able to show both UM patterns in liver (Nodular and Infiltrative).
Based on MRI correlation with histology analysis, ProCA32.collagen1 is capable of detecting
tumors as small as 0.250 mm2 which is much smaller than not only the current detection limit of
10–20 mm but also tumors previously detected by ProCA32-P40. The dynamic range in detection
was significantly improved with a 6-fold enhancement in the relative contrast for the implanted
liver uveal melanoma tumor in mouse taken advantage of both relaxation property and imaging
methodology
In Chapter 7, we have used ProCA32.collagen1 in detection of hepatocellular carcinoma
(HCC) in liver in DEN-induced mouse model. ProCA32.collagen1 has shown promising results in
distinguishing cirrhotic regions in liver from HCC tumors, and finally, in Chapter 8, we have
described our attempt in extending the application of ProCA32.collagen1 in imaging collagen in

258

mouse model of thoracic and abdominal aortic aneurysm (TAA/AAA) with subcutaneous infusion
of angiotensin II (AngII) from implanted osmotic pump.

Figure 10.3 Summary of application of ProCA32.collagen1in diagnosis of chronic diseases.
Overall, by developing ProCA32.collagen1, we have tried to address several challenges in
clinical diagnostics field and facilitate precision diagnostics. We have addressed early diagnosis
to facilitate treatment or reversal of the disease. We have successfully imaged disease
heterogeneity by monitoring spatial and temporal changes of biomarker (Collagen) to facilitate
biopsy. We were also able to monitor drug treatment in liver fibrosis. The development of collagen
targeting contrast agent is expected to have broad applications in detection and staging of various
chronic diseases and probing heterogeneous microenvironment changes upon disease progression
and treatment in different organs. This work will have broad applications in early diagnosis of
chronic diseases as shown in Figure 10.2.

259

REFERENCES

1.

Kirchin, M.A. and V.M. Runge, Contrast agents for magnetic resonance imaging: safety
update. Top Magn Reson Imaging, 2003. 14(5): p. 426-35.

2.

Cheng, L.L., et al., Correlation of high-resolution magic angle spinning proton magnetic
resonance spectroscopy with histopathology of intact human brain tumor specimens.
Cancer Res, 1998. 58(9): p. 1825-32.

3.

Jones, R.A., et al., Magnetic resonance imaging evaluation of renal structure and
function related to disease: technical review of image acquisition, postprocessing, and
mathematical modeling steps. J Magn Reson Imaging, 2011. 33(6): p. 1270-83.

4.

Wang, Z., M.Y. Su, and O. Nalcioglu, Applications of dynamic contrast enhanced MRI in
oncology: measurement of tumor oxygen tension. Technol Cancer Res Treat, 2002. 1(1):
p. 29-38.

5.

Meade, T.J., A.K. Taylor, and S.R. Bull, New magnetic resonance contrast agents as
biochemical reporters. Curr Opin Neurobiol, 2003. 13(5): p. 597-602.

6.

Caravan, P., Strategies for increasing the sensitivity of gadolinium based MRI contrast
agents. Chem Soc Rev, 2006. 35(6): p. 512-23.

7.

Major, J.L. and T.J. Meade, Bioresponsive, cell-penetrating, and multimeric MR contrast
agents. Acc Chem Res, 2009. 42(7): p. 893-903.

8.

Weinmann, H.J., et al., Tissue-specific MR contrast agents. Eur J Radiol, 2003. 46(1): p.
33-44.

9.

Kirsch, J.E., Basic principles of magnetic resonance contrast agents. Top Magn Reson
Imaging, 1991. 3(2): p. 1-18.

260

10.

Wolf, G.L. and J.T. Halavaara, Basic principles of MR contrast agents. Magn Reson
Imaging Clin N Am, 1996. 4(1): p. 1-10.

11.

Aime, S. and P. Caravan, Biodistribution of gadolinium-based contrast agents, including
gadolinium deposition. J Magn Reson Imaging, 2009. 30(6): p. 1259-67.

12.

Nonat, A., et al., Gadolinium(III) complexes of 1,4,7-triazacyclononane based picolinate
ligands: simultaneous optimization of water exchange kinetics and electronic relaxation.
Dalton Trans, 2009(38): p. 8033-46.

13.

Robinson, P.J., Imaging liver metastases: current limitations and future prospects. Br J
Radiol, 2000. 73(867): p. 234-41.

14.

Afdhal, N.H. and D. Nunes, Evaluation of liver fibrosis: a concise review. Am J
Gastroenterol, 2004. 99(6): p. 1160-74.

15.

Weiss, C.R., S.G. Nour, and J.S. Lewin, MR-guided biopsy: a review of current
techniques and applications. J Magn Reson Imaging, 2008. 27(2): p. 311-25.

16.

Joffe, P., H.S. Thomsen, and M. Meusel, Pharmacokinetics of gadodiamide injection in
patients with severe renal insufficiency and patients undergoing hemodialysis or
continuous ambulatory peritoneal dialysis. Acad Radiol, 1998. 5(7): p. 491-502.

17.

Koenig, S.H. and K.E. Kellar, Blood-pool contrast agents for MRI: a critical evaluation.
Acad Radiol, 1998. 5 Suppl 1: p. S200-5; discussion S226-7.

18.

Watrin-Pinzano, A., et al., Quantitative dynamic contrast enhanced MRI of experimental
synovitis in the rabbit knee: comparison of macromolecular blood pool agents vs.
Gadolinium-DOTA. Biomed Mater Eng, 2008. 18(4-5): p. 261-72.

261

19.

Wedeking, P., et al., Quantitative dependence of MR signal intensity on tissue
concentration of Gd(HP-DO3A) in the nephrectomized rat. Magn Reson Imaging, 1992.
10(1): p. 97-108.

20.

Sadowski, E.A., et al., Nephrogenic systemic fibrosis: risk factors and incidence
estimation. Radiology, 2007. 243(1): p. 148-57.

21.

Gibby, W.A., K.A. Gibby, and W.A. Gibby, Comparison of Gd DTPA-BMA (Omniscan)
versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled
plasma atomic emission spectroscopy. Invest Radiol, 2004. 39(3): p. 138-42.

22.

Thomsen, H.S., S.K. Morcos, and P. Dawson, Is there a causal relation between the
administration of gadolinium based contrast media and the development of nephrogenic
systemic fibrosis (NSF)? Clin Radiol, 2006. 61(11): p. 905-6.

23.

Prince, M.R., et al., Nephrogenic systemic fibrosis and its impact on abdominal imaging.
Radiographics, 2009. 29(6): p. 1565-74.

24.

Villaraza, A.J., A. Bumb, and M.W. Brechbiel, Macromolecules, dendrimers, and
nanomaterials in magnetic resonance imaging: the interplay between size, function, and
pharmacokinetics. Chem Rev, 2010. 110(5): p. 2921-59.

25.

Laurent, S., L.V. Elst, and R.N. Muller, Comparative study of the physicochemical
properties of six clinical low molecular weight gadolinium contrast agents. Contrast
Media Mol Imaging, 2006. 1(3): p. 128-37.

26.

Bellin, M.F., MR contrast agents, the old and the new. Eur J Radiol, 2006. 60(3): p. 31423.

262

27.

Cacheris, W.P., S.C. Quay, and S.M. Rocklage, The relationship between
thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging, 1990.
8(4): p. 467-81.

28.

Tweedle, M.F., P. Wedeking, and K. Kumar, Biodistribution of radiolabeled, formulated
gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol,
1995. 30(6): p. 372-80.

29.

Lauffer, R.B., et al., MS-325: albumin-targeted contrast agent for MR angiography.
Radiology, 1998. 207(2): p. 529-38.

30.

Caravan, P., Protein-targeted gadolinium-based magnetic resonance imaging (MRI)
contrast agents: design and mechanism of action. Acc Chem Res, 2009. 42(7): p. 851-62.

31.

Choi, H.S., et al., Renal clearance of quantum dots. Nat Biotechnol, 2007. 25(10): p.
1165-70.

32.

Goel, A., et al., Genetically engineered tetravalent single-chain Fv of the pancarcinoma
monoclonal antibody CC49: improved biodistribution and potential for therapeutic
application. Cancer Res, 2000. 60(24): p. 6964-71.

33.

Olmsted, S.S., et al., Diffusion of macromolecules and virus-like particles in human
cervical mucus. Biophys J, 2001. 81(4): p. 1930-7.

34.

Lund, U., et al., Glomerular filtration rate dependence of sieving of albumin and some
neutral proteins in rat kidneys. Am J Physiol Renal Physiol, 2003. 284(6): p. F1226-34.

35.

Wedeking, P., K. Kumar, and M.F. Tweedle, Dissociation of gadolinium chelates in
mice: relationship to chemical characteristics. Magn Reson Imaging, 1992. 10(4): p.
641-8.

263

36.

Rohrer, M., et al., Comparison of magnetic properties of MRI contrast media solutions at
different magnetic field strengths. Invest Radiol, 2005. 40(11): p. 715-24.

37.

Powell, D.H. and M.D. Hiatt, Auditory and visual recall of forward and backward digit
spans. Percept Mot Skills, 1996. 82(3 Pt 2): p. 1099-103.

38.

Casali, C., et al., Evaluation of Gd-DOTA-labeled dextran polymer as an intravascular
MR contrast agent for myocardial perfusion. Acad Radiol, 1998. 5 Suppl 1: p. S214-8.

39.

Port, M., et al., Physicochemical and biological evaluation of P792, a rapid-clearance
blood-pool agent for magnetic resonance imaging. Invest Radiol, 2001. 36(8): p. 445-54.

40.

Port, M., et al., P792: a rapid clearance blood pool agent for magnetic resonance
imaging: preliminary results. MAGMA, 2001. 12(2-3): p. 121-7.

41.

Fulton, D.A., et al., Efficient relaxivity enhancement in dendritic gadolinium complexes:
effective motional coupling in medium molecular weight conjugates. Chem Commun
(Camb), 2005(4): p. 474-6.

42.

Ranganathan, R.S., et al., Polymethylated DOTA ligands. 1. Synthesis of rigidified
ligands and studies on the effects of alkyl substitution on acid-base properties and
conformational mobility. Inorg Chem, 2002. 41(25): p. 6846-55.

43.

Ranganathan, R.S., et al., Polymethylated DOTA ligands. 2. Synthesis of rigidified
lanthanide chelates and studies on the effect of alkyl substitution on conformational
mobility and relaxivity. Inorg Chem, 2002. 41(25): p. 6856-66.

44.

Zech, S.G., et al., Probing the water coordination of protein-targeted MRI contrast
agents by pulsed ENDOR spectroscopy. Chemphyschem, 2005. 6(12): p. 2570-7.

264

45.

Francesconi, L.C., et al., Technetium-99m N,N'-bis(2-mercapto-2-methylpropyl)-2aminobenzylamine: technetium-99m complexes of a novel bis(aminoethanethiol) ligand. J
Med Chem, 1994. 37(20): p. 3282-8.

46.

Raymond, K.N. and V.C. Pierre, Next generation, high relaxivity gadolinium MRI agents.
Bioconjug Chem, 2005. 16(1): p. 3-8.

47.

Caravan, P., et al., Gadolinium(III) Chelates as MRI Contrast Agents: Structure,
Dynamics, and Applications. Chem Rev, 1999. 99(9): p. 2293-352.

48.

Toth, E., Helm, L., Merbach, A. E. , Relaxivity of gadolinium(III) complexes: theory and
mechanism. 2001: New York.

49.

Vincent-Viry, M., et al., Lack of a genetic polymorphism in the glucuronidation of
fenofibric acid. Pharmacogenetics, 1995. 5(1): p. 50-2.

50.

Troughton, J.S., et al., Synthesis and evaluation of a high relaxivity manganese(II)-based
MRI contrast agent. Inorg Chem, 2004. 43(20): p. 6313-23.

51.

Zhou, X., et al., On the philosophy of optimizing contrast agents. An analysis of 1H
NMRD profiles and ESR lineshapes of the Gd(III)complex MS-325+HSA. J Magn Reson,
2004. 167(1): p. 147-60.

52.

Shoup, D. and A. Szabo, Role of diffusion in ligand binding to macromolecules and cellbound receptors. Biophys J, 1982. 40(1): p. 33-9.

53.

Astashkin, A.V., et al., Pulsed EPR investigations of systems modeling molybdenum
enzymes: hyperfine and quadrupole parameters of oxo-17O in [Mo 17O(SPh)4]. J Am
Chem Soc, 2005. 127(47): p. 16713-22.

54.

Nicolle, G.M., et al., The impact of rigidity and water exchange on the relaxivity of a
dendritic MRI contrast agent. Chemistry, 2002. 8(5): p. 1040-8.

265

55.

Sherry, A.D. and Y. Wu, The importance of water exchange rates in the design of
responsive agents for MRI. Curr Opin Chem Biol, 2013. 17(2): p. 167-74.

56.

Bonnet, C.S., et al., Outer-sphere investigation of MRI relaxation contrast agents.
Example of a cyclodecapeptide gadolinium complex with second-sphere water. J Phys
Chem B, 2010. 114(26): p. 8770-81.

57.

Jacques, V., et al., High-relaxivity magnetic resonance imaging contrast agents. Part 2.
Optimization of inner- and second-sphere relaxivity. Invest Radiol, 2010. 45(10): p. 61324.

58.

Aime, S., et al., Ternary Gd(III)L-HSA adducts: evidence for the replacement of innersphere water molecules by coordinating groups of the protein. Implications for the design
of contrast agents for MRI. J Biol Inorg Chem, 2000. 5(4): p. 488-97.

59.

Caravan, P., et al., Influence of molecular parameters and increasing magnetic field
strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. Contrast
Media Mol Imaging, 2009. 4(2): p. 89-100.

60.

Lohrke, J., et al., 25 Years of Contrast-Enhanced MRI: Developments, Current
Challenges and Future Perspectives. Adv Ther, 2016. 33(1): p. 1-28.

61.

Cheng, Z., D.L. Thorek, and A. Tsourkas, Gadolinium-conjugated dendrimer
nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew
Chem Int Ed Engl, 2010. 49(2): p. 346-50.

62.

Gianolio, E., et al., Relaxometric investigations and MRI evaluation of a liposome-loaded
pH-responsive gadolinium(III) complex. Inorg Chem, 2012. 51(13): p. 7210-7.

63.

Flacke, S., et al., Novel MRI contrast agent for molecular imaging of fibrin: implications
for detecting vulnerable plaques. Circulation, 2001. 104(11): p. 1280-5.

266

64.

Datta, A., et al., High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates:
nanosized MRI contrast agents. J Am Chem Soc, 2008. 130(8): p. 2546-52.

65.

Richard, C., et al., Noncovalent functionalization of carbon nanotubes with amphiphilic
gd3+ chelates: toward powerful t1 and t2 MRI contrast agents. Nano Lett, 2008. 8(1): p.
232-6.

66.

Caravan, P., et al., Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI
contrast agents. Chem Commun (Camb), 2003(20): p. 2574-5.

67.

Lauffer, R.B. and T.J. Brady, Preparation and water relaxation properties of proteins
labeled with paramagnetic metal chelates. Magn Reson Imaging, 1985. 3(1): p. 11-6.

68.

Wikstrom, M.G., et al., Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and
a macromolecular agent. Invest Radiol, 1989. 24(8): p. 609-15.

69.

Brasch, R., et al., Assessing tumor angiogenesis using macromolecular MR imaging
contrast media. J Magn Reson Imaging, 1997. 7(1): p. 68-74.

70.

Karfeld-Sulzer, L.S., et al., Multivalent protein polymer MRI contrast agents: controlling
relaxivity via modulation of amino acid sequence. Biomacromolecules, 2010. 11(6): p.
1429-36.

71.

Matsumoto, Y. and A. Jasanoff, Metalloprotein-based MRI probes. FEBS Lett, 2013.
587(8): p. 1021-9.

72.

Chen, Y., et al., Role of calcium in metalloenzymes: effects of calcium removal on the
axial ligation geometry and magnetic properties of the catalytic diheme center in MauG.
Biochemistry, 2012. 51(8): p. 1586-97.

73.

Shapiro, M.G., et al., Directed evolution of a magnetic resonance imaging contrast agent
for noninvasive imaging of dopamine. Nat Biotechnol, 2010. 28(3): p. 264-70.

267

74.

Qiao, J., et al., Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI
contrast agents. J Biol Inorg Chem, 2014. 19(2): p. 259-70.

75.

Sana, B., C.L. Poh, and S. Lim, A manganese-ferritin nanocomposite as an ultrasensitive
T2 contrast agent. Chem Commun (Camb), 2012. 48(6): p. 862-4.

76.

Sana, B., et al., Iron-based ferritin nanocore as a contrast agent. Biointerphases, 2010.
5(3): p. FA48-52.

77.

Bar-Shir, A., et al., Human protamine-1 as an MRI reporter gene based on chemical
exchange. ACS Chem Biol, 2014. 9(1): p. 134-8.

78.

Xue, S., et al., Design of a novel class of protein-based magnetic resonance imaging
contrast agents for the molecular imaging of cancer biomarkers. Wiley Interdiscip Rev
Nanomed Nanobiotechnol, 2013. 5(2): p. 163-79.

79.

Yang, J.J., et al., Rational design of protein-based MRI contrast agents. J Am Chem Soc,
2008. 130(29): p. 9260-7.

80.

Qiao, J., et al., HER2 targeted molecular MR imaging using a de novo designed protein
contrast agent. PLoS One, 2011. 6(3): p. e18103.

81.

Pasut, G. and F.M. Veronese, PEGylation for improving the effectiveness of therapeutic
biomolecules. Drugs Today (Barc), 2009. 45(9): p. 687-95.

82.

Pasut, G. and F.M. Veronese, PEG conjugates in clinical development or use as
anticancer agents: an overview. Adv Drug Deliv Rev, 2009. 61(13): p. 1177-88.

83.

Xue, S., et al., Protein MRI contrast agent with unprecedented metal selectivity and
sensitivity for liver cancer imaging. Proc Natl Acad Sci U S A, 2015. 112(21): p. 660712.

268

84.

Li, S., et al., PEGylation of protein-based MRI contrast agents improves relaxivities and
biocompatibilities. J Inorg Biochem, 2012. 107(1): p. 111-8.

85.

Pidcock, E. and G.R. Moore, Structural characteristics of protein binding sites for
calcium and lanthanide ions. J Biol Inorg Chem, 2001. 6(5-6): p. 479-89.

86.

Yang, W., et al., The effects of Ca2+ binding on the dynamic properties of a designed
Ca2+-binding protein. Biochemistry, 2005. 44(23): p. 8267-73.

87.

Yang, W., et al., Design of a calcium-binding protein with desired structure in a cell
adhesion molecule. J Am Chem Soc, 2005. 127(7): p. 2085-93.

88.

Moats, R.A., Fraser, S.E., Meade, T.J., A “smart” magnetic resonance imaging agent
that reports on specific enzymatic activity. Angew Chem Int Edit, 1997. 37(7): p. 726–
728.

89.

Louie, A.Y., et al., In vivo visualization of gene expression using magnetic resonance
imaging. Nat Biotechnol, 2000. 18(3): p. 321-5.

90.

Caravan, P., et al., The Gd(3+) complex of a fatty acid analogue of DOTP binds to
multiple albumin sites with variable water relaxivities. Inorg Chem, 2001. 40(26): p.
6580-7.

91.

Vander Elst, L., et al., Stereospecific binding of MRI contrast agents to human serum
albumin: the case of Gd-(S)-EOB-DTPA (Eovist) and its (R) isomer. J Biol Inorg Chem,
2001. 6(2): p. 196-200.

92.

Esqueda, A.C., et al., A new gadolinium-based MRI zinc sensor. J Am Chem Soc, 2009.
131(32): p. 11387-91.

93.

Zhang, Z., et al., Multilocus binding increases the relaxivity of protein-bound MRI
contrast agents. Angew Chem Int Ed Engl, 2005. 44(41): p. 6766-9.

269

94.

Thompson, M.K., et al., Hetero-tripodal hydroxypyridonate gadolinium complexes:
syntheses, relaxometric properties, water exchange dynamics, and human serum albumin
binding. Inorg Chem, 2004. 43(26): p. 8577-86.

95.

Werner, E.J., et al., Highly soluble tris-hydroxypyridonate Gd(III) complexes with
increased hydration number, fast water exchange, slow electronic relaxation, and high
relaxivity. J Am Chem Soc, 2007. 129(7): p. 1870-1.

96.

Foster, T.E., et al., Platelet-rich plasma: from basic science to clinical applications. Am J
Sports Med, 2009. 37(11): p. 2259-72.

97.

Ohgushi, H., [Basic science and clinical applications of mesenchymal stem cells].
Seikagaku, 2009. 81(2): p. 99-104.

98.

Wilkins, A.L., et al., Metal-binding studies for a de novo designed calcium-binding
protein. Protein Eng, 2002. 15(7): p. 571-4.

99.

Yang, W., et al., Structural analysis, identification, and design of calcium-binding sites in
proteins. Proteins, 2002. 47(3): p. 344-56.

100.

Dudev, T., et al., First-second shell interactions in metal binding sites in proteins: a PDB
survey and DFT/CDM calculations. J Am Chem Soc, 2003. 125(10): p. 3168-80.

101.

Wang, X., et al., Analysis and prediction of calcium-binding pockets from apo-protein
structures exhibiting calcium-induced localized conformational changes. Protein Sci,
2010. 19(6): p. 1180-90.

102.

Wang, X., et al., Towards predicting Ca2+-binding sites with different coordination
numbers in proteins with atomic resolution. Proteins, 2009. 75(4): p. 787-98.

270

103.

Kirberger, M. and J.J. Yang, Structural differences between Pb2+- and Ca2+-binding
sites in proteins: implications with respect to toxicity. J Inorg Biochem, 2008. 102(10): p.
1901-9.

104.

Kirberger, M., et al., Statistical analysis of structural characteristics of protein Ca2+binding sites. J Biol Inorg Chem, 2008. 13(7): p. 1169-81.

105.

Deng, H., et al., Predicting calcium-binding sites in proteins - a graph theory and
geometry approach. Proteins, 2006. 64(1): p. 34-42.

106.

Carroll, A., et al., Amyloid fibril formation by a domain of rat cell adhesion molecule.
Cell Biochem Biophys, 2006. 44(2): p. 241-9.

107.

Gore, J.C., et al., Magnetic resonance in the era of molecular imaging of cancer. Magn
Reson Imaging, 2011. 29(5): p. 587-600.

108.

Zhu, W., et al., PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu
receptors by a three-step pretargeting approach. Magn Reson Med, 2008. 59(4): p. 67985.

109.

Caravan, P., et al., Collagen-targeted MRI contrast agent for molecular imaging of
fibrosis. Angew Chem Int Ed Engl, 2007. 46(43): p. 8171-3.

110.

Polasek, M., et al., Molecular MR imaging of liver fibrosis: a feasibility study using rat
and mouse models. J Hepatol, 2012. 57(3): p. 549-55.

111.

Spuentrup, E., et al., Molecular magnetic resonance imaging of myocardial perfusion
with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine
model. Circulation, 2009. 119(13): p. 1768-75.

271

112.

Burtea, C., et al., Magnetic resonance molecular imaging of vascular cell adhesion
molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic
imaging probe. J Med Chem, 2009. 52(15): p. 4725-42.

113.

De Leon-Rodriguez, L.M., et al., MRI detection of VEGFR2 in vivo using a low
molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc, 2010. 132(37):
p. 12829-31.

114.

Schmieder, A.H., et al., Molecular MR imaging of melanoma angiogenesis with
alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med, 2005. 53(3): p.
621-7.

115.

Winter, P.M., et al., Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors
using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance
imaging. Cancer Res, 2003. 63(18): p. 5838-43.

116.

Winter, P.M., et al., Molecular imaging of angiogenesis in early-stage atherosclerosis
with alpha(v)beta3-integrin-targeted nanoparticles. Circulation, 2003. 108(18): p. 22704.

117.

Ouimet, T., et al., Molecular and cellular targets of the MRI contrast agent P947 for
atherosclerosis imaging. Mol Pharm, 2012. 9(4): p. 850-61.

118.

Boles, K.S., et al., MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted
nanoparticles in a B16/F10 mouse melanoma model. FASEB J, 2010. 24(11): p. 4262-70.

119.

Artemov, D., et al., Magnetic resonance molecular imaging of the HER-2/neu receptor.
Cancer Res, 2003. 63(11): p. 2723-7.

120.

Caravan, P., et al., A lysine walk to high relaxivity collagen-targeted MRI contrast
agents. Chem Commun (Camb), 2009(4): p. 430-2.

272

121.

Farrar, C.T., et al., 3D molecular MR imaging of liver fibrosis and response to rapamycin
therapy in a bile duct ligation rat model. J Hepatol, 2015. 63(3): p. 689-96.

122.

Caravan, P., et al., Molecular magnetic resonance imaging of pulmonary fibrosis in mice.
Am J Respir Cell Mol Biol, 2013. 49(6): p. 1120-6.

123.

Zhang, Y.; Available from: https://zhanglab.ccmb.med.umich.edu/I-TASSER/.

124.

Huebsch, N. and D.J. Mooney, Inspiration and application in the evolution of
biomaterials. Nature, 2009. 462(7272): p. 426-32.

125.

Azzarito, V., et al., Inhibition of alpha-helix-mediated protein-protein interactions using
designed molecules. Nat Chem, 2013. 5(3): p. 161-73.

126.

Little, L.E., et al., Exploiting bacterial peptide display technology to engineer
biomaterials for neural stem cell culture. Biomaterials, 2011. 32(6): p. 1484-94.

127.

Tashiro, K., et al., A synthetic peptide containing the IKVAV sequence from the A chain
of laminin mediates cell attachment, migration, and neurite outgrowth. J Biol Chem,
1989. 264(27): p. 16174-82.

128.

Neffe, A.T. and B. Meyer, A peptidomimetic HIV-entry inhibitor directed against the
CD4 binding site of the viral glycoprotein gp120. Angew Chem Int Ed Engl, 2004.
43(22): p. 2937-40.

129.

Collier, J.H. and T. Segura, Evolving the use of peptides as components of biomaterials.
Biomaterials, 2011. 32(18): p. 4198-204.

130.

DeForest, C.A., B.D. Polizzotti, and K.S. Anseth, Sequential click reactions for
synthesizing and patterning three-dimensional cell microenvironments. Nat Mater, 2009.
8(8): p. 659-64.

273

131.

Ouasti, S., et al., Network connectivity, mechanical properties and cell adhesion for
hyaluronic acid/PEG hydrogels. Biomaterials, 2011. 32(27): p. 6456-70.

132.

Ouasti, S., et al., The CD44/integrins interplay and the significance of receptor binding
and re-presentation in the uptake of RGD-functionalized hyaluronic acid. Biomaterials,
2012. 33(4): p. 1120-34.

133.

Zaki, N.M., A. Nasti, and N. Tirelli, Nanocarriers for cytoplasmic delivery: cellular
uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan
nanoparticles in a phagocytic cell model. Macromol Biosci, 2011. 11(12): p. 1747-60.

134.

Zaki, N.M. and N. Tirelli, Assessment of nanomaterials cytotoxicity and internalization.
Methods Mol Biol, 2011. 695: p. 243-59.

135.

Federico, S., et al., Design of Decorin-Based Peptides That Bind to Collagen I and their
Potential as Adhesion Moieties in Biomaterials. Angew Chem Int Ed Engl, 2015. 54(37):
p. 10980-4.

136.

Krishnan, A.S., et al., Detection of cell death in tumors by using MR imaging and a
gadolinium-based targeted contrast agent. Radiology, 2008. 246(3): p. 854-62.

137.

Erdogan, S., et al., Enhanced tumor MR imaging with gadolinium-loaded polychelating
polymer-containing tumor-targeted liposomes. J Magn Reson Imaging, 2008. 27(3): p.
574-80.

138.

Amirbekian, V., et al., Detecting and assessing macrophages in vivo to evaluate
atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A, 2007.
104(3): p. 961-6.

274

139.

Vaccaro, M., et al., Structural and relaxometric characterization of peptide aggregates
containing gadolinium complexes as potential selective contrast agents in MRI.
Chemphyschem, 2007. 8(17): p. 2526-38.

140.

Kandimalla, K.K., et al., Pharmacokinetics and amyloid plaque targeting ability of a
novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's
disease transgenic mice. J Pharmacol Exp Ther, 2007. 322(2): p. 541-9.

141.

De Leon-Rodriguez, L.M., et al., Solid-phase synthesis of DOTA-peptides. Chemistry,
2004. 10(5): p. 1149-55.

142.

De Leon-Rodriguez, L.M., et al., Magnetic resonance imaging detects a specific peptideprotein binding event. J Am Chem Soc, 2002. 124(14): p. 3514-5.

143.

De Leon-Rodriguez, L.M., et al., Responsive MRI agents for sensing metabolism in vivo.
Acc Chem Res, 2009. 42(7): p. 948-57.

144.

Weinmann, H.J., et al., Characteristics of gadolinium-DTPA complex: a potential NMR
contrast agent. AJR Am J Roentgenol, 1984. 142(3): p. 619-24.

145.

Brown, E.M., et al., Cloning and characterization of an extracellular Ca(2+)-sensing
receptor from bovine parathyroid. Nature, 1993. 366(6455): p. 575-80.

146.

Ogurusu, T., S. Wakabayashi, and M. Shigekawa, Functional characterization of
lanthanide binding sites in the sarcoplasmic reticulum Ca(2+)-ATPase: do lanthanide
ions bind to the calcium transport site? Biochemistry, 1991. 30(41): p. 9966-73.

147.

Biagi, B.A. and J.J. Enyeart, Gadolinium blocks low- and high-threshold calcium
currents in pituitary cells. Am J Physiol, 1990. 259(3 Pt 1): p. C515-20.

275

148.

Idee, J.M., et al., Clinical and biological consequences of transmetallation induced by
contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol,
2006. 20(6): p. 563-76.

149.

Ye, Z., et al., Polydisulfide manganese(II) complexes as non-gadolinium biodegradable
macromolecular MRI contrast agents. J Magn Reson Imaging, 2012. 35(3): p. 737-44.

150.

Tweedle, M.F., The ProHance story: the making of a novel MRI contrast agent. Eur
Radiol, 1997. 7 Suppl 5: p. 225-30.

151.

NIST Critically Selected Stability Constants of Metal Complexes: Version 8.0. 2017;
Available from: https://www.nist.gov/srd/nist46.

152.

Yanyi, C., et al., Calciomics: prediction and analysis of EF-hand calcium binding
proteins by protein engineering. Sci China Chem, 2010. 53(1): p. 52-60.

153.

Zhou, Y., et al., Probing Ca2+-binding capability of viral proteins with the EF-hand
motif by grafting approach. Methods Mol Biol, 2013. 963: p. 37-53.

154.

Sherry, A.D., P. Caravan, and R.E. Lenkinski, Primer on gadolinium chemistry. J Magn
Reson Imaging, 2009. 30(6): p. 1240-8.

155.

Fang, M., et al., Collagen as a double-edged sword in tumor progression. Tumour Biol,
2014. 35(4): p. 2871-82.

156.

De Jong, W.H., et al., Particle size-dependent organ distribution of gold nanoparticles
after intravenous administration. Biomaterials, 2008. 29(12): p. 1912-9.

157.

Frenzel, T., et al., Stability of gadolinium-based magnetic resonance imaging contrast
agents in human serum at 37 degrees C. Invest Radiol, 2008. 43(12): p. 817-28.

158.

White, G.W., W.A. Gibby, and M.F. Tweedle, Comparison of Gd(DTPA-BMA)
(Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human

276

bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol, 2006. 41(3):
p. 272-8.
159.

Thakral, C. and J.L. Abraham, Nephrogenic systemic fibrosis: histology and gadolinium
detection. Radiol Clin North Am, 2009. 47(5): p. 841-53, vi-vii.

160.

Thakral, C. and J.L. Abraham, Gadolinium-induced nephrogenic systemic fibrosis is
associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by
microanalysis. J Cutan Pathol, 2009. 36(12): p. 1244-54.

161.

Motola, D.L., et al., Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and
Future Directions. Curr Pathobiol Rep, 2014. 2(4): p. 245-256.

162.

Nunn, A.D., K.E. Linder, and M.F. Tweedle, Can receptors be imaged with MRI agents?
Q J Nucl Med, 1997. 41(2): p. 155-62.

163.

Delli Castelli, D., et al., In vivo MRI multicontrast kinetic analysis of the uptake and
intracellular trafficking of paramagnetically labeled liposomes. J Control Release, 2010.
144(3): p. 271-9.

164.

Kok, M.B., et al., Cellular compartmentalization of internalized paramagnetic liposomes
strongly influences both T1 and T2 relaxivity. Magn Reson Med, 2009. 61(5): p. 1022-32.

165.

Kok, M.B., G.J. Strijkers, and K. Nicolay, Dynamic changes in 1H-MR relaxometric
properties of cell-internalized paramagnetic liposomes, as studied over a five-day period.
Contrast Media Mol Imaging, 2011. 6(2): p. 69-76.

166.

Artemov, D., Z.M. Bhujwalla, and J.W. Bulte, Magnetic resonance imaging of cell
surface receptors using targeted contrast agents. Curr Pharm Biotechnol, 2004. 5(6): p.
485-94.

277

167.

Glunde, K., et al., Magnetic resonance spectroscopy in metabolic and molecular imaging
and diagnosis of cancer. Chem Rev, 2010. 110(5): p. 3043-59.

168.

Yoo, B. and M.D. Pagel, An overview of responsive MRI contrast agents for molecular
imaging. Front Biosci, 2008. 13: p. 1733-52.

169.

Zhang, X., et al., 18F-labeled bombesin analogs for targeting GRP receptor-expressing
prostate cancer. J Nucl Med, 2006. 47(3): p. 492-501.

170.

Lu, P., et al., Extracellular matrix degradation and remodeling in development and
disease. Cold Spring Harb Perspect Biol, 2011. 3(12).

171.

Brodsky, B. and A.V. Persikov, Molecular structure of the collagen triple helix. Adv
Protein Chem, 2005. 70: p. 301-39.

172.

Polasek, M., et al., Molecular MR imaging of fibrosis in a mouse model of pancreatic
cancer. Sci Rep, 2017. 7(1): p. 8114.

173.

Henzl, M.T. and J.S. Graham, Conformational stabilities of the rat alpha- and betaparvalbumins. FEBS Lett, 1999. 442(2-3): p. 241-5.

174.

Dithmar, S., D. Rusciano, and H.E. Grossniklaus, A new technique for implantation of
tissue culture melanoma cells in a murine model of metastatic ocular melanoma.
Melanoma Res, 2000. 10(1): p. 2-8.

175.

Yang, H., S. Dithmar, and H.E. Grossniklaus, Interferon alpha 2b decreases hepatic
micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic
natural killer cells. Invest Ophthalmol Vis Sci, 2004. 45(7): p. 2056-64.

176.

Grynkiewicz, G., M. Poenie, and R.Y. Tsien, A new generation of Ca2+ indicators with
greatly improved fluorescence properties. J Biol Chem, 1985. 260(6): p. 3440-50.

278

177.

Pu, F., et al., Prostate-specific membrane antigen targeted protein contrast agents for
molecular imaging of prostate cancer by MRI. Nanoscale, 2016. 8(25): p. 12668-82.

178.

Ishak, K., et al., Histological grading and staging of chronic hepatitis. J Hepatol, 1995.
22(6): p. 696-9.

179.

Standish, R.A., et al., An appraisal of the histopathological assessment of liver fibrosis.
Gut, 2006. 55(4): p. 569-78.

180.

Sudnick, D.R. and W.D. Horrocks, Jr., Lanthanide ion probes of structure in biology.
Environmentally sensitive fine structure in laser-induced terbium(III) luminescence.
Biochim Biophys Acta, 1979. 578(1): p. 135-44.

181.

Afshar-Oromieh, A., et al., Comparison of PET/CT and PET/MRI hybrid systems using a
68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial
experience. Eur J Nucl Med Mol Imaging, 2014. 41(5): p. 887-97.

182.

Afshar-Oromieh, A., et al., Comparison of (6)(8)Ga-DOTATOC-PET/CT and PET/MRI
hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol, 2015.
17(2): p. 312-9.

183.

Geraldes, C.F., et al., Preparation, physico-chemical characterization, and relaxometry
studies of various gadolinium(III)-DTPA-bis(amide) derivatives as potential magnetic
resonance contrast agents. Magn Reson Imaging, 1995. 13(3): p. 401-20.

184.

Ye, Y., et al., Probing site-specific calmodulin calcium and lanthanide affinity by
grafting. J Am Chem Soc, 2005. 127(11): p. 3743-50.

185.

Frydrychowicz, A., et al., Hepatobiliary MR imaging with gadolinium-based contrast
agents. J Magn Reson Imaging, 2012. 35(3): p. 492-511.

279

186.

Swaminathan, S., et al., Cardiac and vascular metal deposition with high mortality in
nephrogenic systemic fibrosis. Kidney Int, 2008. 73(12): p. 1413-8.

187.

Singh, M., et al., A follow-up of four cases of nephrogenic systemic fibrosis: is
gadolinium the specific trigger? Br J Dermatol, 2008. 158(6): p. 1358-62.

188.

Boyd, A.S., S. Sanyal, and J.L. Abraham, Gadolinium is not deposited in the skin of
patients with normal renal function after exposure to gadolinium-based contrast agents. J
Am Acad Dermatol, 2008. 59(2): p. 356-8.

189.

Wiginton, C.D., et al., Gadolinium-based contrast exposure, nephrogenic systemic
fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol, 2008. 190(4): p.
1060-8.

190.

Abraham, J.L., et al., Dermal inorganic gadolinium concentrations: evidence for in vivo
transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J
Dermatol, 2008. 158(2): p. 273-80.

191.

Khurana, A., J.F. Greene, Jr., and W.A. High, Quantification of gadolinium in
nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of
clinical factors. J Am Acad Dermatol, 2008. 59(2): p. 218-24.

192.

Kay, J., et al., Case records of the Massachusetts General Hospital. Case 6-2008. A 46year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med,
2008. 358(8): p. 827-38.

193.

White, D.H., et al., The thermodynamics of complexation of lanthanide (III) DTPAbisamide complexes and their implication for stability and solution structure. Invest
Radiol, 1991. 26 Suppl 1: p. S226-8; discussion S232-5.

280

194.

Wedeking, P., K. Kumar, and M.F. Tweedle, Dose-dependent biodistribution of
[153Gd]Gd(acetate)n in mice. Nucl Med Biol, 1993. 20(5): p. 679-91.

195.

Muhler, A. and H.J. Weinmann, Biodistribution and excretion of 153Gd-labeled
gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid following repeated
intravenous administration to rats. Acad Radiol, 1995. 2(4): p. 313-8.

196.

Parmelee, D.J., et al., Preclinical evaluation of the pharmacokinetics, biodistribution, and
elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest
Radiol, 1997. 32(12): p. 741-7.

197.

Spinazzi, A., et al., Multihance clinical pharmacology: biodistribution and MR
enhancement of the liver. Acad Radiol, 1998. 5 Suppl 1: p. S86-9; discussion S93-4.

198.

Sieber, M.A., et al., Gadolinium-based contrast agents and their potential role in the
pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson
Imaging, 2008. 27(5): p. 955-62.

199.

Sieber, M.A., et al., Preclinical investigation to compare different gadolinium-based
contrast agents regarding their propensity to release gadolinium in vivo and to trigger
nephrogenic systemic fibrosis-like lesions. Eur Radiol, 2008. 18(10): p. 2164-73.

200.

Sieber, M.A., et al., A preclinical study to investigate the development of nephrogenic
systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol,
2008. 43(1): p. 65-75.

201.

Henzl, M.T., Characterization of parvalbumin and polcalcin divalent ion binding by
isothermal titration calorimetry. Methods Enzymol, 2009. 455: p. 259-97.

202.

Laurent, S., et al., How to measure the transmetallation of a gadolinium complex.
Contrast Media Mol Imaging, 2010. 5(6): p. 305-8.

281

203.

Tenni, R., et al., Interaction of decorin with CNBr peptides from collagens I and II.
Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J
Biochem, 2002. 269(5): p. 1428-37.

204.

McDonald, R.J., et al., Gadolinium Deposition in Human Brain Tissues after Contrastenhanced MR Imaging in Adult Patients without Intracranial Abnormalities. Radiology,
2017. 285(2): p. 546-554.

205.

Gulani, V., et al., Gadolinium deposition in the brain: summary of evidence and
recommendations. Lancet Neurol, 2017. 16(7): p. 564-570.

206.

Khawaja, A.Z., et al., Revisiting the risks of MRI with Gadolinium based contrast agentsreview of literature and guidelines. Insights Imaging, 2015. 6(5): p. 553-8.

207.

Wynn, T.A., Cellular and molecular mechanisms of fibrosis. J Pathol, 2008. 214(2): p.
199-210.

208.

Border, W.A. and N.A. Noble, Transforming growth factor beta in tissue fibrosis. N Engl
J Med, 1994. 331(19): p. 1286-92.

209.

Friedman, S.L., et al., Therapy for fibrotic diseases: nearing the starting line. Sci Transl
Med, 2013. 5(167): p. 167sr1.

210.

Koyama, Y. and D.A. Brenner, Liver inflammation and fibrosis. J Clin Invest, 2017.
127(1): p. 55-64.

211.

Murray, L.A., Editorial: The Cell Types of Fibrosis. Front Pharmacol, 2015. 6: p. 311.

212.

Marcellin, P., et al., Regression of cirrhosis during treatment with tenofovir disoproxil
fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 2013.
381(9865): p. 468-75.

282

213.

Cox, T.R. and J.T. Erler, Molecular pathways: connecting fibrosis and solid tumor
metastasis. Clin Cancer Res, 2014. 20(14): p. 3637-43.

214.

McDonald, L.T. and A.C. LaRue, Hematopoietic stem cell derived carcinoma-associated
fibroblasts: a novel origin. Int J Clin Exp Pathol, 2012. 5(9): p. 863-73.

215.

van den Berg, P.J., et al., Preclinical detection of liver fibrosis using dual-modality
photoacoustic/ultrasound system. Biomed Opt Express, 2016. 7(12): p. 5081-5091.

216.

Tung, J.C., et al., Tumor mechanics and metabolic dysfunction. Free Radic Biol Med,
2015. 79: p. 269-80.

217.

Bachem, M.G., et al., Pancreatic carcinoma cells induce fibrosis by stimulating
proliferation and matrix synthesis of stellate cells. Gastroenterology, 2005. 128(4): p.
907-21.

218.

Fazel, Y., et al., Epidemiology and natural history of non-alcoholic fatty liver disease.
Metabolism, 2016. 65(8): p. 1017-25.

219.

Manning, D.S. and N.H. Afdhal, Diagnosis and quantitation of fibrosis.
Gastroenterology, 2008. 134(6): p. 1670-81.

220.

Chen, D.L., et al., PET imaging approaches for inflammatory lung diseases: Current
concepts and future directions. Eur J Radiol, 2017. 86: p. 371-376.

221.

Jellis, C., et al., Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol, 2010.
56(2): p. 89-97.

222.

Qayyum, A., et al., Evaluation of diffuse liver steatosis by ultrasound, computed
tomography, and magnetic resonance imaging: which modality is best? Clin Imaging,
2009. 33(2): p. 110-5.

283

223.

Canto, M.I., et al., Frequent detection of pancreatic lesions in asymptomatic high-risk
individuals. Gastroenterology, 2012. 142(4): p. 796-804; quiz e14-5.

224.

Giannico, G. and A.B. Fogo, Lupus nephritis: is the kidney biopsy currently necessary in
the management of lupus nephritis? Clin J Am Soc Nephrol, 2013. 8(1): p. 138-45.

225.

Farris, A.B., et al., Morphometric and visual evaluation of fibrosis in renal biopsies. J
Am Soc Nephrol, 2011. 22(1): p. 176-86.

226.

Fryer, E., et al., How often do our liver core biopsies reach current definitions of
adequacy? J Clin Pathol, 2013. 66(12): p. 1087-9.

227.

Popov, Y. and D. Schuppan, Targeting liver fibrosis: strategies for development and
validation of antifibrotic therapies. Hepatology, 2009. 50(4): p. 1294-306.

228.

Gerlag, D.M. and P.P. Tak, How useful are synovial biopsies for the diagnosis of
rheumatic diseases? Nat Clin Pract Rheumatol, 2007. 3(5): p. 248-9.

229.

Mahadevan, D. and D.D. Von Hoff, Tumor-stroma interactions in pancreatic ductal
adenocarcinoma. Mol Cancer Ther, 2007. 6(4): p. 1186-97.

230.

Ueno, H., et al., Clinicopathological significance of the 'keloid-like' collagen and myxoid
stroma in advanced rectal cancer. Histopathology, 2002. 40(4): p. 327-34.

231.

Park, J.H., et al., The relationship between tumour stroma percentage, the tumour
microenvironment and survival in patients with primary operable colorectal cancer. Ann
Oncol, 2014. 25(3): p. 644-51.

232.

Park, J.H., et al., Evaluation of a tumor microenvironment-based prognostic score in
primary operable colorectal cancer. Clin Cancer Res, 2015. 21(4): p. 882-8.

284

233.

Bijlsma, M.F. and H.W. van Laarhoven, The conflicting roles of tumor stroma in
pancreatic cancer and their contribution to the failure of clinical trials: a systematic
review and critical appraisal. Cancer Metastasis Rev, 2015. 34(1): p. 97-114.

234.

Neesse, A., et al., Stromal biology and therapy in pancreatic cancer. Gut, 2011. 60(6): p.
861-8.

235.

Wang, L.M., et al., The prognostic role of desmoplastic stroma in pancreatic ductal
adenocarcinoma. Oncotarget, 2016. 7(4): p. 4183-94.

236.

Ueno, H., et al., Histologic categorization of desmoplastic reaction: its relevance to the
colorectal cancer microenvironment and prognosis. Ann Surg Oncol, 2015. 22(5): p.
1504-12.

237.

Rousselet, M.C., et al., Sources of variability in histological scoring of chronic viral
hepatitis. Hepatology, 2005. 41(2): p. 257-64.

238.

Myers, R.P., A. Fong, and A.A. Shaheen, Utilization rates, complications and costs of
percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int,
2008. 28(5): p. 705-12.

239.

Rotman, Y. and A.J. Sanyal, Current and upcoming pharmacotherapy for non-alcoholic
fatty liver disease. Gut, 2017. 66(1): p. 180-190.

240.

Gerlinger, M., et al., Intratumor heterogeneity and branched evolution revealed by
multiregion sequencing. N Engl J Med, 2012. 366(10): p. 883-892.

241.

Robertson, E.G. and G. Baxter, Tumour seeding following percutaneous needle biopsy:
the real story! Clin Radiol, 2011. 66(11): p. 1007-14.

242.

Diaz, L.A., Jr. and A. Bardelli, Liquid biopsies: genotyping circulating tumor DNA. J
Clin Oncol, 2014. 32(6): p. 579-86.

285

243.

Crowley, E., et al., Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin
Oncol, 2013. 10(8): p. 472-84.

244.

Alix-Panabieres, C. and K. Pantel, Clinical Applications of Circulating Tumor Cells and
Circulating Tumor DNA as Liquid Biopsy. Cancer Discov, 2016. 6(5): p. 479-91.

245.

European Association for Study of, L. and H. Asociacion Latinoamericana para el
Estudio del, EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation
of liver disease severity and prognosis. J Hepatol, 2015. 63(1): p. 237-64.

246.

Xie, Q., et al., The performance of enhanced liver fibrosis (ELF) test for the staging of
liver fibrosis: a meta-analysis. PLoS One, 2014. 9(4): p. e92772.

247.

Shiha, G., et al., Asian-Pacific Association for the Study of the Liver (APASL) consensus
guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.
Hepatol Int, 2017. 11(1): p. 1-30.

248.

Sangwaiya, M.J., et al., Latest developments in the imaging of fibrotic liver disease. Acta
Radiol, 2014. 55(7): p. 802-13.

249.

Genovese, F., et al., The extracellular matrix in the kidney: a source of novel noninvasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair, 2014. 7(1): p. 4.

250.

Blachier, M., et al., The burden of liver disease in Europe: a review of available
epidemiological data. J Hepatol, 2013. 58(3): p. 593-608.

251.

Rehm, J., A.V. Samokhvalov, and K.D. Shield, Global burden of alcoholic liver diseases.
J Hepatol, 2013. 59(1): p. 160-8.

252.

Younossi, Z.M., et al., Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016. 64(1): p.
73-84.

286

253.

Estes, C., et al., Modeling the epidemic of nonalcoholic fatty liver disease demonstrates
an exponential increase in burden of disease. Hepatology, 2018. 67(1): p. 123-133.

254.

Mokdad, A.A., et al., Liver cirrhosis mortality in 187 countries between 1980 and 2010:
a systematic analysis. BMC Med, 2014. 12: p. 145.

255.

Dulai, P.S., et al., Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver
disease: Systematic review and meta-analysis. Hepatology, 2017. 65(5): p. 1557-1565.

256.

Angulo, P., et al., Liver Fibrosis, but No Other Histologic Features, Is Associated With
Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology, 2015. 149(2): p. 389-97 e10.

257.

European Association for the Study of the, L., D. European Association for the Study of,
and O. European Association for the Study of, EASL-EASD-EASO Clinical Practice
Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts, 2016.
9(2): p. 65-90.

258.

Choong, C.C., S.K. Venkatesh, and E.P. Siew, Accuracy of routine clinical ultrasound
for staging of liver fibrosis. J Clin Imaging Sci, 2012. 2: p. 58.

259.

Smith, A.D., et al., Liver Surface Nodularity Quantification from Routine CT Images as a
Biomarker for Detection and Evaluation of Cirrhosis. Radiology, 2016. 280(3): p. 77181.

260.

Van Beers, B.E., J.L. Daire, and P. Garteiser, New imaging techniques for liver diseases.
J Hepatol, 2015. 62(3): p. 690-700.

261.

Sandrin, L., et al., Transient elastography: a new noninvasive method for assessment of
hepatic fibrosis. Ultrasound Med Biol, 2003. 29(12): p. 1705-13.

287

262.

Foucher, J., et al., Diagnosis of cirrhosis by transient elastography (FibroScan): a
prospective study. Gut, 2006. 55(3): p. 403-8.

263.

Castera, L., X. Forns, and A. Alberti, Non-invasive evaluation of liver fibrosis using
transient elastography. J Hepatol, 2008. 48(5): p. 835-47.

264.

Myers, R.P., et al., Feasibility and diagnostic performance of the FibroScan XL probe for
liver stiffness measurement in overweight and obese patients. Hepatology, 2012. 55(1): p.
199-208.

265.

Mueller, S. and L. Sandrin, Liver stiffness: a novel parameter for the diagnosis of liver
disease. Hepat Med, 2010. 2: p. 49-67.

266.

Liu, J., et al., Liver Shear-Wave Velocity and Serum Fibrosis Markers to Diagnose
Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B. Korean J Radiol, 2016.
17(3): p. 396-404.

267.

Feng, Y.H., et al., Shear wave elastography results correlate with liver fibrosis histology
and liver function reserve. World J Gastroenterol, 2016. 22(17): p. 4338-44.

268.

Loomba, R., et al., Magnetic resonance elastography predicts advanced fibrosis in
patients with nonalcoholic fatty liver disease: a prospective study. Hepatology, 2014.
60(6): p. 1920-8.

269.

Imajo, K., et al., Magnetic Resonance Imaging More Accurately Classifies Steatosis and
Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient
Elastography. Gastroenterology, 2016. 150(3): p. 626-637 e7.

270.

Park, C.C., et al., Magnetic Resonance Elastography vs Transient Elastography in
Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-

288

Proven Nonalcoholic Fatty Liver Disease. Gastroenterology, 2017. 152(3): p. 598-607
e2.
271.

Chen, J., et al., Early detection of nonalcoholic steatohepatitis in patients with
nonalcoholic fatty liver disease by using MR elastography. Radiology, 2011. 259(3): p.
749-56.

272.

Venkatesh, S.K., et al., Magnetic resonance elastography for the detection and staging of
liver fibrosis in chronic hepatitis B. Eur Radiol, 2014. 24(1): p. 70-8.

273.

Venkatesh, S.K., et al., Magnetic resonance elastography of liver in healthy Asians:
normal liver stiffness quantification and reproducibility assessment. J Magn Reson
Imaging, 2014. 39(1): p. 1-8.

274.

Dyvorne, H.A., et al., Prospective comparison of magnetic resonance imaging to
transient elastography and serum markers for liver fibrosis detection. Liver Int, 2016.
36(5): p. 659-66.

275.

Xu, G., et al., The functional pitch of an organ: quantification of tissue texture with
photoacoustic spectrum analysis. Radiology, 2014. 271(1): p. 248-54.

276.

Lei, H., et al., Characterizing intestinal inflammation and fibrosis in Crohn's disease by
photoacoustic imaging: feasibility study. Biomed Opt Express, 2016. 7(7): p. 2837-48.

277.

Knieling, F., et al., Multispectral Optoacoustic Tomography for Assessment of Crohn's
Disease Activity. N Engl J Med, 2017. 376(13): p. 1292-1294.

278.

Vogl, T.J., et al., Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and GdDTPA. Radiology, 1996. 200(1): p. 59-67.

289

279.

Hammerstingl, R., et al., Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI
and spiral CT for a therapeutic strategy: comparison with intraoperative and
histopathologic findings in focal liver lesions. Eur Radiol, 2008. 18(3): p. 457-67.

280.

Van Beers, B.E., C.M. Pastor, and H.K. Hussain, Primovist, Eovist: what to expect? J
Hepatol, 2012. 57(2): p. 421-9.

281.

Feier, D., et al., Liver fibrosis: histopathologic and biochemical influences on diagnostic
efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology, 2013.
269(2): p. 460-8.

282.

Ehling, J., et al., Elastin-based molecular MRI of liver fibrosis. Hepatology, 2013. 58(4):
p. 1517-8.

283.

Fuchs, B.C., et al., Molecular MRI of collagen to diagnose and stage liver fibrosis. J
Hepatol, 2013. 59(5): p. 992-8.

284.

Li, F., et al., Molecular imaging of hepatic stellate cell activity by visualization of hepatic
integrin alphavbeta3 expression with SPECT in rat. Hepatology, 2011. 54(3): p. 1020-30.

285.

Kuijpers, B.H., et al., Preparation and evaluation of glycosylated arginine-glycineaspartate (RGD) derivatives for integrin targeting. Bioconjug Chem, 2007. 18(6): p.
1847-54.

286.

Patsenker, E., et al., Pharmacological inhibition of integrin alphavbeta3 aggravates
experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology, 2009.
50(5): p. 1501-11.

287.

Hatori, A., et al., Utility of Translocator Protein (18 kDa) as a Molecular Imaging
Biomarker to Monitor the Progression of Liver Fibrosis. Sci Rep, 2015. 5: p. 17327.

290

288.

Li, D., et al., Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging.
EJNMMI Res, 2015. 5(1): p. 71.

289.

Beljaars, L., et al., The preferential homing of a platelet derived growth factor receptorrecognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol,
2003. 66(7): p. 1307-17.

290.

Friedman, S.L., Hepatic fibrosis -- overview. Toxicology, 2008. 254(3): p. 120-9.

291.

Kenneth D. Kochanek, S.L.M., Jiaquan Xu, Betzaida Tejada-Vera, Deaths: Final Data
for 2014. National Vital Statistics Reports, Centers for Disease Control and Prevention
2016. 65.

292.

Friedman, S.L., Mechanisms of hepatic fibrogenesis. Gastroenterology, 2008. 134(6): p.
1655-69.

293.

Lu, J., et al., NRBF2 regulates autophagy and prevents liver injury by modulating
Atg14L-linked phosphatidylinositol-3 kinase III activity. Nat Commun, 2014. 5: p. 3920.

294.

Wang, Y., et al., Assessment of chronic hepatitis and fibrosis: comparison of MR
elastography and diffusion-weighted imaging. AJR Am J Roentgenol, 2011. 196(3): p.
553-61.

295.

Kim, H.J., et al., Hirschsprung disease and hypoganglionosis in adults: radiologic
findings and differentiation. Radiology, 2008. 247(2): p. 428-34.

296.

Tschirch, F.T., et al., Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in
patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients
with normal liver parenchyma. Eur Radiol, 2008. 18(8): p. 1577-86.

297.

Tamada, T., et al., Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic
enhancement effects in normal and cirrhotic livers. Eur J Radiol, 2011. 80(3): p. e311-6.

291

298.

Namasivayam, S., D.R. Martin, and S. Saini, Imaging of liver metastases: MRI. Cancer
Imaging, 2007. 7: p. 2-9.

299.

Hanaoka, K., et al., The detection limit of a Gd3+-based T1 agent is substantially
reduced when targeted to a protein microdomain. Magn Reson Imaging, 2008. 26(5): p.
608-17.

300.

Albiin, N., MRI of Focal Liver Lesions. Curr Med Imaging Rev, 2012. 8(2): p. 107-116.

301.

Maniam, S. and J. Szklaruk, Magnetic resonance imaging: Review of imaging techniques
and overview of liver imaging. World J Radiol, 2010. 2(8): p. 309-22.

302.

Ersoy, H. and F.J. Rybicki, Biochemical safety profiles of gadolinium-based extracellular
contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging, 2007. 26(5):
p. 1190-7.

303.

Maharaj, B., et al., Sampling variability and its influence on the diagnostic yield of
percutaneous needle biopsy of the liver. Lancet, 1986. 1(8480): p. 523-5.

304.

Abdi, W., J.C. Millan, and E. Mezey, Sampling variability on percutaneous liver biopsy.
Arch Intern Med, 1979. 139(6): p. 667-9.

305.

Regev, A., et al., Sampling error and intraobserver variation in liver biopsy in patients
with chronic HCV infection. Am J Gastroenterol, 2002. 97(10): p. 2614-8.

306.

Venkatesh, S.K., et al., Magnetic resonance elastography: beyond liver fibrosis-a casebased pictorial review. Abdom Radiol (NY), 2017.

307.

Dodd, G.D., 3rd, et al., Spectrum of imaging findings of the liver in end-stage cirrhosis:
Part II, focal abnormalities. AJR Am J Roentgenol, 1999. 173(5): p. 1185-92.

292

308.

Dodd, G.D., 3rd, et al., Spectrum of imaging findings of the liver in end-stage cirrhosis:
part I, gross morphology and diffuse abnormalities. AJR Am J Roentgenol, 1999. 173(4):
p. 1031-6.

309.

Ismail, M.H. and M. Pinzani, Reversal of liver fibrosis. Saudi J Gastroenterol, 2009.
15(1): p. 72-9.

310.

Jung, Y.K. and H.J. Yim, Reversal of liver cirrhosis: current evidence and expectations.
Korean J Intern Med, 2017. 32(2): p. 213-228.

311.

Banerjee, R., et al., Multiparametric magnetic resonance for the non-invasive diagnosis
of liver disease. J Hepatol, 2014. 60(1): p. 69-77.

312.

Papastergiou, V., E. Tsochatzis, and A.K. Burroughs, Non-invasive assessment of liver
fibrosis. Ann Gastroenterol, 2012. 25(3): p. 218-231.

313.

Neuman, R.E. and M.A. Logan, The determination of collagen and elastin in tissues. J
Biol Chem, 1950. 186(2): p. 549-56.

314.

Kolodziej, A.F., et al., Peptide optimization and conjugation strategies in the
development of molecularly targeted magnetic resonance imaging contrast agents.
Methods Mol Biol, 2014. 1088: p. 185-211.

315.

Helm, P.A., et al., Postinfarction myocardial scarring in mice: molecular MR imaging
with use of a collagen-targeting contrast agent. Radiology, 2008. 247(3): p. 788-96.

316.

Pu, F., et al., GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor
Expression in Cancers by MRI. Sci Rep, 2015. 5: p. 16214.

317.

Elpek, G.O., Angiogenesis and liver fibrosis. World J Hepatol, 2015. 7(3): p. 377-91.

318.

Bocca, C., et al., Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol
Gastroenterol Hepatol, 2015. 1(5): p. 477-488.

293

319.

Fernandez, M., et al., Angiogenesis in liver disease. J Hepatol, 2009. 50(3): p. 604-20.

320.

Thabut, D. and V. Shah, Intrahepatic angiogenesis and sinusoidal remodeling in chronic
liver disease: new targets for the treatment of portal hypertension? J Hepatol, 2010.
53(5): p. 976-80.

321.

Zhang, W., et al., Dynamic Contrast-Enhanced Magnetic Resonance Imaging with GdEOB-DTPA for the Evaluation of Liver Fibrosis Induced by Carbon Tetrachloride in
Rats. PLoS One, 2015. 10(6): p. e0129621.

322.

Zhou, L., et al., Liver dynamic contrast-enhanced MRI for staging liver fibrosis in a
piglet model. J Magn Reson Imaging, 2014. 39(4): p. 872-8.

323.

Chen, B.B., et al., Dynamic contrast-enhanced magnetic resonance imaging with GdEOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol,
2012. 22(1): p. 171-80.

324.

Schuppan, D. and N.H. Afdhal, Liver cirrhosis. Lancet, 2008. 371(9615): p. 838-51.

325.

Park, S., et al., Differential Roles of Angiogenesis in the Induction of Fibrogenesis and
the Resolution of Fibrosis in Liver. Biol Pharm Bull, 2015. 38(7): p. 980-5.

326.

EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body
scans. European Medicines Agency, 2017.

327.

Eckhardt, B.L., et al., Strategies for the discovery and development of therapies for
metastatic breast cancer. Nat Rev Drug Discov, 2012. 11(6): p. 479-97.

328.

Van den Eynden, G.G., et al., The multifaceted role of the microenvironment in liver
metastasis: biology and clinical implications. Cancer Res, 2013. 73(7): p. 2031-43.

329.

Singh, A.D., M.E. Turell, and A.K. Topham, Uveal melanoma: trends in incidence,
treatment, and survival. Ophthalmology, 2011. 118(9): p. 1881-5.

294

330.

McLaughlin, C.C., et al., Incidence of noncutaneous melanomas in the U.S. Cancer,
2005. 103(5): p. 1000-7.

331.

Spagnolo, F., G. Caltabiano, and P. Queirolo, Uveal melanoma. Cancer Treat Rev, 2012.
38(5): p. 549-53.

332.

Grossniklaus, H.E., et al., Metastatic ocular melanoma to the liver exhibits infiltrative
and nodular growth patterns. Hum Pathol, 2016. 57: p. 165-175.

333.

Singh, A.D. and E.C. Borden, Metastatic uveal melanoma. Ophthalmol Clin North Am,
2005. 18(1): p. 143-50, ix.

334.

Halenda, K.M., et al., Reduction of Nodular Growth Pattern of Metastatic Uveal
Melanoma after Radioembolization of Hepatic Metastases. Ocul Oncol Pathol, 2016.
2(3): p. 160-5.

335.

Augsburger, J.J., Z.M. Correa, and A.H. Shaikh, Effectiveness of treatments for
metastatic uveal melanoma. Am J Ophthalmol, 2009. 148(1): p. 119-27.

336.

Grossniklaus, H.E., Progression of ocular melanoma metastasis to the liver: the 2012
Zimmerman lecture. JAMA Ophthalmol, 2013. 131(4): p. 462-9.

337.

Liao, A., et al., Radiologic and Histopathologic Correlation of Different Growth Patterns
of Metastatic Uveal Melanoma to the Liver. Ophthalmology, 2017.

338.

Dayani, P.N., et al., Hepatic metastasis from uveal melanoma: angiographic pattern
predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol, 2009.
127(5): p. 628-32.

339.

Sharma, K.V., et al., Hepatic arterial chemoembolization for management of metastatic
melanoma. AJR Am J Roentgenol, 2008. 190(1): p. 99-104.

295

340.

Cardenas-Rodriguez, J., et al., A reference agent model for DCE MRI can be used to
quantify the relative vascular permeability of two MRI contrast agents. Magn Reson
Imaging, 2013. 31(6): p. 900-10.

341.

Yankeelov, T.E., R.G. Abramson, and C.C. Quarles, Quantitative multimodality imaging
in cancer research and therapy. Nat Rev Clin Oncol, 2014. 11(11): p. 670-80.

342.

Mehlen, P. and A. Puisieux, Metastasis: a question of life or death. Nat Rev Cancer,
2006. 6(6): p. 449-58.

343.

Zhou, Z., et al., MRI detection of breast cancer micrometastases with a fibronectintargeting contrast agent. Nat Commun, 2015. 6: p. 7984.

344.

Quail, D.F. and J.A. Joyce, Microenvironmental regulation of tumor progression and
metastasis. Nat Med, 2013. 19(11): p. 1423-37.

345.

Reticker-Flynn, N.E., et al., A combinatorial extracellular matrix platform identifies cellextracellular matrix interactions that correlate with metastasis. Nat Commun, 2012. 3: p.
1122.

346.

Choi, J., et al., Engineered collagen hydrogels for the sustained release of biomolecules
and imaging agents: promoting the growth of human gingival cells. Int J Nanomedicine,
2014. 9: p. 5189-201.

347.

Jin, H.E., R. Farr, and S.W. Lee, Collagen mimetic peptide engineered M13
bacteriophage for collagen targeting and imaging in cancer. Biomaterials, 2014. 35(33):
p. 9236-45.

348.

Damato, B., Developments in the management of uveal melanoma. Clin Exp Ophthalmol,
2004. 32(6): p. 639-47.

296

349.

Mudhar, H.S., et al., A critical appraisal of the prognostic and predictive factors for
uveal malignant melanoma. Histopathology, 2004. 45(1): p. 1-12.

350.

Kaiserman, I., R. Amer, and J. Pe'er, Liver function tests in metastatic uveal melanoma.
Am J Ophthalmol, 2004. 137(2): p. 236-43.

351.

Toivonen, P., et al., Microcirculation and tumor-infiltrating macrophages in choroidal
and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci,
2004. 45(1): p. 1-6.

352.

Donoso, L.A., et al., Metastatic uveal melanoma: diffuse hepatic metastasis in a patient
with concurrent normal serum liver enzyme levels and liver scan. Arch Ophthalmol,
1985. 103(6): p. 758.

353.

Hannsson L, H.A., Bonfrer JMG, Duffy J, Einarsson R., Tumor markers in malignant
melanoma – EGTM (European Group on Tumor Markers) Guidelines. Tumor Biology,
2006. 27: p. 35-S1.

354.

Bonfrer, J.M., et al., The luminescence immunoassay S-100: a sensitive test to measure
circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer, 1998.
77(12): p. 2210-4.

355.

Bosserhoff, A.K., et al., Melanoma-inhibiting activity, a novel serum marker for
progression of malignant melanoma. Cancer Res, 1997. 57(15): p. 3149-53.

356.

Hauschild, A., [Meeting report of the 39th Annual Conference of the American Society of
Clinical Oncology (ASCO), 5/31-6/3/2003, Chicago, USA]. Hautarzt, 2003. 54(10): p.
999-1002.

357.

Hauschild, A., et al., S100B protein detection in serum is a significant prognostic factor
in metastatic melanoma. Oncology, 1999. 56(4): p. 338-44.

297

358.

Tuck, A.B., et al., Osteopontin expression in a group of lymph node negative breast
cancer patients. Int J Cancer, 1998. 79(5): p. 502-8.

359.

Kadkol, S.S., et al., Osteopontin expression and serum levels in metastatic uveal
melanoma: a pilot study. Invest Ophthalmol Vis Sci, 2006. 47(3): p. 802-6.

360.

Rittling, S.R. and A.F. Chambers, Role of osteopontin in tumour progression. Br J
Cancer, 2004. 90(10): p. 1877-81.

361.

Diener-West, M., et al., Development of metastatic disease after enrollment in the COMS
trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study
Group Report No. 26. Arch Ophthalmol, 2005. 123(12): p. 1639-43.

362.

Rietschel, P., et al., Variates of survival in metastatic uveal melanoma. J Clin Oncol,
2005. 23(31): p. 8076-80.

363.

Barbazetto, I.A., et al., Treatment of choroidal melanoma using photodynamic therapy.
Am J Ophthalmol, 2003. 135(6): p. 898-9.

364.

Woodman, S.E., Metastatic uveal melanoma: biology and emerging treatments. Cancer J,
2012. 18(2): p. 148-52.

365.

Pereira, P.R., et al., Current and emerging treatment options for uveal melanoma. Clin
Ophthalmol, 2013. 7: p. 1669-82.

366.

Yang, H. and H.E. Grossniklaus, Constitutive overexpression of pigment epitheliumderived factor inhibition of ocular melanoma growth and metastasis. Invest Ophthalmol
Vis Sci, 2010. 51(1): p. 28-34.

367.

Motola-Kuba, D., et al., Hepatocellular carcinoma. An overview. Ann Hepatol, 2006.
5(1): p. 16-24.

298

368.

Parkin, D.M., et al., Estimating the world cancer burden: Globocan 2000. Int J Cancer,
2001. 94(2): p. 153-6.

369.

Parkin, D.M., Global cancer statistics in the year 2000. Lancet Oncol, 2001. 2(9): p. 53343.

370.

Tsukuma, H., et al., Risk factors for hepatocellular carcinoma among patients with
chronic liver disease. N Engl J Med, 1993. 328(25): p. 1797-801.

371.

Simonetti, R.G., et al., Hepatocellular carcinoma. A worldwide problem and the major
risk factors. Dig Dis Sci, 1991. 36(7): p. 962-72.

372.

Kew, M.C., Hepatocellular carcinoma with and without cirrhosis. A comparison in
southern African blacks. Gastroenterology, 1989. 97(1): p. 136-9.

373.

Chen, T.H., et al., Ultrasound screening and risk factors for death from hepatocellular
carcinoma in a high risk group in Taiwan. Int J Cancer, 2002. 98(2): p. 257-61.

374.

Sangiovanni, A., et al., Increased survival of cirrhotic patients with a hepatocellular
carcinoma detected during surveillance. Gastroenterology, 2004. 126(4): p. 1005-14.

375.

Benvegnu, L., et al., Natural history of compensated viral cirrhosis: a prospective study
on the incidence and hierarchy of major complications. Gut, 2004. 53(5): p. 744-9.

376.

Fattovich, G., et al., Effect of hepatitis B and C virus infections on the natural history of
compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol, 2002. 97(11):
p. 2886-95.

377.

Deuffic, S., et al., Trends in primary liver cancer. Lancet, 1998. 351(9097): p. 214-5.

378.

El-Serag, H.B. and A.C. Mason, Rising incidence of hepatocellular carcinoma in the
United States. N Engl J Med, 1999. 340(10): p. 745-50.

299

379.

La Vecchia, C., et al., Trends in mortality from primary liver cancer in Europe. Eur J
Cancer, 2000. 36(7): p. 909-15.

380.

Corrao, G., et al., Trends of liver cirrhosis mortality in Europe, 1970-1989: age-periodcohort analysis and changing alcohol consumption. Int J Epidemiol, 1997. 26(1): p. 1009.

381.

Roizen, R., W.C. Kerr, and K.M. Fillmore, Cirrhosis mortality and per capita
consumption of distilled spirits, United States, 1949-94: trend analysis. BMJ, 1999.
319(7211): p. 666-70.

382.

Roizen, R., W.C. Kerr, and K.M. Fillmore, Cirrhosis mortality and per capita
consumption of distilled spirits, United States, 1949-1994: trend analysis. West J Med,
1999. 171(2): p. 83-7.

383.

Vong, S. and B.P. Bell, Chronic liver disease mortality in the United States, 1990-1998.
Hepatology, 2004. 39(2): p. 476-83.

384.

Alter, M.J., et al., The prevalence of hepatitis C virus infection in the United States, 1988
through 1994. N Engl J Med, 1999. 341(8): p. 556-62.

385.

Fattovich, G., et al., Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
Gastroenterology, 2004. 127(5 Suppl 1): p. S35-50.

386.

Hussain, S.M., R.C. Semelka, and D.G. Mitchell, MR imaging of hepatocellular
carcinoma. Magn Reson Imaging Clin N Am, 2002. 10(1): p. 31-52, v.

387.

Choi, B.I., K. Takayasu, and M.C. Han, Small hepatocellular carcinomas and associated
nodular lesions of the liver: pathology, pathogenesis, and imaging findings. AJR Am J
Roentgenol, 1993. 160(6): p. 1177-87.

300

388.

Mitchell, D.G., Liver I: Currently available gadolinium chelates. Magn Reson Imaging
Clin N Am, 1996. 4(1): p. 37-51.

389.

Scudellari, M., Drug development: try and try again. Nature, 2014. 516(7529): p. S4-6.

390.

Villanueva, A. and J.M. Llovet, Second-line therapies in hepatocellular carcinoma:
emergence of resistance to sorafenib. Clin Cancer Res, 2012. 18(7): p. 1824-6.

391.

Meads, M.B., R.A. Gatenby, and W.S. Dalton, Environment-mediated drug resistance: a
major contributor to minimal residual disease. Nat Rev Cancer, 2009. 9(9): p. 665-74.

392.

Llovet, J.M., et al., Advances in targeted therapies for hepatocellular carcinoma in the
genomic era. Nat Rev Clin Oncol, 2015. 12(8): p. 436.

393.

Tredan, O., et al., Drug resistance and the solid tumor microenvironment. J Natl Cancer
Inst, 2007. 99(19): p. 1441-54.

394.

Wu, S.D., et al., Role of the microenvironment in hepatocellular carcinoma development
and progression. Cancer Treat Rev, 2012. 38(3): p. 218-25.

395.

Heindl, A., et al., Similarity and diversity of the tumor microenvironment in multiple
metastases: critical implications for overall and progression-free survival of high-grade
serous ovarian cancer. Oncotarget, 2016. 7(44): p. 71123-71135.

396.

Yin, C., et al., Hepatic stellate cells in liver development, regeneration, and cancer. J
Clin Invest, 2013. 123(5): p. 1902-10.

397.

Carpino, G., et al., Alpha-SMA expression in hepatic stellate cells and quantitative
analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver
transplantation. Dig Liver Dis, 2005. 37(5): p. 349-56.

398.

Sokolovic, A., et al., Insulin-like growth factor binding protein 5 enhances survival of
LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair, 2010. 3: p. 3.

301

399.

Friedman, S.L., Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the
liver. Physiol Rev, 2008. 88(1): p. 125-72.

400.

Santamato, A., et al., Hepatic stellate cells stimulate HCC cell migration via laminin-5
production. Clin Sci (Lond), 2011. 121(4): p. 159-68.

401.

Amann, T., et al., Activated hepatic stellate cells promote tumorigenicity of
hepatocellular carcinoma. Cancer Sci, 2009. 100(4): p. 646-53.

402.

Choi, J., et al., Intraperitoneal immunotherapy for metastatic ovarian carcinoma:
Resistance of intratumoral collagen to antibody penetration. Clin Cancer Res, 2006.
12(6): p. 1906-12.

403.

Erikson, A., et al., Physical and chemical modifications of collagen gels: impact on
diffusion. Biopolymers, 2008. 89(2): p. 135-43.

404.

Bruix, J., M. Sherman, and D. American Association for the Study of Liver, Management
of hepatocellular carcinoma: an update. Hepatology, 2011. 53(3): p. 1020-2.

405.

Forner, A., et al., Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis:
Prospective validation of the noninvasive diagnostic criteria for hepatocellular
carcinoma. Hepatology, 2008. 47(1): p. 97-104.

406.

Sangiovanni, A., et al., The diagnostic and economic impact of contrast imaging
techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut, 2010.
59(5): p. 638-44.

407.

Rimola, J., et al., Non-invasive diagnosis of hepatocellular carcinoma </= 2 cm in
cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic
MRI. J Hepatol, 2012. 56(6): p. 1317-23.

302

408.

Schuhmann-Giampieri, G., et al., Preclinical evaluation of Gd-EOB-DTPA as a contrast
agent in MR imaging of the hepatobiliary system. Radiology, 1992. 183(1): p. 59-64.

409.

Frericks, B.B., et al., Qualitative and quantitative evaluation of hepatocellular carcinoma
and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol, 2009.
193(4): p. 1053-60.

410.

Ayuso, C., J. Rimola, and A. Garcia-Criado, Imaging of HCC. Abdom Imaging, 2012.
37(2): p. 215-30.

411.

Golfieri, R., et al., Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced
MRI to Dynamic MRI in the detection of hypovascular small (</= 2 cm) HCC in
cirrhosis. Eur Radiol, 2011. 21(6): p. 1233-42.

412.

Granito, A., et al., Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic
resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a
prospective study. Aliment Pharmacol Ther, 2013. 37(3): p. 355-63.

413.

Golfieri, R., et al., Which is the best MRI marker of malignancy for atypical cirrhotic
nodules: hypointensity in hepatobiliary phase alone or combined with other features?
Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging, 2012. 36(3):
p. 648-57.

414.

Bartolozzi, C., et al., Contrast-enhanced magnetic resonance imaging of 102 nodules in
cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging,
2013. 38(2): p. 290-6.

415.

Bashir, M.R., et al., Hepatocellular carcinoma in a North American population: does
hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for
diagnosis? J Magn Reson Imaging, 2013. 37(2): p. 398-406.

303

416.

Zech, C.J., et al., Vascular enhancement in early dynamic liver MR imaging in an animal
model: comparison of two injection regimen and two different doses Gd-EOB-DTPA
(gadoxetic acid) with standard Gd-DTPA. Invest Radiol, 2009. 44(6): p. 305-10.

417.

Haradome, H., et al., Can MR fluoroscopic triggering technique and slow rate injection
provide appropriate arterial phase images with reducing artifacts on gadoxetic acidDTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging, 2010.
32(2): p. 334-40.

418.

Schmid-Tannwald, C., et al., Optimization of the dynamic, Gd-EOB-DTPA-enhanced
MRI of the liver: the effect of the injection rate. Acta Radiol, 2012. 53(9): p. 961-5.

419.

Feuerlein, S., et al., Hepatocellular MR contrast agents: enhancement characteristics of
liver parenchyma and portal vein after administration of gadoxetic acid in comparison to
gadobenate dimeglumine. Eur J Radiol, 2012. 81(9): p. 2037-41.

420.

Chen, C.Z., et al., Hepatocellular carcinoma 20 mm or smaller in cirrhosis patients:
early magnetic resonance enhancement by gadoxetic acid compared with gadopentetate
dimeglumine. Hepatol Int, 2014. 8(1): p. 104-11.

421.

Wong, K.K., et al., Computational medical imaging and hemodynamics framework for
functional analysis and assessment of cardiovascular structures. Biomed Eng Online,
2017. 16(1): p. 35.

422.

Ray, H.M., et al., Predictors of intervention and mortality in patients with uncomplicated
acute type B aortic dissection. J Vasc Surg, 2016. 64(6): p. 1560-1568.

423.

Gupta, R. and R. Munoz, Evaluation and Management of Chest Pain in the Elderly.
Emerg Med Clin North Am, 2016. 34(3): p. 523-42.

304

424.

Wong, K.K., et al., Medical image diagnostics based on computer-aided flow analysis
using magnetic resonance images. Comput Med Imaging Graph, 2012. 36(7): p. 527-41.

425.

Parsa, C.J. and G.C. Hughes, Surgical options to contend with thoracic aortic pathology.
Semin Roentgenol, 2009. 44(1): p. 29-51.

426.

Sato, F., et al., Newly diagnosed acute aortic dissection: characteristics, treatment
modifications, and outcomes. Int Heart J, 2005. 46(6): p. 1083-98.

427.

Vernhet, H., et al., Abdominal CT angiography before surgery as a predictor of
postoperative death in acute aortic dissection. AJR Am J Roentgenol, 2004. 182(4): p.
875-9.

428.

Godwin, J.D., et al., Evaluation of dissections and aneurysms of the thoracic aorta by
conventional and dynamic CT scanning. Radiology, 1980. 136(1): p. 125-33.

429.

Vasile, N., et al., Computed tomography of thoracic aortic dissection: accuracy and
pitfalls. J Comput Assist Tomogr, 1986. 10(2): p. 211-5.

430.

Iliceto, S., et al., Diagnosis of aneurysm of the thoracic aorta. Comparison between two
non invasive techniques: two-dimensional echocardiography and computed tomography.
Eur Heart J, 1984. 5(7): p. 545-55.

431.

Godwin, J.D., R.S. Breiman, and J.M. Speckman, Problems and pitfalls in the evaluation
of thoracic aortic dissection by computed tomography. J Comput Assist Tomogr, 1982.
6(4): p. 750-6.

432.

Thorsen, M.K., et al., Dissecting aortic aneurysms: accuracy of computed tomographic
diagnosis. Radiology, 1983. 148(3): p. 773-7.

433.

Singh, H., E. Fitzgerald, and M.S. Ruttley, Computed tomography: the investigation of
choice for aortic dissection? Br Heart J, 1986. 56(2): p. 171-5.

305

434.

Mintz, G.S., et al., Two dimensional echocardiographic recognition of the descending
thoracic aorta. Am J Cardiol, 1979. 44(2): p. 232-8.

435.

Kasper, W., et al., Diagnosis of dissecting aortic aneurysm with suprasternal
echocardiography. Am J Cardiol, 1978. 42(2): p. 291-4.

436.

Victor, M.F., et al., Two dimensional echocardiographic diagnosis of aortic dissection.
Am J Cardiol, 1981. 48(6): p. 1155-9.

437.

Mathew, T. and N.C. Nanda, Two-dimensional and Doppler echocardiographic
evaluation of aortic aneurysm and dissection. Am J Cardiol, 1984. 54(3): p. 379-85.

438.

Iliceto, S., et al., Color Doppler evaluation of aortic dissection. Circulation, 1987. 75(4):
p. 748-55.

439.

Borner, N., et al., Diagnosis of aortic dissection by transesophageal echocardiography.
Am J Cardiol, 1984. 54(8): p. 1157-8.

440.

Erbel, R., et al., Echocardiography in diagnosis of aortic dissection. Lancet, 1989.
1(8636): p. 457-61.

441.

Ballal, R.S., et al., Usefulness of transesophageal echocardiography in assessment of
aortic dissection. Circulation, 1991. 84(5): p. 1903-14.

442.

Geisinger, M.A., et al., Thoracic aortic dissections: magnetic resonance imaging.
Radiology, 1985. 155(2): p. 407-12.

443.

Dinsmore, R.E., et al., MRI of dissection of the aorta: recognition of the intimal tear and
differential flow velocities. AJR Am J Roentgenol, 1986. 146(6): p. 1286-8.

444.

Goldman, A.P., et al., The complementary role of magnetic resonance imaging, Doppler
echocardiography, and computed tomography in the diagnosis of dissecting thoracic
aneurysms. Am Heart J, 1986. 111(5): p. 970-81.

306

445.

Dinsmore, R.E., et al., Magnetic resonance imaging of thoracic aortic aneurysms:
comparison with other imaging methods. AJR Am J Roentgenol, 1986. 146(2): p. 309-14.

446.

Hellenthal, F.A., et al., Biomarkers of abdominal aortic aneurysm progression. Part 2:
inflammation. Nat Rev Cardiol, 2009. 6(8): p. 543-52.

447.

Abdul-Hussien, H., et al., Collagen degradation in the abdominal aneurysm: a
conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol, 2007.
170(3): p. 809-17.

448.

Pyo, R., et al., Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B)
suppresses development of experimental abdominal aortic aneurysms. J Clin Invest,
2000. 105(11): p. 1641-9.

449.

Chiou, A.C., B. Chiu, and W.H. Pearce, Murine aortic aneurysm produced by
periarterial application of calcium chloride. J Surg Res, 2001. 99(2): p. 371-6.

450.

Daugherty, A. and L. Cassis, Chronic angiotensin II infusion promotes atherogenesis in
low density lipoprotein receptor -/- mice. Ann N Y Acad Sci, 1999. 892: p. 108-18.

451.

Daugherty, A., M.W. Manning, and L.A. Cassis, Angiotensin II promotes atherosclerotic
lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest, 2000. 105(11):
p. 1605-12.

452.

Deng, G.G., et al., Urokinase-type plasminogen activator plays a critical role in
angiotensin II-induced abdominal aortic aneurysm. Circ Res, 2003. 92(5): p. 510-7.

453.

King, V.L., et al., Selective cyclooxygenase-2 inhibition with celecoxib decreases
angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler
Thromb Vasc Biol, 2006. 26(5): p. 1137-43.

307

454.

Uchida, H.A., et al., Urokinase-type plasminogen activator deficiency in bone marrowderived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms.
Arterioscler Thromb Vasc Biol, 2011. 31(12): p. 2845-52.

455.

Krishna, S.M., et al., A peptide antagonist of thrombospondin-1 promotes abdominal
aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient
mouse. Arterioscler Thromb Vasc Biol, 2015. 35(2): p. 389-98.

456.

Norman, P.E. and J.A. Curci, Understanding the effects of tobacco smoke on the
pathogenesis of aortic aneurysm. Arterioscler Thromb Vasc Biol, 2013. 33(7): p. 1473-7.

457.

Daugherty, A. and J.T. Powell, Recent highlights of ATVB: aneurysms. Arterioscler
Thromb Vasc Biol, 2014. 34(4): p. 691-4.

458.

Liu, J., A. Daugherty, and H. Lu, Angiotensin II and Abdominal Aortic Aneurysms: An
update. Curr Pharm Des, 2015. 21(28): p. 4035-48.

459.

Saraff, K., et al., Aortic dissection precedes formation of aneurysms and atherosclerosis
in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc
Biol, 2003. 23(9): p. 1621-6.

460.

Daugherty, A., L.A. Cassis, and H. Lu, Complex pathologies of angiotensin II-induced
abdominal aortic aneurysms. J Zhejiang Univ Sci B, 2011. 12(8): p. 624-8.

461.

Daugherty, A., et al., Angiotensin II infusion promotes ascending aortic aneurysms:
attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond), 2010. 118(11): p. 6819.

462.

Davis, F.M., et al., Smooth muscle cell deletion of low-density lipoprotein receptorrelated protein 1 augments angiotensin II-induced superior mesenteric arterial and
ascending aortic aneurysms. Arterioscler Thromb Vasc Biol, 2015. 35(1): p. 155-62.

308

463.

Rateri, D.L., et al., Angiotensin II induces region-specific medial disruption during
evolution of ascending aortic aneurysms. Am J Pathol, 2014. 184(9): p. 2586-95.

464.

Lanzer, P., et al., ECG-synchronized cardiac MR imaging: method and evaluation.
Radiology, 1985. 155(3): p. 681-6.

465.

Browning, J.D., et al., Prevalence of hepatic steatosis in an urban population in the
United States: impact of ethnicity. Hepatology, 2004. 40(6): p. 1387-95.

466.

Williams, C.D., et al., Prevalence of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis among a largely middle-aged population utilizing ultrasound and liver
biopsy: a prospective study. Gastroenterology, 2011. 140(1): p. 124-31.

467.

Wong, V.W., et al., Prevalence of non-alcoholic fatty liver disease and advanced fibrosis
in Hong Kong Chinese: a population study using proton-magnetic resonance
spectroscopy and transient elastography. Gut, 2012. 61(3): p. 409-15.

468.

Kanwal, F., et al., Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United
States Cohort of Veterans. Clin Gastroenterol Hepatol, 2016. 14(2): p. 301-8 e1-2.

469.

Younossi, Z.M., et al., Changes in the prevalence of the most common causes of chronic
liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 2011.
9(6): p. 524-530 e1; quiz e60.

470.

Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med, 2002. 346(16): p. 1221-31.

471.

Vernon, G., A. Baranova, and Z.M. Younossi, Systematic review: the epidemiology and
natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in
adults. Aliment Pharmacol Ther, 2011. 34(3): p. 274-85.

472.

Chalasani, N., et al., The diagnosis and management of non-alcoholic fatty liver disease:
practice Guideline by the American Association for the Study of Liver Diseases,

309

American College of Gastroenterology, and the American Gastroenterological
Association. Hepatology, 2012. 55(6): p. 2005-23.
473.

Chalasani, N., et al., The diagnosis and management of non-alcoholic fatty liver disease:
Practice guideline by the American Association for the Study of Liver Diseases,
American College of Gastroenterology, and the American Gastroenterological
Association. Am J Gastroenterol, 2012. 107(6): p. 811-26.

474.

Chalasani, N., et al., The diagnosis and management of non-alcoholic fatty liver disease:
practice guideline by the American Gastroenterological Association, American
Association for the Study of Liver Diseases, and American College of Gastroenterology.
Gastroenterology, 2012. 142(7): p. 1592-609.

475.

Fraser, A., M.P. Longnecker, and D.A. Lawlor, Prevalence of elevated alanine
aminotransferase among US adolescents and associated factors: NHANES 1999-2004.
Gastroenterology, 2007. 133(6): p. 1814-20.

476.

Teli, M.R., et al., The natural history of nonalcoholic fatty liver: a follow-up study.
Hepatology, 1995. 22(6): p. 1714-9.

477.

McPherson, S., et al., Evidence of NAFLD progression from steatosis to fibrosingsteatohepatitis using paired biopsies: implications for prognosis and clinical
management. J Hepatol, 2015. 62(5): p. 1148-55.

478.

Singh, S., et al., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic
steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin
Gastroenterol Hepatol, 2015. 13(4): p. 643-54 e1-9; quiz e39-40.

479.

Pais, R., et al., A systematic review of follow-up biopsies reveals disease progression in
patients with non-alcoholic fatty liver. J Hepatol, 2013. 59(3): p. 550-6.

310

480.

Byrne, C.D. and G. Targher, NAFLD: a multisystem disease. J Hepatol, 2015. 62(1
Suppl): p. S47-64.

481.

Arulanandan, A., et al., Association Between Quantity of Liver Fat and Cardiovascular
Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic
Steatohepatitis. Clin Gastroenterol Hepatol, 2015. 13(8): p. 1513-20 e1.

482.

Yeh, M.M. and E.M. Brunt, Pathological features of fatty liver disease.
Gastroenterology, 2014. 147(4): p. 754-64.

483.

Ekstedt, M., et al., Fibrosis stage is the strongest predictor for disease-specific mortality
in NAFLD after up to 33 years of follow-up. Hepatology, 2015. 61(5): p. 1547-54.

484.

Sanyal, A.J., et al., Nonalcoholic steatohepatitis: association of insulin resistance and
mitochondrial abnormalities. Gastroenterology, 2001. 120(5): p. 1183-92.

485.

Donnelly, K.L., et al., Sources of fatty acids stored in liver and secreted via lipoproteins
in patients with nonalcoholic fatty liver disease. J Clin Invest, 2005. 115(5): p. 1343-51.

486.

Lambert, J.E., et al., Increased de novo lipogenesis is a distinct characteristic of
individuals with nonalcoholic fatty liver disease. Gastroenterology, 2014. 146(3): p. 72635.

487.

Fabbrini, E., et al., Alterations in adipose tissue and hepatic lipid kinetics in obese men
and women with nonalcoholic fatty liver disease. Gastroenterology, 2008. 134(2): p. 42431.

488.

Fabbrini, E., S. Sullivan, and S. Klein, Obesity and nonalcoholic fatty liver disease:
biochemical, metabolic, and clinical implications. Hepatology, 2010. 51(2): p. 679-89.

311

489.

Neuschwander-Tetri, B.A., Hepatic lipotoxicity and the pathogenesis of nonalcoholic
steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology,
2010. 52(2): p. 774-88.

490.

Spengler, E.K. and R. Loomba, Recommendations for Diagnosis, Referral for Liver
Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic
Steatohepatitis. Mayo Clin Proc, 2015. 90(9): p. 1233-46.

491.

Grandison, G.A. and P. Angulo, Can NASH be diagnosed, graded, and staged
noninvasively? Clin Liver Dis, 2012. 16(3): p. 567-85.

492.

Zhang, Y., et al., Ca(2+) dissociation from the C-terminal EF-hand pair in calmodulin: a
steered molecular dynamics study. FEBS Lett, 2008. 582(9): p. 1355-61.

493.

Yang, T. and B.W. Poovaiah, Calcium/calmodulin-mediated signal network in plants.
Trends Plant Sci, 2003. 8(10): p. 505-12.

494.

Huang, Y., et al., Identification and dissection of Ca(2+)-binding sites in the
extracellular domain of Ca(2+)-sensing receptor. J Biol Chem, 2007. 282(26): p. 1900010.

495.

Saucerman, J.J. and D.M. Bers, Calmodulin binding proteins provide domains of local
Ca2+ signaling in cardiac myocytes. J Mol Cell Cardiol, 2012. 52(2): p. 312-6.

496.

Retamal, M.A., et al., Opening of connexin 43 hemichannels is increased by lowering
intracellular redox potential. Proc Natl Acad Sci U S A, 2007. 104(20): p. 8322-7.

497.

Saez, J.C., et al., Connexin-based gap junction hemichannels: gating mechanisms.
Biochim Biophys Acta, 2005. 1711(2): p. 215-24.

498.

Kar, R., et al., Biological role of connexin intercellular channels and hemichannels. Arch
Biochem Biophys, 2012. 524(1): p. 2-15.

312

499.

Peracchia, C., Chemical gating of gap junction channels; roles of calcium, pH and
calmodulin. Biochim Biophys Acta, 2004. 1662(1-2): p. 61-80.

500.

Neyton, J. and A. Trautmann, Physiological modulation of gap junction permeability. J
Exp Biol, 1986. 124: p. 993-114.

501.

Reaume, A.G., et al., Cardiac malformation in neonatal mice lacking connexin43.
Science, 1995. 267(5205): p. 1831-4.

502.

Lai-Cheong, J.E., K. Arita, and J.A. McGrath, Genetic diseases of junctions. J Invest
Dermatol, 2007. 127(12): p. 2713-25.

503.

Bootman, M.D. and M.J. Berridge, The elemental principles of calcium signaling. Cell,
1995. 83(5): p. 675-8.

504.

Berridge, M.J., M.D. Bootman, and H.L. Roderick, Calcium signalling: dynamics,
homeostasis and remodelling. Nat Rev Mol Cell Biol, 2003. 4(7): p. 517-29.

505.

Berridge, M.J., P. Lipp, and M.D. Bootman, The versatility and universality of calcium
signalling. Nat Rev Mol Cell Biol, 2000. 1(1): p. 11-21.

506.

Haiech, J., S.B. Moulhaye, and M.C. Kilhoffer, The EF-Handome: combining
comparative genomic study using FamDBtool, a new bioinformatics tool, and the
network of expertise of the European Calcium Society. Biochim Biophys Acta, 2004.
1742(1-3): p. 179-83.

313

APPENDICES
Appendix A. Identification of Calmodulin Binding Domain in Cx43 Gap Junction Protein
Appendix A.1. Introduction
Cellular communication is an important aspect in maintaining homeostasis within
multicellular organisms. Processes such as hormone signaling, neural transmission, and cell-tocell
adhesion have provided animals with a wide variety of communication mechanisms that operate
with very high specificity. In addition to these mechanisms of cellular communication, individual
cells also contain numerous protein channels that allow communication with the extracellular
environment. In fact, membrane proteins can pass a large number of ions and metabolites across
the cell membrane in very short time periods. With such numerous possibilities of cellular
communication, it may appear that the direct connection between the intracellular environments
of two adjacent cells provided by gap junctions would be redundant [492].
Multicellular organisms require various means of cellular communication to respond to
internal and environmental stimuli. One method of communication is through the use of gap
junctions, which allow the exchange of ions, nutrients and small metabolites from one cell to
neighboring cells [493]. Gap junctions consist of the intercellular channels that mediate the cellto cell transfer of small molecules, including metabolites, second messengers, and ions, in
mammalian cells [494]. Gap junctions are composed of two hemichannels (termed connexons)
with each composed of six connexin (Cx) 3 subunits. The connexon from one cell joins in mirror
symmetry with another connexon of the opposing cell. Currently, at least 20 connexin genes have
been identified in the human genome, with connexin 43 (Cx43) the most ubiquitous connexin
[495].
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Connexins (Cx) are proteins encoded by a multigene family that typically form cell-cell
channels. To date, 21 Cx genes have been identified in the human genome and most of their Cx
orthologues have been described in other vertebrate species. The assembly of connexins into gap
junction channels (GJC) occurs in two main stages. Connexins first oligomerize into hexameric
hemichannels (HC) in the Golgi apparatus, from where they are transported to the cell surface in
vesicles and they fuse to the plasma membrane in an exocytotic process [496].
The number of HCs delivered to the plasma membrane can be represent only the 4-15% of
total Cx protein [497]. Subsequently, hemichannels presented by adjacent cells make contact and
dock to form a complete intercellular channel. During the docking process, the channel interior
becomes isolated from the extracellular environment and the newly formed channel opens,
allowing the direct exchange of ions, second messengers and metabolites between the interior of
the two cells. New intercellular channels aggregate to form plaque-like structures, while older
channels are endocytosed as double-membrane gap junction structures by one of the two
contributing cells, indicating that the hemichannels remain docked during gap junction
degradation. It was previously thought that hemichannels remained closed until docking during
channel formation. However, the opening of undocked hemichannels has been demonstrated in
solitary Xenopus oocytes expressing the lens Cx46 [498] and in isolated horizontal cells of the
catfish retina [499]. Twenty years later, there is now evidence that HCs composed of different
connexins can be electrically and chemically activated [500], and in native cells these HCs can
mediate the rapid flow of ions across the cell membrane to regulate ionic homeostasis, and to
facilitate the release of ATP, NAD+, glutamate or prostaglandins involved in autocrine/paracrine
signaling [501], as well as the transfer of nitric oxide [502].
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Both Ca2+ and H+ play a role in chemical gating of gap junction channels, but, with the
possible exception of Cx46 hemichannels, neither of them is likely to induce gating by a direct
interaction with connexins. Some evidence suggests that low pHi affects gating via an increase in
[Ca2+]; in turn, Ca2+ is likely to induce gating by activation of CaM, which may act directly as a
gating particle. Each Cx43 monomer consists of four highly conserved transmembrane segments,
a short N-terminal cytoplasmic region, one intracellular and two extracellular loops, and a Cterminal tail. Variability in sequence homology across different connexin types is greatest in the
intracellular loop and C terminus. Efforts to map the potential CaM-binding sites in Cx43 have led
to conflicting results [503].
This protein family is related with many diseases, like skin disease, tooth, and heart
diseases (Figure 3). The first inherited abnormality of a gap junction protein was reported in 1993
with mutations in Cx32 in individuals with X-linked charcot-marie-tooth disease [504]. Then in
1997, mutations in Cx26 were identified in case of deafness [505], a finding that led to the
significant discovery that mutations in Cx26 are in fact a common cause for several forms of
deafness. Later, mutations have been discovered in seven Cxs: Cx30, 30.3, 31, 40 43, 46 and 50
to be related with different diseases. Among them, four connexins are associated with skin
diseases, Cx26, Cx30, Cx30.3, Cx31. Cx46 and 50 have been shown to underlie cases of cataract.
Gap junctions play an important role in maintaining cell and tissue function and
homeostasis, and loss of function of connexin43 mutations has been linked to several serious
human diseases. Cx43 is the most abundantly expressed human connexin. Recently, a CaM
binding site was assigned to the second half of the cytoplasmic loop (CL) domain of Cx43, Cx44,
and Cx50 and confirmed using surface plasmon resonance, circular dichroism, fluorescence
spectroscopy, and nuclear magnetic resonance. Gap junctions have been shown to be regulated by
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[Ca2+] and also mediated by CaM interacting directly with the connexin proteins. Zhou et al.
indicated that the 136–158 amino acids of Cx43 bind with CaM with 1:1 stoichiometry in a Ca2+dependent manner [506].

Appendix 1. Molecular organization and schematic topology of a gap-junctional plaque

Recently, CaM binding sites have been identified on the cytoplasmic loop (CL) of at least
three Cxs in the α family. It has been shown that the Ca2+ regulation of Cx43 gap junctions is
blocked by CaM inhibitors. It is proposed that the carboxyl-terminal part of the Cx43 in the
cytoplasmic loop (Cx43136–158) domain is essential in regulation of Cx43 gap junction by CaM
in a Ca2+-dependent manner and eventually closure of Cx43 gap junction. The Cx43 CaM binding
domain follows the 1–5-10 CaM-binding mode subclass with hydrophobic residues at positions 1,
5, and 10 which is similar to the CAMBD of Ca2+/CaM-dependent kinase II (CaMKII). Ca2+-bound
CaM induces a conformational change in cytoplasmic loop of Cx43 or a combination of both steric
hindrance mechanisms cause the closure of the channel. Furthermore, it has been shown that, the
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addition of CaMKII inhibits CaM-Cx43 cytoplasmic loop interaction which causes a subsequent
transition of the channel from close to open state.
Connexin43, which is a CaM target protein, is a membrane protein. Therefore, it is difficult
to study the complex due to the challenges associated with the membrane proteins such as;
difficulty in expression and purification, low solubility and conformational flexibility. Therefore,
the intracellular regions of Cxs are largely “invisible” in the reported X-ray structures. Thus, the
molecular mechanisms for CaM regulation of Cx43 are not well established.
In this section, we have described a strategy to further study the binding between CaM and
Connexin43 and possible role of transmembrane residues in CaM binding to Cx43 (Figure 5). In
this approach, two fusion proteins with the sequences of Cx43(99-154) and Cx43(88-164) were
designed and expressed. A peptide that contains the entire intercellular loop (Cx43, 99-154) was
designed to study the interaction of CaM with the entire loop. Another peptide that contains the
entire intercellular loop and also parts of the transmembrane domains (Cx43, 88-164) was designed
to study the importance of the transmembrane domain to the interaction of CaM with intercellular
loop. Initial studies between D-CaM and the two proteins suggest that there is an interaction
between Cx43(88-164) + Fusion protein, however, the peptides are not purified yet. In order to
purify the peptides TEV protease and thrombin used as enzymes to cleave the rest of the protein
and produce only sequences of Cx43 (99-154) and Cx43 (88-164). Different cleavage conditions
were used to test whether TEV protease can cleave the protein or not.
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Appendix 2 CaM binding sites in gap junction.

Appendix A.2. Expression and purification of His-tagged Cx43 (99-154)
The vector carrying the sequence of thioredoxin protein fused at N-terminal which contains
a histag before the sequence of the Cx43 (99-154) was transformed into BL21(DE3) Green E-coli
cell strain. M9 medium was used for the expression of the protein. (Carbenicillin was used instead
of ampicillin because of better stability). First the protein was expressed in small scale (200 mL)
and the bacterium was grown over night at 37°C, 200 rpm. Then the solution was induced into 2L
of M9 medium and the bacteria was allowed to grow at 37°C until its optical density reached 0.60.8, then 200 μL of IPTG was added for over expression of the protein and then the temperature
was immediately decreased to 28°C and it was allowed to grow over night. Then in the morning
the cell debris was collected. Figure 13 shows the full sequence map of Cx43(99-154) with fusion
protein and TEV cleavage site. Figure 14 demonstrates SDS-page results for expression of
Cx43(99-154).
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Appendix 3 Mechanism of Cx43 purification with TEV protease.

Appendix 4 SDS-page results for expression of Cx43(99-154).

After centrifuge and collecting the cell debris, the following buffer was used: 25 mM
HEPES, 500mM NaCl, 1% sarkosyl, pH=7.2, and after that 5 to 10 mL of the buffer was added
and then Lysozyme was added to the final concentration of 150 μg/mL and the solution was
incubated for 30 min at 37°C. Then it was sonicated 3 times for 30 seconds, and 5 min rest between
each sonication, and then it was centrifuged. The same buffer was used to wash the cell debris for
the second time. For the third time 2M of Urea, 20 mM Tris-HCl, 0.5 M NaCl, and 2% Triton X100 (pH=8) was used to wash and lysate the cell debris and denature the protein in order to make
it more soluble. Finally, after centrifuge and collecting the cell debris, it was washed with 6 M
Guanidine hydrochloride, 1 mM 2-mercaptoethanol, 20 mM Tris-HCl, 0.5 M NaCl, 5 mM
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Imidazole (5 mL), and then let it stir for 1 hour at room temperature, and then it was centrifuged
at 4°C, 7000 rpm, 20 min. The reason for washing with this buffer is again to make the protein
more soluble by denaturing it. Only 5 mL of the last buffer was used to wash the cell debris for
FPLC injection.
Appendix A.3. FPLC Purification of Cx43 (99-154) using His-tag Column
First the column was washed with EDTA to remove any positively charged ions. Then,
FPLC column was charged with Nickel ions, so that the desired protein which has six consecutive
histidine residues can bind to the column. Then the column was washed with high concentration
of Urea (20 mM Tras-HCl, 0.5 M NaCl, 20 mM imidazole, 1mM 2-mercaptoethanol, 6 M of Urea)
to unfold the protein and then it was washed with 0M of Urea (20 mM Tras-HCl, 0.5 M NaCl, 20
mM imidazole, 1mM 2-mercaptoethanol, 0 M of Urea) to refold the protein back again. In order
to equilibrate the column, the buffer with high concentration of guanidine (6M) was used to wash
the column. Since imidazole forms a strong complex with nickel, finally high concentration of
imidazole was used to elute the protein out of the column. These two buffers were used for the
purification in the FPLC column. The buffer which has lower concentration of imidazole was used
to equilibrate the column (Buffer A: 20 mM Tras-HCl, 0.5 M NaCl, 20 mM imidazole, 1mM 2mercaptoethanol, pH=8.0). (Buffer B: 20 mM Tras-HCl, 0.5 M NaCl, 500 mM imidazole, 1mM
2-mercaptoethanol, pH=8.0). After elution, a large peak came out from the column and samples
were taken from the peak fractions for SDS-page to confirm that the protein is pure. As it is shown
in Appendix 5, fractions 28 to 41 contain single band which confirms they contain our protein
based on the molecular size.
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Appendix 5 Purification of Cx43(99-154) with Fusion Protein.

The column was washed with high concentration of Urea (20 mM Tras-HCl, 0.5 M NaCl,
20 mM imidazole, 1mM 2-mercaptoethanol, 6 M of Urea) to unfold the protein and then washed
with 0M of Urea (20 mMTras-HCl, 0.5 M NaCl, 20 mM imidazole, 1mM 2-mercaptoethanol, 0 M
of Urea) to refold the protein back again. After the purification, in order to remove the imidazole,
desalting column was used and the protein solution was passed through the column, and then the
protein was dialyzed against 10 mM Tris in pH of 8.0. After that the concentration and yield of the
protein was calculated. Appendix 6 indicates the FPLC results for desalting column, and Appendix
7 corresponds to concentration and yield of the protein.
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Appendix 6 Imidazole removal from the protein using desalting column.

Appendix 7 Cx43 (99-154) concentration calculation based on UV absorbance.
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Appendix A.4. Testing TEV Protease Cleavage Conditions with Purified Cx43(99-154)
with fusion protein
After the protein was purified, in order to see whether direct addition of the enzyme cleaves
the protein or not, different amounts of the enzyme were directly added to the purified protein. For
this purpose, two sets of experiments were designed. First, the factor of time was changed, and
second, the amount of the enzyme was changed. Appendix 8 summarizes these two sets of
experiments.

Appendix 8 SDS-page results for testing different cleavage conditions of TEV protease,
C1 and C2 correspond to protein and the enzyme, respectively.
For experiment set No.1 (1 to 4), the amount of the enzyme was changed and the time was
kept constant at 4°C overnight for 2 days. As you can see, the more enzyme is added the more
cleavage of the protein occurs and it results in two products: 1. Fusion protein with histag which
is 16.9 kD and 2. The peptide fragment which is 6.5 kD and corresponds to Cx43 (99-154),
therefore, it can be concluded that amount of the enzyme plays a role in the cleavage. In experiment
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set No.2 (1’ to 3’), only the time was changed to 2h, 4h and 6h at room temperature. Based on
SDS-page results, no cleavage occurred during the tested times. We can conclude that if the
cleavage occurs at room temperature, TEV protease will degrade and autolysis happens which
result in a dramatic reduction in the enzyme activity, therefore no cleavage will carry out.
Appendix 9 shows the cleavage products of Cx43(99-154) with fusion protein.

Appendix 9 The cleavage products of Cx43(99-154) with fusion protein.

Appendix A.5. New method for Purification of Cx43 (99-154)
After adding the pure enzyme to pure fusion protein, everything that is in the solution has
histidine tag except our desired peptide, therefore, we have come up with a new purification
protocol. In this procedure, after letting the cleavage reaction complete, nickel beads were added
to the mixture, and they were mixed with the solution for 2 hours at 4°C, then the mixture was
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centrifuged and the supernatant was separated from the beads. Theoretically, the peptide should
be in the supernatant and the enzyme, cleaved fusion protein, and uncleaved protein will bind to
nickel beads. After performing the mentioned experiment, the Cx43 (99-154) was successfully
purified from the mixture. Figure 20 shows the experiment steps for purification of Cx43 (99-154)
peptide.

Appendix 10 The enzyme, uncleaved protein, and cleaved fusion protein have histidine tag
therefore, nickel beads can be used to separate the peptide from the mixture after cleavage.
After obtaining the supernatant, SDS-page was run to make sure the peptide is pure.
Appendix 11 shows the pure peptide after cleavage with molecular weight of 6.5 kDa.
The final concentration of peptide was calculated to be 993 μM with the final yield is 4 mg
L-1.
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Appendix 11 Pure Cx43 (99-154) after Purification.

Appendix A.6. Monitoring the Interaction between Cx43 (99-154) and Calmodulin
After obtaining the pure peptide, steady-state and anisotropy fluorescence spectroscopy
was used to monitor the interaction between CaM and Cx43 (99-154) peptide. For this purpose, in
steady state fluorescence spectroscopy, 4 μM of dansylated CaM was used, and the signal of dansyl
chloride was monitored during the interaction. Different volumes of the peptide were titrated to
CaM. The titration was continued until the total concentration of the peptide in the solution reached
30 μM. After adding different volumes of the peptide no increase in the signal was observed
suggesting there is no interaction between the peptide and dansyl CaM. To further prove there is
no interaction, fluorescence anisotropy was used. Fluorescence anisotropy can be used to measure
the binding constants and kinetics of reactions that cause a change in the rotational time of the
molecules. If the fluorophore is bound to a small molecule, the rate at which it tumbles can
decrease significantly when it is bound tightly to a large protein. If the fluorophore is attached to

327

the larger protein in a binding pair, the difference in polarization between bound and unbound
states will be smaller (because the unbound protein will already be fairly stable and tumble slowly
to begin with) and the measurement will be less accurate. The degree of binding is calculated by
using the difference in anisotropy of the partially bound, free and fully bound (large excess of
protein) states measured by titrating the two binding partners. After performing the experiment,
again no interaction was observed proving our previous steady state fluorescence experiment.
Appendix 12. Illustrates the mentioned experiment.

Appendix 12 Fluorescence Steady State and Anisotropy of Dansyl-CaM and Cx43(99154).
Appendix A.7. Purification of Cx43 (88-163) Peptide
Using the same procedure discussed in section 2.12, another peptide with transmembrane
residues was purified. This peptide consists of the same resides that Cx43 (99-154) peptide had
with additional transmembrane residues at both ends. Figure 23 demonstrates the SDS-page results
for purification of Cx43 (88-163) peptide.
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Appendix 13 The purified Cx43 (88-163) peptide.

After obtaining the other peptide, a preliminary study was performed using steady-state
fluorescence spectroscopy. As you can see in figure 24b, after titrating the peptide to dansyl-CaM,
an increase and blue shift was observed which suggests the possible binding of CaM to Cx43(88163) peptide. Appendix 14 illustrates the interaction and comparison between the two peptides and
their interaction with Dansyl-CaM.

Appendix 14 Comparison between the interactions of two peptides with dansyl-CaM.
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Appendix A.8. Summary and conclusion
Based on the new purification technique that we used, two peptides one consisting of the
whole loop of Cx43 (99-154) and another one which has loop with transmembrane residues were
successfully purified. Fluorescence steady-state and anisotropy were used to monitor the
interaction between Cx43 (99-154) and Cx43 (88-164) peptides with dansyl-CaM. Based on the
preliminary results, Cx43 (88-163) binds to dansyl CaM, however, Cx43(99-154) does not show
any increase or blue shift in the signal of dansyl-CaM which suggests there is not interaction
between them.

